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F O R E W O R D
Thomas Pogge
This book contains a set of sophisticated essays that seek to employ 
intelligent academic analysis to help change the world for the better. 
Such work brings together four elements, memorably abbreviated as 
DEAR.
Description. Each essay describes a particular local health deficit and 
thereby reminds us of the staggering health inequalities that have accu-
mulated in our world. While the vast majority of people in the richer 
countries, and also rich minorities in the poorer countries, live without 
serious health problems well into their 70s or 80s, ill health remains 
a persistent reality for the world’s poor, who continue to die prema-
turely in large numbers, often as children or as a consequence of preg-
nancy or childbirth. While these deepest of inequalities become more 
pronounced, both globally and within most countries, they are also 
becoming less visible as the world’s comfortable minority is increasingly 
segregating itself from the poor. The essays remind us that – despite 
the remarkable global health focus of the last fifteen years (featuring the 
Millennium Development Goals, the Bill and Melinda Gates Founda-
tion, the Global Alliance for Vaccines and Immunization, the Global 
Fund to Fight AIDS, Tuberculosis and Malaria, and the United States 
President’s Emergency Plan for AIDS Relief) – life among the world’s 
disadvantaged still all too often is (in Hobbes’ famous phrase) ‘poor, 
nasty, brutish, and short’.
Explanation. Each essay then contributes to a diagnosis of the prob-
lem in focus: why does the health deficit persist? Such explanations are 
complex and vary from case to case. But prominent factors in many of 
the essays here collected are shortfalls in local public health systems. 
In the poorer countries, public health systems are chronically short of 
resources, for four main reasons. First, they struggle against a much 
larger burden of disease, aggravated as it is by inadequate nutrition, 
clothing, shelter and sanitation, dirty water, rampant threats from para-
sites and infectious diseases, climate change and its associated extreme 
weather events, poor education, as well as poor and often deliberately 
corrupted regulation of resource extraction, manufacturing, construc-
tion, traffic, tobacco, food, drugs, and the like. Second, most patients 
in poor countries do not have the means to purchase health insurance 
or to substantially contribute to their own needed medical expenses; 
and the public health system therefore contributes a higher proportion 
of national health spending. Third, poor-country public health systems 
receive a much smaller percentage of their country’s gross domestic 
product (GDP) – typically around 3 per cent versus 8 per cent in the 
developed countries.1 This discrepancy is in good part due to the fact 
that poor countries’ most capable taxpayers – their own wealthy class 
and especially multinational corporations – have been extremely adept 
at dodging their tax obligations with the help of an extensive network 
of tax havens, secrecy jurisdictions, lawyers, bankers, accountants, and 
lobbyists.2 Fourth, poor countries also have a much smaller GDP per 
capita than rich countries. While annual GDP per capita is around 
$50,000 in the more affluent countries, it is about one thirtieth of 
this ($1,700) in India and below $1,000 in twenty African countries.3 
Despite severe funding shortages, public health systems increasingly 
face first-world prices – not merely for medical equipment, but also 
for patented medicines (after the Trade-Related Aspects of Intellec-
tual Property Rights, Annex 1C of the Agreement to form the World 
Trade Organization, forced developing countries to greatly strengthen 
their patent protections for new pharmaceuticals) and even for medi-
cal personnel (in order to slow the massive brain drain that siphons off 
doctors and nurses into the richer countries). Severely underfunded, 
public health systems in the poorer countries are often also beset by 
discrimination and corruption, withholding needed medical care from 
those who are most in need and legally entitled to it.
Assessment. Each essay also contributes to the moral assessment of 
the local health deficit it analyses, examining the problem through a 
human rights lens, for example, and then also exploring the correla-
tive responsibilities on the part of the agents involved in creating and 
perpetuating the social conditions that aggravate the relevant local 
health deficit. It is no great insight, of course, that bad health is 
morally undesirable. But it is anything but trivial to work out which 
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health problems manifest social injustice and which constitute human 
rights deficits or even human rights violations. And it is even harder 
to allocate moral (and legal) responsibility for socially produced and 
socially avoidable health problems. Of special interest in this context 
is the distinction among the various causal pathways on which agents 
and institutional arrangements may be contributing to the emergence 
and perpetuation of health problems. Here a simple distinction is that 
between (actively) bringing about ill-health problems versus (passively) 
failing to avert or alleviate it. But this distinction is far too simple 
to capture everything that is morally significant about such a causal 
influence, especially in the case of institutional arrangements. Thus, a 
system of national or supranational rules can have an effect on popula-
tion health by:
• requiring that certain people be excluded from specific essential 
nutrients or pharmaceuticals or medical procedures;
• legally authorizing such discriminatory barriers as practised by firms 
or private-sector medical personnel;
• failing to enforce legal restrictions against such private discrimina-
tory practices;
• engendering excessive economic inequalities that foreseeably 
deprive many of the opportunity to access needed nutrients, 
pharmaceuticals, or medical procedures;
• avoidably failing to mitigate the adverse health effects of natural 
causes (such as a flood or earthquake);
• avoidably failing to address congenital health problems; or 
• avoidably failing to address self-caused health problems (e.g. due to 
tobacco consumption).
Holding fixed the dimensions of the resulting health deficit as well 
as the various costs of avoiding it, the moral assessment of the rel-
evant causal contribution to it will still vary across these diverse causal 
pathways.4
Reform. The final purpose of these essays is reform: to provide 
guidance on how crucial health deficits in the poorer countries are 
to be eradicated or at least curtailed. The discussion of reform builds 
upon the preceding elements. It builds, most directly, upon the 
element of Assessment which reveals which humanly avoidable health 
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deficits are morally most problematic from the standpoint of, and 
ought therefore to be prioritized by, some particular agent or class 
of agents (who may, of course, also be confronted with other moral 
claims on their attention and resources). Assessment in turn depends 
heavily on Explanation, which identifies the causal factors involved in 
the creation and perpetuation of a health deficit as well as the nature of 
the contributions these factors are making. And Explanation obviously 
depends on an accurate and comprehensive Description of the health 
deficit in question. Reform also has a more direct link to Explanation 
in that it calls for careful planning that involves a broad analysis of 
how the reformed conduct or policies or institutional arrangements 
would affect the health deficit under consideration as well as other 
morally significant parameters. One such parameter, discussed in 
many of the here-assembled essays, is the agency and empowerment 
of the people whose avoidable health problems are in focus. Any 
reform should ideally be informed by their understandings, needs, 
preferences, and values, should treat and establish them as equals in 
their communities, and vis-à-vis the ‘reformers’, and should empower 
them to defend, continue, and eventually help lead the reform process. 
Success in such an ambitious reform project requires a detailed causal 
understanding (Explanation) that extends well beyond the way things 
are into an analysis of how things would be if specific reform steps were 
successfully implemented.
We can learn a great deal from these essays – about health deficits 
and opportunities in the developing countries as well as, more generally, 
about how to think well about how to change the world for the better. 
For sure, such change is badly needed.
Notes
1 See World Bank at http://data.
worldbank.org/indicator/SH.XPD.PUBL.
ZS
2 See T. Pogge and K. Mehta (2016) 
Global Tax Fairness, Oxford: Oxford 
University Press.
3 Country data as provided by 
the United Nations, the International 
Monetary Fund, and the World Bank 
are collated by Wikipedia at https://
en.wikipedia.org/wiki/List_of_countries_
by_GDP_%28nominal%29_per_capita
4 For a fuller discussion, see my 
(2004) ‘Relational conceptions of justice: 
Responsibilities for health outcomes’, 
in S. Anand, F. Peter, and A. Sen (eds) 
Public Health, Ethics, and Equity, Oxford: 
Clarendon Press, pp. 135–61.
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I N T R O D U C T I O N
Abraar Karan and Geeta Sodhi
[H]ealth deprivation is really the most central aspect of poverty. 
(Amartya Sen, Nobel Laureate)
The poorest parts of the world are by and large the places in which 
one can best view the worst of medicine and not because doctors in 
these countries have different ideas about what constitutes modern 
medicine. It’s the system and its limitations that are to blame. 
(Dr Paul Farmer, founder of Partners in Health)
The right to health was first enshrined as a fundamental human right 
in the constitution of the World Health Organization (WHO) in 1946. 
Although international conventions have repeatedly upheld it for almost 
seventy years, no consensus has been reached about what ‘health’ 
means, what entitlements are guaranteed, and who has the duty of 
safeguarding access. Some protest that the conceptualization of health 
as a human right is irredeemably flawed: no government could ban a 
virus from spreading, or legislate a diseased human body to cure itself. 
If ‘health’ is interpreted as ‘health care’, however, then governments 
could ensure that their citizens have access to adequate medical 
information, effective prevention programmes, and safe treatments. 
But what minimum standards would these programmes have to meet? 
Does the right to health imply that health care must be comfortably 
affordable? And what responsibilities for protecting this right fall upon 
governments, corporations, and individuals themselves?
This volume brings together experts from around the world, 
including academics and in-the-field actors, who vigorously uphold the 
right to health as a universal human right and who consider poverty 
to be the greatest obstruction to this right. Poverty is distinguished 
by a low purchasing power, which restricts access to fee-for-service 
healthcare systems. It is linked to low education status and literacy 
levels, which impede the ability and capacity of the poor to access 
health care. Societal factors, such as the lower status of women 
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globally, can further hinder access for impoverished subpopulations. 
For the poor, barriers to health are posed by microeconomic realities 
at the household level, the larger sociocultural context that influences 
decision-making behaviours, political and economic environments at a 
national level, and variable geopolitical conditions.
The economic and social dimensions of development converge on 
health. If poverty is understood and recognized in terms of deprivation, 
not simply in terms of economics, then poor health can even be an 
effective metric of poverty. However, health is difficult to quantify. In 
1990, the United Nations formulated the Human Development Index 
(HDI) to measure the ‘development’ of countries with reference to 
health (life expectancy at birth), education (actual and expected years 
of schooling), and living standards (gross national income per capita). 
It continued to use the HDI in the Human Development Report 2011 
(UNDP, 2012). The findings are reproduced in Figure I.1, but this 
blunt tool does not reveal that there are many countries in ‘developed 
regions’ with a low HDI (for example Haiti), or that there is significant 
internal variation of development, income distribution, and human 
rights fulfilment within countries. To allow for development and 
inequality levels to be tracked both within and across countries, the 
United Nations developed a new index, the Inequality-Adjusted HDI 
(IHDI), in 2010 (Figure I.2). The striking results revealed that internal 
inequality often exists alongside a staggering lack of development 







I.1 HDI values around the world, 2011 (source: UNDP (undated))
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0.955 and an IHDI of 0.755, indicating a discrepancy between overall 
and internal levels of development.
These indices acknowledge that health is at the core of develop-
ment. Most health indicators show that people in low HDI countries 
are significantly worse off than their high HDI counterparts. In low 
HDI countries, life expectancy is much lower (Figure I.3) and the 
infant mortality rate is much higher (Figure I.4). In fact, according 
to the United Nations World Mortality Report 2011 (DESA, 2012b) 
and WHO (2012), conditions that have been eradicated or are rarely 
fatal in high HDI countries, such as pneumonia and diarrheal dis-
eases, remain major causes of death in low HDI countries (Table 
I.1). Wealthier countries tend to make long-term investments in 
preventative care and routine check-ups, and often have insurance and 
social welfare schemes to protect their citizens from succumbing to 
medical catastrophe. In contrast, as a result of their limited resources, 
the poor often see a physician once their disease is too advanced for 
treatment, or once it is only treatable via expensive interventions 
(Sachs, 2006). Moreover, the fee-for-service systems prevalent in 
many of the low HDI settings result in poorer patients spending 
significant amounts of their own money on catastrophic care. Because 
ill health makes individuals less productive, it can further lower income 
and accelerate poverty cycles (Figure I.5). From the individual to the 
national levels, poverty infringes on the right to health, which in turn 
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I.3 Life expectancy at birth by development group, 1950–2100 (source: DESA 
(2012b))
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Responsibilities for the right to health
The drastic inequity in major health indicators does not point to 
variations in medical care alone, but to the interlinked social, political, 
and economic dimensions of poverty, global health agendas and trade 
or foreign policy priorities, and the political economy and investments 
in public health by national governments.
Even as initiatives such as the Oslo Ministerial Declaration reiterate 
that global health is an important foreign policy issue, the global 
governance systems remain inadequate in addressing difficulties 
emanating from conflicts between global health agendas and foreign and 
trade policy priorities. Tobacco control is a case in point, with efforts 
and investments in combatting the tobacco pandemic challenged by 
trade and foreign policy priorities. Global health, in its nascent stage, is 
essentially a concept waiting to evolve into a discipline. Also, for global 
health to be fully realized, effective governance systems and structures 
need to be put in place. The lack of these systems and structures results 
in the more powerful states continuing to forfeit trade agreements and 
thus contributing to poor health amongst the already deprived/less 
privileged nations. An unfettered tobacco industry and the tobacco 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































These issues, which are shaped by the changing priorities and funding 
levels of the healthcare sector under each governmental administration, 
are determined by politics rather than by recognition of health as a 
right. National-level political economies shape the broad framework of 
national health policies and the details of their formulation, approval, 
and implementation. They also determine what role, if any, civil society 
can play in shaping health policy and facilitating access to health care 
for all. Although many international declarations and covenants, 
whether binding or informal, have recognized health as a human right, 
the countries that are governed by them interpret their obligations and 
duties to ensure the right to health in a wide variety of ways.
Depending on the political situation, national healthcare systems 
can prevent the need for catastrophic spending (defined as 10 per cent 
of a household budget) on health care. In many high HDI countries 
in which social welfare and high taxation are economically and socially 
feasible, such as Scandinavia, Spain, and the United Kingdom, 
single-payer healthcare models have been adopted, typically on the 
assumption that health is a human right for which the government is 
responsible. In many low HDI countries, as well as in some high HDI 
countries, the collection of tax revenue is greatly hindered by mass 
participation in an informal workforce. The resulting revenue shortfalls, 
sometimes coupled with the government’s failure to recognize health 
as a human right, lead to inadequate government spending on welfare 
programmes. This in turn causes the poor to be left to fund their own 
health care and fall prey to loan sharks and/or suffer extreme poverty 
(Ir et al., 2012). This healthcare deficit can be filled by international 
organizations, non-governmental organizations (NGOs), civil society 
organizations (CSOs), etc., but their roles are subject to fluctuations in 
national-level politics.
In many countries, social and cultural barriers to health care can be 
as devastating as the economic costs. The best-known example may be 
the HIV/AIDS epidemic in sub-Saharan Africa: access to services often 
requires financial resources for treatment (although there are some free 
clinics), as well as social support to overcome the stigma (Matovu and 
Makumbi, 2007). The result is a hidden epidemic of HIV-positive 
men and women who are never diagnosed, greatly complicating the 
already difficult challenges of HIV/AIDS prevention and treatment. 
Uganda began to overcome this only through a prolonged high-
publicity campaign led by national political leaders, and a programme 
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of free testing and treatment, exemplifying how national politics can 
lessen both social and economic impediments to health care. The 
health of the global poor can also be influenced by deeply held beliefs 
and cultural mores that are inconsistent with the Western treatment 
paradigm, which can complicate treatment and intervention strategies 
that are devised by actors unfamiliar with the populations whom they 
are hoping to help. Thus a strong partnership between local parties 
and international aid groups is a must when addressing complex global 
issues, and this union needs to collectively strategize a home-grown 
solution that utilizes external resources.
Still, it is important to remember that international and national 
bodies are far from the only actors involved in health rights; the private 
sector, and civil society itself, have a large influence in the health of the 
nation as well. While national governments are normally responsible 
for development concerns, such as clean water, sanitation systems, 
transportation infrastructure, and access to primary care in rural areas, 
many of these spheres are heavily affected by the actions of public 
and private entities. In many countries, the world has witnessed an 
aggressive private sector acting against the collective interest of citizens. 
For example, large pharmaceutical giants can leverage patent law to 
control the cost of pharmaceutical drugs, while healthcare technology 
companies can do the same with novel therapeutic inventions, which 
essentially guarantees the exclusion of the poor from accessing high-
quality medicine. Moreover, instances of public–private collusion, 
such as may have been the case in several global responses to pandemic 
infections, further highlights the reality that health care is dictated by 
market forces. These forces exacerbate systemic problems and ensure 
that the poor, who are particularly vulnerable to exploitation, remain 
sick, fee-paying customers in a profit-seeking healthcare industry in 
both low and high HDI countries.
This volume makes an urgently needed contribution to the health 
and poverty discourse by exploring the complex relationship between 
poverty and poor health. The need for this resource became clear 
during the conference ‘Building Consensus on Global Poverty: New 
Delhi Launch for Academics Stand Against Poverty’ (New Delhi, 
2011), which was organized by the Comparative Research Programme 
on Poverty (CROP), Academics Stand against Poverty (ASAP), the 
Research and Information System for Developing Countries (RIS), 
Incentives for Global Health (IGH), and the Developing Countries 
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Research Centre at the University of Delhi. The conference was wide-
ranging, but this volume goes far beyond its scope by creating the 
potential for synergistic engagement amongst scholars, activists, and 
social entrepreneurs. To empower fundamental, international change, 
it presents success stories, viewpoints, and experiences to demonstrate 
that the responsibility for ensuring the poor’s right to health belongs 
not only to politicians, but to everyone.
Said another way: this volume is an urgent call for action.
About the book
This collection brings together voices from those regions of the 
world in which the poor are concentrated (Latin America, Asia, and 
Africa), and from disciplines including medicine, law, and business, to 
address issues affecting health care for the poor. By dividing these issues 
into ‘legal’, ‘political’, ‘interventional’, and ‘multifaceted’ responses to 
specific health issues, the organization of this volume draws connections 
between issues and actions in different parts of the world. We would 
like to acknowledge that inequality is by no means present in only these 
regions: as mentioned earlier, the United States is a country with great 
internal inequality, although it has a high HDI. However, we wanted 
this volume to be a means by which inequality is highlighted in those 
regions of the world in which it is most heavily concentrated.
Part One of the volume, ‘Legal Movements’, offers perspectives 
on the nature of right-to-health legislation. In Chapter 1, Luz Marina 
Bernal (legal adviser, IFARMA Foundation, Colombia) traces how 
Colombians mobilized in a successful class-action lawsuit against a 
pharmaceutical giant, arguing that its exorbitant, patent-protected 
price infringed their right to health. The movement was primarily 
driven by civil society, exemplifying the potential that people have 
when organizing efficiently and utilizing the legal mechanisms by 
which to counter policies that are inconsistent with a protection of the 
population’s well-being. In Chapter 2, Dr Kwadwo Appiagyei-Atua 
(senior lecturer, Faculty of Law, University of Ghana) contends in a 
health-rights-based critique of international law that the poor’s right to 
health has been sacrificed to further the intellectual property rights of 
multinational pharmaceutical corporations. Together, these chapters 
express the need to empower citizens to take an active role in legislation 
that impacts on their collective right to health.
In Part Two, ‘Political Movements’, leading experts reveal how 
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political trends can produce or increase healthcare-related poverty 
among the poor. In Chapter 3, Dr Germán Velásquez (former head 
of the WHO’s Drug Action Programme) presents evidence to support 
the possibility that the WHO may have exhibited collusive behaviour 
in a government–private sector scheme to grow pharmaceutical profits, 
further marginalizing the health of the poor, by means of the imagined 
swine flu (Influenza A(H1N1)) pandemic.
In Chapter 4, Dr T. V. Sekher (associate professor, Institute for 
Population Sciences, Mumbai), Kaushalendra Kumar (research 
scholar, International Institute for Population Sciences), and V. P. 
Shijith (research officer, International Institute for Population Sciences) 
discuss the interrelated issues of catastrophic health expenses, health 
insurance coverage, and poverty in India. They make a case for national 
governments to provide social security to protect people against 
catastrophic expenditures on health care, in the absence of a global 
system that will protect people from the consequences of prohibitive 
unaffordable healthcare costs by ensuring that the costs of essential 
medicines are not too high. Political economy informing national-level 
decisions regarding social security for the poor is a reality that needs 
to be reckoned with, argue the authors, while advocating with national 
governments to honour the ‘Health for All’ commitment.
In Chapter 5, Dr Francisco Rossi Buenaventura (director, IFARMA 
Foundation, Colombia) and Luis Guillermo Restrepo Vélez (president, 
National College of Pharmacists, Colombia) take another perspective 
on affordability, seeking an alternative model of pharmaceutical 
innovation and income that could delink the sale price of medicines 
from the cost of research and development. These chapters prove that the 
policies of global, political, multilateral organizations can be deleterious 
to those whom they are supposed to benefit, and the authors call for civil 
societies to question these authorities and to hold them accountable.
The negative consequences of the legal and political forces explored 
in all of these chapters can be overcome by means of interventional 
approaches. In Part Three, such ‘Interventional Approaches’ are 
presented in chapters by Arora, and Sodhi and Sahu, as models for 
improving specific health metrics among traditionally marginalized 
groups in low HDI settings.
The model that Dr Monika Arora (director, Health Promotion 
and Tobacco Control Division, Public Health Foundation of India) 
presents in Chapter 6 highlights the role of youth empowerment in 
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a prevention and cessation intervention programme, and argues for 
the engagement of youth as agents of change in any public health 
strategy to dismantle the vicious cycle of tobacco use linked to 
poverty. The chapter describes a community-based movement that 
addresses the tobacco industry’s proliferation: a consequence of the 
lack of a global supra-structure that should have been protecting 
and ensuring health for all. The community-based local movement, 
while coming to the rescue of poor people in the absence of adequate 
governance systems and structures for global health, achieves but 
limited success.
Then, in Chapter 7, Dr Geeta Sodhi (director, Swaasthya, India) and 
Dr Skylab Sahu (assistant professor, Department of Political Science, 
Delhi University) discuss the concrete results from a programme 
developed by Swaasthya, a Delhi-based NGO, to improve maternal 
and newborn health among an impoverished urban population in India. 
The chapter is set in the city of Malegaon, in a context showcasing a 
lack of political will. The people’s movement fills the gaps left by the 
public health system in ensuring quality health services for the poor. 
India, while priding itself on being a world-class healthcare industry, 
has a public health system that is largely unaccountable and which 
continues to ignore the concerns of its poor. The authors describe the 
strategies underlying an effective community-led movement to ensure 
high-quality maternal and newborn health care for the community’s 
poor populations.
The final part of the volume, Part Four, ‘Multifaceted Movements’, 
covers ideas that bridge aspects of these legal and political movements, 
and interventional approaches. In Chapter 8, Dr Camilo Pérez-Bustillo 
(research professor, Graduate Programme in Human Rights and 
Faculty of Law, Autonomous University of Mexico City) compares the 
grass-roots, bottom-up struggles of indigenous groups in Latin America 
to secure basic health and human rights with the parallel struggles 
of ethnic minorities in the United States towards the same ends. 
He focuses on forced migration, demonstrating the critical role that 
social movements (both literal and figurative) have had on community 
health, and he calls for extreme poverty to be recognized as a crime in 
the legal system. In Chapter 9, Abraar Karan (MD candidate, David 
Geffen School of Medicine, University of California-Los Angeles) also 
considers social movements as an agent of change. He enumerates the 
structural problems of a top-down approach, focusing on the disastrous 
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consequences of allowing geopolitical forces to shape the provision of 
international aid to Uganda for HIV/AIDS without reference to the 
sociocultural and contextual realities of recipients. By considering 
poverty from a rights-based perspective, these chapters advocate for 
social movements to be used in conjunction with medical treatment to 
improving health access for the poor.
As a whole, these contributions expose systemic limitations from the 
perspective of those whose right to health remains unfulfilled. Stated 
simply, poor people face barriers to recovery that wealthy people do 
not. Ultimately, this volume is more than a series of essays; it is a plea 
for people around the world to come together and set a comprehensive 
agenda to fight against poverty and to protect the health of the poor. 
Current efforts at the global, national, and local levels are heartening, 
but more must be done to dismantle the oppressive institutions that 
exploit people who are already suffering from, or are vulnerable to, 
disease. The time to act is now.
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Introduction
The patent system is built on the premise that patents incentivize 
innovation by offering a limited twenty-year monopoly to patentees. As 
a result, private industries are able to demand as high a price for their 
patented products as they see fit and new medicines can be prohibitively 
expensive. This can have devastating effects on individuals, who may 
become bankrupt or have to forgo treatment because of the excessive 
expense of new medications that are under patent (and thus cannot 
be produced in a cheaper, generic form). But what happens when the 
costs are artificially inflated to the extent that a government cannot 
afford a treatment that it is legally bound to provide its citizens?
In Colombia, where the government is obliged to provide free 
treatment to citizens with HIV/AIDS, patients are being forced to 
seek access to their right to health through the courts. The national 
health policies have encouraged abuses of the patent system, of which 
the opportunistic pricing of the important drug Kaletra (lopinavir/
ritonavir) is representative. Abbott Laboratories, which produces and 
markets Kaletra in Colombia, abused the patent system to create a 
monopoly and secure significantly higher prices for the drug than in 
surrounding countries. Until 2008, it cost the state US$4,440 per 
patient per year in Colombia. That price has been lowered to $1,067 
as a result of public pressure, but generic versions would cost only 
$396 (70 per cent less) if they could be sold in Colombia (FMC, 
2008).
The pricing of Kaletra in Colombia is representative of the abuse of 
patent law to create monopolies and thereby restrict competition in the 
pharmaceutical sector, which was detailed in a European Commission 
report of July 2009, and which is worsening in developing countries 
– particularly in Latin America (Correa, 2010). Taking Colombia’s 
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experience as a case study, this chapter explores how the increase in 
patent protection in developing countries has constructed barriers that 
have pushed up prices and stifled competition, thereby restricting access 
to the medications and forcing governments not merely to fall short 
of national health policy goals, but to be in breach of national health 
policy – that is, to fail to uphold their constitutional obligations. This 
chapter also outlines advocacy strategy of civil society organizations 
(CSOs) and contextualizes their efforts to request a compulsory licence 
for Kaletra in Colombia.
After providing an overview of Colombia’s national healthcare 
system, which is currently in crisis and undergoing reform, this 
chapter will present a brief introduction to the way in which patents 
determine access to medicine. It will then explore the effects of 
Kaletra’s soaring costs on the Colombian health system and the 
subsequent governmental response, with a particular focus on the 
process of administrative and legal actions leading Colombian civil 
society ultimately to making a request for a compulsory licence. 
Finally, the chapter will conclude with a discussion of developing 
countries’ flexibility vis-à-vis the 1994 Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS), including the 
influence of drug patents extended by TRIPS, as well as resistance to 
this influence in the form of political will for, and social concern over, 
the defence of right to health and life.
Analysis of the Colombian health system
In Colombia, the health system is universal and is regulated by 
the Ministry of Health and Social Protection (Ministerio de Salud y 
Protección Social, or MPS) under constitutional mandate. The system 
is decentralized, with mandatory public enrolment comprising a 
contribution scheme that includes formal workers and their families. 
There is also the so-called Subsidized Plan for the poor and vulnerable. 
Moreover, there are also special regimes for particular groups (such as 
army, police, teacher, and Colombian Oil Company, or ECOPETROL, 
health systems) and a public network to address health problems 
among the uninsured (under the 1993 Social Security Act, or Law No. 
100 of 1993).
The system is operated by the Benefit Plans Administrators (BPA), 
public and private health-promoting entities, and administrators of 
the Subsidized Plan, who act as intermediaries and managers of state 
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resources provided by the annual premium (known as a unit capitation 
payment, or UCP). The central component of the social security 
system in Colombia is the Compulsory Health Plan (CHP), which 
includes integrated services for treatment and disease prevention, as 
well as workers’ compensation for medical and maternity leave (under 
Law No. 100 of 1993).
Economic factors have contributed to a steady dismantling of the 
system at the operational and implementation levels, and has caused a 
crisis in the healthcare sector. The government did not regulate the cost 
of medicines and, as a result, high drug prices contributed to the ongoing 
crisis in the financing of the Colombian health system. The price of 
Kaletra provides a case in point: in addition to monopolistic pricing, 
the entities responsible for delivering the drug to patients have created 
barriers to access, such as increasing the paperwork needed to obtain it.
In the case of people living with HIV/AIDS, the government was 
not fulfilling its legally mandated obligation to provide free treatment, 
forcing patients to go to court to claim guardianship of the fundamental 
right to health and access to services that are not included in the CHP. 
As a result of legal action, Kaletra was included in the CHP in 2004. 
Nevertheless, the Colombian price remains higher than elsewhere in 
the South American Andean region and continues to impose a financial 
burden on the Colombian health system.
Patents and the violation of the right to health
National authorities have traditionally granted patents as an 
instrument of industrial policy to advance national development and 
only to a lesser extent as a right of the inventor. It has been argued that 
higher standards of intellectual property can lead to technology transfer 
(that is, the importation of technological capacity) because foreign firms 
would be encouraged to invest in developing countries and to install 
their technologies. However, there is also a counterargument that 
those foreign firms that have obtained patents in developing countries 
are able to make inroads and profits in these countries without having 
to produce the patented products there, because they can import the 
products and sell them at monopoly prices (Khor, 2005).
There are several ways in which a strong intellectual property rights 
(IPR) regime can hinder developing countries’ access to technology. 
Obstacles to technology transfer make it difficult for developing 
countries and their home-grown firms to upgrade infrastructure to the 
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extent necessary if they are to compete successfully with foreign firms. 
Such obstacles thus impede competition (Khor, 2005). Patents, which 
grant exclusive rights to market a product for twenty years, provide a 
significant barrier of this type. They can also create barriers to access: 
monopolies not only install artificial barriers to other firms entering the 
market, but the exclusive right to market a given product also leads to 
the potential abuse of this dominant position in the form of high prices 
(Khor, 2005).
Human rights are those promises that we, as a global society, should 
collectively employ to protect the existence of every individual. They are 
often expressed and guaranteed by law, embodied by examples such as 
the right to health, the right to privacy, the right to property, the right 
to life, etc. A state interferes with a human right if it limits the exercise 
of that right, encroaches on the right, or fails to fulfil a positive duty 
associated with the right. Article 4 of the 1966 International Covenant 
on Economic, Social and Cultural Rights (ICESCR) adopts the 
approach of examining, first, a limitation to a right, and then possible 
justification for such limitation. The state must guarantee the economic 
accessibility of medicines as part of its fulfilment of Article 4, which sets 
standards for evaluating accessibility, with average household income 
as one among several factors. By allowing monopolistic pricing, patents 
interfere with the right of access to medicine, especially in developing 
countries: unfortunately, governments in developing countries often 
lack the resources to pay for drugs priced artificially high (Hestermeyer, 
2006).
Kaletra: A study of the costs of the patented drug
According to an analysis of the HIV situation in the Andean 
subregion over the period 2003–05, the Benefit Plan in Colombia 
covers highly active antiretroviral therapy (HAART) – that is, first-
line antiretrovirals – but the drug supply is irregular, especially for 
the poor (Kusunoki Fuero and Nagles Peláez, 2007). Regulatory and 
institutional barriers, such as delays in the timely delivery of medicines 
and extended administrative procedures associated with drug delivery, 
limit access to care for high-cost diseases. As a result, patients must 
seek recourse through the legal system to access care and treatment.
The patent protection provided by intellectual property law 
constitutes a barrier to access to essential medicines. In Colombia, 
Kaletra, an antiretroviral treatment for HIV/AIDS produced by 
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Abbott Laboratories, provides a representative case. The drug is 
patented, which provides Abbott with a monopoly on the marketing 
of this medicine. The exorbitantly expensive drug is the only form of 
lopinavir/ritonavir that exists in Colombia.
The cost of antiretroviral drugs in Colombia is the highest in the 
so-called Andean subregion, a group comprising Venezuela, Ecuador, 
Peru, and Bolivia (Trout et al., 2007). Several reasons for this 
discrepancy exist. The first explanation relates to the way in which the 
national health system is structured. There are more than 100 buyers 
for antiretrovirals, who either buy these drugs directly or through 
intermediaries. This restricts their ability to achieve enough purchasing 
power to take advantage of economies of scale. Additionally, unlike many 
Latin American countries, Colombia has no national price referencing 
system that buyers might use when negotiating with pharmaceutical 
companies. In short, Colombia lacks a single purchaser; instead, health 
maintenance organizations (entidades promotoras de salud, or EPSs), 
healthcare providers (instituciones prestadoras de servicios, or IPSs), and 
local health authorities form a fragmented group of intermediates. 
The high number of buyers increases transaction costs, and expands 
the opportunities for corruption among monopolies and oligopolies 
(that is, it raises the risk of anti-competitive practices). Information 
asymmetries give vendors a stronger negotiating position than that of 
buyers. Such monopolies or oligopolies exist because of the patent 
protection and data exclusivity measures provided under the current 
IPR regime in Colombia (Garavito and Ruiz, 2008). Figure 1.1 
provides a comparison of high-cost drugs in Colombia in 2006.
In an analysis conducted by IFARMA–Health Action International 
on the specific impact of the lopinavir/ritonavir patent, it was found 
that the drug accounts for the largest expenditure in the Andean region. 
This product was patented in Colombia, Chile, and Ecuador; however, 
Abbott decided not to seek patents in Peru, Bolivia, and Venezuela. 
The countries used in the comparison in Table 1.1 – Colombia, Chile, 
and Peru – were chosen for their complete dataset (2004–06).
By 2008, Kaletra prices in Colombia had increased to $3,443 through 
institutional channels and $3,296.16 through commercial channels; in 
Peru, the price of the lopinavir/ritonavir generic was only $396 (see 
Figure 1.2). This analysis reveals that the price of the drug tends to 
rise (that is, in Colombia) or remain relatively stable (that is, in Chile) 
when the medicine is under patent. In contrast, the only country in the 
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region that benefits from competition for this medicine is Peru: without 
a patent on the drug, the price has reduced significantly over time.
Later, Kaletra was put on the list of drugs controlled by the state. 
Following the government’s use of references for price (based on prices 
in neighbouring countries), the current Colombian market price stands 
at about $1,000 per patient per year. However, it is still possible to 
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  1  Lopinavir + Ritonavir 167mg (tab)
  3  Eritropoyetina Sln Iny 2000 UI
  5  Infliximab 100mgs (amp)
  7  Somatropina Rec Hum Slniny Genotropin 16ui(amp)
  9  Imatinib Tabletas 400mg (tab) – Glivec
11  Interferón Beta 1A 12.000.000 Ui 44 mcg tratamientos
13  Etarnecept Slniny 25mg (amp)
15  Nelfinavir 250 mg.
17  Lamivudina + Zidovudina Tabletas 450mg – Generico
19  Ciproterona Acetato 50 mg. (tab)
21  Docetaxel 80 mg/vial (vial)
23  Paclitaxel 100mg – Sol. Esteril
25  Somatropina Slniny 24ui Saizen (amp)
27  Toxina Botulinica 100 U.I.
29  Calcitriol 0.25 mcg (tab)
  2  Imatinib Tabletas 100mg (tab) – Glivec
  4  Interferón Beta 1B 8.000.000 UI
  6  Ciclosporina 100 mg. (tab)
  8  Rituximab Slniny 500mg/50ml (amp)
10  Zoledronico Acido Vial 4mg (amp)
12  Indinavir 400 mg. (tab)
14  Vigabatrin 500mg (tab)
16  Ritonavir 100mg.
18  Abac + Zidov + Lamiv tab300+300+150(fco)
20  Valganciclovir 450mgs tabs
22  Factor Antihemofilico Viii Solucion Inyectable 500UI (amp)
24  Micofenolato 500mg (tab)
26  Interferon Alfa 2A Pegasys Vial 1ml 180 mg(amp)
28  Gemcitabina Slniny 1g (amp)















1.1 Expensive drugs in Colombia, 2006 (source: Fundación Ifarma (2006))
TABLE 1.1 Comparison of the history of the price of patented lopinavir/ritonavir vs 
lopinavir/ritonavir without a patent
Country Patent protection 2004 price (US$) 2005 price (US$) 2006 price (US$)
Peru No 2.06 1.88 0.928
Colombia Yes 2.231 2.388 2.44




The compulsory licence request made by Colombian CSOs resulted 
in a reduction in the high price for Kaletra, making the drug more 
accessible in Colombia. These high prices had been possible because 
of the passive and permissive actions of the state, whose behaviour 
ultimately favours the interests of the patent owner. Even though the 
price has since been reduced, at time of writing lower-priced generics 
are not yet available on the market. If there were generics on the market, 
they could generate enormous savings for a health system currently in 
crisis, enabling it to expand access to medicine, and thereby to reduce 
HIV/AIDS-related morbidity and mortality – a scenario that would be 
possible if there were a compulsory licence for Kaletra.
The international framework for the request of a compulsory licence 
in this context comprises:
• TRIPS;
• Decision No. 486 of the Andean Community Establishing the 
















1.2 Evolution of the price of lopinavir/ritonavir in countries in which the drug 
is patented (Colombia and Chile) versus a country without a patent on the drug 
(Peru) (source: IFARMA–AIS (2007))
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• the World Trade Organization (WTO) 2001 Doha Declaration on 
TRIPS;
• the 2001 Declaration of Commitment on HIV/AIDS, ‘Global Crisis, 
Global Action’, of the United Nations General Assembly Special 
Session (UNGASS); and
• the WHO, UNAIDS, and UNICEF initiative ‘Towards Universal 
Access’.
From a legal perspective, national mechanisms used in response to 
the HIV/AIDS epidemic have included:
• the 1991 Constitution of Colombia;
• the Social Security Act (Law No. 100 of 1993);
• Decree No. 1543 of 12 June of 1997 to provide for the Rules for 
the Management of HIV, AIDS, and STDs [sexually transmitted 
diseases];
• the National Policy on Sexual and Reproductive Health, which 
conducts specific actions for the issue of HIV/AIDS, including the 
programme management model against HIV/AIDS;
• the National Public Health Plan;
• Law No. 972 of 15 July 2005 providing for Rules to Improve Care for 
People Affected by Catastrophic Illnesses, particularly HIV/AIDS;
• the new evidence-based guidelines of care for people living with 
HIV/AIDS;
• the National Strategic Plan for HIV/AIDS, 2004–07; and
• the recent National Strategic Plan, 2008–2015.
A licence is a mechanism provided by the patent holder or imposed 
by the state to generate competition in different markets (Maybarduk, 
2008). A compulsory licence requires the owner of a patent or copyright 
licence to forgo its rights of exclusion in exchange for a payment set 
either by law or by some other form of arbitration. In essence, an 
individual or company granted a compulsory licence can market the 
product in question without seeking the patent holder’s consent, as 
long as it pays the patent holder a set fee.
In Colombia, any group interested in obtaining a licence must pay 
a royalty determined by the Superintendent of Industry and Trade 
(Superintendencia de Industria y Comercio, or SIC) according to Decision 
No. 486 (and related regulations). There is also an implied condition: 
no entity can sell any medicine, including lopinavir/ritonavir, without 
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approval of the National Institute of Food and Drug Monitoring 
(Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or 
INVIMA). This is the body responsible for implementing the Ministry 
of Social Welfare’s policies on health monitoring and drug quality 
control.
Compulsory licensing is a mechanism used worldwide. 
Unfortunately, in Colombia, the government denied the compulsory 
licence for Kaletra without even exploring the extent to which its 
action affected the public interest. The decision also contravenes the 
current constitutional trend towards defending the human right to 
access to health care and improvement of quality of life. Moreover, the 
government’s stance violates the right to public health within a social 
security system. Colombia’s social security system and, as a result, the 
public’s right to health has been challenged by the monopoly-driven 
high costs of medicines: a direct result of the construction of a strong 
IPR regime.
In 2001, the WTO announced:
Each member [of TRIPS] has the right to determine what 
constitutes a national emergency or other circumstances of 
extreme urgency, it being understood that public health crises, 
including those relating to HIV/AIDS, tuberculosis, malaria and 
other epidemics, can represent a national emergency or other 
circumstances of extreme urgency. (2001 Doha Declaration, 
Article 5(c))
Andean Community rules also provide for compulsory licensing as a 
means to remedy anti-competitive practices. The legal framework that 
applies to this case in Colombia is Decision No. 486 of the Andean 
Community – specifically Article 65 – and Resolution No. 17585, 
under which the SIC is declared the competent officer to grant licences 
when prompted by public interest.
The United States and the European Union (itself for certain 
sectors and its member states in relation to certain pharmaceutical 
drugs) have been active in non-voluntary licensing. In the United 
States, compulsory licensing focuses on military and nuclear energy, 
while in the case of the European Union, it is more commonly used 
in the computer industry (Maybarduk, 2008). There have, however, 
been several instances in the United States in which a compulsory 
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licence has been used in the pharmaceutical sector. Moreover, in 
several other countries, including Canada, this legal mechanism has 
been used in a systematic manner (as part of economic policy) to 
aid the further development of the national pharmaceutical industry 
(Weissman, 2007). In Canada, for example, until the 1990s, the 
granting of compulsory licences for pharmaceutical products was part 
of a strategy of technology transfer and industrial development for the 
generic drug industry (Rimmington, 2009).
The case of the United States is also particularly significant. The 
American government has pursued a contradictory practice whereby 
it uses disparate policies domestically and internationally, fostering 
competition in the domestic market, while simultaneously restricting 
competition abroad. In January 2008, for example, the Court of Appeals 
for the Federal Circuit lifted the ban against Merck’s use of a patent 
belonging to Innogenetics and ordered the issuance of a compulsory 
licence to Merck. Two months later, in March 2008, Roche agreed to 
court-imposed conditions so that it could sell Mircera, a drug that was 
deemed to violate several patents held by Amgen. Amgen was opposed 
to Roche’s marketing of Mircera, meaning that the judge had to grant 
the licence in spite of opposition. The licence granted to Roche had 
five conditions attached, including a royalty payment of 22.5 per cent 
to Amgen.
It is worth noting that Merck and Roche both benefited from 
the granting of these compulsory licences – and yet, when the Thai 
government issued compulsory licences against their own patented 
products (efavirenz, or Stocrin, in November 2006; erlotinib, or 
Tacerva, in January 2008), both companies reacted very strongly. 
In short, the position of these companies with respect to compulsory 
licensing varied radically, with each acting in each case according to 
its own interests: in the United States, Merck and Roche promoted 
and profited from compulsory licensing; in Thailand, they expressed 
their total dissatisfaction with the compulsory licence and demanded 
that the Office of the United States Trade Representative (USTR) take 
action against the state.
The US Supreme Court granted the ‘well-recognized remedy’ of 
compulsory licences in antitrust actions as early as 1952, in United 
States v. Besser Mfg Co., 343 US 444, 1952. The following examples 
show how the US government has used the compulsory licence to its 
advantage to increase competition since then.
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• In 2001, Secretary Tommy Thompson of the Department of Health 
and Human Services (DHHS), threatened to use section 1498 of 
Title 28 of the federal US Code (28 USC 1498) to authorize the 
importation of generic ciprofloxacin in order to prepare for a possible 
anthrax attack (Love, 2007).
• At the US Congress hearing in November 2005, Secretary Michael 
Levitt of the DHHS testified in the House of Representatives that 
he was then requiring Tamiflu’s patent holders (Roche and Gilead) 
to consider developing US-based manufacturing facilities for this 
product. In this way, the US government sought to ensure greater 
access to Tamiflu if it were to be confronted with a bird flu pandemic 
(Press Trust of India, 2011).
The following examples show how the Brazilian government has also 
used the compulsory licence to its advantage to increase competition.
• Brazil granted its first compulsory licence for drugs in 2007. There 
were 75,000 Brazilians with HIV/AIDS taking the antiretroviral 
efavirenz. The brand-named drug by Merck and BMS, efavirenz, 
cost $1.59 per person per day, but there were generic versions with 
prices of about $0.45 per person per day. The competition between 
generic firms led to a decrease in the price of generic efavirenz to 
$0.25 per day. On 4 May 2007, Brazil issued a compulsory licence 
by means of a decree signed by the Minister of Health and then 
President Lula (Love, 2007).
• In addition, several years ago, Brazil used compulsory licensing as a 
negotiating tool with the pharmaceutical companies. In 2001, Brazil 
announced that it was considering compulsory licences for efavirenz 
and nelfinavir; in the following months, Merck offered discounts for 
both. In 2003, Brazil threatened licences for lopinavir, efavirenz, and 
nelfinavir, and discounts were again obtained. In 2005, the possibility 
that a licence would be used resulted in discounts of 46 per cent 
for Kaletra, 50 per cent for Viread, and 65 per cent for imatinib, a 
treatment made by Novartis for leukaemia (Love, 2007).
Requesting a compulsory licence for Kaletra in Colombia Under 
TRIPS Article 31(b), a compulsory licence cannot be implemented 
until users have spent a reasonable period of time seeking a voluntary 
licence with reasonable terms and conditions. In Colombia, there are 
approximately 12,000 persons living with HIV/AIDS.
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The timeline of major events leading to the compulsory licence 
request (see also Figure 1.3) includes the following events. In April 
2008, the Bureau of Organizations Working on HIV/AIDS and the 
Colombian Network of People Living with HIV (Red Colombiana de 
Personas Viviendo con VIH, or RECOLVIH) requested an open licence 
from Abbot Laboratories for lopinavir/ritonavir (Kaletra) for reasons of 
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1.3 Timeline of request for compulsory licensing of Kaletra in Colombia
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In July 2008, because of the lack of response from Abbott, requests 
were made to the government through an administrative channel: a 
collection of CSOs – including IFARMA, the Health Mission, the 
Bureau of Organizations Working on HIV/AIDS, RECOLVIH, Essen-
tial Action (providing technical support), and several organizations 
from the international civil society community – submitted an applica-
tion for a compulsory licence for Kaletra to the patent office (that is, 
the SIC). They asked that the Ministry of Health declare access to the 
drug a matter of public interest.
In November 2008, the Ministry of Commerce issued Decree No. 
4302. The decree, in accordance with Article 65 of Decision No. 486 
of the Andean Community, established the procedure for declaring an 
issue a matter of public interest.
In accordance with the law, the Ministry of Health formed a technical 
committee that produced Resolution No. 01444 (MPS, 2009). The 
Resolution brought an end to the administrative proceedings regarding 
Kaletra, since it ruled that there were no reasons for declaring access 
to lopinavir/ritonavir a matter of public interest. As a result, the patent 
office refused to issue a compulsory licence.
In May 2009, the CSOs requested the direct repeal of Resolution 
No. 01444. The government replied in depth, denying the request 
and confirming its original position. As a corrective measure to the 
high price of the medicine, the government instead took the decision 
to control the drug’s price and established a reference price according 
to neighbouring countries in the region. The government continues to 
monitor the price of the drug today.
As a response to the Ministry of Health, in order to prevent 
potential consequential damage and the violation of human rights and 
collective interests, several CSOs chose to continue the issue in court. 
On October 2009, CSOs in Colombia filed a class action lawsuit 
(in Spanish, acción popular) that claimed that the collective right 
to access to healthcare services, as well as administrative morality, 
was threatened by the government’s refusal to grant a compulsory 
licence.
Originating in Roman law, class actions are considered the 
procedural means par excellence for the protection of collective rights 
and interests. It is a legal concept that has been developed in a variety 
of countries, including the United States, England and Wales, and 
Germany. In Colombia, it was initially implemented under the Civil 
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Code as a mechanism for protecting public property and preventing 
damages to property.
Class actions are also designed to ensure protection of administrative 
morality. They present a mechanism by which people can enforce the 
protection of the public interest, and they represent a tool for preventing 
and/or repairing resulting damage. In this case, the class action filed by 
the CSOs demanded that the judge order:
• the SIC to grant an open compulsory licence – for the lifetime of 
patents granted to Abbott Laboratories – to produce, manufacture, 
import, export, distribute, offer for settlement, sell, buy, or use the 
medicine called Kaletra (lopinavir/ritonavir);
• Abbott Laboratories to suspend any administrative or judicial action 
the purpose of which was to defend the patent; and
• INVIMA to allow any laboratory with the appropriate manufacturing 
capacity to produce quality drugs to register the active ingredient, 
lopinavir/ritonavir.
Meanwhile, in December 2009, the Colombian president declared a 
health emergency – but, in April 2010, the Constitutional Court ruled 
that the declaration could not be enforced.
In January 2011, Law No. 1438 implemented a health system 
reform that sought to reverse the serious economic crisis affecting 
public health.
Efforts have also been made to promote the cause through social 
media, such as the ‘Campaign for Access to Kaletra’ (Public Citizen, 
2011a). Civil society organizations requesting the licence in question 
have produced educational materials – notably a video clip that shows 
the various communication pieces published in an attempt to raise 
awareness (Morales, 2008).
The Positive Communication Foundation (Comunicación Positiva) 
has also held press conferences, forums, and presentations on the 
subject in public places, aiming to promote the ‘Campaign for the 
Right to Health not Patents’ (Morales, 2010).
Further, a six-part radio series has chronicled the full history of the 
struggle of CSOs in Colombia in pursuing the licence to an essential 
drug for the treatment of HIV. Some podcasts were also produced 
in order to facilitate dissemination by other organizations (Morales, 
2008).
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Another advocacy action has been the Global Kaletra Campaign. 
This is a worldwide campaign aiming to expand access to vital HIV 
treatment. On 10 November 2011, public health groups in a dozen 
countries, including Colombia, launched a global campaign to challenge 
Abbott Laboratories’ monopolistic hold on Kaletra (lopinavir/ritonavir). 
The goal was to spur competition by generic drug makers and thereby 
lower the medicine’s price; the permissions sought were also to allow 
the use of the drug’s components in new, more effective, combination 
treatments. This campaign represents an unprecedented global effort to 
challenge the pharmaceutical industry’s political power and to improve 
access to lifesaving medicines (Public Citizen, 2011b).
On 29 February 2012, a decision by Bogotá’s Administrative Court 
found that Abbott had violated a government pricing order in 2009. The 
Court consequently directed the Ministry of Health to initiate procedures 
for sanctions against Abbott (potentially including financial penalties). 
The Court stated that Abbott had abused its dominant market position 
by pricing an essential medicine 350 per cent higher in Colombia than in 
neighbouring countries (about $3,500 compared to about $1,000). This 
threatened the sustainability of Colombia’s health system and violated 
‘public administrative morality’. According to the Court, ‘mercantile 
utility and patent ownership’ do not justify ‘disobeying the national 
policy of price control for HIV/AIDS medicines’. Its ruling nonetheless 
called for the continuation of Kaletra on a parallel importation list to 
ensure its availability at the international reference price.
At time of writing, parties on both sides of the case – the health groups 
and Abbott – have appealed the Administrative Court’s judgment to the 
Supreme Administrative Court. In the meantime, in September 2012, 
the Administrative Court declared that the Ministry of Health’s failure 
to adopt the necessary measures to regulate Kaletra’s price represented 
a threat and violation of the rights and interests of public health. The 
Court ordered the Ministry of Health to implement the policies necessary 
to regulate the price of Kaletra and also instructed the Ministry to grant 
more favourable conditions for the financial sustainability of the health 
system – but the compulsory licence was again denied.
Analysis
The correct response of the administration would surely have been 
to act within its duties to protect the interests of the community (in 
accordance with Article 2 of Chapter 1 of Colombia’s Administrative 
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Code) and to oversee compliance with the purposes of the state, which 
in this specific case are directly linked to the right to life and to health. 
The common good, as established in Article 333 of the Constitution of 
Colombia for the exercise of economic activity, is negatively affected 
by expedition of the demanded act (Resolution No. 01444).
Article 3 of Chapter 1 of Colombia’s Administrative Code lays out 
the guiding principles for actions aimed at fulfilling the duties of the 
state, providing that administrative proceedings must be ‘conducted 
according to the principles of economy, speed, efficiency, impartiality, 
publicity and contradiction’. These requirements were not taken into 
account.
The evolution of the price of Kaletra in Colombia, according to the 
data reported in Resolution No. 01444 (MPS, 2009), is outlined next 
(see Table 1.2).
TABLE 1.2 Kaletra (institutional channel) vs generic lopinavir/ritonavir in 2008
US$ per patient per year Total annual expenditure (US$)
Kaletra 3,443 18,629,047
Lopinavir/ritonavir 470 2,551,630
Price difference – 16,077,417
Note: n = 5,429 patients
TABLE 1.3 Kaletra (trade channel) vs generic lopinavir/ritonavir
US$ per patient per year Total annual expenditure (US$)
Kaletra 3,296 17,893,984
Lopinavir/ritonavir 470 2,551,630
Price difference – 15,342,354
Note: n = 5,429 patients
TABLE 1.4 Kaletra with ‘regulated freedom’ sale price vs generic lopinavir/ritonavir
US$ per patient per year Total annual expenditure (US$)
Kaletra 1,000 5,429,000
Lopinavir/ritonavir 470 2,551,630
Price difference – 2,877,370
Note: n = 5,429 patients 
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In 2012, the reference price for Kaletra was $1,000. According 
to official data, sales in 2011 were reported as $11,364,763.38. If it 
had bought lopinavir/ritonavir through the generic drug market, the 
Colombian health system would have saved more than 50 per cent of 
this amount. These figures derive from the data reported in Resolution 
No. 01444.
By refusing to issue a declaration of general public interest in 
access to competitive conditions, the administration subjected the 
general public to the economic interest of a private business party. The 
medication was granted the status of ‘regulated freedom’ and there was 
no reduction in the price of the product, which confirms the state’s 
inefficiency.
In this case, the health authority’s decision to deny the compulsory 
licence also runs contrary to its mandated principles. Urgency of 
state action is required when a situation involves state obligations to 
guarantee the rights of its inhabitants to health, dignity, life, and rights. 
This obligation has been established by Colombia’s Constitution, and 
ratified by Colombia in a series of international treaties related to the 
ICESCR and TRIPS.
On the other hand, the right of petition has not been thoroughly 
fulfilled. The Constitutional Court has established in this regard that:
the essential nucleus of the right of petition resides in the prompt 
and timely resolution of the question, given that the possibility 
to recur to the authority will be useless if said authority does not 
resolve or reserves for itself the decision made … The response 
should comply with the following requirements: 1. Timeliness. 
2. It should be resolved in a manner that is thorough, clear, precise 
and congruent with the request. 3. It should be made known 
to the petitioner. If these requirements are not met, a violation 
is incurred of the fundamental Constitutional right to petition. 
(Corte Constitucional Colombia Exp T-478409 M.P, 1 November 
2001, per Manuel José Cepeda Espinosa)
In accordance with Resolution No. 4966 of 2009, partially amending 
Decree No. 4302, the Colombian state has a maximum of three months 
in which to resolve an application to the Ministry. With this in mind, 
note the response time frame established from 7 April 2008 to 14 May 
2009 (in the official gazette), but notified by electronic mail on 22 May 
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2009 (Figure 1.4). After a significantly longer time than expected, the 
price of Kaletra remains high.
Article 4 of Law No. 972 of 2005, by which standards are adopted 
to improve care for people living with HIV/AIDS, addresses the 
importance of regulating costs in the health system. The rules indicate 
that the government may use mechanisms that guarantee access and 
establish a centralized system for negotiation of medication prices in 
order to reduce costs.
Law No. 972 of 2005 also warns that a drug’s inclusion in the 
CHP does not exonerate the government from the duty to obtain 
reasonable prices. Despite not having the direct duty to pay for 
treatments included in the CHP, the Law affirms that the strong 
financial standing of the health system is an indispensable prerequisite 
for the effective provision of the health service and the fulfilment of a 
fundamental right to health. The government’s decision to deny the 
licence request therefore does not adequately respect Law No. 972, 
which addresses issues related to public policies regarding high-cost 
diseases such as HIV/AIDS.
In conjunction with Decision No. 486 of the Andean Community, 
the Doha Declaration of 2001, the UNGASS on HIV/AIDS, and the 
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1.4 Timeline of the request for a compulsory licence
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between property rights and public, social, and general interests. 
If a medicine costs the Colombian system more than it costs those 
in neighbouring countries, the provisions of TRIPS may be used in 
actions pertaining to the public interest, given that the impact achieved 
would be directly related to the financial optimization of the health 
system. This link between medical provision and the public interest 
must be continuously emphasized.
An example is the India Patents Act 1970, as amended in 2005, 
establishing strict requirements for the determination of inventive 
activity. Patents are not automatically issued for different forms of the 
same molecules, such as salts, esters, or polymorphs. Furthermore, 
case-by-case decisions are made to establish the level of inventive 
activity in an effort to prevent the evergreening of molecules.
In strictly legal terms, the concession of compulsory licences, 
together with patent requirements, is one of the few spheres in which 
state sovereignty remains important in economic matters related to the 
management of IPR (Seuba, 2009).
On the other hand, when a medication is in the CHP, universal 
access for the entire population is understood in principle. But when 
medications in the CHP pertain to the treatment of a high-cost disease, 
as does Kaletra, it may gravely affect the financial stability of a system 
that must guarantee a fundamental right to health. For that reason, 
the same law that guarantees access to a given medication imposes an 
obligation on the executive authority to seek better prices. The law also 
allows the executive to apply the provisions of IPR frameworks to the 
context in question.
The law facilitates state intervention to uphold the concepts of 
reasonability and proportionality in private business enterprises with 
broad public interest. Access to certain goods and services for all 
persons – in particular for those with lower incomes – is an inherent 
implication of this law.
The promotion of local productive capacity in developing countries 
is important. To encourage the use of a technological base to expand 
knowledge, it is important to apply strict standards in the granting of 
a patent; discretion at this stage could obviate the political pressure 
involved in the concession of compulsory licences. The increase in 
number of patents for products that are not truly new inventions affects 
access, especially given the difficulty in applying the compulsory licence 
option in developing countries.
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The administrative action assigned a ‘regulated free market’ regime 
to the medication, resulting in a reduction of the high price set for 
the Colombian market (in comparison to the price set by the same 
company in other countries).
With a compulsory licence, Colombia could import high-quality 
generic forms of lopinavir/ritonavir at low costs; alternatively, the 
national pharmaceutical industry could be stimulated to develop 
the medication and enter the market. Public Citizen, a non-profit 
organization based in Washington, DC, leads the charge against 
undemocratic trade agreements that advance the interests of mega-
corporations at the expense of citizens worldwide. It is an important 
actor in global access to medications and specifically recommends the 
use of open licences.
Public law exists that stipulates certain values, principles, and 
individual/collective rights that may not be left in pure theoretical 
terms. These regulations have been established not only to protect the 
lives of all persons through the provision of essential goods, services, 
and rights, but also to assure compliance with the social duties of the 
state and of private parties.
Unnecessary patents not only block access to medications, but also 
affect the production options of these medications in the developing 
countries. The increase in patents for medicines that are not truly new 
inventions affects access and, despite the existence of the compulsory 
licence option, these licences cannot be obtained or applied in 
developing countries.
Conclusions
Kaletra prices have fallen around 70 per cent in Colombia owing to 
the efforts led by CSOs (such as IFARMA, Mission Health, the Bureau 
of Organizations working on HIV/AIDS, RECOLVIH, Essential 
Action, and Public Citizen) to obtain a compulsory licence for the drug, 
the impact of which is evident in the measures taken by the National 
Commission on Drug Prices and Medical Devices (Comisión Nacional 
de Precios de Medicamentos y Dispositivos Médicos) in Colombia to set 
a reference price (Comisión Nacional de Precios de Medicamentos y 
Dispositivos Médicos, 2009).
The lack of ‘universal access’ in Colombia is a function of the cost 
of antiretroviral medications. A licence will create competition against 
Kaletra by means of the introduction of generics into the market, 
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fostering a drastic and immediate change in the drug price. This effect 
will then be reflected in the total health expenditure.
Colombia has the duty to issue compulsory licences for reasons 
of public interest. In the case of Colombian people living with HIV/
AIDS, irregularities in the delivery of drugs represent one such public 
interest. The effects on individuals’ overall health of these treatment 
disruptions and the high cost of Kaletra are the principal factors that 
triggered this request ultimately to promote competition by allowing 
more companies in the market.
Compulsory licences foster access by creating competition in a 
monopoly market. A compulsory licence would mean potential savings 
somewhere between $5,754,000 and $32,280,834 (taking into account 
data supplied by the Colombian Ministry of Health). However, 
Resolution No. 01444 violated the state’s duties, suggesting that the 
issue is also an administrative problem.
In September 2012, the Administrative Court declared that the 
Ministry of Health’s failure to regulate Kaletra’s price represented a 
threat to, and violation of, public health rights and interests. The Court 
ordered the Ministry to implement the policies necessary to regulate 
the price of Kaletra and to establish more favourable conditions for the 
financial sustainability of the health system – yet a compulsory licence 
was denied.
Nonetheless, the movement has yielded the following achievements:
• the Ministry of Health’s actions have been declared a threat to, and 
violation of, public health rights and interests;
• there has been a reduction of 70 per cent or more in the price in 
Colombia of a key HIV drug;
• parallel imports have been adopted in Colombia;
• a policy of price ceilings has been imposed;
• broad national discussion on price, access to medicines, and patents 
has been instigated; and
• price control laws have been issued, the Court ruling in 2013 setting 
the price at $648 per patient per year.
Even if it is possible to issue a compulsory licence for lopinavir/
ritonavir, applicants will expect the government to use this flexibility in 
the interest of public health.
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2  |  I M P A C T  O F  T H E  W O R L D  T R A D E 
O R G A N I Z A T I O N ’ S  A G R E E M E N T S  O N 
A G R I C U L T U R E  A N D  O N  T R A D E - R E L A T E D 
A S P E C T S  O F  I N T E L L E C T U A L  P R O P E R T Y 
R I G H T S  O N  T H E  H E A L T H  O F  C I T I Z E N S 
I N  T H E  D E V E L O P I N G  W O R L D :  A  P O V E R T Y -
P R O D U C T I O N - B A S E D  C R I T I Q U E
Kwadwo Appiagyei-Atua
Globalization has brought an increased flow of money, goods, 
services, people and ideas. Yet, gaps are widening, both within and 
between countries – in life expectancy, in wealth, and in access to 
life-saving technology. Those left behind, and experiencing poverty 
and ill health, feel disempowered, marginalized and excluded. 
(Pillay, 2008)
Introduction
The World Trade Organization (WTO) was founded in 1995 as 
the authority over global trade governance, superseding the General 
Agreement on Tariffs and Trade (GATT) of 1947 (Crowley, 2003). 
The goal was to create a stable and predictable trading system with fair 
and transparent rules for all participants, with a remit greatly expanded 
from goods to include, for instance, the trade in agricultural products 
and intellectual property (Crowley, 2003). However, despite admirable 
aims on the global stage, the WTO’s policies have caused endemic 
poverty at the individual level.
This kind of poverty is difficult to analyse. The standard model, 
known as the ‘poverty reduction approach’, follows the neoliberal 
economic model of development and considers ‘neutral’ factors (such 
as malnutrition) without identifying responsible actors (Appiagyei-
Atua, 2008), and thus tackles the superficial symptoms of poverty. 
In response to its inadequacy, a new structuralist and contextualist 
model, called the poverty production approach, has been developed. By 
identifying the specific actors and/or policies that create poverty and 
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holding them accountable, it addresses the root causes of poverty. This 
‘actors and actions’ model, which represents a paradigm shift, involves 
identifying the origin, context, and effects of poverty-producing forces, 
as well as ways of counteracting them.
This chapter adopts the poverty production approach to understand-
ing how WTO policies have become root causes of poverty, focusing on 
agriculture and intellectual property (especially pharmaceutical patents). 
It analyses the WTO’s mandate and functions, arguing that fulfilling its 
objectives for agriculture and intellectual property has transformed it into 
a poverty-producing machine acting in contravention of international 
human rights agreements. By considering poverty production a human 
rights issue and focusing on its victims, the chapter concludes with rec-
ommendations not simply for helping the victims out of poverty, but 
also for enabling them to access their rights to health and food, amongst 
other things, and for contributing to development in general.
From the GATT to the WTO
The WTO was established through the Uruguay Round negotiations 
that took place between 1986 and 1994.The Agreements setting up the 
WTO were signed at the Marrakesh ministerial meeting held in April 
1994. Article III of the WTO Agreement outlines the functions of the 
WTO, which includes facilitating the implementation, administration, 
and operation of the WTO Agreement, as well as multilateral trade 
agreements (MTAs) and plurilateral trade agreements (PTAs). The 
WTO is also to provide a forum for negotiations among its members 
concerning their multilateral trade relations. The Organization is also 
empowered to administer the Understanding on Rules and Procedures 
Governing the Settlement of Disputes (Annex 2 to the WTO 
Agreement) and the Trade Policy Review Mechanism (Annex 3). 
Finally, with a view to achieving greater coherence in global economic 
policymaking, the WTO is mandated to ‘cooperate, as appropriate, 
with the International Monetary Fund and with the International 
Bank for Reconstruction and Development and its affiliated agencies’ 
(Article III(5) of the Agreement).
The WTO and poverty production under the Agreement on 
Agriculture (AoA)
The Agreement on Agriculture (AoA) is one of the two main sectoral 
agreements in the Uruguay Round that provides the specific rules 
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regarding the liberalization of agricultural products.1 The AoA was 
created to curb agricultural subsidies and import barriers, including 
non-tariff barriers (inherent in the 1947 GATT), with the goal of 
correcting market distortions in the agricultural sector.
The AoA is defined by three main areas aimed at promoting 
trade liberalization: market access;2 domestic support;3 and export 
competition.4 The long-term objective of the Agreement is to establish 
‘a fair and market-oriented agricultural trading system’ (Preamble, 
paragraph 2), whereby a reform process shall be initiated through 
the negotiation and the establishment of strengthened and more 
operationally effective GATT rules and disciplines. In seeking to achieve 
this goal, paragraph 6 of the Preamble provides that commitments 
made by states parties should aim at promoting equity among them:
having regard to non-trade concerns, including food security and 
the need to protect the environment … and taking into account 
the possible negative effects of the implementation of the reform 
programme on least-developed and net food-importing developing 
countries.
Thus, on the face of it, the WTO, by means of the AoA, could take 
into account and incorporate human rights and environmental concerns 
into its modus operandi. Yet these very objectives have been defeated in 
practice, bringing untold hardships on farmers in developing countries. 
Among the negative consequences occasioned by a rigid application of 
the AoA rules have been environmental degradation, food insecurity, 
land-grabbing, and changes in the cultural lifestyle (particularly the 
eating habits) of local farmers. These consequences have culminated in 
producing poverty and have impacted negatively on the right to health 
of people in developing countries.
The major factors responsible for these developments are the 
application of the concept of ‘comparative advantage’ by that WTO, 
and the incapacity of the AoA to deal with the issue of the export 
subsidies and tariff barriers aimed at liberalizing trade in agriculture 
that are applied by developed countries.
Theory of comparative advantage
An issue plaguing the WTO and which is held responsible for the 
health plight of citizens of developing countries is the application of the 
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principle of comparative advantage on which the WTO thrives as its 
underlying economic model. The principle, in theory, provides that:
[E]ach country should produce what it can do best, and trade 
that good with the products other countries are able to produce 
best. With the profit from exports, countries can buy goods 
that they cannot reasonably produce themselves. This increases 
trade and promotes the economic performance of all Member 
States, which eventually raises the standard of living, and ensures 
full employment and the growth of real income. Following this 
economic theory, all countries participating in the international 
trading system will be better off. (Zagel, 2005: 9)
Yet, in practice, the principle does not work in this way. For example, 
emphasis on the production of cash crops for export has encouraged 
the development of homogenization in agriculture and a substitution of 
poly-cropping with mono-cropping (de Schutter, 2009a: 34).
Protection for plants and species, and their resistance to specific 
diseases, drought, or variations in temperature, is achieved through 
the coexistence of different types of plant with different traits. Poly-
cropping makes this possible. However, the application of monocultural 
production techniques, with the goal of maximizing the production of a 
few crops, has had devastating impacts on environmental sustainability 
and food security, and has ultimately resulted in deepening poverty for 
many developing countries. Mono-cropping has led to loss of crop 
genetic diversity as farmers have abandoned their local varieties for 
genetically uniform varieties that produce higher yields under certain 
conditions (de Schutter, 2009b: 2). The result is an increase in 
outbreaks of pests and disease, the depletion of soil fertility, and the 
exposure of vulnerable crops to weather-related events. Yet reaction 
to these negative environmental consequences has been a massive 
application of harmful agrochemicals, which has often exacerbated 
the problem by destroying the pests’ natural enemies, and by enabling 
pests and pathogens to develop pesticide resistance (Gonzalez, 2004: 
421–2).
The end result has been severe damage to food crops and an increase 
in the vulnerability of the world’s food supply. Another effect is a high 
increase in food prices. Another FAO study, conducted in 2001 on the 
impact of AoA on fourteen developing countries, revealed that the:
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AoA’s liberalization policy significantly increased food importation 
in these countries, with many registering sudden increases in the 
value of their food imports in the years following their accession 
to the AoA. The food import bill more than doubled in countries 
that are significant food producers and exporters such as Brazil 
and India and increased 50–100% in countries like Bangladesh, 
Pakistan and Thailand. In fact, many agricultural exporting 
countries in the 70’s and 80’s [sic] like the Philippines have 
been transformed into net food importers as a result of import 
liberalization under AoA … This has led to displacement of small 
farmers and food-insecure groups, further exacerbating hunger and 
food insecurity among rural households. (Glipo, 2003: 6)
Another negative impact of the WTO policies is changing patterns 
in nutrition and food habits in developing countries. But, more 
dramatically, as noted by Yelpaala (2012: 73), there has been a 
cultural shift that has resulted in the redistribution of the global disease 
burden.
The monopolization of agricultural trade by transnational 
agribusiness also places farmers in developing countries at an enormous 
competitive disadvantage, and threatens to perpetuate poverty and 
hunger (Gonzalez, 2004: 425). The conclusion is obvious: absolute 
poverty has increased in sub-Saharan Africa and relative poverty has 
increased in the majority of countries.
Export subsidies and trade barriers
Developed countries have used subsidies to make their farmers’ 
products cheaper on the world market than those from developing 
countries, resulting in ‘dumping’5 in developing countries. At the same 
time, tariff barriers are placed on goods that farmers in developing 
countries would wish to export to markets in the developed countries. 
Under the AoA, these trade-distorting measures are supposed to be 
eliminated. However, ambiguities and exceptions have dogged the 
process, and these have been exploited by the developed countries to 
maintain tariffs and subsidies. The net effect is that subsidy levels in 
industrialized countries actually went up after the coming into effect 
of the AoA. Gonzalez (2004) puts the figures at $308 billion in 1986–
88 and $318 billion in 2002. In this way, the AoA has legitimized 
and ‘institutionalized the double standard in the agricultural sector: 
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protectionism in wealthy countries; liberalized trade in poor countries’ 
(Gonzalez, 2004: 425). One analysis gives a graphic representation of 
the level of injustice done to farmers of developing countries: according 
to that report, the level of daily subsidy of a cow in Europe and the 
United States is about $2.70, while the daily income of a small and 
marginal farmer in the developing world is less than half of this amount 
(Glipo, 2003: 5).
The solution to this predicament, however, does not simply lie in 
the elimination of agricultural subsidies and reduction of tariffs. The 
impact of such an exercise in reducing the inequities in the global 
trading system would be minimal: not enough to promote food security 
and ecological sustainability in the long term.
The major stumbling block is the monopolization of agricultural 
markets by a few multinational corporations, which are in charge of 
supplying inputs (seeds, pesticides, fertilizers), and those that purchase 
their agricultural output (and which use their market power to dictate 
agricultural commodity prices) (Gonzalez, 2004: 425 ff ). Globalization 
has also affected the distribution of innovative technology in agriculture, 
with seed and food production concentrated in the hands of global 
agrobusiness multinational enterprises (Yelpaala, 2012). Application 
of these measures has resulted in poverty production for many farmers 
from developing countries.
As Olivier de Schutter (2009b: 3), UN Special Rapporteur on the 
right to food, notes:
[T]he top 10 seed companies have 67 percent of the global proprietary 
seed market; the world’s largest seed company alone, Monsanto, accounts 
for 23 percent of that market; and the top three companies (Monsanto, 
DuPont and Syngenta) account for 47 percent of the market, including 
65 percent of the maize seed market and over half of the proprietary 
soybean seed market. This means that these companies reap a 
disproportionate portion of the final value of the crop, and that 
the dependency of farmers on the inputs they provide may not be 
sustainable unless antitrust legislation is not used more proactively 
to tackle such concentration. (Emphasis original)
Poverty and health
According to the United Nations’ Committee on Economic, Social 
and Cultural Rights (CESCR, 2001: para. 7), poverty is ‘usually 
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understood more broadly as the lack of basic capabilities to live in 
dignity. This definition recognizes poverty’s broader features, such 
as hunger, poor education, discrimination, vulnerability and social 
exclusion.’ In support, Amartya Sen (1999: 87) contends that ‘poverty 
must be seen as the deprivation of basic capabilities rather than merely 
a lowness of incomes, which is the standard criterion of identification 
of poverty’.
Poverty comes about through denial of rights, since rights are 
needed to help an individual, or a group of people, to meet their needs, 
to participate in development, and to protect the gains of development. 
Thus, when these rights are respected, protected, and fulfilled, they 
provide the key to moving people out of poverty and making them 
contributors to, instead of victims of, development. It is in agreement 
with this view that the CESCR (2001: para. 1) has noted that ‘poverty 
constitutes a denial of human rights’.
Poverty, in turn, has its negative repercussions on health, as 
confirmed by Muennig and colleagues (2010), who concluded that, 
of all of the health factors measured, poverty had the greatest negative 
impact on health.6 Poverty was determined to take away 8.2 years of 
health, meaning that poor people have 8.2 fewer years in which they 
are healthy than those who live at above 200 per cent of the federal 
poverty level (FPL).7 Globally, there is a stark relationship between 
poverty and poor health: in the least developed countries (LDCs), life 
expectancy is 49 years, and one out of every ten children die before 
their first birthday. In developed countries, on the other hand, the 
average life span is 77 years, while the infant mortality rate is six per 
1,000 live births (WHO and World Bank, 2001: 4). It is in the context 
of this unfortunate phenomenon that Kofi Annan (2001) noted that 
‘[t]he biggest enemy of health in the developing world is poverty’.
Also, the then Organization of African Unity (OAU), in its 1987 
Declaration of Health as Foundation for Development, underlined that 
‘agricultural and other efforts at production (macro or microeconomic) 
are frustrated by the inadequate health status of many populations in 
Africa, the vicious cycle of ignorance, poverty and disease persists 
[and that] poor health is delaying economic “take off”’. Thus, in sum, 
poverty induces health problems. It forces people to live in poor and 
unhealthy environments, with deprived sanitation, indecent housing 
or homelessness, and lack of access to potable water, among others. 
Poverty, in turn, causes hunger, or induces the poor to adopt poor eating 
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habits or unhealthy diets, etc. Poverty also perpetuates or worsens the 
health conditions of the poor, or leads to their early death, because 
of inability to afford health care. Ill-health, in turn, fosters poverty, 
because it disables the weak and sick from engaging in productive 
labour. Moreover, changes in eating habits lead to the development of 
new diseases.
When a poor person becomes ill or injured, the entire household 
can become trapped in a downward spiral of lost income and high 
healthcare costs. The cascading effects may also include diverting time 
from generating an income or from schooling to care for the sick. Illness 
in the family may also force the sale of assets. More prone to disease, 
and with limited access to health care and social insurance, poor people 
are more vulnerable to this downward spiral.8 More than a third – 3.5 
million – of all child deaths annually and 11 per cent of the total disease 
burden worldwide are estimated to be the result of maternal and child 
undernutrition, which are directly related to, or induced by, poverty.
Yet, after causing poverty in many a developing country, the pro-
ducers of poverty and its attendant diseases have placed insurmount-
able obstacles in the way of the poor, the sick, and the marginalized to 
prevent them from accessing affordable medicine and health care as 
a result of the introduction of the 1994 Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS).9
The WTO and poverty production under TRIPS 
During the final stages of the Uruguay Rounds, the United States, 
after it had been lobbied and prodded by the pharmaceutical giants, 
adopted the position that the absence of a strong intellectual property 
rights (IPR) regime in developing countries was a barrier to trade that 
needed to be countered. It was estimated that this cost industrialized 
countries about $200 billion in lost royalties every year. Thus TRIPS 
was introduced, with the goal of harmonizing developing countries’ 
IPR laws with those of the Western world, so as to suit the trading 
interests of multinational corporations – particularly those in the 
pharmaceutical and software sectors. The United States was supported 
by the European Union, Canada, Switzerland, and Japan, among 
others, which played a hegemonic role in the negotiations (Adusei, 
2010; Yelpaala, 2012).
The WTO’s TRIPS establishes patentability for product and 
process inventions in ‘all fields of technology, provided that they are 
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new, involve an inventive step and are capable of industrial application’ 
(TRIPS Article 27(1)). These products and processes are then qualified 
as private property rights under TRIPS (Preamble, paragraph 4). 
Yelpaala (2012: 64) laments that, under this trade regime, a state’s 
right to trade was tied to the protection of intellectual property – that 
is, the public interest of states has been subjugated to the protection of 
foreign private IPR.
However, some flexibilities were introduced to allow for a supposedly 
smooth transition for developing countries and LDCs to regulate their 
local patent laws so that they fall in line with the international standards. 
Developing countries were permitted to delay the application of most 
provisions of TRIPS for five years following its entry into force – that is, 
until 1 January 2000 (TRIPS Article 65(2) and (3)). Least developed 
countries, on the other hand, were given to 1 January 2006 (TRIPS 
Article 66(1)).
In spite of this, Adusei (2010: 62) argues that:
[T]he grant of product patents gives the owner exclusive rights 
over the composition of the drug itself regardless of how it is 
produced, and the process patents give the owner exclusive rights 
over the scientific method of producing the drug. Further, the 
enjoyment of patent rights is without discrimination as to whether 
the products are imported or manufactured locally. Moreover, 
TRIPS requires each signatory country to provide an effective 
enforcement mechanism for patents. To cap it all, the grant of 
patents is backed by a dispute settlement mechanism that can hold 
states liable for any infringement.
Under this arrangement, the end-users of drugs patented and 
manufactured by the big pharmaceutical companies are forced to pay 
expensive prices, and governments eventually become ‘toll collectors’ 
for these companies, while their citizens remain impoverished and 
die from diseases such as HIV/AIDS, malaria, and tuberculosis 
(Adusei, 2010; Bhagwati, 2004). Thus, for example, absent patent 
protection, in India, 150 mg of the anti-fungal drug flucanozole (used 
in HIV patients to prevent or treat fungal infections) costs $55 – yet 
in countries such as the Philippines and Indonesia, where the same 
drug is patented, it costs $697 and $703, respectively (Sykes, 2002). 
Thus, when the European Union drafted a free trade agreement 
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(FTA) with India, UN Special Rapporteur on the right to health, Mr 
Anand Grover, had cause to warn that the draft FTA ‘could prevent 
millions of people from gaining access to necessary, life-saving and 
life-prolonging medicines’, owing to the fact that India is currently 
the largest supplier of generic medicines to the developing world 
(PTI, 2010).
In 2003, the World Health Organization (WHO) declared poor 
access to antiretroviral medicines an international health emergency. 
The Organization spearheaded an initiative with the so-called three by 
five target: provision of treatment to 3 million people in poor countries 
by the end of 2005 (WHO and UNAIDS, 2006). Around the same 
time, the Clinton Foundation brokered agreements with ‘big pharma’, 
as well as some leading medical technology companies, to launch 
two major price-reduction agreements. The agreements resulted in 
the reduction of the costs of testing for and treating HIV/AIDS from 
$3,600 to around $250 per patient per year in poor countries (Schoofs, 
2003). Although the goal of 3 million people – out of an estimated 
need for therapy among 9.7 million people – was not reached until 
the end of 2007, ‘three by five’ played an important role in catalysing 
concerted action to expand treatment access in poor countries. There 
are therefore important lessons to be learned from this experience.10
Attempts by countries such as South Africa, Brazil, and India to 
counter TRIPS resulted in legal action, or the threat of legal action, 
or sanctions against them. For example, following the enactment of 
the Medicines and Related Substances Control Act of 1997 by South 
Africa, a number of pharmaceutical companies initiated legal action 
against the country (Nash, 2000).
When the ‘grace period’ for developing countries and LDCs under 
TRIPS was near exhausted, the reality began to sink in: that they had 
made a bad deal under TRIPS. Consequently, some intellectual efforts 
have been exerted in an attempt to resolve the inequities inherent 
in TRIPS (Correa, 2002). However, in the view of Yelpaala (2012: 
67–68), this goes not go deep enough: ‘These studies are mostly concerned 
with content and textualism rather than structure and contextualism. 
Little attention is devoted to the structural and systemic problems 
which seem to be foundational in the problems posed by TRIPS.’
This suggested ‘contextualist’ and ‘structuralist’ approach is 
worth analysing in considering the imbalances inherent in TRIPS 
and as identified by the UN Conference on Trade and Development 
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(UNCTAD), which notes, for example, that an overwhelming 84 
per cent of the patents in developing countries are owned by mainly 
multinational corporations of five developed market economies, as 
opposed to less than 1 per cent by nationals of developing countries 
(DESA/UNCTAD/WIPO, 1974; Oddi, 1987).
Apart from the intellectual effort, some political pressure has also 
been brought to bear on the WTO’s Council for TRIPS to change the 
rules to suit the interests of developing countries. Some fifty developing 
countries from Africa, Asia, Latin America, and the Caribbean put 
forward a joint statement to the Council, in anticipation of the Doha 
Ministerial Conference, asking it to take steps to ensure that ‘the 
TRIPS Agreement does not in any way undermine the legitimate right 
of WTO Members to formulate their own public health policies and 
implement them by adopting measures to protect public health’ (Oh, 
2001).
The Doha Conference recognized the severity and reality of the 
public health problems within the developing countries. However, in 
its 2001 Declaration, it sought only to provide solutions within the 
flexibilities inherent in TRIPS, as long as their use was consistent 
with that agreement. Neither did the 2001 Doha Declaration resolve 
the issue of the right of developing countries lacking the capacity to 
manufacture generic drugs to grant a compulsory licence to others to 
do same for them. The ministers deferred resolution on this matter to 
a later date.
Post-TRIPS
Thus, in the post-TRIPS era,11 it has seemed as though the attempts 
made to respond to the concerns of developing countries – particularly 
by organizations such as WHO, UNCTAD, the United Nations 
Development Programme (UNDP), and the World Intellectual 
Property Organization (WIPO) – have been but piecemeal (Adusei, 
2010). For example, the resolutions passed by these organizations to 
support developing countries are not binding on WTO. In the end, 
patent regulatory and institutional lapses still persist in sub-Saharan 
Africa in particular (Adusei, 2010).
What is worse, the ‘TRIPS-plus’ obligations that developing 
countries in general have had to assume through bilateral and regional 
agreements made with developed countries are even more onerous than 
those to which they bound themselves under TRIPS proper (Adusei, 
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2010). Such relatively high IPR standards limit the fragile flexibilities 
provided under TRIPS and the Doha Declaration, as well as the terms 
of trade of sub-Saharan African countries as primary consumers of 
pharmaceutical products and processes. It is therefore contended that 
such TRIPS-plus agreements violate the spirit of TRIPS (UNCTAD/
ICTSD, 2005).
Relationship between rights and trade: How the WTO got 
it wrong
The Uruguay Round negotiations took place amidst an ambience 
of growing recognition in the international community of a linkage 
between rights and development, largely influenced by the sustainable 
development movement after the two concepts (human rights and 
development) had gone their separate ways, even being seen as being 
inimical to one another other (Ksentini, 1994).
The International Monetary Fund (IMF) and World Bank followed 
this pattern. At their inception, although supposed to be guided by 
human rights issues, both asserted themselves as strictly economic-
focused institutions, the mandates of which did not extend to 
incorporating human rights and environmental concerns into their 
activities and projects. As noted by Peter Uvin (2002: 1), they ‘did not 
consider human rights issues as part of their professional domain: they 
neither weighed the implications of their own work on human rights 
outcomes, nor sought explicitly to affect human rights through their 
work’, which tendency continued until well into the 1990s. The IMF 
and World Bank may be excused for the initial position that they held, 
considering the historical context into which they were born.
Within the UN system, however, one may point to the various 
development debates in which the United Nations recognized the limited 
place given to human rights. In the late 1980s and into the 1990s, the 
intellectual and operational gap between rights and development began 
to narrow and ultimately merge. Reference can be made to the work 
of Amartya Sen (1999), Martha Nussbaum (1999) of the feminist/
gender school of the time – particularly the gender and development 
(GAD) movement – and others, who all focused on the need to 
empower human beings through respect for their rights to enable them 
to contribute more effectively to development. The UNDP, among 
other UN agencies, introduced its Human Development Reports to 
highlight the need to promote human development as the basis for 
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attaining economic development. In its 1996 report, it categorized 
various aspects of growth that, in its observation, were unsustainable. 
Touching on ‘voiceless growth’, for example, the report defined it as a 
type of growth:
in which growth in the economy has not been accompanied by 
an extension of democracy or empowerment. Political repression 
and authoritarian controls have silenced alternative voices and 
stifled demands for greater social and economic participation. 
Policy makers once debated whether they should choose economic 
growth or extensive participation, assuming that these were 
mutually exclusive. That debate is dead. People do not want one 
or the other – they want both. But too many people are still denied 
even the most basic forms of democracy, and many of the world’s 
people are in the grip of repressive regimes. Voiceless growth 
can also be growth that gives women only a minor role in an 
economy’s management and direction. As Human Development 
Report 1995 showed, human development, if not engendered, is 
endangered. (UNDP, 1996: 2–3)
Thus the Uruguay Rounds presented a perfect opportunity for 
states to allow such developments to influence the negations and the 
agreements that ultimately emerged out of them. Yet the WTO rather 
preferred to stick to the ‘watertight compartment’ position originally 
adopted by the IMF and the World Bank: that it is a trade, not a 
human rights, organization and therefore not the appropriate forum 
for addressing human rights concerns (CESCR, 2004: para. 20). The 
rationale for this position, although weak, lame, and unsustainable, has 
yet not been critically challenged from a human rights and international 
law perspective. The result has been flagrant violation of the rights of 
citizens in developing countries as the WTO seeks to implement most 
of its agreements.
The subsequent impact of TRIPS and TRIP-plus on the rights of the 
victims is well captured by bodies such as the former Sub-Commission 
on the Promotion and Protection of Human Rights (2000: para. 6), 
which noted the ‘apparent conflicts between the intellectual property 
rights regime embodied in the TRIPS Agreement, on the one hand, and 
international human rights law, on the other’. Yet the WTO is under 
international obligation not to drag the world back into the 1950s, for 
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we now live in an era of human rights consciousness and human rights 
are supposed to be mainstreamed into every aspect of human lives, 
including trade (Bobbio, 1996; Epp, 1998).
Not only are the terms of the WTO agreement not human-rights-
friendly, but they are fundamentally opposed to certain rights of citizens 
in developing countries, including the right to work, the right to life, 
the right to food, the right to water, the right to a healthy environment, 
and the fundamental right of a state to trade, all of which culminate in 
an impact on the right to health. These rights and others have a ‘direct 
and immediate bearing upon the eradication of poverty’ (CESCR, 
2001: para. 1). It is apparent that the WTO violates rights in three 
principal ways:
• by disallowing its own introduction of rules linking human rights to 
development;
• by imposing the same limitation on member states; and
• by directly violating certain rights, including those noted above and 
elsewhere in this chapter – particularly the right to health.
Right to health
Article 12(1) of the International Covenant on Economic, Social 
and Cultural Rights (ICESCR) explicitly recognises ‘the right of 
everyone to the enjoyment of the highest attainable standard of physical 
and mental health’. The right to health is considered to be one of the 
fundamental rights that links with almost every other right, including 
those elaborated earlier. In its General Comment on the right to 
health, the CESCR (2000: para. 1) noted the all-encompassing nature 
of this right, confirming that ‘[h]ealth is a fundamental human right 
indispensable for the exercise of other human rights’ and that ‘[e]very 
human being is entitled to the enjoyment of the highest attainable 
standard of health conducive to living a life in dignity’.
The Committee interpreted the right to health as an inclusive right 
extending not only to timely and appropriate health care, but also to the 
underlying determinants of health, such as access to safe and potable 
water, and to adequate sanitation, an adequate supply of safe food, 
nutrition, and housing, and healthy occupational and environmental 
conditions (CESCR, 2000: para. 11). In this way, the Committee 
confirms the insidious role of poverty in denying people access to such 
determinants and ultimately impacting on their health.
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In this regard, it is pertinent to refer to the Committee’s General 
Comment on the right to food to properly situate the role and place of 
food in the equation:
[T]he right to adequate food is indivisibly linked to the inherent 
dignity of the human person and is indispensable for the fulfilment 
of other human rights enshrined in the International Bill of 
Human Rights. It is also inseparable from social justice, requiring 
the adoption of appropriate economic, environmental and social 
policies, at both the national and international levels, oriented to 
the eradication of poverty and the fulfilment of all human rights for 
all. (CESCR, 1999: para. 4)
Furthermore, the Committee noted in its General Comment on the 
right to health (CESCR, 2000: para. 39) that:
To comply with their international obligations in relation to 
article 12, States parties have to respect the enjoyment of the 
right to health in other countries, and to prevent third parties 
from violating the right in other countries, if they are able to 
influence these third parties by way of legal or political means, in 
accordance with the Charter of the United Nations and applicable 
international law.
Further, the General Comment provides that:
States parties should ensure that the right to health is given due 
attention in international agreements and, to that end, should 
consider the development of further legal instruments. In relation 
to the conclusion of other international agreements, States parties 
should take steps to ensure that these instruments do not adversely 
impact upon the right to health. (CESCR, 2000: para. 39)
In this respect, when drafting, adopting, and signing treaties such 
as the WTO Agreement itself, and related ones such as the AoA and 
TRIPS, the obligation of international actors to ensure that these treaties 
are in conformity with the ICESCR should be taken into account and 
respected. Yet the opposite is the case in a number of instances.
More directly, the Committee notes:
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[C]oordinated efforts for the realization of the right to health 
should be maintained to enhance the interaction among all the 
actors concerned, including the various components of civil 
society. In conformity with articles 22 and 23 of the Covenant, 
WHO, The International Labour Organization, the United 
Nations Development Programme, UNICEF [the United Nations 
Children’s Fund], the United Nations Population Fund, the World 
Bank, regional development banks, the International Monetary 
Fund, the World Trade Organization and other relevant bodies 
within the United Nations system, should cooperate effectively 
with States parties, building on their respective expertise, in 
relation to the implementation of the right to health at the national 
level, with due respect to their individual mandates … The 
adoption of a human rights-based approach by United Nations 
specialized agencies, programmes and bodies will greatly facilitate 
implementation of the right to health. (CESCR, 2000: para. 39)
This segment of the General Comment on the right to health firmly 
indicts the WTO and requires it to align its activities and practices with 
international law, affirming that the Agreement establishing the WTO 
– the raison d’être of improving trade – is not an end in itself; rather, 
the aim of improvement in trade should be to serve the goal of human 
development. Inherent in these objectives is the requirement that the 
WTO applies human rights principles, or at least establishes the proper 
relationship between human rights and trade. Among some key rights 
that can be inferred from the Preamble to the WTO Agreement are 
the right to food, right to health, right to work, right to development, 
and right to a healthy environment. Also, for example, paragraph 1 of 
the Preamble notes that, in performing its functions, the WTO should 
focus trade and economic relations on, among other things:
raising standards of living, ensuring full employment and a large and 
steadily growing volume of real income and effective demand, and 
expanding the production of, and trade in, goods and services, 
while allowing for the optimal use of the world’s resources in accordance 
with the objective of sustainable development, seeking both to protect and 
preserve the environment. (Emphasis added)
The WTO therefore cannot dissociate itself from applying human 
rights principles in seeking to promote world trade.
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In this way, then, the WTO can be seen to be violating international 
law by producing poverty, and thereby violating the ‘right to not be 
poor’ of sick people, farmers, etc., which can be inferred from the 
various international human rights instruments – in particular, the 
International Bill of Rights.12
The WTO and the environment
Another contention is that sustainable development is also reflected 
in the Preamble to the WTO Agreement (although this has not impacted 
much on the operations of the WTO), which came into force about 
six months after the 1992 UN Convention on Biological Diversity 
(CBD).13 Incidentally, the WTO has provisions that seek to trump the 
CBD so that a country that adopts policies to protect the environment 
in good faith may end up violating TRIPS. This is because, among 
other things, TRIPS is intended to grant private property rights over 
products and processes in order to provide monopoly control to those 
who claim to have ‘invented’ new plants, animals, or micro-organisms, 
or uses thereof (GAIA and GRAIN, 1999). Further to this, it is 
estimated that, each year, up to 30 million hectares of farmland are 
lost to environmental degradation, conversion to industrial use, and 
urbanization, partly or largely attributed to implementation of the 
AoA (OHCHR, 2010). Yet sustainable development and protection 
and preservation of the environment are also considered cornerstone 
policies of the UN Charter, as reflected, for example, in the CBD.
The CBD, among other things, affirms the sovereign rights of a 
country over its natural resources as a way of strengthening its capacity 
to conserve and use biological diversity on a long-term basis. Article 3 
of the Convention stipulates that:
States have, in accordance with the Charter of the United Nations 
and the principles of international law, the sovereign right to 
exploit their own resources pursuant to their own environmental 
policies, and the responsibility to ensure that activities within their 
jurisdiction or control do not cause damage to the environment of 
other States or of areas beyond the limits of national jurisdiction.
Also, paragraph 20 of the Preamble to the CBD provides that the 
conservation and sustainable use of biological diversity are of critical 
importance for meeting the food, health, and other needs of the growing 
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world population, for which purpose access to, and sharing of, both 
genetic resources and technologies are essential.
Yet these noble attempts to protect the biological diversity of the 
world are being challenged by TRIPS, which seeks to take away the 
sovereign rights of states over their natural resources, and convert them 
into private rights for individuals and corporations.
How, then, can this be seen as aligning with Article 22 of the CBD, 
which stipulates that, where the exercise of rights and obligations 
provided for in any existing international agreement ‘would cause a 
serious damage or threat to biological diversity’, those rights and 
obligations shall not be affected? This Article provides strong grounds 
to question and invalidate portions of TRIPS and the AoA, because 
there is ample evidence to show the devastating and irreparable 
harm that these agreements are causing to biodiversity, in developing 
countries in particular.
The WTO and the United Nations
Although the WTO is not a UN agency, its Agreement establishes 
some links with the United Nations. Parallels can be seen, for 
example, between the phrase ‘raising standards of living, ensuring full 
employment and a large and steadily growing volume of real income and 
effective demand’ (emphasis added), which appears in paragraph 1 of 
the Preamble to the WTO Agreement, and the Preamble to the UN 
Charter, in which the United Nations expresses its determination:
to establish conditions under which justice and respect for the 
obligations arising from treaties and other sources of international 
law can be maintained, and to promote social progress and better 
standards of life in larger freedom, and for these ends to employ 
international machinery for the promotion of the economic and 
social advancement of all peoples.
More directly, the phrase in the WTO Preamble mirrors Article 
55(a) of the UN Charter, which makes reference to the fact that 
‘the United Nations shall promote higher standards of living, full 
employment, and conditions of economic and social progress and develop-
ment’ (emphasis added). This can be interpreted as meaning that 
the WTO rules are subordinate to the principles of the UN Charter 
(FIDH, 1999).
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In fact, Article 103 of the latter explicitly states that: ‘In the event 
of a conflict between the obligations of the Members of the United 
Nations under the present Charter and their obligations under any 
other international agreement, their obligations under the present 
Charter shall prevail.’ Furthermore, under the UN Global Compact, 
its specialized agencies and other worldwide intergovernmental 
organizations, such as the WTO, agree to integrate universally 
recognized human rights into their law and practice (Weiler, 2001; 
Yelpaala, 2004).
The WTO and international law: The contradictions
It can be argued that the treacherous process through which the WTO 
came into being provides a basis for its invalidation under the Vienna 
Convention on the Law of Treaties (VCLT).14 As noted by several 
scholars and writers, the WTO Agreement and TRIPS, in particular, 
were drafted under coercive and repressive conditions dictated by the 
United States and other Western countries. Gathii (2002: 294), for 
example, writes that, ‘[d]uring the Uruguay Round, the United States 
unilaterally pressured developing countries opposed to its negotiating 
position, such as Brazil, Thailand, and India. Therefore, the Agreement 
was negotiated “within a coercive bargaining context”’.
Adusei (2010: 60) also notes that:
First, there are glimpses of coercion by the West to procure the 
consent of less developed countries to cede their autonomy on 
IP matters. This coercion is evidenced by threats of retaliatory 
sanctions under the US Trade Act and a possible forfeiture of 
GATT/WTO status … In addition, developed countries used their 
superior bargaining power to ensure compliance by less developed 
countries.
Consider, then, Article 9 VCLT, which provides that ‘the adoption 
of the text of a treaty takes place by the consent of all the States 
participating in its drawing up except as provided in paragraph 2’. 
Thus consent is crucial to ensuring the recognition of a state as a party 
to a treaty. Where this consent is lacking, the treaty will be deemed to 
be invalid, as expressed in Article 51: ‘[T]he expression of a State’s 
consent to be bound by a treaty which has been procured by the 
coercion of its representative through acts or threats directed against 
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him shall be without any legal effect.’ Furthermore, Article 52 VCLT 
stipulates that ‘a treaty is void if its conclusion has been procured by 
the threat or use of force in violation of the principles of international 
law embodied in the Charter of the United Nations’. Moreover, the 
actions of the United States and its allies also violate Article 2(4) of 
the UN Charter, which provides that: ‘All Members shall refrain in 
their international relations from the threat or use of force against the 
territorial integrity or political independence of any state, or in any 
other manner inconsistent with the Purposes of the United Nations.’
It is also noteworthy that the WTO’s Uruguay Round of 
negotiations did not meaningfully involve countries from sub-Saharan 
Africa. What is worse, those few that participated were constrained 
by insufficient access to information that was freely available to 
Western negotiators (Gervais, 2007: 10). In addition, it has been 
argued that the LDCs were ignorant of the extensive nature of the 
obligations that they adopted (Yu, 2006: 375). The result, according 
to Adusei (2010), is that LDCs embraced high Western standards 
of IPR protection as part of their domestic laws without a proper 
appreciation of the ramifications of such acceptance. Had there been 
no coercion, marginalization, lack of information, etc., developing 
countries would not have raised so strong a voice to argue against 
TRIPS and ask for changes.
These phenomena also offend the VCLT and provide a solid basis 
on which to invalidate a treaty, because they may be interpreted as 
constituting fraud or error. Article 49 VCLT states that ‘if a State has 
been induced to conclude a treaty by the fraudulent conduct of another 
negotiating State, the State may invoke the fraud as invalidating its 
consent to be bound by the treaty’. Furthermore, Article 48 provides 
that:
[A] State may invoke an error in a treaty as invalidating its consent 
to be bound by the treaty if the error relates to a fact or situation 
which was assumed by that State to exist at the time when the 
treaty was concluded and formed an essential basis of its consent 
to be bound by the treaty.
Conclusion and recommendations
This chapter has examined the manner in which goods are produced, 
trade is regulated, and wealth is distributed under the WTO, the 
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successor to the GATT, and how this impacts on poverty and the 
health of citizens of the developing world.
It has revealed that WTO policies have engendered large-scale 
poverty and relegated millions to the fringes of society, fighting for 
survival in insanitary conditions, bereft of food and access to potable 
water. What is worse, changes in eating habits occasioned by AoA 
conditionalities have led to the development of new diseases. Yet the 
producers of poverty and its attendant diseases have placed insur-
mountable obstacles in the way of the access of the poor and the sick 
to affordable medicine and health care by means of the introduction of 
TRIPS. The TRIPS Council, for instance, has usurped the functions 
of some international organizations such as WIPO originally invested 
with the mandate controlling intellectual property in a manner that will 
evenly benefit citizens of the developing and developed worlds.
At the same time, the WTO has adopted a watertight compartment 
policy that sidelines human rights from its operations and activities, 
claiming that they lead to trade distortions and that the organization 
itself is not a human rights, but a trade-oriented, body. Consequently, 
the WTO has acted in violation of the UN Charter, the Vienna VCLT, 
the CBD, and the other major human rights treaties.
The very rights that are violated hold the key to turning around the 
fate of the millions who have been condemned to poverty, ill-health 
and indignity, and marginalization. To end these violations, rights 
should be used as a tool of empowerment to turn victims of poverty into 
actors who should fully participate in ending poverty and contributing 
to development at large, by recognizing their right to health and food, 
among other things. The goal is not simply to help the victims out 
of poverty, but also to enable them to contribute to development. 
Therefore globalization needs to be reoriented towards human rights, 
rule of law, and sustainable development – and away from the financial 
enrichment of a few.
Notes
1 The other is the Agreement on 
Textiles.
2 See AoA, Pt III, Arts 4 and 5. This 
covers the process of ‘tariffication’, 
which involves the elimination of 
non-tariff barriers, such as import 
bans, import quotas, or quantitative 
restrictions on imports, and their 
conversion into tariffs.
3 AoA, Pt IV, Arts 6 and 7, deal with 
government support to farmers, to 
identify those mechanisms that result in 
trade distortion and how these can be 
eliminated.
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4 AoA, Pt V, Arts 8–11, touch on the 
elimination of export subsidies to avoid 
trade distortion.
5 ‘Dumping’ is the importation of 
a product at an export price below its 
‘normal value’ (that is, usually the price 
of the product in the domestic market 
of the exporting country), which imports 
cause injury to a domestic industry in the 
territory of an importing contracting party. 
See, e.g., Art. VI of the WTO Agreement.
6 The other factors at which they 
looked included smoking, obesity, lack of 
health insurance, and binge drinking, all 
of which had a less significant impact on 
health outcomes than living in poverty.
7 This is a standard measure of health 
burden, used by the WHO.
8 Derived from comments provided 
by Dr Gijs Walraven during workshop 
proceedings in Delhi, India.
9 Annex 1C of the Marrakesh 
Agreement Establishing the World Trade 
Organization, signed in Marrakesh, 
Morocco, on 15 April 1994.
10 Information originally derived 
from comments made by Dr Walraven 
during the Delhi workshop.
11 This represents the fourth juridical 
phase in the attempt to internationalize 
patent rules.
12 See, e.g., ICESR Art. 11 and Art. 25 
of the Universal Declaration of Human 
Rights (UDHR).
13 The Convention was opened 
for signature on 5 June 1992 at the 
UN Conference on Environment and 
Development in Rio de Janeiro, Brazil, 
and came into force on 29 December 
1993.
14 Adopted on 22 May 1969 and 
entered into force on 27 January 1980.
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Germán Velásquez1
Introduction
Journalists are frequently criticized for the sensationalist reporting 
of natural disasters or epidemic outbreaks. Surprisingly, the public 
discussion of the 2009 pandemic of swine flu, influenza A(H1N1),2 was 
characterized by responsible coverage in media outlets, but melodramatic 
statements from international organizations and national health 
ministries. Especially in the aftermath of the inappropriate response of the 
World Health Organization (WHO), journalists asked questions that the 
experts could not answer: was there ever a high risk of a pandemic, and if 
so, of what magnitude? Could it be possible that billions of dollars were 
wasted on a drug that had not been proven effective against A(H1N1) 
owing to a series of escalating mistakes, or were WHO’s actions part 
of a calculated financial scheme? Five years later, those journalists’ 
concerns have been vindicated by means of independent evaluations by 
entities including the European Council (Cassel, 2010) and the French 
Parliament (Assemblée Nationale, 2010).
The story begins in 2000, when the company Roche considered 
withdrawing the antiretroviral oseltamivir INN (marketed as Tamiflu) 
from the market because of low sales. When bird flu, influenza A(H5N1), 
broke out in 2005, developed countries amassed vast stocks at WHO’s 
recommendation. Because of the scale of the overestimate – it caused 
300 deaths, not 150 million – there seems to have been an incentive for 
WHO to cover its tracks. Although oseltamivir had not yet undergone 
human trials for A(H1N1) in 2009, hundreds of millions more doses 
were purchased at the urging of WHO advisers, some of whom stood to 
benefit financially from the hundreds of billions of dollars of sales.
The mishandling of the response to A(H1N1) has been disastrous 
for WHO, and the discrepancy between the quantity and shelf life of 
the pharmaceuticals acquired by developed and developing nations is 
representative of the way in which developing countries are penalized 
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in regards to access to antiretrovirals. This chapter explores how 
oseltamivir was transformed from an unpopular drug to one that came 
to represent international corruption, flawed and potentially dangerous 
public health policies, and wasteful spending. It then analyses the 
motivations of decision makers at the international, national, and 
corporate levels, and concludes by exploring the lasting ramifications 
of the response to A(H5N1) and A(H1N1).
Stockpiling oseltamivir: The case of A(H5N1)
In the case of avian influenza H5N1, when the threat arose in 2005, 
there was stockpiling of the medicine oseltamivir, which had unproven 
effectiveness for an illness that had not even yet propagated. This decision 
was unprecedented in the history of medicine. These medicines were to 
be kept in stock for about 20–50 per cent of the population in several 
developed countries, including Canada, the United States, Japan, the 
United Kingdom, and France (see Table 3.1). However, given that 
oseltamivir’s shelf life is only between five and seven years, these stocks 
have most likely already been destroyed at the time of writing.
If we look at the history of public health through the twentieth 
century, we will see that there have been hundreds of variants of 
influenza viruses. Apart from A(H1N1), which is of swine origin, how 
many have actually caused human infections? The answer is: only 
four. During the height of the threat of the avian influenza, A(H5N1), 
leading scientists informed the media that the virus was highly 
pathogenic. In August 2005, the chief of cabinet of the WHO Director 
General’s office announced in a press release that 150 million people in 
the world could die as a result of this possible pandemic. In October of 
the same year, only two months later, WHO said that the number was 
more likely to be roughly 20 million people. In January 2006, it was 
announced that it could be approximately between 2 million and 7.4 
million (Dawn, 2001). In October 2010, WHO reported a total of just 
331 deaths (over the course of nine years), with most concentrated in 
Indonesia and Vietnam (WHO GIP, 2011).3 Most common illnesses 
have a higher mortality rate than that of A(H5N1).
With such a disparity in expected and observed outcomes, it must be 
asked how the original estimates for number of deaths were calculated. 
When WHO predicted that between 2 million and 7.4 million people 
would die, the answer that epidemiologists presented was that this 
calculation was made based on historical experience (WHO, 2005a). 
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According to the recorded historical experiences, we can see that, in the 
Spanish flu (H1N1) epidemic of 1918–20, approximately 40 million 
people had died globally. For the Asian flu of 1957–58, 2 million 
people had died. During the more recent outbreak of Hong Kong flu 
H3N2 in 1968–69, 1 million people had died. The basis of the WHO 
mortality estimate for the H5N1 strain of 2–7.4 million people, given 
the historical figures, is still unclear.
The drug oseltamivir (registered as Tamiflu) was developed by 
the American company Gilead Sciences,4 which gave an exclusive 
licence to Swiss company Roche in 1996 for the period of validity of 
TABLE 3.1 Comparison of international oseltamivir/zanamavir stockpiling trends, 2008
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the patent (that is, twenty years).5 In 2000, several years before the 
threat of pandemic, Roche considered the possibility of withdrawing 
this medicine from the market on the grounds of its low sales volumes 
worldwide. The threat of the financial losses from oseltamivir have 
therefore been considered by many to be the driving force behind the 
creation of what may have been a faux pandemic. In general terms, 
oseltamivir is effectively a more sophisticated version of aspirin, serving 
solely to attack flu-like symptoms and to diminish them.
On 27 October 1999, the US Food and Drug Administration (FDA) 
issued the first approval of the treatment for type A and B influenza 
without any complications.
On 20 November 2000, the FDA extended the prophylaxis 
indications, precisely one year after talks began about the possible 
epidemic and pandemic risk of avian influenza. However, the question 
was: how could the indications be extended without any opportunity of 
carrying out clinical trials to test whether this medicine could prevent 
the infection and spread of the disease?
In 2004, WHO recommended the stockpiling of oseltamivir (WHO, 
2004). In France, for example, a stock for 50 per cent of the population 
was made: a situation that had never before been seen in relation to 
other diseases. Stockpiling also occurred in many developing countries 
following WHO recommendations.
Unfortunately, the oseltamivir stockpiling especially penalized 
developing countries. Developed countries received a large supply of 
raw materials that have a shelf life of ten or fifteen years more than 
the finished product, which has only five years of validity. Most of the 
developing countries received that finished product, which five-year life 
span, in good storing conditions, could be extended by a maximum of 
one or two years. Thus developing nations were to have a much shorter 
window of protection from a possible pandemic than developed nations, 
which could utilize the raw materials to produce effective drugs.
On the constitution of a stock (stockpiling), the US Center for 
Disease Control and Prevention (CDC) in Atlanta, GA, published 
a study suggesting that, despite the steep initial outlay, governments 
would save money by stockpiling the antiviral drug oseltamivir as a 
hedge against a future influenza pandemic (Balicer et al., 2005).
The study, based on mathematical modelling, argued that since there 
was a flu pandemic at least once every eighty years, governments could 
save more than US$3.50 for every $1 that they invested in the drug.
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In August 2005, WHO announced that it had received 3 million 
doses of oseltamivir from Roche in order to constitute a stock, and the 
recommendation of establishing stocks later appeared in the form of a 
WHO manual and guide (WHO, 2005b).
Yet it appears that Roche may have been involved in a commercial 
strategy more than a public health intervention. After Roche supplied 
the 3 million doses, the WHO director general was thankful for the 
donation, implying that it had started the stockpiling purely out of public 
health necessity (WHO, 2005b). The next morning, at a meeting of the 
ministries of health of the member states of the European Union, the 
importance of having a stock was ratified,6 following WHO’s example.
In this context, a lot of questions emerge: why have a stock of 
oseltamivir instead of a stock for antiretroviral drugs? Why not 
prepare the world for HIV/AIDS in the same way as for pandemic 
influenza A (H1N1)? Why and how was the efficacy of existing drugs 
announced before knowing the results of human clinical trials? Clearly, 
there was no time for developing those clinical trials and the drugs 
were distributed without a clear indication of their safety or efficacy. 
When the stockpiling started, there was very little reference to possible 
resistance; today, there would have been serious resistance (Baz et 
al., 2009). All of these questions indicate that this medicine should 
not have been massively distributed as it was (Moscana, 2009). No 
reference was made by national or international health authorities to 
these problems or the implications of resistance in a case of massive 
use.
In Japan, there had even been several cases of suicide among young 
people aged 14–25 who were under treatment with oseltamivir: side 
effects that were known at the time of mass distribution, but were not 
well publicized.7
The FDA, WHO, and Roche made various comments after 
stockpiling had occurred. The FDA clearly affirmed that it did not 
consider any aspect related to preparedness in relation to avian 
pandemic or A(H1N1) (US FDA, 2014).
On the other hand, WHO asserted that ‘evidence suggests that 
some antiviral drugs, notably Oseltamivir, can reduce the duration 
of viral replication and improve prospects of survival’ (WHO, 2014). 
Several WHO documents even referred to oseltamivir as the one and 
only effective medicine against the possible avian pandemic. Yet this 
fervent support of oseltamivir is dubious, given that most authorities 
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would argue that there are other medicines, such as zanamivir, as well 
as cheaper alternative such as alcohol-based solutions and masks, 
which could also be effective. The WHO statement itself was also 
somewhat premature given that transmission among humans had not 
yet developed. It was known that there was some effectiveness of the 
medicine in common seasonal flu, but for this new type of influenza, 
although there was some sensitivity in the in vitro experience, medical 
trials had not yet been carried out.
Nevertheless, Roche’s website called the medicine ‘one of the most 
important medicines currently available to fight both seasonal and 
pandemic influenza’ (Roche, 2007).
New pandemic, old response: Looking at A(H1N1)
The estimated number of deaths attributable to common seasonal 
flu every year is approximately 500,000 cases per year (Laporte, 2009). 
Reports cited 18,449 deaths as being caused by A(H1N1) (WHO, 
2010). As reported by the media and scientific literature, the most 
serious concern was that the severity and mortality of the disease was 
not considered in the decision for the announcement of ‘phase 6’ – the 
final phase in which a disease outbreak has reached global proportions 
– of the pandemic (Walsh, 2009).
A study published in The Lancet has estimated the death toll from 
the 2009 A(H1N1) pandemic to be fifteen times higher than originally 
reported by WHO (Dawood et al., 2012). While 18,449 deaths from 
the flu virus were confirmed in 2009, the authors suggest that as many 
as 500,000 may have died. Nonetheless, this falls several magnitudes 
short of the estimated death toll of 2–4 million that WHO had originally 
stated prior to the several billion dollar’s worth of sales of vaccines 
(BBC News, 2010).
After explaining the statistical model used to count possible deaths 
in developing countries, The Lancet article concludes that it will be 
necessary to improve the global response to possible future pandemics, 
and to develop the capacity to produce enough influenza vaccines for 
the African continent and Southeast Asia (Dawood et al., 2012). In 
some countries of the North, more than 90 per cent of the vaccine 
stock was not used and had to be destroyed.
The greatest peculiarity with oseltamivir is that there was no proven 
efficacy for its use in the H1N1 pandemic, but yet WHO recommended 
its use regardless. This may have been the Organization’s attempt 
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to justify the relevance of the A(H5N1) stockpiling, which it had 
recommended with little actual usage years earlier.
In September 2010, WHO Director General Margaret Chen 
announced the end of the A(H1N1) pandemic. Alongside her 
announcement, the publication of statistics also came to an end. The halt 
in reporting of statistics is another unusual response, particularly when 
it would have been useful to continue monitoring the disappearance of 
the virus to ensure that the pandemic was completely over.
However, during the time that the pandemic was considered active, 
WHO had established an operations room in Geneva, with people 
working shifts to check surveillance on death and harm from the virus 
24 hours a day. There were live broadcasts around the world on a case-
by-case basis. What was the justification for this quick communication? 
Given that the Organization knew that death rates were actually 
turning out to be much lower than expected, it is likely that it wanted 
to over-report to create the sensation that the pandemic was real and 
more prevalent than it actually was. Deaths caused by high-mortality 
diseases are usually reported by WHO once a year.
Pushing vaccines for H1N1: Faulty calculations
Following the same logic in the management of the pandemic, let 
us analyse how some European governments – of highly sophisticated 
countries that could afford all of the necessary planning – calculated 
the required number of vaccines in order to face the pandemic in their 
country (see Table 3.2).
Germany, with 82 million inhabitants, bought 50 million vaccines. 
Belgium, with 10 million inhabitants, bought 12.6 million doses. 
France is a very interesting case, since, with only 60 million inhabitants, 
it purchased 94 million doses of the vaccine. Lastly, Switzerland and 
Holland bought doses twice the size of their populations (Velasquez, 
2010).
In the case of France, the French Parliament carried out an 
investigation about the management of the pandemic. This enquiry 
questioned the Ministry of Health about the purchase of the 94 
million vaccines (L’Express, 2009), and the justification given was that 
the population would possibly have needed a second dose. Still, the 
amount purchased seems arbitrary: more than enough to provide every 
citizen with a single dose, yet not nearly enough to provide each with a 
second dose. When the pandemic ended, the official information from 
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the French Ministry of Health indicated that only 6 million people had 
received the vaccine.
In the beginning, it was announced that excess doses from developed 
countries would be donated to poor countries, but some countries from 
the Global South indicated no intention of receiving this gift, because 
influenza was not a dire health risk given the high temperatures (30–
35°C in most African countries), which mean that the likelihood of 
developing influenza is much lower than it is in the North.
In relation to oseltamivir, as mentioned earlier, there had been no 
human clinical trials to justify prophylaxis in the case of the A(H1N1) 
pandemic. Scientists informed the media that the virus had a high 
mutation capacity and suggested that the mutation could become 
much worse. However, they did not mention that this influenza could 
self-extinguish, as had other types of avian influenza before – most 
notably, the Holland H7N7 Dutch flu outbreak in 2003 (Bio Report, 
2006) and A(H1N1), which apparently diminished its intensity and 
practically disappeared.
There has been an incredible waste in terms of stockpiling. In the 
United States, for instance, 40 million vaccines against swine influenza, 
worth about $260 million, were incinerated (O’Callaghan, 2010).8 
Only 6 per cent of the vaccines purchased by the French government 
for H1N1 were actually used; the remaining doses have to be destroyed. 
It is difficult to understand the public health rationale for the massive 
purchases of A(H1N1) vaccines by the governments of the North.
As reported by Deborah Cohen and Philip Carter in the British 
Medical Journal (Cohen and Carter, 2010), some of the experts 
TABLE 3.2 Government purchases of vaccines for H1N1
Country Population No. vaccines purchased
Germany 82 m 50 m
Belgium 10 m 12.6 m
Spain 47 m 37 m
France 60 m 94 m
Italy 60 m 48 m
Netherlands 16 m 34 m
Switzerland 7 m 13 m
Sources: Various
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advising WHO on the pandemic had declarable financial ties with 
drug companies that were producing antivirals and influenza vaccines. 
According to Cohen and Carter (2010), the WHO guidance on the use 
of antivirals in a pandemic was authored by an influenza expert who, at 
the same time, was receiving payments from Roche, the manufacturer 
of oseltamivir (Tamiflu), for consultancy work and lecturing.
Conclusions
There was confusion and a complex mix of interests of different, 
and sometimes opposite, actors. The first group of actors – WHO 
and the national health authorities – legitimately intended to protect 
the population using clear public health values and perspectives, 
notwithstanding the fact that some mistakes were made. Nonetheless, 
it is quite suspect that several of the WHO advisers on the pandemic 
management had financial ties to Roche and Gilead, which monetarily 
gained significantly from the oseltamivir sales. Moreover, because 
stocks of oseltamivir were already stockpiled from the A(H5N1) 
pandemic scare of 2005, it was strategic for WHO to promote it as the 
primary drug of choice for A(H1N1), so that the existing stocks would 
be of use, reducing the criticism of WHO for advising stockpiling in 
that earlier instance.
The second group – the governments and political leaders, who 
perhaps did not have public health concerns as their priority – may 
have been more interested in protecting or promoting themselves from 
a political point of view. In a situation in which the public is alarmed by 
the possibility of a pandemic, governments have almost no choice but to 
react with precautionary measures, such as stockpiling vaccines. Given 
that the public has historically distrusted European governments when 
it comes to health matters – the AIDS-contaminated blood scandal that 
killed several hundred people in France being a noteworthy example 
(Dorfman, 1991) – it is unsurprising that European governments acted 
quickly to obtain oseltamivir stocks.
The third group of actors – the pharmaceutical (and para-
pharmaceutical) industries – were obviously led by their own commercial 
interests. Oseltamivir is produced by Swiss pharmaceutical company 
Roche and developed by Gilead Sciences, both of which are likely to have 
benefited to the tune of billions from the global sales of the drug. Given 
that several members of the WHO advisory committees have associations 
with Roche, it is likely that they financially benefited as well.
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According to the Council of Europe report entitled The Handling 
of the H1N1 Pandemic: More Transparency Needed, relations and 
interactions between these three groups were not always clear at the 
national and international levels, complicating the management of the 
A(H1N1) pandemic (Flynn, 2010).
In conclusion, there were both positives and negatives in relation 
to the pandemic response. On the positive side, a process of sanitary 
education was put in place on a worldwide level and at an unprecedented 
scale. In a matter of hours, the world was alerted to the potential risk of 
a pandemic of lethal proportions and in the event that the flu actually 
did begin to spread, at least people would be aware.
The global response was also demonstrative of the fact that, in cases 
of global risk, there are available resources that nations are willing to 
use for the protection of their citizens. A market valued at $400 billion9 
was created for the vaccine in a matter of days.
On the negative side, the concept of vaccination itself was put 
at risk. The most important therapeutic tool in public health is our 
ability to prevent a disease and we do not yet know the consequence 
of this lapse. Messages were improperly spread, and this double-edged 
communication between the media and the scientific community 
resulted in a mixed public response. In France and Spain, many health 
workers themselves refused the vaccine (Cannet, 2009), as documented 
by many popular journals, with even hospital workers quoted as saying 
‘I will not take the vaccine’ (Wyderko, 2009). These messages pose 
a potentially harmful influence on future public opinion regarding 
vaccination and related public health responses.
Finally, WHO, the ministries of health in several countries, and some 
scientific communities were implicated in poor decision making in the 
face of a public health crisis (Flynn, 2010), resulting in a significant 
loss of credibility. There remains an unanswered question about how 
their authority was affected and how this loss of credibility is going to 
influence their ability to address similar problems in the future.
Notes
1 We would like to recognize our 
editor, Abraar Karan, for his significant 
contribution to this chapter.
2 According to the World Health 
Organization (WHO, 2009), a pandemic 
alert ‘phase 5’ is characterized by human-
to-human spread of the virus into at 
least two countries in one WHO region. 
Pandemic ‘phase 6’ (the highest stage) 
is characterized by community-level 
outbreaks in at least one other country in a 
different WHO region. The H1N1 pandemic 
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was first described by WHO in April 2009; 
on 10 August 2010, WHO Director-General 
Margaret Chan announced the end of the 
H1N1 pandemic.
3 Indonesia reported 146 and 
Vietnam, 59 (WHO GIP, 2011).
4 One of the main shareholders 
of this pharmaceutical company, as 
revealed in several media news at that 
time, was Donald Rumsfeld, who acted 
as general manager until 2001, when he 
was appointed US Secretary of Defense. 
The English press mentioned that when 
the United States decided to constitute 
a stock of oseltamivir, Mr Rumsfeld had 
to abandon the room of the Secretaries 
Council owing to the possible conflict of 
interests that his presence in the meeting 
could represent.
5 From the filing date of the patent 
application.
6 In relation to the national antiviral 
stockpile in thirty European countries 
that are members of the European 
Influenza Surveillance Scheme (EISS). All 
countries except Ukraine had a stockpile 
of the neuraminidase inhibitor (NAI) 
oseltamivir (Meijer et al., 2007).
7 ‘In March 2007 the Japanese 
authorities advised against prescribing 
oseltamivir (Tamiflu, Roche) to 
adolescents aged 10–19 years. This 
unusually severe measure resulted from 
the separate suicides of two 14 year-olds 
who jumped to their deaths while taking 
oseltamivir; 52 other deaths (14 in children 
or adolescents) have been associated with 
the same drug. So far, similar action has 
not followed in Europe. When a regulatory 
authority warns doctors not to prescribe 
a drug but decides not to retract its 
marketing authorisation prescribers and 
patients are entitled to be concerned and 
a little confused.’ (Maxwell, 2007)
8 ‘Yet in addition to the roughly 40 
million doses that have already expired, 
the AP reports that another 30 million will 
likely go unused and eventually expire 
— meaning that a total of 43% of the 
swine flu vaccine supply will be wasted.’ 
(O’Callaghan, 2010)
9 ‘Vaccine makers could produce 
4.9 billion pandemic flu shots per year 
in the best-case scenario’ (Margaret 
Chan, WHO Director General, quoted 
by Reuters, 21 July 2009); ‘Wealthier 
countries such as the U.S. and Britain will 
pay just under $10 per dose [of the H1N1 
flu vaccine] … Developing countries will 
pay a lower price [circa $400 billion for 
Big Pharma] (Business Week, July 2009).’ 
(Chossudovsky, 2009)
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Every year, around 150 million people face financial catastrophe and 
about 100 million suffer poverty as a result of out-of-pocket (OOP) 
payments for health care. More than 90 per cent of them reside in low-
income countries (Xu et al., 2007). India, along with Bangladesh and 
Vietnam, has some of the highest burdens of OOP payments for health 
care in Asia (van Doorslaer et al., 2007). Each year, 5 per cent of Indian 
households experience catastrophic health expenditure (Shahrawat 
and Rao, 2011), meaning that health care consumes at least 10 per 
cent of the household budget and cannibalizes resources for basic 
human needs such as food (Hubbard et al., 1995; Wagstaff and van 
Doorslaer, 2003). Most studies of catastrophic health expenditures 
are insensitive to the payment mechanisms, but households may 
be forced to exhaust savings, sell assets, and go into debt (Russell, 
2004; Sauerborn et al., 1996; Wilkes et al., 1998). Because the poor 
have fewer resources on which to draw, the incidence and intensity 
of catastrophic health expenditure is concentrated among them: it 
makes the poor even poorer, rather than drawing the affluent into 
poverty (Wagstaff and van Doorslaer, 2003). Because many Indians 
have no alternative to private health care, which is unaffordable, 
unreliable, and impoverishing (Shiva et al. 2011), access to health 
care is a major producer of poverty and creator of inequity in India 
(Gumber and Arora, 2006).
Several factors are driving increasing numbers of Indians into 
healthcare-related poverty. First, as a developing nation, India has a 
very high level of private healthcare spending (the majority of which 
is OOP) compared to government spending (Berman et al., 2010), 
which puts an undue financial burden on poor households (Shahrawat 
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and Rao, 2011). Second, the real cost of health care is increasing: the 
average expenditure per hospital admission tripled between 1986 and 
2004, in both government and private hospitals, and in both rural 
and urban areas (Shiva et al., 2011). Third, privatization continues, 
following from the liberalization policies from 1991. Most significantly, 
there is a lack of mechanisms to finance health care. The most robust 
solution would be a social security system, which is urgently needed, 
but improbable in the short term (Mahal et al., 2010). Protecting the 
poor from catastrophic OOP expenditure by means of health insurance 
is crucial, especially in such a highly privatized system, but there are 
economic, practical, and cultural significant barriers to its uptake. 
For instance, existing health insurance coverage is insufficient, varies 
greatly between rural and urban areas, is limited to a small proportion 
of people in the organized sector (IIPS/WHO/WHO RO, 2006), and 
normally covers only in-patient hospital care even though medicine is 
normally a greater expense (Shahrawat and Rao, 2011). Thus most 
schemes fail to protect the poor from high OOP payments.
This chapter addresses the nature and magnitude of health insurance 
coverage in India, which is expected to grow rapidly in coming years. 
It estimates the proportion of the household budget allocated to 
health care in different socio-economic groups and it explores coping 
mechanisms of the households to meet healthcare costs. By doing so, 
it examines the impoverishment effects on households of catastrophic 
health expenditure. Finally, it revisits the situation of health insurance 
in India and its potential for meeting the economic burden of health 
care.
Data
We used the household data collected in the Study on Global AGEing 
and Adult Health (SAGE), India, undertaken by the International 
Institute for Population Sciences (IIPS) during 2007–08 and sponsored 
by the World Health Organization (WHO) (WHO/IIPS, 2011; Kowal 
et al., 2012). This is a nationally representative sample survey covering 
9,626 households (completed interviews) from six states of India: 
Assam; Karnataka; Maharashtra; Rajasthan; Uttar Pradesh; and West 
Bengal. In a way, these six states represent the geographical, economic, 
and demographic variations in India.
A sample size of 10,000 households at national level was targeted and 
the number was allocated to the six states according to their population 
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size. The national-level estimates were computed by pooling the data 
of all six states. The study used two-stage sampling in rural areas 
and three-stage sampling in urban areas. The primary sampling units 
(PSUs) in rural areas were villages, while in urban areas, the PSUs 
were city wards. From each city ward, two census enumeration blocks 
(CEBs) were selected. The last level of selection was households. The 
households selected were distributed among rural and urban areas in 
proportion to the distribution of the state’s population. The survey 
comprises 2,494 (26.9 per cent) urban and 7,132 (73.2 per cent) rural 
households. The module gives weekly, monthly, and yearly household 
consumption expenditure, including food, non-food, and health 
payments.
For the purpose of analysis, all household expenditures were 
converted into monthly consumption expenditure. Each household 
has been asked about the coping strategy adopted to meet unforeseen 
health payments.
In this chapter, we have considered the monthly consumption 
expenditure to be a direct measure of the economic well-being of 
households.
Definitions
Household consumption expenditure comprises both monetary and in-
kind payments for all goods and services, and the money value of the 
consumption of home-made products.
Health expenditure implies the OOP health payments made by 
households for the health services received by any household member. 
Out-of-pocket health payments include doctor’s consultation fees, 
purchases of medication/traditional medication, and hospital bills, but 
expenditure on ambulance/transportation and special nutrition are 
excluded. Any reimbursement (from insurance, employer, government, 
etc.) is deducted to find out the net OOP payments.
Food expenditure is the amount paid on all foodstuffs by the 
household, excluding expenditure on alcoholic beverages, tobacco, 
and food consumption outside the home.
Non-subsistence spending constitutes the expenditure aggregate of the 
household’s health and non-food items. Household capacity to pay is 
defined as a household’s non-subsistence spending.
Catastrophic spending on health occurs when a household is forced 
to reduce its basic expenses over a certain period of time in order to 
sekher et  al .  | 83
cope with healthcare expenses for its members. In this study, when the 
health expenditure of the household is more than the non-subsistence 
spending, then it is considered to be catastrophic health spending.
Findings
Health expenditure The OOP health expenditure and different 
dimensions of health expenditure across groups of sample households 
are presented in Table 4.1. Mean household expenditure was INR6,671, 
out of which INR852 was being incurred as OOP expenditure on health, 
which amounts to an average of 10 per cent of the total household 
expenditure and 22 per cent of the non-subsistence spending. Almost 
24 per cent of the households spend either equal to or more than their 
capacity to pay (non-subsistence spending) on healthcare services; 
consequently, they have to forgo their basic subsistence consumption. 
Almost a third (31 per cent) of the total households are living below 
the poverty line. According to this survey, 35 per cent of the poorest 
households incurred catastrophic health expenditure.
Mean monthly consumption expenditure of the households 
incurring catastrophic health expenditure is INR5,724 compared 
to INR6,968 for those households without catastrophic health 
expenditure. However, households with catastrophic health 
expenditure incurred six times more OOP health expenditure than 
those households without. The households with catastrophic health 
expenditure, on average, spend 29 per cent of household consumption 
expenditure and 60 per cent of non-subsistence expenditure, 
respectively, for OOP health payment. As a result of this spending, it 
was found that 24 per cent of these households became impoverished. 
Out-of-pocket health payments accounted for 28 per cent of the non-
subsistence expenditure among the poorest households, compared 
with only 15 per cent among the richest households.
The impoverishment effect of catastrophic health expenditure is 8 
per cent among uninsured households, with INR823 monthly OOP 
health payments, while it is only 1 per cent for households with at 
least one member insured, at a monthly OOP health expenditure of 
INR1,240. The share of OOP health payments of non-subsistence 
spending was 22 per cent for uninsured households and only 12 per 
cent for those insured households with three or more insured members. 
According to this survey, only 21 per cent of urban households were 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































areas. The impoverishment effect resulting from catastrophic health 
payments is 8 per cent in rural areas and 5 per cent in urban areas. 
The economic status of the households measured in terms of wealth 
quintiles shows a positive association with the OOP health payments 
and negative association with the catastrophic health payments. Only 
13 per cent of households belonging to the highest wealth quintile 
incurred catastrophic health expenditure, compared to 33 per cent of 
households from the lowest wealth quintile.
Sources of healthcare financing Households resort to many strategies to 
meet their OOP health expenditure. These range from current income 
(74 per cent) as the major source of finance, followed by savings (26 per 
cent), borrowings from family or friends (20 per cent), and selling of 
household items (8 per cent). Twelve per cent of households sold their 
assets in order to finance catastrophic health expenditure, compared 
with only 6 per cent of households without catastrophic health 
expenditure, while 34 per cent of households borrowed from family or 
friends to finance catastrophic health expenditure, compared with only 
14 per cent of households without catastrophic health expenditure (see 
Table 4.2). The percentage of households borrowing from family and/
or friends consistently declined, from 25 per cent among the poorest to 
9.5 per cent for the richest households. Even among households with 
one or two insured members, only 10 per cent paid health expenditure 
from the insurance.
Households headed by elderly persons (aged 66 or over) are 1.27 
times more likely (CI = 1.025–1.565) to incur catastrophic health 
expenditure than those households headed by a person of aged 18–35. 
Households in which the main earner completed high school have a 
lower chance (OR = 0.78, CI = 0.655–0.926) of incurring catastrophic 
health expenditure than those households in which the main income 
earner is illiterate. Rural households are 1.65 times more likely (CI 
= 1.431–1.890) to incur catastrophic health expenditure than their 
urban counterparts. The odds ratio of incurring catastrophic health 
expenditure decreases from 0.77 (CI=0.667–0.880) for the poor 
households to 0.33 (CI=0.268–0.396) for the richest households (see 
Table 4.3).
Households incurring catastrophic health expenditure are 12.67 
times (CI = 10.351–15.513) more likely to be impoverished than those 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 4.3 Odds ratio of incurring catastrophic health expenditure and impoverishment 














Age of head of household 
18–35 1.00 1.00
36–50 0.84** 0.724–0.978 0.90 0.692–1.166
51–65 1.00 0.833–1.194 1.01 0.732–1.404
66+ 1.27** 1.025–1.565 1.13 0.768–1.648
Education level of main income earner 
Illiterate 1.00 1.00
Less than primary and 
primary school completed
0.91 0.802–1.041 1.03 0.825–1.278
Secondary school completed 0.94 0.807–1.095 0.88 0.671–1.146
High school completed 0.78** 0.655–0.926 0.84 0.611–1.157
College and above 0.74** 0.588–0.935 0.63* 0.374–1.063
Household members aged 50+ 
None 1.00 1.00
One 1.15* 0.994–1.338 0.76** 0.577–0.993
Two 1.15 0.947–1.399 0.87 0.614–1.243
Three or more 0.95 0.662–1.367 0.98 0.517–1.866
Catastrophic health expenditure 
No 1.00
Yes 12.67*** 10.351–15.513
Place of residence 
Urban 1.00 1.00
Rural 1.65*** 1.431–1.890 1.45** 1.089–1.917
Household members insured 
None 1.00 1.00
One 0.94 0.678–1.298 0.23** 0.071–0.733
Two 1.16 0.756–1.774 1.15 0.521–2.530
Three or more 0.85 0.572–1.259 0.64 0.249–1.632
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are 1.45 times (CI = 1.089–1.917) more likely to be impoverished 
than urban households. Households with one insured member are less 
likely (OR = 0.23, CI = 0.071–0.733) to be impoverished than those 
households without any insured members. Households belonging to 
the rich (OR = 0.64, CI = 0.472–0.858) and richest (OR = 0.27, CI = 
0.176–0.430) wealth quintiles are less likely to be impoverished than 
the poorest households.
Health insurance coverage in India Health insurance is one of the 
measures of social security by which members of the community are 
assured the benefit of medical care when they fall sick. The health 
insurance movement has a history spanning a century and a half. Its 
origins are largely found in the Industrial Revolution and developments 
in the field of medicine.
The entry of many private insurance companies into the sector will 
surely have an impact on the cost of health care, equity in the financing 
Household size 
Single member 1.00 1.00
2–5 members 1.19 0.791–1.804 2.02 0.835–4.888
6–10 members 1.58** 1.046–2.397 2.04 0.841–4.960
11+ members 1.54* 0.977–2.417 3.52*** 1.387–8.960
Wealth quintiles 
Poorest 1.00 1.00
Poor 0.77*** 0.667–0.880 0.95 0.752–1.191
Middle 0.61*** 0.512–0.719 1.02 0.772–1.351
Rich 0.50*** 0.424–0.587 0.64*** 0.472–0.858
Richest 0.33*** 0.268–0.396 0.27*** 0.176–0.430
* p < 0.00
** p < 0.05
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of care, its quality, and its cost-effectiveness (Mahal, 2002). However, 
many believe that community-based health insurance, rather than 
market-mediated or government-provided insurance, is an appropriate 
way of reaching the poor (Ahuja, 2004). The choice between public 
health financing or private insurance is hardly available in India, 
however, because of the government’s limited ability to marshal 
sufficient resources to finance health spending.
Since the independence of India, the healthcare system has been 
expanded and modernized to some extent, with the availability of 
modern healthcare facilities and better training of medical personnel 
(Ellis et al., 2000). At the same time, the healthcare sector in India is 
still mainly focused in urban areas only, even though the majority of 
the people are living in rural areas. The paradox is that around 73 per 
cent of rural people get 20 per cent of the healthcare facilities, while 
around 27 per cent of urban people get the remaining 80 per cent 
of the facilities. Infrastructure, human resource, and quality-related 
inequities in the availability, utilization, and affordability of health care 
are a matter of concern. Government health facilities are perceived 
as not functioning well and as being of poor quality. Because of this, 
the majority of people when they are ill seek outpatient care from the 
private sector.
As regards health insurance coverage in India, only 11 per cent of 
the country’s population has access to insurance policies (Shahrawat 
and Rao, 2011). The majority of curative healthcare spending is met 
by households only. Some studies reveal that around 69 per cent of 
health spending is financed as OOP expenses. As a consequence of 
the liberalization and privatization of the healthcare system, healthcare 
expenses have also increased. Since 1994–95, health expenditures 
have grown at 14 per cent and this growth is higher for inpatient 
care (Government of India, 2005). These financial burdens arise 
mainly because consumers are either not insured at all, or are insured 
inadequately for their healthcare expenses.
Health insurance is not a familiar concept among the people of India, 
so neither is its coverage adequate. However, there is some evidence 
that health insurance coverage is gradually increasing (Shijith, 2011). 
This may be as a result of high healthcare costs, the entry of private 
players into the insurance sector, the government’s universal health 
insurance policy, and the community-based health insurance schemes 
in some states (see Table 4.4). Health insurance, as we know it today, 
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Scheduled tribes of Gudalur Taluk 
who are members of Adivasi 
Munnetra Sangam (AMS), the 
tribal union
(n = 13,070 individuals)





Uruli Kanchan, Pune, 
Maharashtra, 2001
Poor women members of the 
community banking scheme and 
living in the 22 villages around 
Uruli Kanchan town
(n = 1,500 women)









Farmers living in Buldhana district
(n = 175,000)







Theni District, Tamil 
Nadu, 2000
Poor women members of the 
community banking scheme 
and living in the villages of 
Mayiladumparia Block
(n = 190,499)




T Narsipur Block, 
Mysore District, 
Karnataka, 2002
Total population of T Narsipur 
Block and Bailhongal Block, with a 
focus on the scheduled tribe and 
scheduled caste population
(n = 634,581 individuals)







Small farmers and landless 
labourers living in the 40 villages 
around Kasturba Hospital
(n = 30,000 individuals)








Select scheduled caste individuals 
in two blocks of Pathan district, 
North Gujarat
(n = n/a)







Korba districts of 
Chhattisgarh, 1980
Poor people living in the 
catchment area of the 92 rural 
health centres and hostel students
(n = 92,000 individuals)
Type I Has its own 
providers
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SEWA 
11 districts of Gujarat, 
1992
534,674 SEWA Union women 
members (urban and rural), plus 
their husbands, living in 11 districts
(n = 1,067,348 individuals)






Kolkata, West Bengal, 
1952
Full-time students in West Bengal 
state, from class 5 to university 
level
(n = 5.6 million students)





Chennai, Tamil Nadu, 
1972
Total population of the catchment 
area of 14 mini health centres in 
the suburbs of Chennai
(n = 104,247 individuals in town 
blocks)






Members of the cooperative 
societies in Karnataka
(n = 25 lakhs)
Type II No linkages; 
operates the 
scheme itself
Note: In India, there appear to be three basic designs of community health insurance 
scheme, depending on who is the insurer. In Type I, the hospital plays the dual role of 
providing health care and running the insurance programme. In Type II, the voluntary 
organization is the insurer, while purchasing care from independent providers. In Type 
III, the voluntary organization plays the role of an agent, purchasing care from providers 
and insurance from insurance companies.
Source: Devadasan et al. (2004)
was introduced only in 1912 when the first Insurance Act was passed 
(Devadasan et al., 2004). The current version of the Insurance Act 
was introduced in 1938. Since then, there was little change until 1972, 
when the insurance industry was nationalized and 107 private insurance 
companies were brought under the umbrella of the General Insurance 
Corporation (GIC). Private and foreign entrepreneurs were allowed to 
enter the market with the passing into law of the Insurance Regulatory 
and Development Act (IRDA) in 1999 (Rao, 2004). In the aftermath 
of the new economic policies (liberalization and globalization), some 
of the major national and international private insurance companies 
entered the insurance industry. But only a few companies are working 
in the field of health insurance.
The main reasons for inadequate health insurance coverage in India 
are low levels of awareness about health insurance among people and 
the high cost of private health insurance, which is unaffordable for the 
majority of people. Before the IRDA, government insurance companies 
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such as LIC and GIC were the major players in the health insurance 
sector. In 1986, GIC’s ‘Mediclaim’ policy became the first health 
insurance policy available to the general public in India. Mediclaim is a 
reimbursement-based insurance for hospitalization and does not cover 
outpatient treatment. Since the premium is on higher side, it remained 
limited to rich and middle class segments.
Low expenditure on health care in India has led to vast inequities 
in the distribution of healthcare services between the different strata of 
society (Narayanan, 2008). Owing to low health insurance coverage 
and the cost of curative healthcare services, the vast majority of the 
health spending is financed by OOP payment in India (Shahrawat 
and Rao, 2011). India spends around 6 per cent of its gross domestic 
product (GDP) on meeting healthcare needs, through both private 
and public sectors. Of these expenditures, 75 per cent is private OOP 
costs spent by households. The health insurance constitutes a small 
proportion of total financing. It is estimated that less than 10 per cent 
of the total financing in the health sector is through various types of 
insurance (Bhat and Reuben, 2001).
The financial burden of healthcare expenditure in India is enormous 
and is growing day by day. Almost all segments of the Indian community 
face some direct or indirect OOP expenses for utilization of the 
healthcare services. The heaviest burden is borne by the people engaged 
in non-formal rural and urban activities. Bhat and Saha (2004) found 
that new economic policy, such as liberalization and globalization, the 
rapid growth of medical technology, and a rising middle class have 
led to a huge increase in private medical care expenditures in India. 
Mavalankar and Bhat (2000) argued that, with the proliferation of 
various healthcare technologies and a general price rise, the cost of 
health care has also become very expensive and unaffordable to large 
segment of population. Liberalization of the Indian economy and 
important legislation such as the IRDA Act, allowing private health 
insurance players into the Indian market has had considerable impact.
According to Bhat and Reuben (2001: 3):
Health insurance can be broadly defined as financial mechanisms 
that exist to provide protection to individuals and households from 
the costs of health care incurred as a result of unexpected illness 
or injury. Under this mechanism insurer agrees to compensate or 
agrees to guarantee the insured person against loss by specified 
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contingent event and provide financial coverage. Against this 
protection the insured party pays a premium and the insurer 
provides required services or pays the agreed sum spent on 
hospitalization in case of illness of insured person.
Health insurance can be defined in a very narrow sense, whereby an 
individual or group purchases health coverage in advance by paying a 
fee called a ‘premium’. But it can also be defined broadly, by including 
all financing arrangements whereby consumers can avoid or reduce 
their expenditures at the time of use of services (Mavalankar and Bhat, 
2000).
Health insurance is very well established in many countries, 
but in India it is a new concept (except for the insurance provided 
to organized sector employees). Health insurance needs to be given 
higher priority in India, because of the rising cost of health care and 
the financial burden it places on households. One of the important 
points that does need to be understood is that health insurance per 
se is simply a financing mechanism, and does not in any way ensure 
that health services are delivered efficiently and effectively (Ahuja, 
2004). Similar questions were raised by Bhat and Saha (2004), who 
argued that expanding insurance services without considering whether 
medical services are available or sufficient may not serve any purpose; 
the cost and quality of these services is equally important. Another 
important issue in this context is: who will regulate the practices of 
insurance providers? Government in India may be seen to be trying 
to divert attention from an inefficient healthcare delivery system by 
emphasizing health insurance as a solution. Indeed, Rao (2004: 3835) 
points out that:
High priority accorded to health insurance in these days could 
have some reasons: (1) push of the private, including the 
corporate and for profit sector, which is unable to maximize 
returns due to lack of effective demand; (2) enhance FDI by 
promoting India as a health destination for foreign clientele; 
(3) pull of the private insurance companies and third party 
administrators to deepen the insurance market through financial 
incentives such as tax exemptions and subsidies for premiums; 
and (4) protect the poor from impoverishment due to high 
medical costs.
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A mushrooming of private healthcare facilities, the increasing cost 
of healthcare services, the financial burden of healthcare costs among 
poor and marginalized people, and a changing epidemiological pattern 
of diseases all influence the attitude of the people and government. 
The government and people have therefore started exploring various 
health financing options such as health insurance (Mavalankar and 
Bhat, 2000). The limitations of health insurance in India can partly 
be attributed to the lack of standardization of healthcare provision and 
to the absence of data on which insurance companies can base their 
health insurance products (Ahuja, 2004). The increasing competition 
among these companies has, however, started to make its mark on 
the insurance sector in the form of a wider range of product offerings, 
aggressive marketing, and the provision of better customer care.
According to two nationwide demographic surveys, the National 
Family Health Survey (NFHS-3) (IIPS/Macro International, 2007) and 
the District Level Household and Facility Survey (DLHS-3) (IIPS, 2010), 
only 5 per cent of the households in India are covered under any type of 
health insurance. However, 2009–10 data on health insurance revealed 
that, from 2007–08 onwards, the number of health insurance policies 
and the number of covered members were on the rise. In 2008–09, 
the number of policies was 45,75,725; it had increased to 68,84,687 
(serviced by third-party administrators, or TPAs) only a year later, in 
2009–10. Higher coverage of health insurance is reported in urban 
areas. The coverage in rural areas is still very low, as is evident from 
both the DLHS-3 (3.2 per cent) and NFHS-3 (2.2 per cent).
According to the DLHS-3, among the insured, central or state 
government health schemes are the most subscribed (39.2 per cent), 
followed by the employee state insurance (ESI) scheme (17 per cent). 
This clearly points out the dominance of public mandatory schemes 
and employer-based schemes, even after the entry of private players 
into the health insurance market. Among households belonging to 
the lowest three wealth quintiles, however, less than 3 per cent were 
covered by any health scheme or health insurance (Shijith, 2011).
Table 4.5 shows the distribution of health insurance coverage 
of household members by characteristics of the households. Only 
6 per cent of households had at least one insured member in 2007. 
Disaggregation of the households by number of insured members 
shows that about 3 per cent of households have only one insured 
member and nearly 2 per cent of households have at least three insured 
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TABLE 4.5 Number of household members covered under health insurance by 












Age of head of household 
18–35 96.1 2.3 0.9 0.8
36–50 94.4 3.0 1.2 1.4
51–65 93.1 2.8 1.7 2.4
66+ 93.2 2.6 1.6 2.6
Education level of main income earner 
Illiterate 97.6 1.2 0.6 0.7
Less than primary and primary 
school completed
96.0 1.8 1.0 1.2
Secondary school completed 95.1 2.1 1.8 1.0
High school completed 92.0 4.8 1.2 2.0
College and above 81.2 7.0 4.0 7.9
Household members aged 50+ 
None 95.6 2.4 0.9 1.1
One 93.9 3.2 1.3 1.6
Two 92.7 2.7 1.8 2.8
Three or more 91.3 2.4 3.0 3.3
Catastrophic health expenditure 
No 93.3 3.1 1.5 2.2
Yes 96.6 1.7 1.0 0.7
Place of residence 
Urban 90.1 3.7 2.0 4.2
Rural 95.5 2.4 1.1 1.0
Household size 
Single member 96.9 3.2 0.0 0.0
2–5 members 93.1 3.2 1.5 2.2
6–10 members 94.8 2.4 1.3 1.5
11+ members 95.4 1.8 1.4 1.4
Wealth quintiles 
Poorest 99.1 0.5 0.2 0.2
Poor 98.3 0.9 0.5 0.4
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members. Only 2.5 per cent among households with an illiterate main 
income earner have at least one insured member, whereas it is 19 per 
cent among those households with a main income earner educated 
to college level or above. Only 3 per cent of households incurring 
catastrophic health expenditure have at least one insured member, 
compared to 7 per cent of those households that did not experience 
catastrophic health expenditure. There is considerable rural–urban 
difference in health insurance coverage: 10 per cent of households 
in urban areas have health insurance coverage, compared to only 4 
per cent in rural areas. Most importantly, only 1 per cent among the 
poorest households has health coverage, compared with 15 per cent 
of the richest households. The private health insurance policies can 
be afforded only by the economically better-off households. However, 
recent experiments in community health insurance schemes for poor 
families are encouraging.
Discussion and conclusions
Healthcare payments are pushing many Indian households into 
poverty year after year. It was found that a third of poor households 
incurred catastrophic health expenditure, and that the impoverishment 
effect of catastrophic health payments is 8 per cent among uninsured 
households, while it is only 1 per cent for households with at least one 
insured member. Twenty-six per cent of sample households borrowed 
from family or friends and others, while 8 per cent sold their assets 
to meet healthcare expenses. Rural households are more likely to 
experience catastrophic health spending than their urban counterparts. 
Only 6 per cent of Indian households have health insurance coverage, 













Middle 96.5 1.9 1.2 0.5
Rich 90.4 5.3 2.0 2.4
Richest 85.1 5.8 3.3 5.8
India (Pooled) 94.0 2.8 1.4 1.8
Source: WHO/IIPS (2011)
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per cent among the poorest households has health coverage, indicating 
that most health insurance policies existing today are affordable only to 
economically better-off households.
Who is responsible for providing health insurance cover to the people? 
Those with health problems will definitely spend money to save their 
lives, even if it results in their financial disaster. In this context, health 
insurance has emerged as an alternative financing tool with which to meet 
the healthcare needs of the people. However, this alternative financing 
has not yet reached vast sections of the people in India. How can 
India achieve universal health insurance coverage without an adequate 
number of healthcare facilities and resources? This is even more critical 
since a large proportion of India’s population is poor and a significant 
number of households gets pushed into the poverty trap every year by 
catastrophic health expenditure. Some community health insurance 
schemes targeting poor families in different states are, however, showing 
encouraging trends. The governmental agencies therefore need to play 
a more active role in facilitating and ensuring health insurance coverage 
for the people of India – particularly its poor.
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Introduction
The global model of fostering innovation in medicines is in deep 
crisis. In developed countries, it has long been argued that there is 
a direct correlation between intellectual property protection for 
pharmaceuticals and pharmaceutical innovation: the more protection, 
the more innovation. However, the model has become market-
oriented, based on intellectual property rights (IPR), and controlled 
by multinational pharmaceutical companies. As a result, intellectual 
property protection has enjoyed an unprecedented expansion in recent 
decades, while innovation has stagnated. Stated another way, the use of 
intellectual property protection as a tool for promoting pharmaceutical 
innovation has so profoundly failed to fulfil the needs of society that it 
has become counterproductive.
Developing countries in particular suffer from being forced to enter 
a comprehensive, global, market-based system that is driven by IPR 
protection to increase the already-exorbitant costs of medication. 
Because they cannot benefit from the costly innovations that they 
help to finance, the global model of innovation has become an 
obstacle to innovation and access to medicines in these countries. As 
pharmaceutical innovation is transformed from a national issue into 
an international catastrophe controlled by global industry, developing 
countries are victims of both edges of the sword: (a) they are charged 
extortionate costs for medicines for chronic diseases, which (b) fund 
innovation programmes that neglect the specific health problems that 
they face.
Health is a fundamental human right and access to life-saving 
medicines is a concrete expression of that right. In this chapter, we 
address two ways in which the right to health is being eroded:
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• the lack of access to essential medicines resulting from exorbitant 
prices that place them beyond the means of patients and healthcare 
providers; and
• the non-availability of effective medicines as a result of the lack of 
innovation (Hogerzeil and Mirza, 2011; Love, 2007).
First, the chapter offers the perspective of the authors’ own 
countries on poverty and its relation to health, disease, and access 
to medicines. Next, we discuss the current IPR-focused model of 
innovation and its impact on the South. Then, we demonstrate why 
we believe this model to be in crisis. Finally, we present potential 
remedies that are being discussed globally and call for fundamental 
change to remove intellectual property protection from healthcare 
innovation.
The chapter represents the view of Alliance, a consortium of civil 
society organizations (CSOs), not that of the authors’ governments 
or local industries. Because our main focus is to defend the public 
interest by bringing the voice of citizens (as interpreted by participating 
organizations) to all situations, we strive for scientific and technical 
rigour, but do not take an academic point of view. Our presence 
has been controversial in the World Health Assembly (WHA), 
governmental consultation meetings in Latin America, the Pan 
American Health Organization conference on regulatory harmoniza-
tion (PANDRH), and consultations with CSOs on HIV/AIDS. Yet, 
in many of these participation spaces, multinational pharmaceutical 
companies themselves act as CSOs. For instance, they finance 
patients’ organizations (composed of patients suffering from chronic, 
orphan, and rare diseases) that claim to represent civil society, but are 
instead a lobbying strategy to debilitate our arguments and to obtain 
additional influence (Alves et al., 2010; IAPO, 2010). Such obstacles 
underscore the importance of our mission to offer the perspective 
of CSOs in low- and middle-income countries on the model of 
innovation, the crisis, the costs incurred by the Global South, and 
viable alternatives.
Poverty, health, and access to medicines
For our organizations and the Alliance, the fundamental societal 
problem to solve in developing countries is poverty. For the purpose of 
this chapter, ‘poverty’ is understood as inequality and exclusion. Given 
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that we are moving towards democratic market societies, ‘poverty’ in 
this context can be described as the exclusion of the needs of citizens 
produced by market responses (ECLAC, 2009).
Today, the international community recognizes the strong 
relationship between poverty and health. Three of the eight Millennium 
Development Goals (MDGs) call for specific health improvements 
by 2015: reducing child mortality; reducing maternal mortality; and 
slowing the spread of HIV/AIDS, malaria, and tuberculosis. Following 
the publication of multiple World Health Organization (WHO) global 
health reports demonstrating links between health and economic 
development, several global public–private partnerships (PPPs) were 
established as part of the Global Fund to Fight AIDS, Tuberculosis 
and Malaria in 2002 (WHO, 2002).
While increasing resources for health is necessary, it is not sufficient 
to improve the well-being of the poor and to meet the MDGs for public 
health. The majority of health spending disproportionately benefits the 
wealthy. This is evident from the increasing inequality with respect 
to health globally, and particularly in Latin America (United Nations, 
2010).
According to a WHO study conducted in 2011, at least a third of 
the global population suffers from lack of regular access to essential 
medicines (Hogerzeil and Mirza, 2011). The case of HIV/AIDS is 
emblematic. In 2008, WHO, UNAIDS, and the United Nations 
Children’s Fund (UNICEF) estimated that, out of 9 million people 
needing treatment, only 3 million were receiving it, the vast majority 
of whom were situated in sub-Saharan Africa (Velásquez, 2008). 
Today, there is substantial evidence that demonstrates the efficacy of 
antiretrovirals for the treatment of HIV/AIDS; yet, after thirty years, 
these medicines are still not available for all those in need.
It is interesting to note that, during the negotiations of some free 
trade agreements (FTAs), rich countries argued that citizens in 
developing nations were unfairly benefiting from innovations in 
medicines without sharing the costs of innovation, while citizens 
in developed countries paid higher prices owing to the stringent 
IPR regimes in their nations (Drahos and Braithwaite, 2002). After 
the FTAs are implemented, however, developing countries certainly 
‘contribute’ to the costs of research and development (R&D) of new 
medicines, because they must incorporate stronger intellectual property 
measures in their legislation, and these measures often result in 
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high-cost medicines that are unaffordable for most patients and 
healthcare providers (Rossi Buenaventura, 2007).
This lack of access occurs at the same time as the developed 
world is facing an overuse of drugs: an increase in consumption of 
medicines and an increase in consequent side effects. It is similar to 
the coexistence of nutritional deprivation and obesity, of poverty and 
opulence (Farmamundi and Solanes, 2013).
On the other hand, there is no incentive to invest in research for 
the diseases of poor people. Developing countries not only face the 
frustration derived from lack of access; we also face the frustration 
that results from lack of innovation for diseases prevalent among our 
populations (Trouiller et al., 2002). This is the case for ‘type III diseases’, 
such as malaria, tuberculosis, Leishmaniasis, schistomiasis, and Chagas 
disease, which disproportionately affect developing countries (WHA, 
2008) and for which there are no incentives to dedicate resources for 
R&D. The proportion of innovations developed to address the medical 
needs of the poor in low-income countries is always minimal compared 
to the total number of innovations brought to markets throughout the 
world as a whole (Trouiller et al., 2002).
Yet the poor in developing countries also suffer from diabetes, 
cardiovascular diseases, and cancer. For these diseases, there are 
new innovations entering to the market that are beyond the means of 
individuals, families, and health systems in developing countries. This 
form of exclusion is striking, especially in light of the fact that, too 
often, there are health services and medicines exclusively available to 
the elite, particularly in middle-income countries. Latin America is the 
most unequal continent and disparities there have reached frightening 
proportions (ECLAC, 2009).
In many cases, mortality is much more related to poverty, exclusion, 
inequality, and lack of health services. Lack of access to medicines, 
even if they are low-cost, is only an additional element of the vicious 
circle of poverty, disease, and premature death.
We have learned that access to medicines is a national issue and that 
countries are using different mechanisms to face this complex situation. 
As each of our countries tries to find ways in which to guarantee their 
citizens the right to health, the following section will show how large 
pharmaceutical industries are using myriad techniques to shape the 
system in a way that protects their own interests.
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Global system of innovation
Following the establishment of the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) in 1994, members 
of the World Trade Organization (WTO) were required to provide 
minimum standards for IPR protection. All developing countries were 
forced to join this global system of innovation.
The vast majority of these nations did not previously grant patents 
for drugs, as was the case in some developed countries (UNCTAD/
ICTSD, 2005).
The process of accession to the WTO differs from accession 
processes to other international entities. It is not like an invitation from 
an intellectual property agency such as the World Intellectual Property 
Organization (WIPO), or from an entity that promotes industrial 
innovation, such as the United Nations Conference on Trade and 
Development (UNCTAD). And certainly it is not an invitation aimed 
at helping countries to fight against poverty. Instead, an interested 
government must enter a process of bilateral and multilateral 
negotiations with the WTO. The applicant government must abide by 
certain terms to which both it and other WTO members agree.
The cost of not acceding to the WTO is exclusion from the global 
market. The majority of developing countries compete for market access 
for agricultural commodities in which there is ample competition. 
According to the 2005 Human Development Report, rich countries 
typically apply minimum trade tariffs to other developed countries, 
while maintaining very high tariffs for poor countries (UNDP, 2005). 
The application of different tariff schemes provide developed countries 
with a level of political influence and control over the countries of the 
periphery.
One of the well-known schemes that imposes pressure on developing 
countries to incorporate, enhance, and enforce IPR for pharmaceuticals 
(and for copyrights) is the ‘Special 301 Report’ of the United States 
Trade Representative (see, for example, USTR, 2010). This report 
requires the USTR annually to create ‘watch lists’ and ‘priority watch 
lists’ of foreign countries that do not provide adequate and effective 
protection to US intellectual property. If the country fails to alter its 
patent system in a way that the USTR deems inappropriate, that country 
can become subject to sanctions. For example, the USTR characterized 
Thailand’s efforts to expand access to high-cost treatments for HIV, 
heart disease, and cancer as ‘a weakening of respect for patents’ and 
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elevated the country to the priority watch list in 2007: the year in which 
Thailand granted several compulsory licences (USTR, 2007).
Historically, governments in developed countries have used IPR 
regimes to better their economic interests, modifying the regimes as 
their perception of these interests evolve.
In times of colonialism, imperial countries employed an economic 
model that favoured the monopoly of strategic products. It was precisely 
in opposition to these monopolies that some colonized countries 
established more flexible systems that favoured the development of 
local industries.
Between 1790 and 1836, the United States issued patents only to 
its own citizens, since it was a net importer of technology. After 1836, 
foreign companies were allowed to obtain patents in the country, but 
they faced fees that were ten times the rate for US citizens. It was only 
after 1861 that the US government treated foreign patent applicants 
on a (almost wholly) non-discriminatory basis (Commission on 
Intellectual Property Rights, 2002).
In the global trade negotiations that led to the WTO, developed 
countries submitted proposals that promoted the monopoly power 
of their industries. Today, we are repeating history in the form of 
international agreements of forced compliance, such as TRIPS and 
bilateral trade agreements (BTAs) (Khor, 2007).
It is important to note that, prior to TRIPS, a number of countries 
applied exceptions for patents for some sectors of industry. These often 
included medicines and foods, because they were considered essential 
goods. The 1994 Agreement eliminated this option, because it obliged 
WTO countries to grant patents in all fields of technology (CIPIH, 
2008).
Intellectual property protection confers different degrees and 
different time frames of exclusivity in the market. ‘Exclusivity’ means 
that a patent holder can prevent others from using the invention 
(making, selling, importing) without its authorization. This protection 
allows the patent holder to fix and modify the price of the product 
in order to maximize profits. After the implementation of TRIPS, 
all countries paid similar prices for pharmaceutical innovations 
(although there are reports that, often, poor countries pay higher 
prices than those in developed countries), yet not everyone benefits 
equally – certainly not poor countries (UNCTAD/ICTSD, 2005). 
Big pharma invests enormous amounts of resources (especially in 
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lobbying efforts) to shape a global patent protection scheme that 
favours its own interests.
The agenda to globalize and enforce intellectual property rights 
globally (Drahos and Braithwaite, 2002) developed at a time when the 
Reagan Administration implemented legislation in the United States to 
reform relations between universities and enterprises: the Drug Price 
Competition and Patent Term Restoration Act of 1984 (known as the 
‘Hatch-Waxman Act’). This legislation allowed universities to license 
the results of their research to for-profit pharmaceutical companies 
– that is, publically funded knowledge became ‘privatized’. As a result, 
the pharmaceutical industry experienced an unprecedented soar in 
profits and growth during the last quarter of the twentieth century 
(Angell, 2004).
During this time, the term ‘blockbuster drugs’ emerged, referring to 
products that generated annual sales of at least US$1 billion (Goozner, 
2004). The success of these drugs encouraged pharmaceutical 
companies to invest significant resources on their marketing and 
development.
To maximize profits, the pharmaceutical industry altered its 
business model. Companies focused primarily on increasing the value 
of their stocks and expanding their portfolio of patented products. 
They engaged in a number of mergers, concentrating the power of the 
industry in the hands of a few large firms.
The implications of these mergers and acquisitions, although 
successful for the value of stocks and for profits, included a reduced 
scope and diversification of research lines, dried pipelines, and resources 
concentrated only on potential blockbuster drugs (LaMattina, 2011).
In parallel, the companies pursued aggressive lobbying strategies and 
patent litigation efforts. Expanding exclusivity in the market became 
a primary focus, given the consequent skyrocket in sales and profits 
(CIPIH, 2008). Combined with the concentration of marketing efforts 
and resources in blockbuster drugs, the practices of pharmaceutical 
companies have created an environment in which the variety of 
therapeutically efficacious drugs is limited, generic manufacturers 
face significant risk, and the price of medicines is maintained at an 
exorbitantly high level.
As a result, expenditures on drugs in developed and developing 
countries are concentrated in new and costly medicines, regardless of 
safety or efficacy (Farmamundi and Solanes, 2013; HCAAM, 2008).
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Nowadays, this innovation model is well entrenched. Actors 
face serious difficulties when trying to modify these practices. In 
industry, those that propose alternatives are fast replaced. Close ties 
between politicians and industry, combined with the effectiveness of 
pharmaceutical lobbyists, discourage new policies. And even patients’ 
organizations mitigate their own opposition, since they rely on funding 
and discounts from pharmaceutical companies, and experience 
significant marketing pressure (Alves et al., 2010).
This is precisely the situation that led the Intergovernmental 
Working Group on Public Health, Innovation, and Intellectual Property 
(IGWG) to establish the World Health Assembly Global Strategy and 
Plan of Action on Innovation, Intellectual Property and Access to Medicines 
(WHA, 2008; see also Velásquez, 2011).
Crisis of the innovation model
We have described the global architecture of pharmaceutical 
innovation and the role of intellectual property. Now, we want to argue 
that this intellectual-property-based model of innovation is facing a 
deep crisis. The crisis, from the perspective of developing countries, is 
expressed in the absence of research and innovation that address the 
health problems of their citizens – that is, in the neglected diseases. 
From a global perspective, it is evident that our society as a whole faces 
a crisis of the innovation model: a crisis of costs, transparency, results, 
and, above all, a crisis of relevance.
Crisis of costs In the September 2011 issue of the The Lancet Oncology, 
experts including healthcare professionals, policymakers, and cancer 
survivors examined the prospects for cancer management in high-
income countries. Their conclusions were certainly overwhelming: 
according to the article, developed countries are unable to finance the 
cost of treatments and innovation of new drugs for the disease (Sullivan 
et al., 2011).
Almost four years ago, the European Parliament, with the support 
of some non-governmental organizations (NGOs) – notably Health 
Action International (HAI) Europe – convened a meeting in Brussels 
headed ‘Can We Afford the Current Model of Medical Innovation?’ 
At that meeting, while all welcomed the progress made in investment 
in neglected diseases, the participants asserted that the rising costs 
of innovation were creating an untenable situation not simply for the 
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developing world, but also for the countries of the European Union 
(HAI, 2010).
Expenditures on medicines constitute an increased share of general 
expenditures on health in developed countries. A decade ago, no 
industrialized country spent more than 10 per cent of its health budget 
on medicines; today, Germany spends 15.2 per cent, Spain, 22.8 per 
cent, Finland, 16.3 per cent, France, 16.6 per cent, Italy, 20.1 per cent, 
and the United States, 12.48 per cent (Velásquez, 2011). In successive 
annual reports from the social security system in France, a constant 
growth in health expenditures was registered, mostly attributable 
to medicines. The September 2008 report attributes the increase in 
expenditures to the ‘structure effect’, a phenomenon that implies that 
there is a higher concentration of prescriptions and expenditures on the 
newest and the most expensive medicines (HCAAM, 2008). One can 
conclude that, at least for members of the Organisation for Economic 
Co-operation and Development (OECD), the model of innovation is 
creating an unsustainable growth in expenditures.
Certainly, the global market is concentrated in the OECD countries. 
By 2011, nine countries accounted for 85 per cent of the global 
consumption in medicines, almost half of which was in North America 
(IMS Health, 2011) (see Table 5.1).
Table 5.2 presents the distribution of expenditures on medicines 
by main countries in each region. It includes growth rates between 
January 2010 and January 2013.
Given the outstanding difference among growth in OECD and 
developing countries, the term ‘emerging markets’ is used for those 
TABLE 5.1 Sales of medicines per region, 2011
Region Sales (US$bn) %
North America 244.6 47.31
Europe (top five) 107.3 20.75
Japan (including hospitals) 86.8 16.79
Australia/New Zealand 9.5 1.84
China (hospital) 32.8 6.34
Latin America (top four) 36 6.96
Total 517
Source: IMS Health (2011)
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whose growth is above 10 per cent (IMS Health, 2011). From the 
perspective of developing countries, the pharmaceutical industry’s 
business model will have worrisome implications for these emerging 
markets. Since the business model creates an imperative to increase 
sales annually, companies will expand their lobbying efforts and 
marketing resources in emerging markets. A prospective analysis 
forecasts an increase in consumption of drugs in the emerging markets 
and a decline in the United States (IMS Institute for Healthcare 
Informatics, 2011).
TABLE 5.2 Sales of medicines through retail pharmacies and growth rates per region/
country, 2010–13
2010–11 2011–12 2012–13






North America 244.6 3 253 –3 257.7 0
United States 225.2 3 234.8 –3 238.7 0
Canada 19.4 2 19.3 –3 19 –1
Europe (top five) 107.3 3 103 –7 104.6 0
Germany 36 8 38 –4 38.5 4
France 27.8 1 26.2 –9 26.5 –3
Italy 15.7 1 14.1 –10 14.5 –1
Spain 14.2 0 12.7 –14 12.1 –4
United Kingdom 13.6 2 13 –3 14 –1
Japan (including hospitals) 86.8 1 96.2 –5 87.4 2
Australia/New Zealand 9.5 5 12.7 –2 11.3 –2
China (hospitals) 32.8 22 52.3 20 56.2 14
Latin America (top four) 36 43.2 4 43.8 15
Brazil 17.9 20 22 –2 22.7 15
Mexico 7.9 3 9.6 4 8.9 4
Venezuela 6.2 32 7.9 21 6.4 24
Argentina 4.1 26 6.7 10 5.8 22
Source: IMS Health (2011)
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The particular case of Colombia is illustrative. The Colombian 
General System of Social Security in Health (Sistema General de 
Seguridad Social en Salud) has an essential medicines list that includes 
around 660 active principles, selected following the recommendations 
of WHO and of evidence-based medicine. Nevertheless, if a physician 
writes a prescription for a drug that is not on the list, patients can use 
a legal mechanism to obtain it. This mechanism was made available 
following the global movement promoting health as a human right. A 
similar mechanism can be found in other Latin American countries, 
including Brazil, Uruguay, Argentina, and Bolivia, where terms for 
it include Amparo Constitucional, tutela, and recurso de amparo, among 
others. In all of these countries, there has been a growing tendency to 
use the legal mechanism to access newer, more exclusive, and more 
expensive medicines.
Annual expenditures on these medicines in Colombia have grown 
from around COP4.2 billion (US$2.3 million) in 2000 to COP2.4 
trillion (US$1.2 billion) in 2010, as is shown in Figure 5.1. Most of the 
top twenty medicines responsible for this increase in sales are new and 
expensive; a form of IPR protection, including patents, data exclusivity, 




















































5.1 Annual spending on medicines not on the essential medicines list, 
Colombia 2000–10 (in millions of Colombian pesos) (source: 
https://bournepartners.wordpress.com)
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Typically, we have attributed barriers to access of medicines to 
patents. However, recent assessments have shown that data exclusivity 
protection can also contribute to the high cost of drugs. In the few 
countries that have implemented data exclusivity protection measures, 
the impact on the pharmaceutical market has been severe (Shaffer and 
Brenner, 2009).
In the same way, people tend to ignore the weight of trade marks, 
which are a class of intellectual property that have a significant impact 
on access. A study conducted by IFARMA in Colombia showed that, 
in a sample of fifty essential drugs of high consumption, pioneer brand 
medicines cost twenty-two times more than their generic equivalent on 
average and secondary brands cost six times more (Vásquez Serrano, 
2010). Given that these drastic price differences are not attributable 
to quality differences, as is common in luxury goods markets, there is 
no justification. From a health perspective, these price differences are 
unacceptable, especially in contexts of poverty.
Crisis of transparency There are two aspects that make the pharmaceu-
tical industry and this intellectual-property-based innovation model 
one of the least transparent. First, there is an absence of public data on 
the real costs of R&D and other activities as a result of the pharmaceu-
tical companies’ strong resistance to providing this information and, 
instead, the publication of data that fails to reflect real costs. Second, 
pharmaceutical companies have been increasingly manipulating data 
from clinical trials to advance marketing goals.
In the last ten years, estimations of the cost of introducing successful 
products to market have been the subject of intense debate. The well-
known study by DiMasi and his group at Tufts University estimated 
the cost of innovation at about $800 million in 2000 (Goozner, 2004), 
rising to $1.2 billion in 2003 (DiMasi, 2003) and to about $1.5 billion 
in 2010 (DiMasi, 2010), or (according to Andreas Seiter of the World 
Bank) $2 billion in 2006 (Seiter, 2010). Both of these calculations are 
remarkably close to those suggested by big pharma.
These high costs have been used to justify the high price of new 
drugs and price increases for newer innovations. Understanding that 
intellectual property is an arrangement between society and those who 
specialize in innovation, and that the arrangement should be beneficial 
for both parties, such costs show a huge imbalance in favour of rich 
societies. For societies with high levels of poverty, it is a significant 
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burden that compounds distressing scenarios of poverty and inequality 
(CIPIH, 2008).
It must be noted, then, that these figures have been the subject of 
controversy. Many academics have disputed them on the grounds that 
such calculations exaggerate costs to justify high prices and enable 
maximization of profits. A recent publication in the London School 
of Economics journal Bio Societies challenges these calculations, 
estimating that the cost of drug development could range from as little 
as $13 million to as much as $234 million, averaging about $43 million 
(Light and Warburton, 2011).
In a systematic review, authors considered that despite three decades 
of research in this area, no published estimate of the cost of developing 
a drug could be considered acceptable (Morgan et al., 2011). In most 
of the studies, there is a lack of a reasonable audit and disclosure of – at 
the very least – the drugs that the authors used for their estimations. 
Certainly, an important part of the debate rests on the way in which 
big pharma has managed to keep its figures secret. Like few other 
industries in the world, the pharmaceutical industry has achieved data 
industrial secrecy; it is not required to report its data to authorities or 
public information systems.
But this manipulation of data is not restricted to the economic and 
financial aspects. There is a growing global concern over the handling 
of information from clinical studies – namely, safety and efficacy data. 
Each year, we are surprised by new scandals about dangerous products, 
the adverse effects of which were minimized, or even hidden. Less 
publicized, but equally distressing, is the fact that there is a strong 
tendency to disclose only favourable results for products and to silence 
negative ones. In some cases, this bias has led to lawsuits against 
scientists who questioned the way in which the results were presented. 
The behaviour is so widespread that there have been global initiatives 
to establish an international clinical trials registry platform (Reveiz 
et al., 2010; WHO ICTRP, 2004).
This particular issue has been used as the storyline of several 
popular films: The Constant Gardener, directed by Fernando Meirelles; 
The Fugitive, starring Harrison Ford; Michael Clayton, starring 
George Clooney; Limitless, starring Robert De Niro; and I am Legend, 
starring Will Smith. From a more academic perspective, there are a 
lot of publications compiling the most representative examples of this 
manipulation of data from clinical trials. Table 5.3 provides a selection 
rossi  buenaventura and restrepo vélez | 115
of these cases based on a systematic review conducted by Martin Cañas 
of the Medical Federation of Buenos Aires (Femeba).
The manipulation of data from clinical trials can be seen to be getting 
worse, in light of growing evidence of bias in the publication and the 
management of results. This bias is also apparent in the preparation 
of reports for scientific journals, some of which have included ghost 
authors. The relocation of clinical trials from universities and public 
hospitals into clinical research organizations in which researchers are 
TABLE 5.3 Cases of manipulation of data from clinical trials
Year Product Laboratory Case
1980 Benoxaprofeno Ely Lilly The publication of safety risks 
prompted the company to issue a 
lawsuit threat against the researchers.
1987 Levotiroxine Boots Boots managed to block the publication 
of results from a clinical trial until 
journalistic research findings revealed 
that the company had exerted pressure 
on the researchers.
1996 Deferiprona Apotex The publication of severe side effects 
prompted the company to fire and issue 
a lawsuit against the researcher.
2002 Rofecoxib Merck In the studies CLASS and VIGOR, 
an important risk of cardiovascular 
effects was hidden. An independent 
publication claimed scientific fraud and 
the author was sued. Two years later, 
the product was retired from the global 
market.
2004 Paroxetine Glaxo A publication in the Canadian Medical 
Association Journal (CMAJ) revealed 
that trials showing no advantages of the 
product (compared to the placebo) had 
been silenced.
2004 Gabapentine Pfizer and 
Warner-Lambert
Between 1994 and 2000, Pfizer engaged 
in illegal off-label promotion of the 
drug. In 2003, total sales reached more 
than €2.2 million; 90% of these sales 
had been prescribed for unapproved 
indications. Pfizer pleaded guilty and 
received a fine of US$400 million.
Source: Cañas (2011)
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less independent also raises doubts about the integrity and reliability of 
the data (Cañas, 2011).
These practices have sullied the reputation of medical journals to 
such an extent that thirteen of the most recognized journals signed 
a unified declaration in 2001 obliging researchers to declare conflicts 
of interest and sponsors. The declaration also required researchers to 
register all clinical trials, and to assume responsibility for trials, data, 
and timely publication (Angell, 2004).
From our perspective, we also consider the fact that this industry is 
more oriented towards marketing than towards R&D as an expression 
of the crisis of transparency. Figures from the balance sheets of major 
laboratories show much higher marketing expenses compared to 
research expenditures (see Table 5.4).
Crisis of results During the negotiations of FTAs, one of the 
arguments presented by the developed countries is that there is a 
direct relationship between intellectual property protection and 
innovation. But there was an impasse in innovation during the last 
decade of the last century despite a dramatic increase in intellectual 
property protection.
The 1994 TRIPS greatly increased the number of countries granting 
patents to pharmaceuticals and, in subsequent years, as a result of 
FTAs, protection has been increasingly broadened and enforced.
TABLE 5.4 Investment in marketing vs investment in R&D of nine major pharmaceutical 
laboratories in 2002
Firm % of income for marketing % of income for R&D
Merck 13 5
Pfizer 35 15




Eli Lilly 30 19
Schering Plough 36 13
Allergan 42 15
Source: AIS LAC (2002)
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However, Figure 5.2 shows that the number of new chemical entities 
has declined since the mid-1990s. According to the US Federal Trade 
Commission (US FTC, 2003) and the European Commission’s 
Directorate General Competition (DG COMP, 2009), the proliferation 
of patents and the increasing amount of litigation have led to a complex 
network system in which research has become a risky activity. Perhaps 
the intellectual property protection has exceeded a limit after which, 
far from being a stimulus to innovation, it has become an obstacle. 
The 2009 report of DG COMP’s pharmaceuticals sector enquiry 
also concluded that excessive focus on litigation is hampering generic 
competition and weakening innovation (DG COMP, 2009).
The particular case of antibiotics is very illustrative. The number of 
newer and more potent antibiotics has declined over the past couple 
decades as a consequence of reductions in investments in this critical 
therapeutic group. Antibiotics are usually taken over short periods; thus 
it can be seen as more advantageous to invest in products for chronic 
diseases that are consumed over a longer period of time. Moreover, 
many new antibiotics have been developed for infections that are 





















































5.2 Decline of number of new chemical entities of pharmaceutical use, 
1994–2010 (source: US FDA, 2010)
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preserve their effectiveness; thus the sales of these products will be 
limited, regardless of the size of investments in marketing. In this case, 
then, a model exclusively based on intellectual property is not a good 
incentive for R&D (So et al., 2011).
Crisis of relevance Even more worrying than the decline in the number 
of new chemical entities is the fact that the therapeutic value of some 
innovative products is inflated by marketing campaigns and that they 
do not actually solve health problems in society.
The top products sold in the world are statins, products whose 
therapeutic relevance is poor (Greving et al., 2011). Products for sexual 
performance, initially presented as remedies for erectile dysfunction, 
fall into one of the fastest-growing groups of the business. Novel 
antidepressants have increased their sales and indications, despite huge 
doubts about their efficacy. In other words, we have more ‘blockbuster’ 
drugs, but fewer effective responses to health needs.
In 2002, in the United States, the National Institute for Health 
Care Management (NIHCM) evaluated new medicines that had been 
introduced during the 1990s. Almost 60 per cent were active principles 
already in the market, with only minor modifications, very little 
innovative value, and very little therapeutic gain (Chokley, 2002).
In France in 2002, the prestigious newspaper, Prescrire, published an 
evaluation of commercialized medicines spanning 1981–2001: just 3.1 
per cent represented an authentic therapeutic innovation; the rest of 
the products were effectively ‘me too’ products (Prescrire, 2002). This 
is commonly the case, because companies face much lower risk when 
they invest in the modification of successful products than when they 
invest in truly innovative products, despite claims about commitments 
to health and innovation (Angell, 2004).
Technology transfer and local innovation
One of the many promises made to developing countries by the 
developed world and never fulfilled has been the promise of technology 
transfer, and to help with the promotion of local research groups and 
industries.
A study conducted in Argentina, Brazil, Colombia, India, and South 
Africa, sponsored by the International Development Research Centre 
of Canada, showed that, between 2004 and 2008, the majority of 
patents were granted to foreign multinationals, except in India, where 
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most of patents filed and granted were for local industries (Correa, 
2011). The exception in the case of India is certainly not a consequence 
of intellectual property protection. India was one of the few countries 
that used the transition period term under TRIPS to grant patents to 
medicines until 2005. But India also implemented aggressive industrial 
promotion policies in the previous century that helped to generate the 
industry that it has today. These policies were intended to promote 
local development and to improve export revenues; they were not 
specifically aimed at fulfilling local health needs. Thus the drug needs 
of the population of India are still large and access is still unequal.
Another promise of TRIPS and IPR regimes relates to the 
dissemination of the information that leads to inventions: through 
patent information systems, it is said, the scientific community can 
learn about the scientific and technological advances made by research 
groups. However, in recent years, examinations of databases in 
several developing countries have demonstrated that information is 
not transparent and is not intended to facilitate the dissemination of 
research results. Instead, key information remains secret, to encourage 
litigation. Finding which products are covered by one or more patents 
can be both very difficult and expensive (Correa, 2011): the Global 
Fund to Fight AIDS, Tuberculosis and Malaria, for example, uses a 
significant portion of its resources to determine whether patents protect 
a product that it seeks to purchase.
Civil society’s perspective on alternatives
What makes this expensive and inefficient model capable of being 
maintained and expanded? There are two factors: the enormous 
power of the pharmaceutical industry – that is, the monster; and 
the great weakness of governments and intergovernmental spaces. 
Market democracies, especially those located in OECD countries, 
are becoming increasingly the expression of corporate interests, since 
corporate lobbyists have a strong influence on policymaking processes. 
Sometimes, this influence is denounced and scandals come to light, but 
most of the time, it remains hidden in the process (Chomsky, 2011).
Building democratic societies that serve primarily the needs of the 
majority has not been easy, especially in developing countries, and 
there is certainly still a long way to go. That task – which, by nature, is 
the responsibility of governments – has failed. The UN agencies, which 
were established to avoid a third world war, have become forums for 
120 | f ive
debate, analysis, and the development of programmes and strategies 
to make societies more just, more equal, more egalitarian, and more 
democratic. Yet, since they are governmental organizations and 
governments seem to have an increased tendency to respond to interest 
groups, the United Nations has fallen short as well. Governments and 
the United Nations spend too much time, effort, and money responding 
to those who support them. There seems therefore to be an important 
role here for NGOs.
What do we want? We want a model of innovation without intellectual 
property – no more, no less. We want a model that is capable of 
delinking innovation and the price of medicines. Proposals to improve 
the current model, such as patent pools, transfer certificates, or prizes 
to neglected diseases, are insufficient.
There are a few research initiatives that focus on developing cheap, 
very simple interventions, with important gains in public health, such 
as trace elements supplementation (for example zinc for the treatment 
of diarrhoea, or magnesium for hypertension). Even so, there is 
negligible interest in developing these forms of drugs because of the 
poor business prospects that they offer. For example, some meetings 
were organized with industrial parties to discuss the use of magnesium 
in hypertension, but the discussion was abandoned, since there was no 
business perspective: there was only a limited opportunity to develop 
and market a ‘product’, and to ‘create’ a market.
Within the Banco del Sur (South Bank) of the Union of South 
American Nations (UNASUR), the Alliance of NGOs for access 
to medicines has proposed the creation of a prize for innovation in 
medicines for certain diseases – that is, neglected diseases (Banco del 
Sur, 2008). This would also allow us to benefit from innovation as we 
continue our battle against the strengthening of intellectual property 
protection for medicines. The proposal is currently under analysis 
in the Bank. We are optimistic about the outcome of this proposal, 
because the Bank is an entity that considers social investment a priority 
for the regional ambitions of UNASUR.
It is needless to say that there was once a time when innovation arose 
from research groups whose motivation was science, knowledge, and 
solidarity with human suffering. Their results were the subject of open 
debate and always remained in the public domain. Today, innovation 
decisions are no longer to be in the hands of scientists, researchers, and 
universities; instead, corporations, chief executive officers (CEOs), 
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and the value of stocks determine the fate of millions in the world. 
It does not seem that these populations are faring well: not from the 
perspective of society, humanity, or the species, nor according to long-
term analyses. But from the perspective of market fundamentalism, 
this is irrelevant.
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Introduction
Tobacco use is an emerging threat to the health of young persons 
in India, and young persons (10–24-year-olds) constitute 28 per cent 
of India’s population. This is a bigger problem for those growing up in 
a disadvantaged urban setting, where the prevalence of tobacco use is 
especially high. Of those living below the poverty line in India, more than 
40 per cent are children and adolescents. To effectively tackle tobacco 
use among disadvantaged populations, Project ACTIVITY (Advancing 
Cessation of Tobacco in Vulnerable Indian Tobacco-Consuming 
Youth) – a community-based, group randomized trial to prevent the 
onset of tobacco use and to promote tobacco cessation among young 
people (age 10–19) residing in low socio-economic communities in 
Delhi – was conducted during 2007–11. This chapter describes the 
results of the study, which employed qualitative methods to highlight the 
role of youth empowerment in a tobacco-use prevention and cessation 
intervention among socio-economically disadvantaged communities.
In this study, fourteen slum communities were matched and 
randomized to intervention (seven communities) and control (seven 
communities) groups. The two-year intervention was designed to 
target intrapersonal and socio-environmental risk factors to prevent 
the onset of tobacco use and to promote tobacco cessation, using four 
intervention strategies: training workshops; community-based cessation 
camps; interactive activities; and policy enforcement. Peer leaders, 
adult community leaders, and non-governmental organization (NGO) 
personnel were identified and trained to facilitate the intervention. 
Thirty-five focus group discussions (FGDs) with young persons (504 
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individuals) and parents (forty-one individuals), and in-depth interviews 
with adult leaders (seven individuals) were conducted using separate 
FGD and interview guides, respectively, at the end of the intervention.
The study revealed that most of the participants were aware of 
different components of the two-year intervention implemented in 
their communities. All felt that they had gained knowledge about the 
harmful consequences of tobacco use, the provisions of the Cigarettes 
and Other Tobacco Products (Prohibition of Advertisement and 
Regulation of Trade and Commerce, Production, Supply and 
Distribution) Act 2003 (the Tobacco Control Law), and myths related 
to tobacco use and quitting. Young persons participated in intervention 
activities, such as leadership training, rallies, street plays, and tobacco 
cessation camps. Some youth participants reported that their family 
and community members successfully reduced their own tobacco use 
following the intervention. Moreover, the sale of tobacco products 
to minors by tobacco vendors in their community also diminished. 
Adult community members supported youth participation and created 
tobacco-free zones. Parents and adult leaders reported that they 
benefited from this programme, which brought about change in both 
their own and community members’ perceptions towards tobacco use, 
and that they looked forward to similar interventions.
The chapter concludes that engaging young persons as change 
agents to prevent tobacco use and to promote tobacco cessation in 
socio-economically disadvantaged communities may be an effective 
public health strategy to counter the vicious cycle of tobacco use and 
poverty.
Background
Globally, poverty is both a cause and an effect of tobacco use. 
Dealing with the tobacco burden is especially important in resource-
poor, low- and middle-income countries (LMICs), where 80 per cent 
of the world’s smokers and the majority of smokeless tobacco users 
reside and where tobacco-related deaths, as well as illness, are highest 
(WHO, 2011). A major reason for high tobacco burden in LMICs is 
the shift in focus of the tobacco giants from developed to developing 
countries, targeting vulnerable women and children, who are still 
largely non-users (Gilmore et al., 2015). Across the globe, prevalence 
of tobacco use is highest among the poor (WHO, 2004). This has 
major implications, threatening the achievement of the United Nations’ 
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Millennium Development Goals (MDGs) of eradicating extreme 
poverty and hunger, as well as supporting development, in LMICs.
Tobacco use by the poor has immediate short-term, as well as 
long-term, adverse economic effects. As an immediate consequence, 
increased spending on tobacco products by the poor diverts financial 
resources from other basic necessities, such as food, shelter, education, 
and health care (WHO, 2004). Thus tobacco affects not only the user, 
but also the entire family and, more importantly, the children. It has 
been estimated that, in India, household expenditure on tobacco ranges 
from 0.54 per cent to 6.3 per cent in rural, and 0.5 per cent to 7.24 
per cent in urban, households (John, 2008), with spending reported 
to be much higher in China (17 per cent) and Mexico (9–22 per cent) 
(Gong et al., 1995; Vazquez-Segovia et al., 2002). In the long term, 
continued tobacco use causes the poor to succumb early to adverse 
health effects, such as cancers, cardiovascular disease, and respiratory 
diseases. This leads to additional healthcare costs for both the 
patient and the government, and represents an additional financial 
burden in the form of loss of income and absenteeism, leading to 
yet further impoverishment (WHO, 2004). Tobacco consumption 
impoverishes about 15 million people in India, and estimates indicate 
that direct expenditure on tobacco would increase rural and urban 
poverty rates by 1.5 per cent and 0.72 per cent, respectively (John et al., 
2011).
Low socio-economic status (SES) is a strong determinant of tobacco 
use among adolescents. According to a World Health Organization 
(WHO) report, low parental income and education are independently 
associated with higher adolescent smoking rates (WHO, 2010). The 
report also suggests that disadvantaged adolescents are more likely to 
have parents who use tobacco and to have a permissible attitude towards 
tobacco use, peers who use tobacco, easy access to tobacco products, 
exposure to targeted advertising, and lack of supportive tobacco-free 
environments, all of which are conducive to tobacco uptake in this 
group. Furthermore, less advantaged adolescents are more likely to 
continue tobacco use into adulthood as compared to those that are 
better off. The less-advantaged group experiences higher stress levels 
as a result of unemployment and poverty, and thus perceives tobacco 
use to be a stress-reliever (Haustein, 2006).
India, which is the world’s second largest consumer and third 
largest producer of tobacco products in the world (WHO, 2015), 
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also has the highest number of adolescents in the world (UNICEF, 
2012a). Of those living below the poverty line in India, more than 40 
per cent are children and adolescents (UNICEF, 2012b). Moreover, 
60–80 per cent of the children in India live in low-resource settings 
(PLAN, 2005). Adolescence is the age at which experimentation with 
tobacco most commonly begins (US CDC, 2001). However, in low 
SES communities in India, the age of initiation has been reported to 
be as low as 6 years old (Arora et al., 2010a). Consistent with the 
global fact that tobacco use is higher in the poor, a previous study 
conducted by the authors with students in sixth and eighth grades 
in thirty-two schools in Delhi and Chennai demonstrated that the 
prevalence rate for ever having used any tobacco product was 18.9 per 
cent for government school students (representative of low SES), as 
compared with 12.2 per cent for private school students (representative 
of high SES) (Mathur et al., 2008). A recent publication by the 
authors suggests that the prevalence of ever having used and current 
use of tobacco among adolescents (10–19 years old) staying in low 
SES communities, including communities participating in the study 
reported in this chapter, is 8 per cent and 4.88 per cent, respectively 
(Arora et al., 2010b). Data from a biochemical validation study of these 
respondents suggest that the actual prevalence of current tobacco use is 
almost double that of the current self-reported estimate (Dhavan et al., 
2011). Poor students experience greater psychosocial risk for tobacco 
use as compared to those of high SES (Mathur et al., 2008). Another 
study conducted in Mumbai with 400 street children engaged in petty 
jobs observed that the average income of these children was INR29 
(that is, less than US$1) per day and that a variety of tobacco products 
were consumed by these children: most commonly, gutkha (a mixture 
of tobacco, areca nut, catechu, and flavouring substances), which was 
consumed by about 46 per cent of the children (Path Canada, 2002). 
This was followed by beedi (a local hand-rolled cigarette), cigarettes, 
and other products in that order. The study also suggested that, among 
these children, the highest expenditure was on gutkha (more than INR6 
per day) and that the spending increased with increasing income up to 
INR200 per day.
As observed in the developed countries, several individual, as well 
as socio-environmental, factors have been shown to be associated with 
tobacco use among young persons in the Indian context (Perry, 1999; 
Reddy et al., 2006; Stigler et al., 2006). Intrapersonal factors, such as 
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social susceptibility to tobacco use, advocacy skills, and self-efficacy, 
and socio-environmental factors, such as the perceived prevalence of 
tobacco use, exposure to tobacco advertising, and a lack of support for 
tobacco-control-related public policies, were found to be consistently 
associated with tobacco use among children and adolescents (Stigler 
et al., 2006). Also, other factors, such as tobacco use by peers and 
parents, the social acceptability of tobacco use by adults, and the easy 
availability and accessibility of myriad varieties of tobacco products, are 
important to address for prevention and control of youth tobacco use. 
Children and adolescents belonging to the low SES group are exposed 
to a pro-tobacco environment in their homes and neighbourhoods, and 
this group also lack the necessary skills with which to resist peer pressure 
as compared to the better-off, all of which are important contributors 
to tobacco use among this group (Mishra et al., 2005).
Because poverty and tobacco use are closely associated with each 
other, strategies to deal with these also need to be linked. Community 
mobilization is a promising concept, with the potential to contribute 
to both poverty alleviation and tobacco control programmes (Dongier 
et al., 2003; Forster et al., 1998). Such community involvement 
gives control of decisions and resources to local community groups. 
Well-designed programmes with a major community involvement 
component are inclusive of the poor and the vulnerable groups, build 
positive social capital, and give representation and a voice to the poor in 
community, as well as government entities, and thus such programmes 
are more responsive to the needs of the poor (Dongier et al., 2003). 
Such a process has been employed in the National Rural Employment 
Programme (NREP) in West Bengal, India, where public participation 
through the local governing bodies called panchayats have resulted in 
the decentralization of implementation authority from the central and 
state governments, granted instead to those better acquainted with local 
needs (John, 1992). Hence the projects have been more responsive to 
local needs and received wide public support. Focusing further on the 
community, the United Nations Population Fund (UNFP) recommends 
empowering the young persons in the communities by providing them 
with education, opportunities, and resources for enhancing the overall 
health of the communities (UNFP, 2003). Youth empowerment is 
now employed as a frontline strategy in tobacco control (Altman and 
Feighery, 2004). Peer-led health activism has been employed elsewhere 
in a school-based tobacco prevention intervention in India, where the 
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intervention was able to reduce the prevalence of tobacco use by 17 per 
cent in the intervention group, as compared to a 68 per cent increase in 
the control group (Perry et al., 2009).
Offering help to quit through treatment facilities for tobacco 
dependence is an important measure recommended by the WHO 
for tobacco control (WHO, 2008). Behavioural counselling alone is 
recommended as an effective treatment for tobacco dependence among 
adolescents. A number of clinical trials conducted with pharmaceutical 
aids, such as nicotine patches and Bupropion, have shown limited 
success among young people in the form of low quit rates, low 
sustained abstinence at three and six months, and rapid relapse after 
stopping drug therapy (Colby and Gwaltney, 2007). Pharmacological 
treatments for tobacco cessation are expensive for the poor population 
in India. A pack of ten Bupropion tablets can cost anywhere between 
Rs60 and Rs400 (depending on the brand), and the complete course 
lasts for between seven and twelve weeks (meaning a total cost for 
the full Bupropion course of Rs540–9,660). A pack of ten nicotine 
gums (Nicorette) can cost around Rs50 and the complete course lasts 
for about four to six weeks (making total cost for a full nicotine gum 
course of Rs980–1,120, assuming that the person starts with ten gums 
a day and reduces by two gums a day each week).
Currently, there are only nineteen tobacco cessation clinics (TCCs) 
in India, located in tertiary care hospitals that cater to twenty-nine 
districts out of the forty-two included within the National Tobacco 
Control Programme (NTCP), launched in 2007. The majority of 
these TCCs are linked to psychiatric clinics. The taboo associated with 
mental illness leads to hesitation among the patients, especially children 
and adolescents, to seek treatment in these TCCs, which hesitation is 
complemented by lack of knowledge about cessation services and lack 
of access to these hospitals, especially among the poor. Because of the 
stigma attached to visiting the TCCs, it is necessary that community-
based innovative programmes for the prevention and cessation of 
tobacco use are developed and tested in India. These interventions 
engaging with children and adolescents are innovative, with trained 
and converted adolescents acting as agents of behavioural change in 
the community. Moreover, the number of TCCs is inadequate to reach 
the 275 million tobacco users in the country; thus efforts beyond the 
government’s initiative on tobacco cessation need to be tested and 
scaled up.
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Evidence suggests that there are large numbers of poor children and 
adolescents in low-resource settings in India who are highly vulnerable 
to tobacco use. Hence targeted interventions are deemed to be necessary 
for this group before experimentation with tobacco begins. There is 
a need for low-cost, community-based tobacco-use interventions for 
socio-economically disadvantaged young persons living in low-income 
communities in India.
Based on their previous experience of developing settings-based 
interventions for the prevention and control of tobacco use (Perry et 
al., 2008, 2009; Stigler et al., 2007), the authors, in collaboration with 
University of Texas, embarked upon Project ACTIVITY in fourteen 
low SES communities of Delhi, India, to address the prevention and 
cessation of tobacco use among young persons belonging to these 
communities (Arora et al., 2010b). This chapter describes how Project 
ACTIVITY changed community norms by means of improving 
knowledge and positively altering perceptions of community members, 
and hence changing their tobacco use behaviour, particularly among 
those belonging to the poorer section of the society, who experience 
higher exposure to market forces perpetuated by the tobacco industry. 
In doing so, this chapter focuses on youth empowerment and leadership 
as key strategies for mobilising the community and influencing 
community norms. Also, this study tested for the first time the use 
of technology-based strategies such as mobile health (m-health) for 
tobacco-use prevention and cessation in low SES Indian settings.
Materials and methods
Study design Project ACTIVITY is a community-based, group 
randomized trial, designed to test the efficacy of an intervention that aims 
to prevent the onset of tobacco use and to promote tobacco cessation 
among young persons (aged 10–19) residing in low SES communities 
in Delhi. Fourteen slum communities were matched and randomized 
to intervention (seven communities) and control (seven communities) 
groups. Communities in the intervention condition received a 
community-based, multi-component intervention implemented across 
two years (2009–11). Communities in the control group received free 
eye and dental care services as a token of participation in the study.
A qualitative study was conducted post-intervention (in 2011) to 
assess the perspectives of young persons, parents, and adult leaders 
through FGDs and in-depth interviews in the seven intervention 
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communities. Repeated surveys of participants before (2009), during 
(2010), and after (2010) the intervention were conducted to evaluate 
the efficacy of Project ACTIVITY, and the results from these surveys 
are under review for publication elsewhere. Ethical clearances for the 
study were obtained from the Independent Ethics Committee (IEC), 
Mumbai, India, and the Institutional Review Board (IRB), University 
of Texas Health Science Centre, at Houston, TX. Project ACTIVITY 
was funded by Fogarty International Center (FIC) and the National 
Institutes of Health (NIH), Award #R01TW007933.
Study setting Communities were recruited systematically from a list 
of forty-four registered resettlement colonies and Jhuggi Jhopri (JJ) 
clusters/slums (1,079) obtained from the Municipal Corporation 
of Delhi (Arora et al., 2010a). The eligibility criteria for the study 
included:
• a resettlement colony with a neighbouring JJ cluster;
• residence within a radius of 25 kilometres from the research office;
• more than 500 households in each of the resettlement colony and 
the JJ cluster;
• no demolition during the study period; and
• the presence of a known NGO working in the community and 
willing to participate.
The local NGOs provided a channel for establishing connectivity 
with people residing in the community. Before randomization, the 
communities were matched based on similar demographic profiles 
(such as ethnicity, religion, language, occupation of adults, number 
of households, population per block, school-attending/non-school-
attending children living with family, etc.).
Participants Thirty-five FGDs were conducted with 504 young persons 
(including boys and girls, aged 9–21) and forty-one parents (including 
men and women, aged 35–50) in all of the intervention communities. 
Twenty-eight FGDs were conducted with young persons in four groups 
based on age and gender (that is, 9–14-year-old boys, 9–14-year-old 
girls, 15–21-year-old boys, 15–21-year-old girls), and seven adult 
FGDs were conducted separately by gender. Each group comprised 
between eight and ten participants (both literate and illiterate, and 
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tobacco users and non-users). In-depth interviews were also conducted 
with seven adult community leaders (including men and women, 
aged 35–70) residing in each of these intervention communities. The 
purpose of conducting the discussions with different groups was to 
reach as many groups of young persons and adults as possible, and to 
obtain the wider perspective on the issue, so as to be able to triangulate 
emerging findings and confirm impact as reported.
Data collection and analyses The FGDs were conducted with the use of 
two separate FGD guides, one for parents and one for young persons. 
The guidelines comprised a list of semistructured questions in Hindi. 
Parents and young persons were asked to share their awareness level 
of the tobacco-related programme run by Health Related Information 
Dissemination amongst Youth (HRIDAY) in their communities and 
their participation in different activities as part of Project ACTIVITY. 
They were also asked about any new information on the health 
consequences of tobacco and various provisions of the Tobacco 
Control Law. There were some questions on any changes in their own, 
their families’, and their communities’ views towards tobacco use and 
tobacco cessation in the last two years. In addition, there were some 
questions such as ‘Did you notice any change in yourselves, your family 
members and in your community with regard to tobacco use practices?’, 
and ‘Were strategies employed like rallies, street plays, peer leadership 
effective, useful and empowering?’ Participants were also asked to share 
their opinions on the need to run such programmes in the community.
In-depth interviews were conducted with community adult leaders 
using an interview guide. Adult community leaders were asked to 
share their opinions on tobacco use among adults and children in 
their communities. They were asked about any initiative to enforce 
provisions of the Tobacco Control Law within the community. Their 
opinion was also explored on quitting tobacco – that is, the ideal age 
at which to quit, and the support and type of support needed for 
quitting. Some questions were asked such as ‘In your opinion, if a 
tobacco user decides to quit tobacco, whom would he/she approach?’, 
and ‘What kind of information would he/she need?’ The FGDs and 
interview guides were translated and conveyed in the local language of 
the participants (that is, Hindi). The discussions were conducted at a 
scheduled time and place, at the convenience of the participants and 
within the community.
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Triangulation of data from youth and parent FGDs and interviews 
with adult leaders was employed to increase the credibility and 
validity of results (Bryman, 2012). The confidentiality of responses 
during FGDs and interviews was assured. A moderator, assisted by 
a notetaker, conducted the FGDs and interviews. Each FGD and 
interview lasted for about 35–40 minutes, was audio-taped, and was 
later transcribed and translated into English to ensure reliability of the 
data. NVivo software was used to develop the coding scheme, and the 
data were coded and organised under finalised themes congruent with 
the purpose of the study (Morse and Richards, 2002).
Project ACTIVITY intervention The two-year intervention embraced 
multiple comprehensive, community-based, cost-effective strategies to 
promote awareness and skills around the prevention and cessation of 
tobacco use among young persons (Jarvis and Wardle, 2006; Milton et 
al., 2004; Perry et al., 2008; Sussman, 2002). The intervention model 
was based on social cognitive theory (Bandura, 1986). Intervention 
strategies were employed to influence intrapersonal and socio-
environmental risk factors to prevent the onset of tobacco use and to 
promote tobacco cessation (Arora et al., 2010a). These strategies are 
described in Figure 6.1.
Project ACTIVITY intervention material consisted of a colourful 
and pictorial booklet on tobacco cessation, activity manuals for adult 
leaders, peer leaders, and NGO personnel, a pictorial comic book 
for children, pictorial situation cards, interactive board games, and 
colourful handouts, developed to sensitize community members to 
various aspects of tobacco.
Strategies and implementation The four intervention strategies 
included:
• training workshops for project staff, partner NGOs, youth peer 
leaders, and adult community leaders;
• community-based interactive activities and outreach programmes;
• community-based cessation camps; and
• enforcement of the key provisions of the Tobacco Control Law in 
India.
Peer leaders, adult community leaders, and NGO personnel were 
identified and trained to facilitate the intervention programme, and 
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served as intervention implementers and important change agents in 
the community. In the first year, the intervention included six interactive 
activities, which made use of films, street plays, rallies, and role play. 
The second year of intervention was implemented with the help of 
a support group, comprising adult leaders and young people already 
motivated to become leaders and agents of change in their communities, 
focused on the issue of tobacco-use prevention and cessation, as well 
as the enforcement of the tobacco control laws through leadership 
education.
The peer leaders were provided six weeks’ extensive training to 
enhance their leadership capacity and to motivate them to work 
collectively, with trust and cooperation, towards change in their 
respective communities. The first week was dedicated to group 
building followed by group visioning, and then community mapping 
to learn about tobacco-use norms, tobacco vendors’ familiarity with 
the Tobacco Control Law, and barriers to adhering with some of its 
provisions. The programme devoted extensive sessions of advocacy 
skill building among the youth leaders to help them to communicate 
effectively, and also trained them to engage community members 
individually and in groups to understand the norms and motivations 
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6.1 Project ACTIVITY intervention strategies
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Multiple community-based interactive activities and tobacco 
cessation camps, an SMS text campaign, and outreach programmes 
were organized in the second year of the study. Repeated sessions for 
each activity were carried out at different strategic locations in the 
communities to reach the maximum number of children and young 
persons enrolled in the study. Community-based cessation camps were 
organized to provide access to group counselling services and face-to-
face counselling for tobacco cessation. All activities were life-skills-
based to build skills among young persons so that they could effectively 
prevent and reduce tobacco use among their peers both now and in the 
future.
Process measures To assess the fidelity of the implementation of 
intervention components, feedback from youth leaders and adult 
leaders was collected. In the first year of intervention implementation, 
feedback forms for all activities were completed by peer leaders, adult 
leaders, and project staff at the end of each session of the activity. In the 
second year, FGDs and interviews were conducted with peer leaders 
and adults to collect their feedback after each session. Attendance 
records for each session were also maintained.
Results
The results from the FGDs and key informant interviews with 
parents, adult community leaders, and youth leaders are presented 
in this section, grouped under the themes that emerged from these 
discussions.
Awareness about tobacco and its multiple adverse impacts The majority 
of parents felt that they learned many new things related to tobacco 
because of the intervention. During the discussions, it was revealed 
that the children who were involved in the intervention did share 
the information with their parents and family members. Parents 
reported hearing new information, such as about the ill-effects of 
tobacco use (of which they were not aware) from their children. 
One of the parents said: ‘I used to smoke one to three cigarettes but 
my children opposed this habit by saying that it can cause throat 
problem[s] and cancer.’ Parents could recall having seen pictures 
of cancer victims during different programme activities, which they 
felt were threatening and were effective in motivating tobacco users 
to quit. One parent shared: ‘There were two to three users in our 
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street but [they] quit tobacco use completely when they saw these 
pictures.’
Youth participants in all of the groups shared that they received new 
information from the intervention. They also talked about the harmful 
health effects of tobacco. One of the boys shared: ‘We watched a film 
through which we came to know about the harmful effects of tobacco.’ 
They also mentioned that use of tobacco leads to various illnesses, such 
as hair loss, cataracts, weakness of limbs, brain damage, throat cancer, 
etc., and also learned how they could help their tobacco-using friends 
to quit. The majority of boys aged 9–14 also mentioned that ‘[t]obacco 
use not only causes wastage of money, but it also leads to illnesses such 
as throat cancer’. They also came to know about the harmful effects 
of tobacco on the environment, and how it may deteriorate the social 
status and the economic position of a person. One of the girls aged 
9–14 shared: ‘Tobacco use is nothing but wastage of money.’
The girls aged 9–14 also reported receiving information about the 
various types of tobacco (smoking, chewing) such as gutkha, cigarette, 
beedi, and hookah, and also about snuffing, which involves naswar and 
other tobacco products. Some of the participants mentioned alternatives 
for tobacco. One of the participants suggested that, ‘[w]henever there 
is urge for using tobacco, elaichi [cardamom] should be used’.
Community youth (aged 15–21) and their parents both reported 
becoming aware about the Tobacco Control Law. They shared 
information around issues such as the prohibition of tobacco sales to 
minors and the prohibition of smoking in public, but they conveyed 
that enforcement of smoke-free law still needs to be sufficiently 
strengthened in their communities. One of the parents reported:
If we ask children to go and buy gutkha for us, they refuse as 
a result of intervention and inform us that it is a punishable 
offence, so we have also stopped sending our children to buy 
tobacco for us.
One of the adult leaders who owned a shop shared: ‘I do not give 
tobacco products to minors, I explain [to] them that it is illegal and 
their parents also understand and cooperate now.’
The majority of parents and youth participants shared that the 
intervention helped in changing certain perceptions related to tobacco 
use. One of the young persons shared: 
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Earlier people used to take tobacco to get relief from tooth ache, 
and used to smoke to get relief from gastric problem but after 
getting information that tobacco use is addictive and may cause life 
threatening diseases, they think before consuming it.
In most of the cases, immediate family members, such as a father or 
brother, made an attempt to quit tobacco use during the intervention. 
In certain cases, young persons too reported quitting. Some girls aged 
15–21 shared: ‘A sudden change in the perception of tobacco users 
was difficult to achieve but small changes in practices were observed 
such as decrease in the number of cigarettes used by an individual in 
a day.’
Many of the adult leaders also shared that the intervention was able 
to clear some of the myths regarding tobacco use. As one participant 
shared: ‘Earlier we thought that tobacco use can ease dental pain and 
abdominal discomfort. Now we tell our family members and others, 
if there is pain in their teeth, they should go to the doctor and people 
listen to us.’
Effective community mobilization strategies The majority of parents 
shared that their children and community members were involved in 
the ‘tobacco control programme’ organized by the research group. 
They were aware of all of the activities of the intervention, such as 
health-focused films, rallies, cessation camps, and interaction with 
tobacco vendors. They shared that the rallies and films were very 
effective in disseminating information related to the harmful effects of 
tobacco use. They appreciated the intervention effort and expressed 
the need to organize such interactive sessions at regular intervals. Very 
few participants were aware about the messages sent to them via text 
on their mobile phones, however, informing them about the harmful 
effects of tobacco use and ways in which they could prevent its uptake 
among young persons. Most of the parents were not sure about the 
duration of the intervention; according to them, it varied from six 
months to more than two years.
For adult leaders, rally seemed to be a favourite medium with 
which to spread awareness: ‘People come out and listen to slogans 
raised by youth, it really made an impact.’ They were also aware of 
the street plays, but most could not watch the performance. Tobacco 
cessation camps were appreciated by all, although some participants 
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expressed their concern about the timings and duration of the camps: 
‘Tobacco cessation camps should be organized on a holiday and in 
the evening.’
Girls aged 9–14 mentioned that they organized camps and played 
the game ‘card jodo’ (a join-the-cards board game), which was a skill-
building exercise to learn about the harmful consequences of tobacco 
use, about tobacco cessation, and about the Tobacco Control Law. 
Most of the youth leaders shared their experiences of working as 
support group. One of the girls mentioned:
My father used to smoke beedi extensively and I was scared talking 
to him about this habit however, after the intervention, without 
any hesitation, I could tell him about the ill-effects of the tobacco, 
due to which he has reduced his beedi consumption.
The majority of youth leaders reported that they were very 
enthusiastic about being members of support groups.
They also added that they completed a survey of shopkeepers selling 
tobacco products and made them understand some provisions of the 
Tobacco Control Law. Most of the selected youth leaders attended 
the six-week-long leadership training and were highly appreciative of 
saathi dal neta training (training for peer leaders), finding it very useful 
and effective: ‘We learnt to talk about tobacco with confidence from 
the programme.’ Boards with advertisements of the ban on sale of 
tobacco products to minors were distributed among shopkeepers. As 
quoted by one girl: ‘We distributed boards which had information that 
selling tobacco to children below 18 years is an offence.’ They further 
conveyed that they interacted with the tobacco vendors, distributed the 
warning boards, and persuaded them to display these. Inculcation of a 
sense of ownership by these youth and other community members for 
the programme was evident, with the youth participants often referring 
to the programme initiatives as initiatives taken by them, for example, 
‘We distributed boards …’ and ‘We created tobacco-free zones …’ 
(emphasis added). Adults too displayed ownership: ‘We used to tell 
tobacco users …’
The majority of the youth leaders reported that they shared the 
information with their family and friends. They often went home and 
passed the information to their parents by talking to them or by showing 
them the materials given. One of the girls aged 15–21 mentioned: ‘The 
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pictures given in the book were very effective in making a mark in the 
minds of people about the problems caused due to tobacco use.’
Youth participants across groups and communities participated 
in intervention activities, such as leadership training, rallies, street 
plays, and tobacco cessation camps. Boys aged 9–14 participated 
enthusiastically in the rally, street play, and camp, in which people were 
informed about the ill effects of tobacco and laws on tobacco control. 
One parent conveyed that children played a very important role in 
dissemination of the information: ‘They have spread the information 
in whole community through innovative health messaging used as a 
part of the programme.’ The peer-to-peer learning approach among 
young persons was widely appreciated and contributed to community 
mobilization for tobacco control. Some members of the community 
considered tobacco-cessation camps to be a very important and effective 
feature of the intervention. One youth mentioned: ‘People approached 
us even after the tobacco cessation camp to know about ways to quit 
tobacco.’ They shared that the intervention was effective for illiterate 
people as well, because their children shared the information and 
showed them pictures of cancer victims, which were very effective.
Boys added that, with the knowledge received through the 
intervention, they felt capable of, and confident in, approaching a 
person and persuading him or her to quit tobacco use, saying that they 
could now easily justify their action. The intervention made them more 
informed and aware of the burden of tobacco, tobacco control laws, and 
strategies to quit tobacco use. But, at the same time, girls mentioned 
that there were also instances in which, even after repeatedly giving 
information, individuals were not interested in quitting.
Some parents actively participated in intervention implementation. 
Other parents encouraged their children to participate in the 
intervention. Initially, there were some inhibitions among community 
members related to the participation of girls in the intervention, but 
they themselves later took the initiative and supported their children 
and project staff whenever they needed support.
Many of the adult leaders agreed that increase in tobacco use was 
a cause of concern and a major issue in their communities, and thus 
they supported intervention through active participation in ensuring 
effective implementation of tobacco control policies.
Some girls talked about playing board games and creating tobacco-
free zones: ‘We have created tobacco free zone[s] and performed street 
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plays during the rally.’ They were also aware of the SMS campaign 
and shared that, ‘[d]uring the programme, SMS was sent regarding 
tobacco control and we enquired by going door to door to check 
whether community people received SMS or not’. Tobacco-free 
zones were created with the help of adult community members and 
peer leaders. Some adult community members, including the women 
and girls, monitored the designated area to check for tobacco use. An 
adult leader reported: ‘We used to request tobacco users not to use 
tobacco products in the areas designated tobacco free zones in our 
community.’
Changing behaviours of community members During the discussions, 
most of the parents shared that many of their fellow community 
members quit tobacco use after the implementation of intervention 
activities. Most of them claimed that they knew friends, or children, or 
family members who had given up tobacco use (gutkha, cigarettes, or 
beedi) as a result of this intervention. Change in community norms and 
practices around tobacco use were also reported by parents and families. 
As one of the parents reported: ‘Shopkeepers used to sell cigarettes to 
children earlier but since the time [the] programme started, things have 
changed for better.’ Another participant commented: ‘After the rally 
which was organized during the programme, the nearby shopkeeper 
stopped selling gutkha to children.’ During the discussions, one parent 
shared: ‘Now, if you sit and observe near our lane, you will not be 
able to find even one person who smokes in front of small children.’ 
Additionally, a mother mentioned: ‘My husband used to smoke two 
bundles of beedi in a day, but now he has quit completely.’
Discussion
Overall, Project ACTIVITY’s intervention strategies appear to have 
changed community norms about tobacco use, improved youth, parent, 
and community member’s knowledge about the negative health effects 
of tobacco, positively altered the perceptions of community members, 
and increased youth exposure to non-tobacco-using role models, 
and hence potentially changed tobacco use behaviour. Evaluation 
of Project ACTIVITY through student surveys complements the 
findings of the current study and suggests that, in the resettlement 
colonies, any tobacco use significantly decreased in the intervention 
group over the study duration, while it increased in the control 
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group; the increase in knowledge about tobacco control policies and 
the harmful effects of tobacco was also significantly higher in the 
intervention group compared with the control group (data yet to be 
published). The effective implementation of tobacco control policies 
in these communities, by means of the project’s activities, may help to 
sustain this behaviour change over time. The most important feature 
that was highlighted as emerging from the study is how potent youth 
engagement and empowerment for tobacco control initiatives can be in 
this community context, and how this can be a useful strategy to secure 
parental and adult leader support.
Previous research from developed countries shows that community 
participation in health-related programmes was restricted to voluntary 
and advisory work for the community members; however, the 
scenario has changed over the years, with emerging local councils 
and groups consisting of active community membership, including 
young people, who are involved in the decision-making process and 
its implementation (Holden et al., 2004). Such community ownership 
and involvement in the project’s activities were also observed in our 
intervention. Traditionally, females in India, especially in rural and 
low SES settings, have not been granted an equal status as compared 
to males when it comes to household decisions, because the male is 
usually the breadwinner for the household (Prakash, 2003). Support 
for the participation of girls in the intervention activities over time 
suggests that the intervention was effective in achieving change from 
initial inhibition to parental support and active participation. Usually, 
there exists a normative vacuum and lack of communication between 
children and their parents in Indian society when it comes to issues 
such as substance abuse. Yet research shows that intergenerational 
communication plays an important role in promoting healthy behaviours 
(Rajiv and Rimal, 2003). This strategy was successfully utilized in this 
intervention, wherein the young persons were able to communicate 
the harmful effects of tobacco and provisions of the Tobacco Control 
Law with the adults and persuade them to change their tobacco-use 
behaviours.
Community-based models are not only effective in empowering 
youth, but also go beyond that by creating an enabling environment 
by positively changing community norms and the enforcement of 
policies (Dongier et al., 2003). Most importantly, with their efforts, 
the young persons appear to have been able to persuade their close 
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affiliates to make an attempt to quit. Congruent with pre-existing 
literature, this represents a change in the community norms wherein 
the children and young adults are now accepted as agents of behaviour 
change. Through peer leadership, these young people have been 
actively engaged as agents of change in tobacco control interventions 
and advocacy efforts in developed, as well as developing, countries 
over the past few years (Arora et al., 2010a; Perry et al., 2009; US 
CDC, 2010). Adult support and reaction to youth advocacy efforts 
are considered critical to the success and sustainability of such efforts 
(Ribisl et al., 2004). In the current study, the young people were able 
to gain support among the adult community members and to establish 
tobacco-free zones in their communities, as well as garner participation 
in the multiple activities of the intervention, which appears to be a 
major reason why the intervention was effective in bringing about 
changes in community environment. Community ownership, which 
is recognized as a key element for sustainability of the programme, 
and environmental and behavioural change (Werner, 2002) were at the 
core of the intervention.
By means of the SMS text campaign, the intervention utilized the 
potential of ‘m-health’ as an innovative and contemporary public 
health strategy to advance tobacco control knowledge in the community 
through mobile phone connections. In developed countries such 
as Norway, the United Kingdom, and the United States, sending 
mobile-based text messages for smoking cessation has been shown 
to be between two and six times more effective as a cessation tool 
than traditional cessation methods (WHO, 2012). Although 86 per 
cent of parents recruited in this study owned a mobile phone, very 
few participants in our study were aware of the SMS sent to them, 
because of limited knowledge of the phones’ messaging function. This 
suggests that technology-based solutions such as ‘m-health’ need to be 
adapted carefully for use in low SES settings, even in urban areas, in 
developing countries such as India. This could be done by adapting the 
text messages and converting these into pictorial or voice messages, to 
account for illiterate and mobile-novice populations.
Sustainability This community-based intervention programme was 
successful in changing the community norms regarding tobacco use 
by means of NGO’s community outreach efforts and by positioning 
tobacco control as a development activity. A multi-component, 
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evidence-based intervention led by trained peer leaders led to 
ownership of the issue, and these trained and committed personnel are 
expected to sustain the momentum of tobacco control. Three factors 
– innovation, leadership education, and self-help group approaches 
– are key to scaling up such intervention programmes for poor and 
disadvantaged groups. In the past, sustained advocacy efforts by 
HRIDAY with the Government of India, backed by robust research 
evidence from a school-based tobacco use prevention intervention, 
Project MYTRI (Mobilising Youth for Tobacco Related Initiatives 
in India), resulted in convincing the Ministry of Health and Family 
Welfare to incorporate school health programmes on tobacco control 
into the NTCP (Arora et al., 2011). By demonstrating the effectiveness 
of the Project ACTIVITY intervention, the authors aim to develop an 
evidence base with which to advocate for scaling up this community-
based programme to complement the NTCP. This proposed scaling-
up exercise will further ensure that a sustainable campaign for demand 
reduction is initiated at national level for supporting effective tobacco 
control in the country.
Limitations Because of the prolonged nature of the intervention (two 
years), peer and community leaders developed a strong rapport with 
the research staff. Because tobacco use among young people is still 
associated with a cultural taboo in the Indian context, it is possible that 
the respondents provided socially desirable responses: an issue described 
as problematic respondent behaviour inherent in qualitative research 
(Collins et al., 2005). This qualitative assessment of effectiveness 
will further be corroborated with analysis of the quantitative surveys 
conducted as a part of the end-line evaluation.
Conclusion
The use of tobacco is deeply rooted in Indian society and the 
behaviour is reinforced by its acceptability as a social norm. Tobacco 
use, being both a cause and an effect of poverty, leads to diversion 
of scarce economic resources, leading to further impoverishment 
of users belonging to the low socio-economic strata of society. This 
vulnerable group experiences higher pro-tobacco risk factors, both 
intrapersonal (such as lack of knowledge, skills, self-efficacy) and 
socio-environmental (for example exposure to tobacco advertising, 
peer and parent tobacco use, easy access, etc.), as compared to those 
arora et  al .  | 147
with higher educational levels and SES. The tobacco industry therefore 
continues to exploit the health and well-being of this low SES group, 
particularly its young members. Interventions involving community 
mobilization by engaging young people as change agents to prevent 
tobacco use and promote tobacco cessation in low SES communities 
in India appears to be feasible and potentially efficacious. This may 
be a crucial public health strategy to effectively counter the vicious 
cycle of tobacco use and poverty that persists globally today. Film 
screenings, street plays, pictorial booklets, rallies, and tobacco cessation 
camps appear to be appropriate and favoured strategies with which to 
mobilize communities, and positively influence community norms and 
health-promoting behaviours. The knowledge and skills gained by the 
participants through such interventions enable them to take control 
of their own health, to create health-promoting environments and 
policies, and also to alter the pervading social norms. Such strategies 
can counter the tobacco industry forces and therefore improve the 
health of the poor.
This was the first community-based, multi-component intervention 
in India targeting youth tobacco use in low SES settings in Delhi – that 
is, among the group most vulnerable to tobacco use, and its related 
health and economic effects. The results of this study, along with a 
subsequent quantitative evaluation, will overcome barriers resulting 
from a lack of research evidence to support the upscaling of the Project 
ACTIVITY interventions to low SES settings elsewhere in India and 
other LMICs.
Evidence available from the developed country settings suggests that 
technology-based strategies such as m-health are effective in tobacco 
cessation. Considering the tremendous potential of such strategies 
to be able to reach a large population quickly, with high availability 
of mobile phones, we tested an SMS-based mobile phone campaign 
for the prevention and control of tobacco use in this low SES setting. 
However, a low level of awareness about the SMS sent highlights the 
need to be careful when using such strategies in a low SES setting. 
Further research should test the use of alternative delivery methods, 
such as the use of pictorial messages or voice messages, instead of text 
messages in Indian low SES settings.
This study was also limited to urban low SES settings. Further 
research is required to develop and test strategies for the prevention 
and control of tobacco use among young people and communities 
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in rural settings. Further research should also focus on tobacco 
cessation among young people (particularly belonging to low SES) 
to address issues such as availability, accessibility, and affordability 
of cessation services, including socio-economic aspects of tobacco 
cessation.
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Introduction
In 2013, 289,000 mothers died from complications during 
childbirth and 6.3 million children died before their fifth birthday (One 
International, undated). The vast majority of maternal and neonatal 
deaths occur in the world’s poorest countries. The less developed 
countries account for as many as 98 per cent of all reported neonatal 
deaths (Zupan, 2005). Maternal mortality is unacceptably high, 
with some 800 women dying from pregnancy- or childbirth-related 
complications around the world every day. Almost all of these deaths 
occur in low-resource settings and most could have been prevented. Of 
maternal deaths globally, 99 per cent occur in developing countries. 
More than half of these deaths occur in sub-Saharan Africa and almost 
a third occur in South Asia.
The maternal mortality ratio (MMR) in developing countries in 2013 
was 230 per 100,000 births, compared with a ratio of 16 per 100,000 in 
developed countries (WHO, 2014). There are large disparities between 
countries: a few have extremely high MMRs of 1,000 or more per 
100,000 live births. There are also large disparities within countries: 
between people with high and low incomes, and between those living 
in rural and urban areas (WHO, 2014). The high number of maternal 
deaths in some areas of the world reflects inequities in access to health 
services, and highlights the gap between rich and poor.
Neonatal mortality rates – that is, the number of deaths predicted 
within twenty-eight days from birth per 1,000 live births – are becoming 
increasingly significant as mortality generally improves among those 
aged under 5, yet the proportion of those deaths that occur during 
the neonatal period increases. With that increase occurring in every 
region and across almost all countries, systematic action is required 
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among governments and their partners to extend effective care 
to women and babies. Over the last two decades, improvement in 
neonatal mortality has been slower than improvements in mortality 
among those aged under 5 in almost all regions. Globally, neonatal 
mortality declined only 28 per cent between 1990 and 2010, from 32 
deaths per 1,000 live births to 23 (an average of 1.7 per cent a year), 
compared with an improvement of 2.2 per cent per year for mortality 
among the under-5s and 2.3 per cent per year for maternal mortality 
(You et al., 2011).
Maternal and neonatal deaths are major health concerns in India. A 
high number of women in India die each year as a result of complications 
during pregnancy and childbirth. The World Health Organization 
(WHO) estimates that, of 529,000 annual maternal deaths, 136,000 
(that is, 25.7 per cent) and almost 30 per cent of neonatal deaths occur 
in India alone. The global neonatal mortality rate (NMR) is 23 per 
cent – yet India has a rate of 32 per cent, worse even than many of its 
immediate neighbours: Nepal has an NMR of 28 per cent; Bangladesh, 
27 per cent; Bhutan, 26 per cent; and Sri Lanka, 10 per cent (You 
et al., 2011).
Even within India, there are variations in MMRs and NMRs between 
rural and urban areas, as well as between highly and less developed 
states. In states such as Kerala and Tamil Nadu, the MMR (in 2011–13) 
is 61 and 79, respectively, whereas in states such as Madhya Pradesh 
and Uttar Pradesh, the respective MMR is 221 and 285 (Office of the 
Registrar General and Census Commissioner India, 2013). Similarly, 
the NMR is highest in less-developed Chhatisgarh and Orissa, at 51.1 
and 45.4 respectively, while it is lowest in Kerala and Tamil Nadu, 
at 11.5 and 19.1 respectively (IIPS and Macro International, 2007). 
Similar differences also emerge in healthcare coverage: the percentage 
of women who had three or more antenatal care visits in Bihar, for 
example, is an abysmally low 17 per cent compared with more than 90 
per cent in the more highly developed states Kerala, Goa, and Tamil 
Nadu.
The direct causes of neonatal deaths include prematurity, low birth 
weight, neonatal infections, birth asphyxia, and birth trauma; the 
direct causes of maternal deaths include postpartum haemorrhage, 
anaemia, obstructed labour, hypertensive disorders, postpartum sepsis, 
and unsafe abortions (Government of India Planning Commission, 
2003). There are, however, several underlying factors that contribute 
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to neonatal and maternal mortality, including limited access to safe 
abortion services, a lack of skilled birth attendants, low antenatal or 
postnatal care coverage, inadequate referrals, compromised access 
to services for those without transport, and low availability of client-
centred, high-quality services.
Effective maternal health services are still not within reach of the 
majority of the Indian population. In 2007, it was reported that while 
more than 75 per cent of women who had a live birth in the preceding 
five years (2000–05) reported receiving antenatal care, the quality of 
that care was far from satisfactory (IIPS and Macro International, 
2007). Few of these women received a complete package of antenatal 
care services: most of these women started antenatal care only after 
their first trimester and only about half reported an adequate number 
of antenatal check-ups. Moreover, only a little over a third (36 per 
cent) reported receiving information about possible complications 
during pregnancy (IIPS and Macro International, 2007).
The Indian government has been taking steps to improve 
maternal and newborn health. Through its National Rural Health 
Mission (NRHM), the government reaches out to pregnant women 
in underserved areas in an attempt to ensure that they receive three 
essential antenatal check-ups and are made aware of the importance of 
a hospital or health centre delivery. In an attempt to improve newborn 
health, the government took steps such as launching an immunization 
project, operationalizing newborn care facilities in districts identified 
as weak, promoting a policy of breastfeeding exclusively to the age of 
6 months, developing the role of community-based midwives (known 
as dai), and implementing dai training to provide key messages for 
newborn health in 166 districts (WHO, 2005). Non-governmental 
organizations (NGOs) have been supplementing these governmental 
efforts, either taking the initiative or following the government’s lead in 
their attempts to improve maternal and newborn health.
This chapter analyses the efforts of, and the outcomes emanating 
from, an initiative on maternal and newborn health (MNH) undertaken 
by Swaasthya, an Indian NGO, in the urban slum areas of Malegaon, a 
small city in Maharashtra, one of the western states of India. Swaasthya 
set up and implemented its MNH initiative in collaboration with the 
Programme for Appropriate Technology in Health (PATH), its lead 
partner for Malegaon, under Sure Start, an initiative intended to 
catalyse sustainable improvements in maternal and newborn health. 
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Swaasthya was supported by the Bill and Melinda Gates Foundation, 
and implemented by PATH in selected districts within Uttar Pradesh 
and urban sites within Maharashtra.
Background
Swaasthya Swaasthya is an India-based NGO focusing on health 
matters. It undertakes intervention research to develop innovative and 
evidence-based community programmes that are replicable, as well 
as sustainable. Since its inception, Swaasthya has been implementing 
health programmes in the slums of Delhi.
Swaasthya follows an enabling and empowering process wherein the 
community is provided with new knowledge and is supported in taking 
well-informed decisions. The planning model adopted is bottom-up 
rather than top-down – that is, Swaasthya engages with the community 
across all stages of programme development and implementation, so 
that communities own the problem as well as its solution.
With regards to its MNH initiative, the organization worked in 
Malegaon, an urban poor slum area with high numbers of maternal 
and neonatal mortality cases. The organization took several innovative 
measures in the area, including empowering the people to participate 
in a community-based accountability mechanism to ensure a better 
quality of health care. The Swaasthya programme also focuses on 
how governments can successfully collaborate with national and 
international organizations to improve maternal and newborn health.
Vulnerable populations The problems relating to maternal and new-
born health are more acute for hard-to-reach communities, such as 
urban slums, in which the majority of the people are poor and vulner-
able, as well as among religious minorities. Slums in India, as else-
where, are usually inhabited by the very poor or socially disadvantaged 
(Sud, 2007). Urban poverty is characterized by food insecurity, 
extremely poor living conditions, and a lack of job security; thus the 
urban poor are vulnerable in multiple ways. Their dependence on the 
informal sector makes their income highly insecure. Events such as 
serious illness typically lead to financial shock for the household. The 
environmental conditions in which they live, and the lack of access 
to water, sanitation, and safe drinking water, increase their physical 
vulnerability (World Bank Human Development Unit, South Asia 
Region, 2004).
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Health conditions among the urban poor are similar to, or worse 
than, those of the rural population and far worse than urban averages. 
Often, the aggregate data for urban populations mask the realities of the 
urban poor. For instance, the rural average for mortality rates among 
the under-5s is 103.7 per 1,000, compared to the urban average of 
63.1, but averages among the urban poor are 101.3 – that is, almost as 
high as the rural averages. Likewise, the infant mortality rates (IMRs) 
for rural, urban, and the urban poor are 73.3, 47, and 66 per 1,000, 
respectively.
Similar patterns are seen with regard to access to health services. 
Home deliveries comprise 68.9 per cent of the total in rural populations, 
as opposed to 30.6 per cent in urban populations and 54.1 per cent 
among the urban poor. Complete immunization by the age of 23 
months in urban populations is 57.6 per cent, as compared to 38.6 per 
cent for rural populations and 42.9 per cent among the urban poor. 
The patterns hold for health behaviours as well. For example, figures 
for the initiation of breastfeeding among the rural population stand at 
21.5 per cent compared to 28.9 per cent for the urban population and 
17.9 per cent among the urban poor (analysis of NFHS 3 (2005–06): 
Agarwal, 2007). Also, the primary health infrastructure in urban slums 
is inadequate, with only one urban family welfare centre or health post 
per 1,500,000 residents (Srivastav and Agarwal, 2006).
Religious minorities are yet another vulnerable population 
subgroup. Various studies conducted during the past decade have 
shown that Muslims have been increasingly socially and economically 
marginalized. As a result, Muslims are the furthest behind in terms 
of education and employment. A review of monthly consumption 
patterns shows that the percentage of Muslims in the bottom 20 per 
cent is far higher than that of those in the top 20 per cent, in both rural 
and urban areas (Sachar et al., 2006). The participation of Muslims 
in regular salaried jobs – especially in the government, or large public 
and private sector enterprises – is much lower than that of workers 
from other socio-religious communities. Instead, Muslims have higher 
than average reliance on self-employment, home-based work, and are 
concentrated in self-employed manufacturing and trade activities. 
Given the informal nature of their work participation, they tend to be 
more vulnerable than other workers (Sachar et al., 2006).
A large number of Indian Muslims inhabit slums and thus are 
likely to have extremely poor health outcomes (Huda, 2007). In such 
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populations, the different sets of vulnerability factors combine not only 
to produce poor health indices, but also to bar the success of routine 
large-scale health programmes. Interventions are required at the local 
level, developed and implemented with community participation: 
‘Local populations have a genuine role in crafting and improving health 
care provision in their neighbourhoods and these programmes have a 
far greater chance of success’ (Urban Health Resource Centre, 2007: 
ix). In order to address the health concerns of vulnerable populations 
effectively, health programmes have to adopt a rights-based approach: 
‘Transparent partnerships with standard protocols, based on the rights 
and entitlements of all citizens would prove very effective in improving 
health of the urban poor’ (Urban Health Resource Centre, 2007: ix). 
The focus then has to be on capacity building within the community, 
so that the community itself can demand accountability from service 
providers and negotiate for better services: ‘Improving efficiency of the 
system through decentralization and convergence between different 
departments, NGOs and ULBs [urban local bodies], is yet another 
critical strategy for improving health of urban poor’ (Urban Health 
Resource Centre, 2007: ix).
Malegaon The city of Malegaon is often called the ‘city of slums’. 
Forty per cent of the Malegaon population live in slums and almost 
all slum residents are Muslim. The Muslim community in Malegaon 
historically grew from waves of migration, particularly from northern 
India. Famine in 1862 forced Muslim weavers in the Varanasi area 
to move to Malegaon, as did the political upheavals in Hyderabad in 
the late 1940s and 1950s. Communal riots, especially from the 1960s 
onwards, have undoubtedly contributed to swelling numbers of Muslim 
migrants to Malegaon (Philipose, 2006).
The slums of Malegaon are lacking in basic amenities such as drinking 
water and toilet facilities. It is not surprising then that Malegaon has 
poor health indicators such as a high population density, a high birth 
rate, a high death rate, and high maternal mortality rates.
Women in this community remain particularly vulnerable to poor 
health outcomes as a result of factors such as low literacy levels, a lack 
of decision-making power, their young age at marriage, high fertility 
rates, and the overall low priority accorded within the family to their 
health. These sociocultural factors combine with limited access to 
health care to result in high maternal and infant mortality.
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Situational analysis of Malegaon
To assess the basis for setting up a collaborative MNH initiative 
in the most vulnerable slums of Malegaon, Swaasthya carried out a 
community-based situation review and analysis, aiming to understand 
the knowledge levels and practices in the community and among the 
care providers with regard to maternal and newborn health. It was a 
way of gauging needs, defining key issues, and identifying assets within 
the defined community. A defined set of MNH issues was explored to 
expose prevailing practices and influential factors. For this purpose, 
the study used focus group discussions and in-depth interviews with 
community members and healthcare providers as its techniques.
Key findings
• Socio-economic status (SES) People in Malegaon live in abject 
poverty, with an average monthly income of INR1,200–1,500 per 
month, to support an average family size of between ten and twelve 
members.
• Health infrastructure and services Malegaon has a total of three 
referral hospitals and nine urban health posts, run by the Malegaon 
Municipal Corporation (MMC). Each urban health post has a staff 
strength of one medical officer, four auxiliary nurse midwives, one 
public health nurse, and ten link workers (for community outreach). 
In addition, there are several charitable hospitals and dispensaries.
• Women from many areas have to travel quite a distance to access 
facilities. Road access and public (or other) transport is poor in many 
areas, yet is necessary to reach facilities, especially during deliveries 
or during the rainy season.
• Community reports frequently cite medicine stocks running out, 
equipment failures, and a lack of availability of care providers and/
or beds.
• It was also said that care providers within the public health service 
were abusive, with behaviours ranging from taunts and threats, to 
physical abuse.
• Community members were unaware of their health entitlements 
and the government’s health programmes and policies.
• Dai (that is, traditional community-based birth attendants, mostly 
without any formal training) were perceived as being caring towards 
women, and also as being able to provide a comprehensive package 
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of services and care. The community seems to pay no attention to 
whether or not a dai has received any formal training.
• Antenatal care Prevalent myths and misconceptions compromise 
pregnant women’s consumption of nutritive foods. For example, it 
is believed that consumption of hot foods, including fish, eggs, and 
meat, can also cause bleeding and miscarriage.
• The community seemed to lack a proper understanding about, and 
therefore did not ensure, rest and a proper diet for pregnant women. 
Pregnant women did not take iron or folic acid supplements through 
either their pregnancy or postnatal periods.
• Pregnant women were registered for antenatal care mostly only 
during the third trimester.
• Only three out of ten women reported going to the hospital during 
pregnancy.
• Delivery Deliveries most commonly took place at home, facilitated 
by untrained dai in unclean settings.
• Women’s control over their decisions regarding place of delivery 
was limited.
• Postnatal and newborn care For the first few days, newborns were 
given a range of foods, including honey, arandi oil, goat’s milk, and 
onion juice.
• Breastfeeding was initiated only by the second or third day of life.
• First milk (that is, colostrum) was discarded.
• Postnatal care was marked by no rest or proper diet for the new 
mother.
The intervention programme was therefore developed on the 
basis of these findings. A set of behavioural change communication 
messages was developed, to be packaged as contextually sensitive and 
appropriate tools.
Maternal and newborn health initiative in Malegaon
Swaasthya set up and implemented the MNH initiative in Malegaon 
in a population base of 50,000 from February 2007 to August 2011. 
The organization implemented the programme in partnership with the 
MMC.
The project population was divided into two slum clusters, situated 
around two different urban health posts within the city. The project 
population was identified in consultation with MMC officials based 
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on the inadequate coverage of, and poor health indicators within, the 
public health service.
The MMC, established in 1998, was a relatively new corporation 
with inadequate healthcare facilities, as well as an inadequate skill set 
with which to tackle some of the grave health problems in the city. This 
led to the need to mobilize the community with regard to maternal and 
newborn health, as well as the need to develop and build the skills with 
which to tackle the problems related to service delivery and quality 
of care at the facility level; it also raised a concern about outreach in 
one of the most closed and conservative community structures in the 
state.
The project in this city thus not only aimed to build the capacity 
of the MMC to improve upon poor maternal and newborn health 
indicators, but also addressed questions related to outreach.
Objectives of Swaasthya’s MNH initiative in Malegaon 
The goal of the MNH initiative was to substantially enhance 
maternal and newborn health by means of effective community action 
among urban poor families dwelling in the slums of Malegaon. Its 
objectives were expressed as follows.
Objective 1 To significantly increase individual, household and 
community action that directly and indirectly improves maternal 
and newborn health.
Objective 2 To enhance systems and institutional capabilities for 
sustained improvement in maternal and newborn care and health 
status.
Towards these objectives, Swaasthya adapted and replicated the 
implementation strategies, processes, and tools that had proved suc-
cessful in its MCH programme in Delhi slums. The integration of such 
prior experience and learning was ensured at all stages – that is, through-
out all of conceptualization, formative research, programme planning, 
capacity building, implementation, monitoring, and documentation.
Key elements of the MNH initiative
Linkages with the MMC Links with the MMC were developed to 
emphasize and ensure its commitment to enhancing maternal and 
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newborn health in Malegaon. Interactions were held with public 
health service functionaries at different levels at Malegaon and firm 
commitments were sought. The aim of these links were to:
• try to reduce the number of maternal and newborn deaths in the 
community;
• enhance understanding about quality-of-care norms among urban 
health post staff, community members, programme managers, and 
community-based care providers;
• ensure the quality of the public health services provided by the 
MMC; and
• ensure the continuity of Swaasthya-led activities beyond the 
conclusion of the MNH initiative in Malegaon.
Behaviour change communication (BCC) Communication strategies 
aiming to change behaviours were used in different forms and among 
different sets of beneficiaries. Interpersonal communication – both one-
on-one and in small groups – formed the backbone of this component of 
the programme. These communicators actively engaged in developing 
and field testing communication tools.
The behavioural change communication component focused on:
• building community awareness of maternal health entitlements, 
programmes, and policies to increase uptake and demand for quality 
maternal and newborn public health services; and
• expanding the knowledge base at individual, household, and 
community levels on maternal and newborn health issues.
A set of clearly articulated key messages was developed on relevant 
topics such as comprehensive antenatal services, comprehensive 
antenatal care, the danger signs during pregnancy, preparing for 
delivery, the danger signs during delivery, the danger signs after delivery, 
comprehensive postnatal services, comprehensive postnatal care, 
comprehensive newborn care, and danger signs for the newborn. These 
key messages were incorporated into interpersonal communication 
tools that were developed using a participatory approach, thus ensuring 
that they were contextually appropriate.
The tools were used by trained, community-based, interpersonal 
communicators during behavioural change communication sessions, 
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conducted as semi-structured discussions in small groups at the 
following intervention levels:
• small, unorganized (unstable) groups of women in different streets 
within the target area, which intervention helped to build community-
level awareness of, and support for, maternal and newborn health 
issues;
• organized (stable) groups comprising pregnant women, lactating 
women, and key persons in their immediate environments, such as 
mothers in law, which sessions ensured peer support in addressing 
some of the sociocultural barriers, facilitated by means of establishing 
linkages at community level with the local government Integrated 
Child Development Services (ICDS) programme; and
• home-based sessions offering individual antenatal and postnatal 
care to women and their family members during home visits, which 
interventions helped to enhance household-level support.
Referral services A system was set up for referring community members 
to appropriate public health services. The purpose of this component of 
the programme was to facilitate access to services and thus to convert 
demand into service seeking. As a part of this referral service, service 
seekers were provided with information about appropriate service 
delivery points, along with details such as location, timing, distance, 
fee structure, and other relevant information relating to the service. 
In addition, service seekers were also provided with referral tokens, 
which were subsequently collected from service delivery points to track 
service utilization.
Capacity building among government functionaries Functionaries 
of the health department as well as the ICDS were included under 
this component. Swaasthya’s approach included a mix of structured 
training workshops, on-the-job training, and handholding sessions. 
The training comprised:
• technical modules on maternal and newborn health;
• skills-building modules focusing on interpersonal communication 
skills, the conducting of behavioural change communication sessions, 
providing referrals, counselling skills, and supervisory skills; and
• perspective-building modules centred on quality of care.
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Community-based accountability mechanisms regarding quality of 
care A mechanism was established under the programme to review the 
quality of services provided under the public health service. It brought 
together the service providers (the system itself), service seekers (the 
community), and facilitators (Swaasthya workers), providing a platform 
from which the community could raise issues and concerns related to 
health services, prompting responses from the service providers, and 
facilitating their seeking of solutions collectively.
Towards setting up of this forum, exercises to build perspectives 
among care providers on issues of quality of care, gender, clients’ rights, 
and ethical considerations were undertaken. Thereafter, Swaasthya 
developed a set of client satisfaction norms based on discussions with 
the community and service providers. These were also displayed at 
service delivery points, so that community members could refer to 
them, helping to shape their expectations of the public health service. 
Subsequently, a mechanism, in the form of exit polls, was set up to 
monitor the adherence of the public health service to these defined 
norms, the findings of which were reported through the quality-of-care 
mechanism.
The quality-of-care meeting continues to observe discussions by all 
representatives once every three months. The meetings also include a 
social audit of maternal and newborn deaths, along with feedback from 
the community about the kind of services being delivered at the urban 
health posts and the community’s satisfaction with these services.
Community-based network groups ‘Cluster groups’ – that is, community- 
based social mobilization networks comprising community members 
– were formed to collectively facilitate and support women’s access 
to health care. Leaders of these groups represented the community’s 
interests at the quality-of-care meetings (see above). Cluster groups 
were formed with a vision of sustaining, convening, and leading quality-
of-care discussions beyond the duration of the MNH initiative.
Results
Between February 2007 and August 2011, Swaasthya reached out 
to 50,000 people across two urban health posts. As a result of strong 
strategies and their effective implementation, the MNH initiative was 
able to influence the community positively, to build capacities among 
members of the public health service, and strengthen the service overall. 
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The programme changed behaviours and practices at individual, 
household, and community levels. Members of the implementation 
team, all of whom were from the community, experienced change in 
their own attitudes and thus in their practices related to health. There 
was also a positive effect on the health providers within the public 
health service.
These changes can all be evidenced with quantitative and qualita-
tive data analysis.
Community effects We analysed quantitative data to assess the effects 
of the MNH initiative on practices related to maternal and newborn 
health. A comparison of yearly averages for a set of four indicators 
between 2008 and 2011 is presented in Figures 7.1–7.4. There was an 
increase in the percentage of women registered within the first twelve 
weeks of pregnancy: from 38 per cent in 2008 to nearly 88 per cent 
in 2011 (Figure 7.1). Data were not available for 2008 for women 
reporting for antenatal check-ups, but a more than threefold increase 
was seen between 2009 and 2011, at 27 per cent and 96 per cent 
respectively.
There was a significant increase in the number of institutional 














7.1 Pregnant women registering for antenatal care within first twelve weeks of 
pregnancy, %
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delivery at an institution increased from 50 per cent in 2008 to 87 per 
cent in 2011 (Figure 7.2).
Indicators related to newborn health also showed strong positive 
trends. The percentage of newborns weighed within 24 hours of birth 






























7.3 Newborns weighed within 24 hours of birth, %
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Finally, data show that, in 2011, nearly all newborns (97 per cent) 
were reported to have been breastfed within the first hour of life in 
contrast to a meagre 21 per cent in 2008 (Figure 7.4).
Qualitative data, in the form of narrations by women from the 
target community, provide further evidence in support of these 
changes. The story of ‘Shabeena’ (name changed) shows the kind of 
change that community women experienced as a result of the MNH 
initiative:
Shabeena, when approached by a field worker during home visits, 
narrated her past experience. When first contacted, she had a 
history of 5 earlier pregnancies and deaths of three children. She 
was ignorant about antenatal care package and also the benefits of 
institutional delivery.
 The field worker gave her the required information on the 
benefits of the antenatal care package and consequences of home 
delivery. The mother-in-law and husband were also told about the 
above information who then agreed for a check-up as well as for 
institutional delivery. The woman delivered her fourth baby at one 
of the government hospitals. The baby weighed 3.7 kgs at birth 
and survived to grow up as a healthy child.
 Her previous ignorance had cost her the lives of her three kids 















7.4 Breastfeeding initiated within one hour of birth, %
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going for check-ups and for institutional delivery. But at the same 
time, I think how could I have done so? I lacked the information 
and moreover, the constant fear of going against the wishes of my 
in-laws prevented me from doing so’.
Muslim women residing in the slums of Malegaon do not practise 
any form of family planning because of religious constraints and 
therefore have large families. However, even though family planning 
was not on the agenda for this MNH initiative, Swaasthya introduced 
a relevant behavioural change communication package in response to 
requests from women in the community.
There is anecdotal evidence of change in the attitudes and practices 
of some of the community members towards family planning. ‘Fatema’ 
(name changed) is an example of a woman who accessed family 
planning services despite her Islamic context:
Fatema, a woman residing in the slum clusters in Malegaon, was 
keen on using family planning measures in order to have less 
children. Her husband, however, did not agree to her suggestion, 
saying they will have the number of kids they are destined to have. 
She attended the sessions on family planning held under this 
initiative and through that was informed about various practical 
measures and resorted to one of those.
Leaders of community-based women’s groups also emerged as 
informal sources of information and support for their neighbours. They 
now accompany pregnant women to hospitals and give them the required 
information on antenatal care, such as the need for early registration, and 
the importance of three antenatal check-ups, of institutional delivery, 
and of two postnatal care check-ups, and about the care of newborns.
Through this initiative, community members acquired a strong 
understanding of quality of care, and their right to demand accountability 
from the public health service for every maternal and/or newborn death. 
Capacities of community leaders were developed to convene discussion 
where a social audit of maternal and newborn deaths was conducted in 
the presence of the public health service representatives.
Effects on Swaasthya’s field workers A significant change was also seen 
among the outreach workers employed within this initiative, who were, 
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as a point of policy, from the community itself. The story of ‘Ayesha’ 
provides some insight into the kind of changes that outreach workers 
experienced:
Ayesha, a 24 year old woman from Numani Nagar, one of the 
intervention areas, worked on the initiative as an outreach worker 
from the start of the project. She shared her experience that 
reflects how her style of living was changed and how she felt 
empowered after she joined Swaasthya. In the past, she used 
to be at home but now she went out for work and she became 
independent. With this, there had been a marked difference in 
her behaviour and way of talking. Her knowledge has increased 
immensely. For example – ‘khana khane ke baad chai nahin 
pite’ (one should not have tea soon after a meal). This has also 
translated into some behaviour change with respect to more 
nutritious dietary intake and the consumption of milk in the 
household has gone up. Before she joined Swaasthya during her 
first pregnancy and delivery, she did not have her check-ups 
done but during the subsequent one, while she was working with 
Swaasthya, she got checkups done at Ali Akbar Hospital. She also 
took IFA [iron and folic acid] tablets and TT [tetanus toxoid] 
injection. Her delivery took place at the hospital, was a normal 
delivery and had healthy a newborn. She also availed benefit of 
JSY [Janani Suraksha Yojana, a safe motherhood intervention 
under the NRHM] (the government scheme) as she had learnt 
about it and the procedures involved.
Public health service effects One of the significant outcomes of this 
initiative was an enhanced and shared understanding of quality of care 
among community members and managers and care providers within 
the public health service. The public health service’s commitment to 
quality of care also increased. A set of quality-of-care norms, developed 
jointly, were displayed at the various health service delivery units. 
Furthermore, the public health service’s accountability to community 
members fell into place, and there were efforts by the service to 
institutionalize its social audits on maternal and newborn death by 
incorporating these into the agenda for monthly staff meetings.
As a result, there was a change reported in the way in which services 
were provided at the urban health posts. This was validated by the data 
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collected through periodic exit polls conducted with clients attending 
these facilities (Table 7.1).
TABLE 7.1 Results of exit polls conducted in December 2010
Indicators reported %
Good behaviour by doctors and auxiliary nurse midwives 84
Administration of complete antenatal care package 96
Provision of counselling services 45
Cleanliness within the facility 100
Observation of right to privacy 50
Sustainability and replicability
Even while designing the MNH initiative, Swaasthya envisaged 
that the sustainability of the interventions and outcomes would be 
addressed by means of a set of key strategies.
• The organization hired fieldworkers from the community itself, so 
as to create a resource pool that would remain with the community 
even beyond the life of the initiative.
• Also towards achieving sustained outcomes, the focus was on 
strengthening public health services and building capacities among 
its functionaries.
• Community-based social mobilization networks were set up to 
ensure, collectively and in a sustained manner, the demand for, and 
access to, high-quality, client-sensitive health services.
• It was planned that responsibility for the various intervention 
elements of this initiative would be handed over to one or another 
of the local stakeholders for sustained implementation beyond the 
initiative, after building their capacities to do so:
° the monitoring of public health services for adherence to quality-
of-care norms through exit polls was to be handed over to 
community-based cluster groups,
° referrals services were to be handed over to community-based 
cluster groups and community-based functionaries of the ICDS 
and health department; and
° the quality-of-care discussion platform was to be handed to 
leaders of the community-based cluster groups.
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The MNH initiative was able to effectively and successfully roll out 
these sustainability strategies. Moreover, with several achievements to 
its credit, it influenced several government organizations and NGOs to 
adapt and replicate, or even scale up, one or more of its components. The 
local authorities hired many of the community group members whom 
Swaasthya had trained. The MMC also adopted and took to scale the 
communication tools developed and used within the MNH initiative.
Conclusion
In the poverty-stricken slums of Malegaon, Swaasthya’s community-
based intervention programme enabled communities to:
• acquire an understanding about maternal and newborn health issues, 
and adopt healthy practices;
• develop perspectives on quality of health care, and define acceptable 
standards and norms for the public health service’s maternal and 
newborn health services; and
• set up community-based mechanisms to demand accountability 
from the public health service.
Through these interventions, the marginalized community’s access 
to quality services was enhanced, and the programme was able to 
achieve a number of positive and desirable outcomes, including:
• an increase in the percentage of newborns breastfed within an hour 
of birth (from 21 per cent to 94 per cent);
• an increase in the percentage of pregnant women registering for 
antenatal care within their first twelve weeks of pregnancy (from 38 
per cent to 87 per cent); and
• an increase in the percentage of women reporting recent delivery at 
an institution (from 50 per cent to 87 per cent).
The Malegaon initiative provides precious learning regarding effective 
healthcare programming for vulnerable, marginalized communities. It 
demonstrates how the inclusion of otherwise marginalized communities 
can be ensured. It also provides insights into useful principles that 
should underpin such initiatives.
To ensure optimal benefits and desirable outcomes from health 
services, programmes need to be designed, planned, and implemented 
sodhi  and sahu | 171
using a bottom-up, participatory approach whereby communities 
are seen not as passive recipients of services, but as actively engaged 
partners, with rights.
Intervention programmes or health services that rely on either service 
delivery or health education, each to the exclusion of the other, are not 
effective. For optimal results, service delivery and demand-generation 
activities need to be implemented in tandem.
Demand-generation interventions must also address gaps in 
information about the health service itself, so as to enhance access and 
thus convert ‘demand’ – that is, the felt need for services – into actual 
service-seeking behaviours.
To ensure the delivery of high-quality services and high levels of 
client satisfaction, a multipronged approach is required, as follows.
• Community-specific desirable key attributes of a high-quality health 
service need to be understood, defined, and adhered.
• Training programmes for care providers should not only include 
technical issues, but also provide orientation on quality-of-care 
concepts and parameters, as well as build communication skills.
• Community members also need to be oriented on quality-of-care 
concepts, parameters, and attributes, so that they can pressure 
managers and care providers to provide high-quality services.
• Community-based mechanisms need to be set up whereby clients’ 
voices and stories of discontent with services can be heard and 
resolved jointly by managers, care providers, and community 
representatives.
The Malegaon experience is, in essence, a reiteration of the rights-
based approach that places the right to health of communities and ‘all 
people’ at the centre when designing, planning, and implementing 
healthcare programmes. It is therefore particularly relevant in the 
context of protecting the health of the poor.
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M I G R A N T S ,  A N D  T H E  D I S P L A C E D
Camilo Pérez-Bustillo
Dedicated to the memory of Doña Ernestina Ascensión Rosario (1934–
2007)
Introduction
In the notorious Dred Scott case of 1857, the US Supreme Court 
held that black people in the United States, whether free or slave, had 
‘had no rights which the white man was bound to respect’, except 
‘[rights] such as those who held power and the government might 
choose to grant’ (Dred Scott v. Sandford, 60 US (19 How) 393, 407, 
405 (1857)). The legal status of African American slaves in the United 
States of the 1850s is broadly analogous to that of the global poor 
within the framework of today’s ‘world system’. In the era of neoliberal 
capitalist globalization, do the poor and powerless have any rights that 
the rich and powerful are ‘bound to respect’?
The right to health is an essential component of the internationally 
recognized economic, social, and cultural rights that shape the 
relationship between human rights norms and issues of poverty and 
inequality. These provisions must be understood as part of an overall 
shift in emphasis in United Nations’ policy towards the characterization 
of state policies that produce and reproduce extreme poverty as the 
causes of serious human rights violations, within the framework of 
what I have referred to elsewhere as ‘international poverty law’ (Pérez-
Bustillo, 2003, 2014). This shift is reflected in the May 2001 Statement 
on Poverty of the UN Committee on Economic, Social and Cultural 
Rights, and in the UN Guiding Principles on Extreme Poverty and 
Human Rights, which were approved by the General Assembly in 
December 2012 (United Nations, 2012).
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In Latin America, entire sectors of society are systematically 
denied the right to health. Capitalist and liberal hegemonic notions 
of rights assume them to be necessarily embedded in exploitative and 
ecocidal market economies. But for the last twenty years they have 
been challenged ‘from below’ by the emergence of counter-hegemonic 
paradigms of human rights and alternative governance, including 
indigenous experiences of community-based autonomy. These 
reimagined notions of rights have arisen from popular social movements 
rooted in the poorest and most excluded sectors of the region, for 
example indigenous peoples and ‘peoples in movement’, such as 
migrants, refugees, and the displaced. They tend to be characterized 
by an insistence upon the equality and interdependence of all rights 
(civil, political, economic, social, environmental, etc.). By prioritizing 
the recognition of the rights of ‘peoples’ (communities), ‘persons’ 
(without borders, as opposed to ‘nation states’), and social interests 
that transcend private property and the market, these alternative visions 
seek to undermine these systems’ universalist, globalizing pretensions 
regarding their theoretical promises of freedom and democracy.
In this chapter, I explore the historical origins of contemporary 
notions of human rights, and what these reveal about where we are 
in the struggle for the globalization of human rights and for the con-
struction of alternative, counter-hegemonic (or anti-systemic) para-
digms of global justice and human rights. Starting with the rape and 
murder of the 73-year-old indigenous woman Doña Ernestina Ascen-
sión Rosario in Mexico in 2007, I present a number of case studies 
from across Latin America to demonstrate that the contributions of 
Latin American experiences are central both to ‘making’ this history 
and to ‘remaking’ it, or shaping the alternatives that may determine 
its liberatory potential. I suggest the outlines of a re-reading of the 
history of human rights and of potential new directions from a Latin 
American perspective, drawing on the contributions of the struggle 
for African American rights. In doing so, I explore initial theoretical 
aspects of the evolving relationship between contemporary grass-roots 
social movements in Latin America, and the emergence of alterna-
tive, counter-hegemonic paradigms of global justice and human rights 
throughout the world (Santos and Rodríguez Garavito, 2005; Dussel, 
2012; Rajagopal, 2003; Zibechi, 2008). In sum, my argument here 
is that Latin American social movements of this kind have contrib-
uted to rethinking and reshaping key aspects of hegemonic paradigms 
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of human rights, which are characterized by largely unexamined 
assumptions as to the supposedly uniquely Western, and specifically 
European, character and origins of contemporary human rights and 
international law.
My approach, which makes use of a number of theoretical frame-
works, assumes that contemporary human rights norms – and their 
conceptual and structural characteristics and limitations – are the 
historical product of the struggles of social movements and their 
impact on evolving patterns of reflection, discourse, and practice. This 
includes examples such as struggles against feudalism, colonialism, 
imperialism, slavery, racism, and national oppression, the exploitation 
of workers, and the domination of women. The largely unwritten 
history of the ‘making’ (Thompson, 1963) of international human 
rights is the history of the ebbs and flows in a non-linear trajectory 
regarding the extent of recognition of the rights of those most margin-
alized and excluded in each historical period. Such an approach also 
involves a distinct rupture with epistemological assumptions of a posi-
tivist, functionalist, and determinist character that are still prevalent in 
many circles. It includes an insistence upon a critical understanding of 
legal definitions of rights in any specific historical period as minimums 
rather than maximums (‘floors’, not ‘ceilings’), and thus as points of 
departure instead of destinations in themselves.
Right to health in the context of hegemonic and counter-hegemonic 
human rights notions and practices
The theoretical implications of contemporary efforts to secure 
a meaningful right to health for indigenous peoples, migrants, and 
the displaced in Latin America and among Latino communities in 
the United States, and the relationship of those efforts with broader 
processes seeking to develop alternative paradigms and strategies of 
human rights advocacy and activism ‘from below’, must be addressed. 
My point of departure for these reflections is the now-lifeless broken 
body, but indomitable spirit, of Doña Ernestina Ascensión Rosario, 
a 73-year-old indigenous woman of Nahua ethnicity (a speaker of 
Nahuátl, the language of the powerful Mexica, or ‘Aztec’, civilization 
devastated by the Spanish invasion, conquest, and colonization that 
began in 1521), who, according to the most reliable available accounts 
(including her own deathbed declarations), was beaten, raped, and 
killed by Mexican military personnel in the Zongolica region of 
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Veracruz in February 2007 (Moncada Cota, 2007a, 2007b; Sieder and 
Sierra, 2010).
Zongolica is one of the poorest, most marginalized regions in 
Mexico, where – as in others such as Chiapas, Guerrero, and Oaxaca, 
and in fact throughout the country, as throughout Latin America – to 
be indigenous is, by definition, to be poor and hungry, and to live 
in ill health. The impoverishment of the country’s indigenous peoples 
leads directly to their dispossession and forced migration, which is 
further exacerbated by the militarization of their communities by the 
Mexican government. This has intensified throughout the last four 
years in the name of the so-called wars against terrorism and against 
drugs, resulting in more than 100,000 civilian deaths and thousands of 
forced disappearances. Doña Ernestina’s case highlights the complex 
issues regarding the right to health in the Mexican context and that of 
Latin America’s indigenous peoples, since it arises in a region in which 
the stereotypical explanation for such a death would reflect the overall 
violations of this right that are characteristic of such communities.
These characteristics are what might lend passing plausibility to 
Mexican President Felipe Calderón’s otherwise ill-founded assertion 
that Doña Ernestina’s death was the result of ‘neglected chronic gastritis’ 
(Sieder and Sierra, 2010: 14)1 and most assuredly not attributable to 
the troops whom she died claiming had ‘forced themselves upon’ her. 
Similarly, when the state Attorney General’s office closed the case in 
May 2007, it concluded that the cause of death was ‘parasitosis’ – yet 
four out of the five medical opinions, examinations, exhumations, and 
autopsies available concur that the death was related to vaginal and anal 
lacerations, and cranial and other contusions resulting from a severe 
beating, and confirm the presence of ‘abundant’ seminal fluids, all of 
which clearly tends to substantiate Doña Ernestina’s own allegations.
Eight years later (at time of writing), no one has been prosecuted 
for Doña Ernestina’s death. Instead, two of the officials in the state 
medical examiner’s office and at the hospital in which she was treated 
have been removed from their positions in apparent reprisal for their 
insistence on the non-official version of her murder, and the case is 
pending before the Inter-American Human Rights Commission, with 
the support of organizations such as Amnesty International. What 
does the ‘right to health’ (or to life, for that matter) mean in a context 
that is so thoroughly marked by issues of gender, racism, poverty, and 
inequality? My hypothesis, based on Doña Ernestina’s case and others 
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of a more collective character that will follow, is that there can be no 
meaningful discussion of the right to health and its implications unless 
such vectors of dispossession and disempowerment are situated as the 
point of departure.
Relevant theoretical frameworks Theoretical frameworks developed by 
scholars such as Balakrishnan Rajagopal, Upendra Baxi, Boaventura 
de Sousa Santos, and Enrique Dussel, among others, are crucial for 
understanding the importance of differentiating between hegemonic 
and counter-hegemonic, non-Eurocentric approaches to globalization 
and human rights. Such approaches also lay the basis for an emphasis 
on the development of alternative perspectives grounded in the Global 
South, as part of broader efforts seeking ‘global justice’. Santos and 
Rodríguez Garavito (2005), for example, identify struggles for global 
justice with the same impulses that have given rise to the emergence of 
what they define as ‘subaltern legal cosmopolitanism’ – that is, a new 
form of globalized, authentically universalist ‘common sense’, which, for 
Rajagopal (2003), takes the form of a reconceptualization of the history 
and implications of ‘international law from below’. Rajagopal draws 
here on Baxi’s (1985, 1986) long-standing emphasis on refashioning 
human rights from a perspective centred on the alleviation of ‘human 
suffering’ and ‘rightlessness’, grounded in turn in his recognition 
that discourses about rights are ‘always and everywhere’ ultimately 
discourses on the state, and on the mitigation and transformation of its 
diverse forms of ‘justified violence’, which annul what he, together with 
Norwegian theologian Hans Egil Offerdal (2003), describes as the ‘right 
to be human’ and/or to a ‘dignified life’. Dussel (2008), meanwhile, 
weaves together strands derived from the philosophy, theology, ethics, 
and politics of ‘liberation’, as he defines it, in the context of the age of 
‘globalization and exclusion’ (with globalization itself understood as a 
form of exclusion on a global scale), the point of departure of which is 
Doña Ernestina’s suffering ‘from the perspective of the victims’. Baxi 
similarly emphasizes how the hegemonic, occidentalist, and Eurocentric 
version of the history of human rights itself reflects and reproduces the 
‘logic of exclusion and inclusion’, which he identifies at the core of 
dominant discourses and practices (Rajagopal, 2003).
Indigenous peoples and ‘peoples in movement’ (migrants, refugees, 
and the displaced) represent key case studies of global exclusion. The 
essence of my argument here is that indigenous peoples, on the one 
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hand, and migrants, refugees, and the displaced (reframed here from 
the perspective of their integrality as ‘peoples in movement’), on the 
other, share key characteristics as groups conceptually and structurally 
excluded from the contemporary global system – groups who have had 
their rights to dignity and equality systematically violated. My focus 
will be on examples drawn from the experiences of indigenous peoples 
in the context of Latin America and of Latino immigrant communities 
in the United States, where an increasing number of those forced to 
migrate from Latin America and those who are forcibly displaced are 
of indigenous origin, in settings such as Alabama, where the second 
largest sector of Latino immigrants is of Guatemalan indigenous 
Mayan origin, and where state anti-immigrant legislation was adopted 
in 2011 severely restricting or eliminating the access of undocumented 
immigrants to publicly funded education and healthcare services. 
Similar legislation has been adopted in states ranging from California 
in 1994 to Arizona, Georgia, South Carolina, Indiana, and Utah 
within the last few years, and reflects equivalent trends in US national 
policy that have been replicated in the European Union and Australia 
as part of the imposition of a new global paradigm following the 
events of 11 September 2001 (‘9/11’) – a paradigm that subordinates 
migration policy to the supposed imperatives of ‘national security’ and 
‘anti-terrorism’.
My approach here reflects Santos and Rodríguez Garavito’s 
(2005) epistemological redefinition of the ‘Global South’, beyond its 
geographical referent, to include all forms of exploitation and suffering 
induced by global capitalism. Their framing of this approach has its 
roots in key categories of dependency and ‘world systems’ theory, and 
includes an attention that I embrace here to the nuances of ‘North–
South’ analysis. These include the extent to which the experiences of 
indigenous peoples and migrants highlights the presence of a deeper 
‘south’ located within semi-peripheral settings such as Mexico, which 
itself constitutes a ‘southern’ domain in the face of the hegemonic North 
embodied by the United States in the form of structures and processes 
such as the North American Free Trade Agreement (NAFTA). This 
also includes counter-intuitive cases in Latin America such as Costa 
Rica and Argentina, which, although located geographically to the 
south, are more prosperous in relative terms and thus have become 
key destinations for those migrating from poorer countries to the north 
(Nicaragua, Bolivia, and Paraguay).
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Similar echoes of complexity are present in the insistence of the UN 
Development Programme (UNDP) on disaggregating Human Develop-
ment Index (HDI) indicators into specific sectors (women, indigenous 
peoples, children, etc.) and regions. This laid the basis for comparing 
trends across regions, and, in cases such as Mexico (classified overall as 
a country of medium wealth with a medium HDI value), for detecting 
correlations and convergences between markedly lower HDI values in 
regions in which indigenous peoples are concentrated, such as Chiapas, 
Oaxaca, and Guerrero. Equivalent patterns can also be seen in cases such 
as Peru, Ecuador, and Colombia, in which racism and ethnic/cultural 
discrimination emerge as key causal factors that reflect the genocidal 
implications of convergent modes of state and market violence.
Guerrero’s Montaña region: A case study Indicators of this kind also 
make it possible to discern implicit correlations at deeper levels of 
analysis, reflected, for example, in the fact that those municipalities 
with the lowest HDI values in the Mexican state of Guerrero (in 
which long-standing tourist destination Acapulco is situated) – which 
also have the highest rates of infant and maternal mortality, lowest 
birth weights, most stunted growth, most hunger, and highest rates 
of preventable childhood mortality from disease – happen too to have 
populations overwhelmingly (80 or 90 per cent) of indigenous origin 
(SIPAZ, 2012). These populations are primarily located in the region 
known as La Montaña (‘The Highlands’), which includes eight of the 
fifty municipalities in the country with the lowest HDI values – values 
that are roughly equivalent to those of Gambia or Rwanda, which are 
among the lowest ranking in the world: 154th and 155th out of the 
172 countries included in the HDI rankings, respectively (UNDP, 
2011). The Highlands are also the communities of origin that expel 
the largest numbers and proportions of their residents into increas-
ingly intertwined circuits of internal and external (international) 
migration, overwhelmingly to the northern, more prosperous regions 
of Mexico itself and to the United States. A leading human rights 
non-governmental organization (NGO) operating in the region, the 
Tlachinollan Human Rights Center, has described the desperate, 
survival-driven character of these engrained, recurrent migration 
patterns with a phrase that encapsulates the underlying dilemmas: 
Migrar o morir (‘Migration or death’) (Centro de Derechos Humanos 
de la Montaña, 2005).
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As Kerry Kennedy (2011), head of the RFK Center for Justice and 
Human Rights, wrote in an open letter to her daughters published 
upon her return from a site visit to Guerrero (‘the poorest area in the 
poorest state in the country’):
To be indigenous in Guerrero is like being African-American in 
Mississippi 50 years ago. People barely subsist in abject poverty, 
and starvation is rampant. Racism has a long, wicked history and 
a stronghold on the present. Those who dare speak truth to power 
are threatened, imprisoned, tortured, disappeared, raped, and 
murdered with absolute impunity.
Abel and his team from Tlachinollan are the civil rights lead-
ers of our times. They arm communities with the tools of activ-
ism, track abuses, confront perpetrators, and forge ahead under 
constant threat of death. They are legal aid attorneys, defense 
bar, community organizers, environmental activists. Tlachinollan 
staff engages both indigenous and peasant grassroots groups, and 
advocates to improve access to legal representation, healthcare, 
housing, education, plumbing, electricity and more. Rising vio-
lence related to the Mexican government’s recent efforts to combat 
narco-trafficking led Abel to condemn excessive militarization and 
denounce abuses. In turn, he and his team have endured increas-
ing threats and violence …
All of this violence, the duplicity, and the impunity take place 
in the context of the horrific poverty and marginalization of the in-
digenous people in rural Mexico. In much of the Montaña region, 
as in so many indigenous communities across Guerrero, access to 
basic services is nearly non-existent.
One man I met left his home at 1 AM to walk down the moun-
tain with his wife and two-year-old, in order to reach the closest 
pharmacy for dysentery medicine at 8 AM. The pharmacy was 
closed.
One community was told the students would need to bring 
their own chairs and desks to school, buy a desk for the teacher, 
and pay the teacher’s salary, even though all of this is supposed to 
be provided by the government. When the community managed 
to jump through all these hoops, instead of sending an educator, 
the government sent a part-time student who was also in charge of 
grounds-keeping.
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For these indigenous children, there are no books at all which 
teach the native languages, traditions, and stories, or hold up a 
single indigenous person as a role model. Classes are taught in 
Spanish, and students are often made to feel ashamed of their 
indigenous neighborhoods, language, and community roots. In the 
midst of widespread poverty, as Abel says, this treatment amounts 
to ‘cultural genocide’ …
Many others talked about the federal government’s granting 
of mining concessions on native lands that are considered sacred. 
These grants are given without consultation with, permission from, 
or plans for revenue sharing with the indigenous communities. 
Environmental desecration is a major concern.
Still others talked about losing whole neighborhoods to migra-
tion, both within Mexico to northern agricultural fields, and to 
‘Tlapa York’, otherwise known as Manhattan and Queens, where 
so many indigenous families from Guerrero have been forced to 
seek work. Migration widows are abandoned to fend for them-
selves and their children. Communities are torn asunder. In the 
fields, conditions are even more horrendous than in the villages 
left behind, as indigenous men and women become indentured 
servants to their employers, and families confront wage theft, child 
labor, and sexual assault.
The intertwined causes (and/or effects) of such migration and dis-
placement include structural conditions of poverty, inequality, and 
discrimination, and preventable illnesses. Inequality and discrimina-
tion can be characterized by systematic violations of the right to a ‘dig-
nified life’, which is typically framed in terms of the evolving categories 
of economic, social, and cultural rights. These include the right to 
health, which is clearly violated in contexts characterized by high rates 
of hunger, and maternal and child mortality. Such conditions are, in 
turn, often induced and/or exacerbated by neoliberal economic and free 
trade policies such as those promoted by every Mexican government 
since 1982, and by environmental devastation and the dispossession of 
land and resources, militarization, paramilitarism, and other forms of 
state terror (reflected, for example, in the so-called wars against terror 
and drugs), which tend to be intertwined with the multiple forms of 
systemic violence inherent in the capitalist mode of production. All of 
this together poses virtually insurmountable obstacles to compliance 
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with Article 28 of the Universal Declaration of Human Rights, one 
of its most sweeping provisions, which demands the construction of 
a ‘social and international order in which the rights and freedoms set 
forth in the Declaration can be realized’ (emphasis added).
Under such adverse conditions, the free exercise of the rights 
‘to migrate’, ‘not to migrate’, and ‘not to be arbitrarily or forcibly 
displaced’, which together lay the basis for the universal right to free 
human mobility derived from Articles 13 and 14 of the Universal 
Declaration of Human Rights, is impossible, in a manner analogous 
to Amartya Sen’s (1998) insistence that poverty itself is fundamentally 
a lack of control over one’s own circumstances, and thus ultimately 
a violation of an individual and collective right to self-determination. 
My approach to the ‘right to health’ in this chapter is, in large part, 
centred on the genocidal implications precipitated by its violations in 
the context of indigenous peoples, as highlighted by Abel Barrera’s 
statement in the extract above.
Indigenous peoples in Guatemala The same kinds of recurrent patterns 
as relate to infant and maternal mortality, hunger, etc. that are evident 
in the Highlands of Guerrero are present in HDI data for Guatemala’s 
primarily Mayan indigenous majority, with equivalent correlations 
between indigenous status, poverty, and ill health manufactured 
by deprivation (Escobar, 2009–10). Given the prevailing levels 
of impoverishment among Guatemala’s indigenous majority (in 
comparison with Mexico, where indigenous peoples constitute a 
minority in the country as a whole, despite being a majority in the 
poorest regions, such as Chiapas, Guerrero, and Oaxaca), 49 per cent 
of the country’s population is malnourished, according to data made 
available in 2007 by the Guatemalan government (which is prone, 
of course, to underreporting), while the malnutrition rate among the 
country’s indigenous majority is a staggering 69 per cent – the highest 
in Latin America and the sixth highest in the world (higher, as of that 
date, than the prevailing continental rates in Africa and Asia). Similar 
rates prevail for incidences of rickets.
The foreseeable results of this routinized holocaust include data 
indicating that 53 per cent of the deaths of children aged under 5 are 
attributable to causes related to malnutrition (Pérez-Bustillo, 2007). 
All of this has led to intermittent ‘waves’ of infant deaths in recent 
years resulting from acute malnutrition in regions of Guatemala such 
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as Chiquimula, mostly inhabited by the Ch’orti indigenous people 
(whose HDI value, at 0.367, is very close to that of the poorest 
communities in the Highlands of Guerrero, and falls between those 
of Sudan and Afghanistan), and Alta Verapaz, in the community of 
San Juan Chamelco, as well as others elsewhere, such as Camotàn and 
Jocotàn.
Indigenous communities in Northern Mexico (Tarahumara moutains, 
Chihuahua) As of January 2012, a similar wave of deaths and 
hospitalizations resulting from hunger was raging in the long-
marginalized Rarámuri indigenous communities located high in the 
Tarahumara mountains of the northern state of Chihuahua in Mexico. 
In one community alone (the municipality of Creel), thirty children 
under the age of 5 had been hospitalized for malnutrition compared 
to four a year previously, while at the same time over 50 per cent of 
Chihuahua’s territory in those regions most afflicted by hunger has 
been ceded to mining operations exploited by transnationals such 
as Canada’s Blackfire Exploration Ltd, which devastate the local 
ecology and do not return any discernible benefits to the communities 
affected.
The theoretical approaches highlighted in this chapter (that is, those 
of Rajaghopal, Baxi, Santos, and Dussel) include attention to the impact 
of recognizing substantive human rights claims within constitutional 
frameworks (as in South Africa, India, Venezuela, Bolivia, Ecuador, 
Colombia, Brazil, and Mexico, to varying degrees), as well as to the 
central contributions of counter-hegemonic social movements to more 
radical processes emphasizing the reconceptualization and redefinition 
of traditional notions of sovereignty, and those relating to hegemonic 
configurations of the nation state and state power, citizenship, 
identity, territory, democracy, and participation. The latter include 
efforts to redress health-related rights in the context of the Permanent 
People’s Tribunal and other tribunals of conscience, emerging models 
of alternative health provided through autonomous structures in 
indigenous communities that reject funding and interference from 
the national government, such as those of the Zapatistas in Mexico 
and their equivalents in contemporary Bolivia and Ecuador, and 
community-based efforts to resist denials of such rights promoted 
by anti-immigrant laws such as those of Arizona and Alabama in the 
United States.
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Origins and prospects The overall trend towards increasing inequities on 
a global scale – which has led Dussel (2008) to characterize this historical 
period as the age of ‘globalization and exclusion’, and others, such as 
Luigi Ferrajoli (2004), to define it as that of ‘global social apartheid’ 
– and its implications can best be grasped ‘from the perspective of its 
victims’ (Dussel, 2008). More specifically, it is imperative to ground 
our critique as to the origins and possible trajectory of the global system 
within those groups most affected by its polarities. This insistence on 
approaching issues of human rights ‘from below’ is closely related 
to that suggested by Rajagopal (2003) in relation to international 
law, and by Santos and Rodríguez Garavito (2005) in relation to 
the overall relationship between law and processes of globalization. 
This perspective is rooted in the critical insight suggested by thinkers 
such as Amartya Sen, Thomas Pogge, and Pierre Sané, and by social 
movements such as Mexico’s Zapatistas, that the essence of poverty 
is in fact the absence of meaningful human rights. (The Zapatistas 
similarly suggested, for example, that it is Mexico’s widespread poverty 
and inequality that makes its democracy dysfunctional.)
This also necessarily implies that poverty can be effectively 
addressed and overcome only if it is approached from a perspective that 
understands it to be a violation of such rights. There is an increasingly 
significant trend in recent jurisprudence from the Inter-American and 
European human rights systems, and from constitutional courts in 
South Africa and India, among others, which seeks to ground human 
rights claims closely connected to conditions of poverty, such as those 
regarding economic, social, and cultural rights, in an underlying right 
to a dignified life (as is already suggested in Article 23 of the Universal 
Declaration of Human Rights).
Willem van Genugten and I have suggested elsewhere that the 
systematic denial of justiciable and enforceable rights to the poor (for 
example in terms of the economic, social, and cultural rights that shape 
their conditions of life in relation to education, work, health, housing, 
land, participation, discrimination, etc.) should be understood as 
a ‘poverty of rights’ (Pérez-Bustillo and van Genugten, 2001) and 
‘inequality of rights’ (Pérez-Bustillo, 2007) that is characteristic of 
excluded and marginalized sectors throughout the world, and which, 
according to Upendra Baxi (1986) and Hans Egil Offerdal (2003), 
results in the denial of their ‘right to be human’ as such. This approach 
builds on Hannah Arendt’s (1951) insistence in her seminal critique 
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of the limits of the Universal Declaration on Human Rights that the 
fundamental human right from which all others flow is the ‘right to 
have rights’, which Arendt argued is disturbingly absent from the 
Declaration (and much of the contemporary normative machinery 
of international law and international human rights) because of its 
emphasis on the protection of the rights of those with recognized 
membership of national communities and thus its failure to recognize 
the rights of the stateless.
All of this includes a recognition of how initially hesitant advances 
at one moment can be completed at a much higher level of complexity 
later, as the result of the pressure of vigorous social movements. A key 
example is the adoption of the Declaration of the Rights of Man and 
the Citizen in 1789 in the context of the early stages of the French 
Revolution, which, despite its classical liberal rhetoric of ‘liberty, 
equality, and fraternity’, denied all three of these dimensions of human 
freedom to millions of African slaves within the French colonial 
empire, to women, and to men who were not property owners. The 
Declaration’s failure to address the issue of slavery was not remedied 
until the rebellion of slaves in Haiti, led by Toussaint Louverture in 
1791, compelled the French National Assembly to finally abolish it in 
1794 (Blackburn, 1988; James, 1963). Despite such initial advances 
in France, and then in the United Kingdom (and only much later 
in the United States and Brazil), the first enforceable international 
convention against slavery and the slave trade was not adopted until 
1926. Similarly, the Nazi genocide was completely ‘legal’ during the 
period in which it was carried out and the first international convention 
against genocide was not adopted until 1948.
Debates in the international community regarding the rights of 
indigenous peoples thus highlight the extent to which the world 
system and hegemonic versions of international law and human 
rights discourses and practices are characterized by inequalities of 
rights. This is particularly so given the fact that the history of efforts 
to secure international recognition of the rights of indigenous peoples 
is completely intertwined with the origins of international law (and 
what we have now come to understand as ‘human rights’). The 
recent adoption of the UN Declaration on the subject is, in this sense, 
simply the latest stage in a continuing and still incomplete process of 
recognition of such rights, which in fact existed before the so-called 
international community itself. These efforts began with early scholars 
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such as Bartolomé de Las Casas, Francisco de Vitoria, Francisco 
Suárez, and Hugo Grotius in the sixteenth and seventeenth centuries, 
who laid the foundations of what has come to be known as the 
‘Salamanca school’, which developed the first systematic approach to 
what we currently define as ‘international law’ and thereby engendered 
its most precocious stepchild, ‘international human rights’ (Dussel, 
2008). The still widely unacknowledged origins of these rights lie in Las 
Casas’ arduous efforts to explore, document, and ultimately critique 
the theological, legal, and ethical bases for the Spanish conquest of the 
New World (Gutiérrez, 1995).
Las Casas’ work drew in large part upon the widespread resistance 
of indigenous peoples to these processes, and insisted upon the legality 
and legitimacy of their assertions of self-defence, sovereignty, and armed 
rebellion (Gutiérrez, 1995). The echoes of their defiance continue 
to resonate today. The new UN Declaration would not exist if there 
had not been a notable resurgence in demands for the recognition of 
the rights of indigenous peoples as a result of widespread controversy 
regarding the implications of the observance in 1992 of 500 years since 
the European conquest of the Americas, the awarding of that year’s 
Nobel Peace Prize to Guatemalan human rights activist Rigoberta 
Menchú, Mexico’s Zapatista rebellion in 1994, and analogous 
movements in countries such as Ecuador and Bolivia (culminating in 
the election in the latter in 2005 of its first indigenous president, Evo 
Morales). The significance and limits of the new UN Declaration can 
be fully understood only in this context.
Contemporary debates in the international community tend to 
reflect the imperatives of ‘state logic’ and ‘market logic’ (Falk, 2000), 
which continue to be dominant in such contexts. These logics are 
centred on the defence of the interests of existing nation states as 
the most privileged subjects of international law, understood as 
the framework for governing relations among states, as distinct, for 
example, from an international system structured around the ‘rights 
of peoples’ (the 1976 Universal Declaration of the Rights of Peoples 
or Declaration of Algiers) – also evident in the African Charter on 
Human and People’s Rights, adopted in Banjul in 1981, which is the 
basis of the African regional human rights system. But, according to 
Falk (2000), this dominant statist logic is in turn subordinated to the 
imperatives of transnational capital, as reflected, for example, in the 
neoliberal economic policies imposed by the International Monetary 
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Fund (IMF), the World Trade Organization (WTO), the World Bank, 
and free trade agreements (FTAs).
Indigenous peoples fall somewhere along the edges of the traditional 
understanding of ‘self-determination’ in hegemonic versions of 
international law. The prevailing, somewhat Orwellian, understanding 
is that all peoples are theoretically equal, but not all have an equal 
right to self-determination. The new UN Declaration on the Rights 
of Indigenous Peoples (adopted finally by the UN General Assembly 
in September 2007) is the latest effort to somehow square this 
troublesome circle, at least in the context of indigenous and tribal 
peoples. It specifically recognizes the right of indigenous peoples to 
self-determination (Article 3), which has already been universally 
accorded to all ‘peoples’ by Article 1(2) of the 1945 UN Charter, and 
Article 1 of each of the 1976 International Covenants on Civil and 
Political and on Economic, Social, and Cultural Rights. Deep divisions 
regarding such issues and their implications were reflected in the 
complex, multilayered process leading up to the approval of the 2007 
Declaration, which included thirteen years of deliberation regarding 
its specific contents and the failure ultimately to adopt it, as had been 
expected, after its initial approval in an earlier version by the new UN 
Human Rights Council in 2006.
The amendments that made the Declaration’s final approval possible 
in somewhat diluted form included most notably an insistence, in 
language added to the initial draft of Article 46(1), on disavowing any 
exercise of indigenous people’s right to self-determination under Article 
3 that ‘would dismember or impair totally or in part, the territorial 
integrity or political unity of sovereign and independent states’ (an 
implicit allusion to the implications in the indigenous rights context 
of cases such as Kosovo, Tibet, and the Basque region). The standard 
for assessing whether military activities conducted on the lands or 
territories of indigenous peoples are justified was also diluted from an 
original requirement that the state at issue demonstrate a ‘significant 
threat to relevant public interest’ by striking the first (italicized) part of 
the phrase, so that now simply demonstrating a ‘relevant public interest’ 
is enough. And yet, because the rest of this Article continues to insist 
on free agreement or a request by the indigenous peoples involved 
in such situations, Colombia, a state in which traditional indigenous 
authorities insist upon the right to bar all armed groups from operating 
on their territories, felt obliged to abstain in the final vote.
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Article 3 of the Declaration on the Rights of Indigenous Peoples 
specifically contributes a much-needed bridge between civil and 
political rights, on the one hand, and economic, social, and cultural 
rights, on the other, by adding that ‘by virtue of that right they freely 
determine their political status and freely pursue their economic, 
social, and cultural rights’. These words reaffirm in essence that the 
rights of self-determination held by indigenous peoples have both the 
civil and political dimensions traditionally associated with this concept 
and the equally important additional dimensions related to the full 
and equal enjoyment of economic, social, and cultural rights. This 
in turn means that violations of the economic, social, and cultural 
rights of indigenous peoples have both an intrinsic significance in and 
of themselves, in relation to each other (in terms of rights in specific 
dimensions such as education, work, health, housing, etc., and their 
interdependence), and an additional significance because they reflect, 
and serve as indicators of, the extent to which the underlying right to 
self-determination is being respected. The Declaration is particularly 
notable from the perspective of poverty research because more than 
half of its Articles (that is, Articles 1, 2, 7–8, 10, 17–24, 26–29, 
31–32, and 38–44) focus on those economic and social dimensions 
of indigenous rights that have a direct relationship with issues of 
poverty.
Overall landscape
Aspects of these Latin American movements are analogous to 
Thompson’s (1963: 9) approach in his epic history of the English 
working class, which he summarized as ‘a study in an active process, 
which owes as much to agency as to conditioning’, to Du Bois’ 
(1935) classic Black Reconstruction in America, and to James’ (1963) 
Black Jacobins. Common features on which I seek to draw in this 
chapter include: Thompson’s (1963: 9) insistence on the creativity 
and resilience of resistance movements characterized by people who 
‘were told that they had no rights’ (in convergence with Baxi’s notion 
of ‘rightlessness’), but who insisted ‘that they were born free’; Du 
Bois’ revolutionary affirmation of the centrality of African American 
traditions and values of democratic struggle to US history, civilization, 
and democracy (Levering Lewis, 1995); and James’ (1963) equally 
momentous recentring of the history of the French Revolution, and 
of the origins of contemporary notions of human rights, from the 
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perspective of Haitian resistance and rebellion against slavery and 
colonialism (Dubois, 2004; Nesbitt, 2008).
These three advocate a reconceptualization centred on the 
contributions of counter-hegemonic thinkers and activists such as Las 
Casas, of the indigenous people’s resistance movements to which he 
gave voice in the sixteenth century, of their contemporary successors 
(for example Mexico’s Zapatistas), and of the Haitian Revolution 
between 1791 and 1804 (as explored in James, 1963). Together, the 
traditions of critical reflection and struggle founded by Las Casas and 
by the Haitian Revolution and their contemporary equivalents – from 
the Zapatistas to Brazil’s Movimento dos Trabalhadores Rurais Sem Terra 
(MST), or ‘movement of the landless’, plus the region’s human rights 
movements for justice and against impunity – provide the basis for 
articulating and advancing alternative, counter-hegemonic paradigms 
of rights and governance from below with global implications.
Such movements have also vigorously questioned and sought to 
undermine the primacy given in this context to nation states as the 
most privileged subjects of rights, and as themselves ‘rights givers’ 
to structures of representative, rather than participatory, democracy 
and to individual, rather than collective or group, rights of a civil or 
political character. The tendency from a hegemonic perspective is to 
prioritize the latter – particularly those associated with interests related 
to liberty and property within a market framework, rather than those of 
an economic, social, or cultural character, associated with imperatives 
of equality. These efforts have included ongoing activism and advocacy 
regarding such issues at the grass-roots level by means of direct 
organizing and the construction of alternative spaces of power, and 
also in many instances by means of influential voices to varying degrees 
‘inside’, or at the gate of, state structures of power and influence, and 
their equivalents in transnational normative spaces such as the United 
Nations.
Significant components of the international and regional human 
rights agendas associated with such visions have been enacted into law 
and policy in many key states to varying degrees, at least in formalistic 
terms, with many inconsistencies and gaps in actual implementation 
throughout the last twenty years. Much of this has been accomplished 
at least in part through processes of legal and constitutional 
transformation in the context of ‘transitions to democracy’ (often 
including truth commissions and/or trials of key human rights violators) 
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in the aftermath of US-backed authoritarian regimes (Eckstein and 
Wickham-Crowley, 2003; Roht-Arriaza, 2005).
Such approaches are also reflected in processes involving the direct 
incorporation (‘constitutionalization’) of international human rights 
standards into constitutional texts on a scale unprecedented elsewhere 
in the world. This makes it possible to enforce these standards in 
domestic courts and, where necessary, through recourse to the Inter-
American Human Rights Court of the Organization of American 
States (the judgments of which, by contrast, are not recognized as 
binding by either the United States or Canada), and in some cases have 
succeeded in translating such achievements into broader instruments 
of international law or policy in key normative spaces with significant 
potential impact beyond their country of origin. A key example is 
how Mexico’s Zapatista rebellion in 1994 became the decisive spark 
for unprecedented (albeit only partially successful) efforts to reform 
Mexico’s own constitution, federal and state laws, and overall state 
policy to finally recognize the cultural and linguistic dimensions of the 
existence and rights of the country’s indigenous peoples. Moreover, it 
also ultimately promoted the adoption of the UN’s Declaration on the 
Rights of Indigenous Peoples by the General Assembly in September 
2007 and the intensification of an equivalent process within the 
Organization of American States.
The critical, highly contradictory, factor in this context was the way 
in which the Zapatista uprising itself and its implications served to ‘name 
and shame’ the Mexican state into becoming the leading rhetorical 
champion of the Declaration within the United Nations. Most of the 
heavy lifting in this complex process was ironically undertaken by 
leading Zapatista advisers from Mexico and indigenous advocates from 
elsewhere in Latin America. Here, as with the Mexican state’s similar 
rhetorical championing in the United Nations of the rights of migrants 
and of its version of market-friendly environmentalism as host of the 
Sixteenth Conference of State Parties (COP) in December 2010, there 
is a vast, largely unnavigable gulf between its supposedly respectable 
standing regarding such issues in the ‘international community’ and 
its actual policies and practices on a daily basis with respect to its own 
people – practices that include the systematic violation of the rights 
of indigenous peoples and migrants, both Mexican and in transit 
through the country’s territory from Central America and elsewhere, 
as especially notable patterns.
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All of this coincides and must be contrasted dramatically, for 
example, with the Mexican state’s continuing militarization of Chiapas 
and every other region characterized by indigenous unrest. It should also 
be contrasted with the unleashing of a US-backed counter-insurgency 
process, which has included reliance upon paramilitary forces 
responsible for massacres such as that of Acteal in December 1997 
(which left forty-five dead, thirty-six of them women and children), 
reminiscent of similar instances of state savagery in Guatemala, Peru, 
and Colombia. It was only, relatively speaking, a small step from this 
precipice to Mexico’s current free fall as the latest example of generalized 
state terror (or ‘Colombianization’) in the region (in the name of the 
‘war against drugs’), with the encouragement of persistent mechanisms 
of US domination, such as the Security and Prosperity Accord of North 
America (the national security complement to NAFTA), the Mérida 
Initiative (Mexico’s version of Plan Colombia, explicitly modelled after 
its predecessor), and Mexico’s leading role with its Central American 
neighbours to the south in the Meso-American Project (formerly the 
Plan Puebla Panamá) (Carlsen, 2007).
Despite such dialectical complexities, it is nonetheless crucial to 
recognize that the advances in UN recognition of indigenous rights 
symbolized by the adoption of the 2007 Declaration would not have 
been achieved without the impetus and leadership provided by the 
Zapatista rebellion and its effects. This case exemplifies the direct 
impact that a counter-hegemonic movement can have ‘against the 
grain’, from the ‘outside’ and ‘from below’ in relation to hegemonic 
structures and processes from above and the transformation of their 
normative content. Given the highly contested character of issues 
regarding indigenous and minority rights to self-determination and 
autonomy in the contemporary international arena, my argument here 
is that the Zapatista rebellion’s contribution to reshaping the terrain 
as to such issues is equivalent to that of the Haitian Revolution and its 
impact, leading to the abolition of slavery in Paris in 1794.
Similarly, Latin American social movements elsewhere, which were 
indispensable factors in shaping the conditions that made possible a 
shift away from the most rapacious variants of neoliberal policies in 
the region (such as indigenous movements in Ecuador and Bolivia, 
movements of the landless in Brazil, and urban popular movements 
in Venezuela and Argentina), have also made significant contributions 
to the ‘refoundation’ of several of these states through extensive 
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constitutional reform processes (foreshadowed previously in Colombia 
in 1991 and Nicaragua in 1987). The two most far-reaching examples 
are the new constitutions of the ‘refounded states’ of Bolivia in 2009 
and Ecuador in 2008. Both of these include the redefinition and 
institutional restructuring of their respective states as ‘plurinational’ 
and ‘pluricultural’ in character, which thereby at least rhetorically go 
beyond the limits of liberal multiculturalism (see Van Cott, 2000; 
cf. Santos, 2010), which is generally associated with much more 
limited discursive affirmations of cultural diversity and pluralism (as in 
Mexico’s 1992 and 2001 constitutional reforms, which fell well short 
of the demands of the Zapatista movement based upon the 1996 San 
Andrés Accords, a key part of the still-stalled peace process between 
the Mexican state and the Zapatistas).
Enrique Dussel’s (2008) conceptualization of a Latin American 
‘political spring’ stresses the relationship between advances of this 
kind at the level of state power in terms of electoral victories by 
centre-left political forces (which he highlights to varying degrees 
in contexts such as Bolivia, Venezuela, Ecuador, Brazil, Argentina, 
and Uruguay, between 1998 and 2006, joined later by El Salvador 
in 2009, offset by notable defeats for such forces in 2006 in Mexico 
and Peru, and a right-wing military coup in Honduras in 2009) and 
their origins in counter-hegemonic social movements. Examples of 
the latter within the same period include those led by indigenous 
sectors in Bolivia and Ecuador, by urban popular and human rights 
movements and other allies in the cases of Venezuela and Argentina, 
and by former left insurgent movements transformed into political 
parties or into significant sectors of governing centre-left political 
parties or coalitions in Nicaragua, El Salvador, Uruguay, and 
Brazil. The specific landscape varies greatly in each case, and is also 
highly contested in terms of the extent to which this overall trend 
has actually contributed to the region’s ultimate liberation from US 
domination and that of its domestic allies in each country (Barrett 
et al., 2008; Stahler-Sholk et al., 2008). The electoral advances 
cited are also key in terms of providing spaces and opportunities for 
formal political, constitutional, and legal ruptures with the ‘internal 
colonialism’ (Casanova, 2006; Lander, 2006) or racist neocolonialism 
characteristic of Latin American states post-independence. Peruvian 
scholar Aníbal Quijano (2000) is particularly persuasive regarding 
the deeply rooted structural dimensions of the colonialist paradigm in 
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the region, which he describes in terms of the ‘coloniality of power’ in 
Latin American states and societies.
Conclusions
The alternative approaches and experiences highlighted in this 
chapter by means of a necessarily limited range of representative 
examples provide an emerging normative basis for Amartya Sen’s 
(1998) suggestion that poverty, as reflected in conditions that 
violate the right to health, must be understood as the deprivation of 
an individual’s and a community’s ability to control his or her or its 
own circumstances. This in turn, once translated into the language of 
rights, would imply that the conditions of poverty that undermine and 
violate the right to health take their most concrete form as violations of 
individual and/or collective rights to self-determination in both a literal 
and metaphorical sense. This leads us then to a further understanding 
of poverty as a deprivation of rights to full and equal citizenship, which is 
drawn in part from, and enriched by, Brazilian educator Paulo Freire’s 
notion of an inextricable link between education and citizenship, with 
education itself reconceived as a vehicle for self-determination in the 
most intimate sense – that of making history your own, and that of 
your community, and ultimately that of giving history a human face, 
in which the global poor would be finally recognized as equal subjects, 
with ‘the right to have rights’ (Arendt, 1951).
Contemporary efforts to develop counter-hegemonic paradigms of 
global justice and human rights, including the right to health, must 
include legacies, fruits, and lessons rooted in the contributions and 
limitations of previous struggles to dignify economic, social, and 
cultural rights overall, and they must seek to fashion a weave capable 
of drawing together the disparate strands of the demands for a non-
colonialist international order yet unmet since the 1955 Bandung 
Conference (which was a step towards the Non-Aligned Movement, 
the UN Conference on Trade and Development, or UNCTAD, the 
G77, etc.). These include the recognition of the ‘right to development’ 
and ‘sustainable development’, and respect for the ‘rights of Mother 
Earth’, as serious alternative paradigms rather than as panaceas, 
together with the construction of alternative institutional structures 
on a global scale equivalent to those being developed in the Latin 
American region within the context of the Bolivarian Alliance for 
the Peoples of Our Americas (Alianza Bolivariana para los Pueblos de 
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Nuestra América, or ALBA), the Southern Common Market (Mercado 
Común del Sur, or Mercosur), the Union of South American Nations 
(Unión de Naciones Suramericanas, or UNASUR), and the recently 
established Conference of Latin American and Caribbean States, 
and initiatives such as the creation of a Bank of the South and of 
an alternative Latin American currency, the African-Latin American 
Summits, and the April 2010 Global People’s Summit on Climate 
Change and the Rights of Mother Earth in Cochabamba, convened 
by the Bolivian government. To varying degrees, all of these efforts 
are derived from critiques of the depredations of neoliberalism 
first launched by the Zapatistas and of the international financial 
institutions, such as those at Seattle, Porto Alegre, Genoa, Cancún, 
and elsewhere, and lay the basis for the construction, from below, of 
a new global ‘social and international order in which the rights and 
freedoms’ recognized by the international community ‘can be fully 
realized’ (as articulated by Article 28 of the Universal Declaration of 
Human Rights).
The time has come to convene an ‘International Poor People’s 
Tribunal’ building on the spirit and contributions of the Russell 
Tribunal, its primary successor, the Permanent People’s Tribunal 
based at the Lelio Basso Foundation in Rome, and related counter-
hegemonic experiences of alternative justice in the context of tribunals 
of conscience and truth commissions, the mandate of which should 
be centred on the characterization of poverty as a grave violation of 
human rights that ought to trigger levels of scrutiny, and ultimately 
punishment and reparations akin to that applied to crimes against 
humanity, within the overall framework of international criminal law.
But the ethical force – the ‘army of ideas’ necessary to bring this 
about, as Puerto Rican revolutionary pro-independence activist, poet, 
and philosopher Clemente Soto Vélez (1991: 118) once characterized 
it – can come only from among the victims of the global system of 
domination themselves and those of us who cast our lot with them, 
because, as Ernst Bloch (1996: xxix) argued:
[L]iberation and dignity are not automatically born of the same 
act; rather they refer to each other reciprocally – with economic 
priority we find humanistic primacy. There can be no true 
installation of human rights without the end of exploitation, no 
true end of exploitation without the installation of human rights.
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Mexico’s Zapatistas have come to symbolize the essence of such an 
approach, both as a movement that prefigured the critique of neoliberal 
globalization that has since become generalized in the ‘global justice’ 
movement, and more particularly because of their rigorously ethical 
wedding of critical theory and humane praxis. Much of this is reflected 
in their approach, for example, to issues regarding the relationship 
between ‘reason’ and ‘force’ in the context of globalized struggle that 
confronts such movements:
If you cannot have both reason and force, always choose reason, 
and let the enemy have force. In many battles force may obtain 
victory, but in the struggle as a whole only reason will triumph 
in the end. Those who are powerful will never be able to wrest 
reason from their force, but we will always be capable of deriving 
force from our reason. (Marcos, EZLN Subcommander, 1997)
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Abraar Karan
When HIV/AIDS first broke out in Uganda in 1979, scientists were 
forbidden from speaking its name. The authors of the 1985 Lancet 
article describing the first rural outbreak had to call it ‘Slim’, a colloquial 
term referring to wasting (Serwadda et al., 1985). The veil was thin, 
but the combination of denialism and homophobia was so powerful 
that Ugandan authorities would not have allowed the publication had 
the authors used ‘HIV/AIDS’ (Kinsman, 2010: 55). When the article 
was published, 20 per cent of Ugandans had already been infected 
with ‘Slim’; within the next ten years, Uganda’s HIV/AIDS prevalence 
rate was transformed from the highest in the region to the only rate in 
significant decline.
This celebrated victory was achieved by means of a complex, 
sustained, multifaceted campaign that responded to specific social 
and cultural concerns. Both from the ground up and the top down, 
profound change was realized on a vast scale across the socio-economic 
spectrum, from community-level, national, and international actors. 
However, donors effectively froze funding levels in 2009. The effects 
were devastating and quickly resulted in a reversal of many of these 
astonishing advances. This chapter asks how, in the context of 
diminishing donor support, Uganda can revive the internal mobilization 
and societal behaviour change that allowed the ‘Pearl of Africa’ to first 
curtail HIV in the early 1990s.
After offering an overview of the consequences of the plummeting 
funding for the treatment of HIV/AIDS patients in Uganda, this 
chapter situates the crumbling infrastructure within the complex 
socio-political history of AIDS prevention and treatment programmes 
in Uganda, from what may be the earliest emergence of the disease to 
the present (see Figure 9.1). It traces the development of sweeping 
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ideological shifts that enabled the successful turnaround of AIDS 
prevention and treatment, from fighting an initial cultural and 
religious backlash against condoms to profoundly modifying sexual 
choices at the individual level. After reviewing the culturally specific 
myths, misconceptions, and challenges facing treatment strategies, 
from antiretroviral therapy (ART) to voluntary counselling and testing 
(VCT), the chapter concludes that a social-behavioural movement is 
the best strategy for continuing Uganda’s success against HIV/AIDS in 
the future despite disadvantageous donor politics.
Introduction
In October 2009, a memo from the US Center for Disease Control 
and Prevention (CDC) to the Ugandan government cautioned that 
‘funding for HIV programmes is not expected to increase in the near 
future’ and that, as a result, ‘PEPFAR [the US President’s Emergency 
Plan for AIDS Relief] Uganda [could not] continue to support scale-
up of antiretroviral treatment without a plan from the Government of 
Uganda on how these patients [would] be sustained’ (US CDC, 2009). 
These warnings were issued in light of an economic crisis and shifting 
donor interests, and they held true: by fiscal year 2009, PEPFAR 
funding to Uganda had relatively flatlined, with an increase of just 
US$2 million as compared to increases of past years of around $50 
million (see Figure 9.2); in 2010, PEPFAR’s estimated commitment 
actually decreased by about $1 million (PEPFAR, 2010b).
Unfortunately, this financial reduction had already been felt on the 
ground in Uganda. In early 2010, Dr Peter Mugyenyi, head of the Joint 
Clinical Research Centre (JCRC), lamented that, ‘every day, we have 
to turn away patients who need treatment ... [and] tell them “There 
is a [funding] freeze” ’ (Stockman, 2010). Furthermore, the medical 
coordinator of the Mulago branch of The AIDS Support Organization 
(TASO), Uganda’s largest indigenous non-governmental organization 
(NGO) for AIDS care, said that there had been a fourfold increase in 
the number of new patients approaching the Kampala clinic, most of 
whom had been turned away from smaller clinics that had lost funding 
(interview with the author, July 2010). She explained that people used 
to be convinced that there would always be drugs with which to treat 
the disease; now, they were telling each other, ‘If you get the disease, 
you will die.’
This scenario has haunting similarities to that in the 1980s, when 
an HIV-positive blood test was essentially a death sentence. In a study 
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formally examining the effects of the donor aid flatlining in Uganda 
between 2009 and 2010, it was found that, of 1,309 eligible patients who 
made visits to a clinic sponsored by PEPFAR and the Global Fund, only 
819 were started on treatment (Geng et al., 2010). There was a 50 per 
cent decrease in ART initiation for those presenting between February 
and March 2010, and newly initiated patients were largely covered by 
the Family Treatment Fund (FTF), a small private foundation that was 
also quickly reaching capacity. Most clinics lacked insulating bodies such 
as the FTF and thus the actual rate of enrolment is likely to have been 
even lower. Along with the economic downturn, the ‘political winds 
ha[d] changed’, said Sharonann Lynch, a senior health policy adviser 
at Médecins sans Frontières (MSF) (McNeil, 2010). She expressed the 
belief that ‘world leaders feel the heat is off’ and that ‘they’re fatigued’. 
Furthermore, in a meeting with African leaders in August 2010, 
President Obama asserted that the global community was ‘never going 
to have enough money to simply treat people who are constantly getting 
infected’ (Rukmundo and Lirri, 2010). With the launch of his $63 billion 
Global Health Initiative, which refocused the United States’ global 
health concerns from HIV to child and maternal health, the waiting lists 
among those in Uganda and other PEPFAR recipient countries could 
only grow longer (McNeil, 2010; PEPFAR, 2010a).
In mid-2010, US Global AIDS Coordinator Dr Eric Goosby 
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countries soon’ (McNeil, 2010). A December 2011 MSF report noted 
that Uganda had been denied Global Fund grants in its last two rounds 
and that the Clinton HIV/AIDS Initiative that supported paediatric 
treatment was expected to end its funding in 2012 (MSF, 2011). In 
March 2012, the Ugandan Ministry of Health announced the results 
of the Ugandan AIDS Indicator Survey, reporting that the incidence 
rate had slightly risen from around 6.4 per cent in preceding years to 
6.7 per cent (Masaba, 2012). As of 2013, according to Joint United 
Nations Programme on HIV/AIDS (UNAIDS), the number of people 
living with HIV/AIDS was at 7.4 per cent, accounting for roughly 1.6 
million people. While PEPFAR funding did eventually increase in 
2011, it once again fell in 2012 and remains subject to a dangerously 
tenuous international political environment (see Figure 9.2).
As the global struggle against AIDS slowly worsens with regard to 
funding and support for treatment programmes, Uganda’s future is 
therefore likely to depend on its ability to recreate the past.
Uganda’s early successes: Behaviour change before the 
availability of antiretroviral therapy
Politics of perception: Initial shaping of the epidemic Kasensero, a small 
fishing village roughly 8 kilometres north of the Uganda–Tanzania 
border, is thought to be the epicentre of the first population-wide 
outbreak of HIV in the world (Kinsman, 2010: 45). The war with 
Tanzania brought with it a migration of illness, delivered in the form 
of rape by soldiers of the Tanzanian People’s Defence Forces in 1979. 
The first days of the outbreak were marked by confusion and myth, and 
the word ‘witchcraft’ was thrown around frequently (Kinsman, 2010: 
46). As is evident in the Lancet article about ‘Slim’ in 1985 (Serwadda 
et al., 1985), the notion of AIDS denialism in Uganda was present 
from the beginning of the epidemic. A paper by Carl Saxinger and 
colleagues (1985) published in the journal Science suggested that the 
HTLV-III virus was actually harmless and that it was not a marker for 
AIDS, further denying the evidence that AIDS was present in Uganda. 
Absent any acknowledgement of AIDS in the early 1980s, Ugandan 
society was unable to respond to the threat. The shaping of the disease 
was thus a key aspect of people’s reactions and behaviours.
From the start, the illness was made a product of its environment 
and people took ownership of it: they gave it a name (‘Slim’); they 
gave it a cause (‘witchcraft’); and they posited certain unquestionable 
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‘facts’ (‘Slim was not AIDS because AIDS was a homosexual, white 
man’s disease’) (Kinsman, 2010: 55). The reaction to this outbreak 
carried a distinctly sociocultural element that shaped the initial (lack 
of) response, and was rooted in the way in which Ugandans perceived 
illness and health. Ultimately, the sociocultural element of Ugandan 
society was a critical component of how successfully the country was 
able to manage the HIV epidemic. As will be elaborated, Uganda’s 
eventual success in the early 1990s, as well as the decline of that 
response since, has much to do with the politics of perception and 
culture, and the way in which this perception will evolve is a factor that 
will determine the outcome of the AIDS epidemic.
The prevalence rate in Uganda in the 1980s was much higher 
than in other surrounding countries, either in fact or reported as such 
because of better monitoring. In 1984, it was estimated that one in five 
Ugandans was infected with the virus (Kinsman, 2010: 57); over the 
next decade, Uganda was the only country to experience substantial 
declines in those prevalence rates – albeit that the exact numbers differ 
according to various sources (see Figures 9.3 and 9.4).
What was it about Uganda’s response to the AIDS pandemic 










































9.3 Median HIV prevalence among pregnant women in Uganda (source: 
Adapted from USAID (2002))
Note: Interpolated for one-year gaps in site data
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UNAIDS’s Drug Access Initiative was established in Uganda, there 
was virtually no population-wide access to ART (Kinsman, 2010: 113). 
Furthermore, condom use was not expansively promoted until 1995, at 
which point prevalence had already began to significantly decline. The 
Ugandan people’s perceptions of HIV and their subsequent personal 
choices regarding sexual behaviour during the years prior to 1995 have 
been exalted as one of Africa’s AIDS triumphs. Uganda’s campaign, as 
compared to those of any neighbouring countries, has been lauded for 
its ‘intensity, depth, breadth, and extensiveness’ (Slutkin et al., 2006: 
358). A significant national movement to educate, warn, and inspire 
Ugandan citizens, effected by means of determined action taken by 
both civil society and President Yoweri Museveni’s government, has 
been credited with the historical reversal of the epidemic. In retrospect, 
then, Uganda can be described as having had the ‘strongest planned 
and best supported national AIDS program, with the largest national 
and international staffing and most intensive, broadly inclusive, 
decentralized and community based public education program in 
Africa’ (Slutkin et al., 2006: 358).
Museveni’s march: Starting off on the right foot When Yoweri Museveni 
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extremely active in pursuing answers to the questions of what AIDS 
was, what impact it was having on the population, and what was to be 
done about it (Kinsman, 2010: 59). He was described as being both 
serious and pragmatic about HIV from the start. An encounter with 
Museveni, in which he was shown pamphlets urging readers to ‘Love 
Carefully’, resulted in outright rejection: the president pointed out that 
most people could not read, let alone read English, which rendered the 
pamphlets pointless (Kinsman, 2010: 59). In an era of AIDS denialism, 
President Museveni quickly and openly recognized the presence of HIV, 
acting as a catalyst for the behavioural movements that emerged soon 
afterwards. In October 1986, the Ugandan government established the 
National Committee for the Prevention and Control of AIDS, later to 
become the National AIDS Control Programme (NACP). The initial 
social movement that was established by means of this mechanism was 
that of ‘zero grazing’, a double entendre referencing both livestock and 
sexual activities in the bedroom. By using agricultural vernacular that 
was familiar to the rural populations, Museveni encouraged Ugandans 
to talk about sex and about HIV via a comfortable, satirical perspective 
on the notion of sexual concurrency that stripped it of taboo (Kinsman, 
2010: 74).
In 1986 and 1987, President Museveni gave speeches throughout 
local districts emphasizing that AIDS was not the result of witchcraft, 
mosquitoes, or an act of God, but of sexual contact. He assured that 
all people could get AIDS, that there was no cure, that it ended in 
death, and that Ugandans could fight it by having only a single sexual 
partner (Kirby, 2008: 14). While Museveni did mention that condoms 
could provide imperfect protection, he was hesitant, fearing that this 
would offer a false sense of security that might lead to increased sexual 
behaviour (Kirby, 2008: 14). Not only have the president’s speeches 
at the time been characterized as ‘impassioned pleas for people to 
change their behaviour’ (Kirby, 2008: 15), but also he ended every 
major speech that he gave during the late 1980s and early 1990s with a 
message about HIV (Slutkin et al., 2006).
Uganda’s initial openness to AIDS was the starting point in initiating 
behavioural change, and the country was unique in its ability to shed 
stigma and instead identify in an illness a common enemy. Factors that 
allowed Uganda to be far more open than its neighbouring countries 
included the lack of a tourist industry and the presence of a committed 
president. The civil war had devastated most of Uganda’s national 
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parks, the only attraction that had sustained a small tourist trade, and 
thus acknowledgement of an AIDS epidemic was no threat to that sector 
(Kirby, 2008: 12). Comparatively, a country such as Kenya, which had 
a far more developed tourist industry, would have been affected by 
such acknowledgement and thus did not declare AIDS an emergency 
until 1999 (Kinsman, 2010: 65). Another factor that guided an open 
policy was the personal background of President Museveni: his military 
history and connection to the war that brought AIDS to Uganda, as 
well as his fear that many soldiers were being infected (his political 
power lay in the support of the army), led him to approach the illness 
as a personal battle more so, perhaps, than other leaders of his time 
(Kinsman, 2010: 65).
Movement: Civil society and social change The shaping of Uganda’s 
response to the AIDS epidemic can be categorized into three periods, 
as outlined by Kinsman (2010: 68). During the first (1986–1992), 
there was a strategy focusing on faithfulness as the epidemic was being 
constructed and understood. Moreover, surveillance was being better 
established to track prevalence and incidence. With no drugs available, 
becoming HIV positive was essentially a death sentence during this 
phase. According to a previous adviser of the administration working 
with the NACP at the time, the policy was, ‘Tell people, and then the 
instinct for self-preservation will help them avoid it’ (Kinsman, 2010: 
73). Most of the efforts of the early 1990s were focused heavily on 
being faithful and abstaining from sex, with condoms being a distant 
alternative (Kirby, 2008: 23). According to Dr Sam Okware, head 
of the NACP in 1987, condoms were not culturally appropriate, and 
thus ‘zero grazing’ and ‘loving carefully’ were the focal points of the 
campaigns (Kinsman, 2010: 74).
These early years of the epidemic were dependent on social 
movements among churches, mosques, radio stations, schools, and 
even members of civil society who would not typically be involved in 
health issues, including political, community, and religious leaders, 
who spread information about AIDS to the public (Green et al., 2006). 
Non-governmental organizations began addressing various aspects 
of the epidemic and grew exponentially in number throughout the 
1990s (see Figure 9.5). In fact, Green and colleagues (2006) suggest 
that face-to-face communication within communities, facilitated 
particularly by NGOs and faith-based organizations, may have been 
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the most important and distinctive aspect of the campaigns. Changes 
at the village level have been documented anecdotally, with reports 
of teachers and police officers who engaged in sexual relations with 
younger women being removed from their posts and forced to leave 
the village (Slutkin et al., 2006). The Catholic Church was involved in 
mobile care for AIDS victims, as well as support programmes for AIDS 
widows and orphans. The Islamic Medical Association of Uganda also 
began educational efforts to train religious leaders in rural areas and 
was successful enough to be named a UNAIDS ‘Best Practices Case 
Study’ (Green et al., 2006). The Anglican Church’s peer education 
approach included AIDS education messages in sermons and a later 
evaluation by UNAIDS of those targeted by this project showed a 
significant reduction in number of partners during the early 1990s 
(Green et al., 2006).
In 1987, the United Nations Children’s Fund (UNICEF) launched 
an AIDS education programme in schools for children aged 10 and 
over. Science teachers were trained to teach about HIV/AIDS, with a 
message of ‘strictly abstinence’, and students engaged in projects and 
presentations that taught about the effects of HIV on health (Kirby, 
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initiated in 1987 that trained teachers to integrate HIV education 
and sexual behaviour change messages into the school curriculum. 
By 1987, the thirty-three district health educators had been trained in 
the curriculum as well (Kirby, 2008: 21). Radio stations all employed 
the same sombre drumbeat to be played before messages about ‘Slim’, 
the killer illness soon to be identified as AIDS (Kirby, 2008: 22). The 
Association of Performing Artists of Uganda created a nationwide 
competition in 1989 for the best plays, songs, and poems about AIDS, 
and celebrities also used performances to create a national dialogue 
regarding AIDS and its consequences (Kirby, 2008: 22). One such 
celebrity, Philly Lutaya, was the first major musician to reveal his 
serostatus (that is, his status as HIV positive), and he engaged in public 
speeches and presentations in several venues. The event at which he 
revealed his serostatus was attended by more than 10,000 students and 
workers, and his message was to love carefully and responsibly (Kirby, 
2008: 22).
A number of local programmes and groups were also extremely 
important in communicating the message on the ground. Straight Talk, 
a mass media communication programme established in 1993 and still 
active today, used radio shows, newspapers, and health fairs, among 
other things, to create a network of educated youth who were aware 
of sexual infections such as HIV and were motivated to abstain from 
sex at a young age (Straight Talk Foundation, 2010). For example, 
Straight Talk published a four-page insert in Uganda’s New Vision, the 
largest English-language newspaper in the country (Kirby, 2008: 37), 
in which it too emphasized that abstinence was the safest approach.
A combination of the government and external organizations was 
also highly impactful. The Ministry of Health and UNICEF printed 
thousands of pamphlets and stickers, most of which needed revisions 
over the years, because they still left people fearful of the possibility 
of spread through non-sexual contact or mosquitoes (Kirby, 2008: 
13). Early in 1987, some 400,000 posters and 500,000 leaflets were 
printed in English and three Ugandan languages (Kirby, 2008: 13). 
By February 1988, they had been translated into twenty-two languages 
and by January 1989, according to local newspapers, ‘Love Carefully’ 
posters were ubiquitous (Kirby, 2008: 14). Members of mission 
trips to Uganda in the early 1990s recall the extent of messaging in 
Uganda appearing on posters, billboards, and other public materials; 
they claim that there was simply ‘no comparison’ between awareness 
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efforts in Uganda and those of other countries in the region, such as 
Rwanda, Burundi, Kenya, Tanzania, Malawi, and Zambia (Slutkin 
et al., 2006).
Interestingly, Uganda’s approach effectively maintained a balance 
between raising awareness and perceptions of the risk of the disease 
and preventing its stigmatization (Halperin, 2006). As the first director 
of TASO remembers: ‘Most of these initial campaigns adopted a “fear 
approach” to HIV prevention, based on the theme: “Beware of AIDS. 
AIDS kills” ’ (Kaleeba et al., 2000: 12). Also, members of the NACP 
recalled that they first ‘focused on instilling fear in the population’, at 
which point behavioural change recommendations were taken more 
seriously (Okware et al., 2001: 1114). The arousal of fear was expected 
to force ownership of behaviour and to promote the acceptance of 
personal responsibility with regard to infection. This balance between 
fear and stigma is important, because it prevents the alternative 
reactions that result from either removing personal responsibility (when 
risk is downplayed) or creating stigma (when risk is overemphasized) 
(Halperin, 2006).
Undeniably, attitudes were largely affected by the individual biases 
of the participating organizations – especially religious ones. Churches 
were opposed to condoms as a tool for prevention, because they 
felt that it would not improve sexual behaviours and would instead 
encourage ‘sinfulness’. The public’s perception of the condom was 
quickly coloured by demonstrations at the Catholic Church, such 
as one in which pepper was shown to pass through the plastic of the 
condom suggesting that the virus would also be able to do so (Kinsman, 
2010: 76). Thus the initial movements toward personal responsibility, 
faithfulness, and abstinence, and away from condoms, were largely 
buttressed by churches and mosques (Green et al., 2006).
The actual effectiveness of these measures in terms of behavioural 
change is difficult to isolate, because surveillance was still in its begin-
ning stages, but the atmosphere of activism, concern, and responsibility 
was definitely apparent by the early 1990s. As surveillance improved 
and data on prevalence were released in 1991, it seemed as though, 
despite the focus on abstinence and the educational campaigns, the 
virus was spreading at an increasing rate (Kinsman, 2010: 78). Ante-
natal mothers presenting in the national referral hospital in Kampala 
showed a prevalence increase from 25 per cent in 1988 to 39 per cent 
in 1990 (Kinsman, 2010: 78). It is likely, however, that this drastic 
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increase is accounted for by an increase in the availability of testing 
for those who would typically not have access to a testing centre or 
health facility. Nonetheless, the data convinced President Museveni 
to promote condoms despite his ideological leanings. While condoms 
seemed to be a short-term solution, their longer-term impact on the 
way in which the population would deal with the epidemic is a signifi-
cant learning point in the context of the epidemic today.
Condoms: From condemning to condoning The politics of perception 
are wholly relevant to condom promotion, as demonstrated by the 
initial backlash against condoms promoted especially by religious 
organizations. At first, local sentiment was marked by conspiracy 
theories about and fear of condoms, including myths that they were 
a means by which the West was trying to infect Africans with HIV 
or cause impotency (Kinsman, 2010: 78). How quickly condoms 
were actually taken up and used by the population is questionable, 
and the actual effect that condoms had on reducing incidence (that is, 
the number of new infections) and prevalence rates is also difficult to 
isolate. What is known is that incidence rates fell during the 1990s by 
more than half; results from the UK-funded Medical Research Council 
(MRC) Programme in Masaka showed a reduction from 7.6 infected 
per 1,000 people in 1990 to 3.2 per 1,000 in 1998 (Mbulaiteye et al., 
2002).
It is important to examine HIV incidence and prevalence, and to 
attempt to align them with both behavioural interventions (abstinence 
and being faithful to one partner) and condom promotion. Estimates 
suggest that incidence fell between 1990 and 1995, and has since 
remained steady, while prevalence has been on a continuous decline 
since 1990 (UNGASS, 2010). However, condoms did not reach their 
zenith in Uganda until the late 1990s, with most growth occurring 
largely between 1995 and 1999 (see Figures 9.6 and 9.7).
According to the Masaka intervention trial, which compared 
two HIV prevention strategies in 1994, there were ‘significant 
misconceptions about and opposition to condoms from the general 
community, and also ... small retailers feared ridicule and a loss of 
clientele if they stocked condoms’ (Kinsman, 2010: 85). The success 
of condoms by 2000 is exemplary: the 2004 Uganda Sero-Behavioural 
Survey reported that 59 per cent of men and 38 per cent of women with 
non-regular sexual partners said that they had used a condom during 
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their last sexual encounter, and by the late 1990s condom use among 
commercial sex workers had risen to almost 100 per cent in Kampala 
(Green et al., 2006). Nonetheless, the time frame in which condom use 
grew and became accepted spans a period after incidence was already 
relatively stable and prevalence had already been declining for years, 
meaning that condoms were unlikely to be primarily responsible for the 
changing face of the epidemic.
Additionally, condoms may have inhibited Uganda’s early 
behavioural movements from progressing into the next century. 
The concept of ‘risk compensation’, as applied to HIV prevention 
by Harvard scientist Edward Green, suggests that the availability of 
condoms may have had a somewhat counterproductive effect in certain 
circumstances, especially in Africa (Green, 2009). When people feel 
safer, they are willing to take more risks; when in the context of HIV-
causing behaviours, a reliance on condoms may create a false sense of 
security that encourages sexual activity. Green and colleagues (2006) 
do note, however, that Cambodia and Thailand were able to effectively 
promote condom use in brothels, but in many African countries the 
epidemic derives from multiple-partner relationships, which may 
actually be exacerbated by condom use. According to articles published 
in local newspapers, wives complained that the free condoms provided 
to their husbands at work were encouraging the men to have sex outside 
of their marriages (Kirby, 2008: 43).
Condom usage has proven more complex than it might initially 
appear, particularly in Africa, for example the forced use of condoms 
in relationships being said to imply distrust between partners 
(Asiimwe et al., 2003). Along these lines, condom promotion is a 
symptomatic approach that neglects the realities of African life for 
both men and women: it does not address the central issues of gender 
and sexual inequality, or the cultural norms that have catalysed the 
spread of HIV (Asiimwe et al., 2003). Additional risk factors complicate 
the transmission of the virus: the number of sexual partners, the 
duration of relationships, the extent to which relationships overlap, the 
frequency of sex, specific sexual practices, the proper use of condoms, 
and the stage of infection of an HIV-positive partner are all additional 
factors that become relevant when looking at interventions other than 
absolute behavioural change (Cohen, 2004).
Ultimately, the evidence suggests that labelling condoms as the 
propellant of a waning epidemic is unlikely to be accurate: to some 
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extent, condoms were culturally incongruous with African culture 
and social structures, thus are unlikely to have been responsible for 
the declining incidence or prevalence – and they may even prove 
counterproductive on occasion as a result of risk compensation.
Attempting the impossible? Isolating behavioural change While it is 
unlikely that condoms were the main agent responsible for Uganda’s 
successful control of HIV, to say with reasonable certainty that it was 
indeed a socio-behavioural revolution would require the isolation of this 
as an independent variable. According to the models of Stoneburner 
and Low-Beer (2004), HIV incidence was likely already to have been 
in decline in Uganda by the late 1980s (see Figure 9.8).
By 1995, the incidence rate of HIV was lower than the HIV death 
rate, especially among younger cohorts, indicating a reversal of the 
epidemic and a declining prevalence. To isolate behavioural change as 
the possible critical factor, Stoneburner and Low-Beer (2004) traced 
the epidemic in Kenya, Zambia, and Malawi as well. The epidemic was 
afflicting these countries within one year of its emergence in Uganda and 
demonstrated similar growth curves with respect to initial prevalence. 
However, Uganda’s declining prevalence – for example by 75 per cent 
in 15–19-year-olds and 60 per cent in 20–24-year-olds, according to 
data from Kampala and other urban sites (Stoneburner and Low-Beer, 














































9.8 Models of estimated HIV incidence in Uganda (source: Adapted from 
Stoneburner and Low-Beer (2004))
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Important behavioural changes that were determined included a 
rise in the age of sexual debut (see Figures 9.10 and 9.11), a decrease 
in indicators that would suggest casual or non-regular sexual partners 
(see Figure 9.11), and an increase in the use of condoms (Stoneburner 
and Low-Beer, 2004). In relation to the behaviours of the group most 
responsible for the spread of the epidemic, men with multiple sexual 
partners, among Ugandans in this population there was a decrease in 
the percentage of non-regular sexual partners from 15 per cent in 1989 
to 3 per cent in 1995 – approximately the same years during which 
incidence was dropping (Stoneburner and Low-Beer, 2004). Moreover, 
the proportion of males reporting three or more non-regular partners 
fell between 1989 and 1995, from around 20 per cent to less than 5 per 
cent (Stoneburner and Low-Beer, 2004), all of which indicates that a 
shift in the sexual choices of individuals was at the core of Uganda’s 
social movement.
In comparison, the proportions admitting to casual sexual 
partnerships in Malawi, Kenya, and Zambia at around this time were 
much higher, and the proportions of 15–19-year-olds who abstained 

























































9.9 Comparison of prevalence in antenatal surveillance sites (Malawi, Zambia, 
Uganda) (source: Adapted from Stoneburner and Low-Beer (2004))




























1994 (n) = 287 2001 (n) = 4001996 (n) = 280
9.10 Delayed sexual debut among primary school pupils (aged 13–16) following 
information education and communication, Soroti District, Uganda (source: 






































Males never sex age 15–24 Females never sex age 15–24
Females non-regular partnerMales non-regular partner
9.11 Reduction in non-regular partners and age of sexual debut (source: 
Adapted from Stoneburner and Low-Beer (2004))
karan | 219
2004). In the meantime, condom use rose relatively equally in Uganda, 
Zambia, Malawi, and Kenya (Stoneburner and Low-Beer, 2004) – the 
years during which incidence was falling (UNGASS, 2010), which 
strongly suggests that behavioural change, as opposed to condom use, 
was responsible for the reduction of HIV incidence in Uganda during 
the mid-1990s.
The question remains, however, why this change occurred only in 
Uganda. Although behavioural movements are generally identified 
as the reason, it is important to look at the more tangible elements 
of these movements. Personal networks and personally knowing 
someone who had died from AIDS are reported as being important 
indicators, in line with Green and colleagues’ (2006) assertion of 
face-to-face communication as the most relevant aspect of Uganda’s 
social movement. In Uganda, 82 per cent of women had heard of 
AIDS through a personal network, as compared to 40–65 per cent 
in other sub-Saharan African countries (Stoneburner and Low-Beer, 
2004). Also, by 1995, 91.5 per cent of Ugandan men and 86.4 per 
cent of women had known someone with AIDS, as compared to 68–
71 per cent of the population in Kenya and Malawi, and less than 
50 per cent in Zimbabwe and South Africa (Stoneburner and Low-
Beer, 2004). In acknowledging Uganda’s open policy towards AIDS, 
including the push for ‘zero grazing’, Stoneburner and Low-Beer 
(2004) substantially attribute Uganda’s success not to condoms, but 
to ‘public-health interventions that triggered a social process of risk 
avoidance manifested by radical changes in sexual behaviours’. By 
avoiding the waves of AIDS denialism that are present even today in 
countries in sub-Saharan Africa, Uganda was able to create internal 
change among its population.
Behavioural programmes did eventually catch on in other sub-
Saharan African countries, where they have also showed successes. For 
instance, Zambia’s ‘Helping Each Other Act Responsibly’ (HEART) 
programme, funded by the US Agency for International Development 
(USAID) evidenced promising outcomes after the first year of its 
initiation. Those who participated in the programme were 46 per cent 
more likely to delay sexual intercourse and 67 per cent more likely to 
have used a condom the last time they had sex as compared to pre-
programme (USAID, 2008).
In the dialogue surrounding Uganda’s success, the debate over 
whether abstinence or condoms was more effective has often emerged. 
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Many conclude that a derivative of the ‘A’ and ‘B’ of ‘ABC’ (that is, 
‘abstinence, being faithful, condoms’) – the reduction of multiple 
partners and later sexual debut – was Uganda’s primary cause of reduced 
prevalence and stabilized incidence (Kinsman, 2010: 97). However, 
regardless of how impactful condoms actually were in the Ugandan 
epidemic, it is counterproductive to pit one prevention strategy against 
another. This simply reveals the larger battle of ideologies, such as 
those of the church or bipartisan donor politics, which influence these 
policy decisions. Ultimately, it is more productive to accept that both 
strategies in conjunction with one another may be the most useful for 
the future.
Shifting ideology: Dangers of dependency Donor politics determine the 
fate of any dependent country and this dependency has proven danger-
ous in Uganda’s past. In 2004, there was a shift back from condoms to 
the promotion of abstinence and being faithful, as a result of Republi-
can political and ideological sentiments. Through its dependency on the 
United States, Uganda had put itself at risk of a massive public health 
disaster, first realized with the 2004 recall of Engabu-branded condoms 
because of issues of ‘quality’. This recall (conveniently) occurred at 
the same time as PEPFAR delivered a $91 million grant – at a time 
when PEPFAR was shifting its ideological priority away from condoms, 
towards abstinence and monogamy (Kinsman, 2010: 102). The number 
of condoms being freely distributed in the country fell from 90 million 
in 2003 to 39 million in 2004 (Kinsman, 2010: 102). Stephen Lewis, 
UN Special Envoy on AIDS in Africa, openly blamed US policy for 
the shortage, claiming that the ‘significant decline in the use of condoms 
... [is] significantly orchestrated by the policies of the [US] government’ 
(quoted in Kinsman, 2010: 103). There was immediate worry among 
those who had been fighting for condom promotion:
‘We’re almost back to square one,’ one of the organization’s 
staff members said, adding: ‘[B]ecause of our culture, it was 
very difficult for us to get people to use condoms. Now, trying to 
promote abstinence in this social environment is very difficult. If 
you tell people to abstain, they’ll say, “You were the people telling 
us to use condoms, and now you’re telling us to abstain. Does 
this mean condoms weren’t effective and you were lying to us?” ’ 
(Cohen and Tate, 2005: 74)
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The situation fuelled confusion about the best prevention strategy 
and paralysed the population (Kinsman, 2010: 102).
The international shift in strategy was mirrored by President 
Museveni, who was criticized for spreading contradictory messages 
during the Fifteenth International AIDS Conference in Bangkok in 
2004. He first confirmed Uganda’s national condom policy, saying 
that it was an ‘effective means of preventing HIV/STI transmission’, 
yet soon after he indicated that the condom was ‘an improvisation, 
not as a solution’ (Kinsman, 2010: 100). A few months later, State 
Minister for Information Dr Nsaba Buturo is quoted as saying ‘we have 
erroneously given more prominence to condoms [than to abstinence 
and faithfulness] and this is going to change’ (Kinsman, 2010: 101). 
Opinions on the ground strongly supported the notion that pressure from 
the Bush Administration is what caused Museveni to take his strongest 
stance against condoms since the early 1990s. Interviews conducted 
by Kinsman (2010: 101) exposed feelings that ‘the Bush money has 
changed the way [Museveni] faces the epidemic’. One resident district 
commissioner appointed by Museveni himself explained that, ‘having 
watched [Museveni] over the years, [he’d] never heard him so openly 
denouncing [condoms]’, and the commissioner suggested that the 
‘strong message may have come from [Museveni’s] Republican friends 
in Washington’ (Kinsman, 2010: 101). The trouble, of course, was that 
while the supply of condoms could be stopped overnight, behaviours 
and culture cannot be so quickly changed. Once condoms were 
withheld, it was unreasonable to expect that levels of sexual activity 
would consequently decrease.
Uganda in the age of antiretrovirals: Drawing parallels 
with the past
From condoms to antiretrovirals: Same game, new name On 28 January 
2003, PEPFAR committed $15 billion towards combatting the AIDS 
pandemic, to be disbursed throughout Africa and the Caribbean 
(Kinsman, 2010: 93). Allocation of the funds was to see 55 per cent 
going toward treatment and 25 per cent towards prevention, with a 
third of this latter portion to be used to fund abstinence programmes. 
While there was debate over how prevention funds were to be allocated 
(Democrats wanted to promote condom use; Republicans wanted to 
preach abstinence), the shift from prevention towards treatment was 
clear.
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The introduction of free ART to Uganda in 2004 was a move 
that had been feared by many who advocated prevention for years 
before drugs first landed in the country. In the 1970s, access to drugs 
completely changed the landscape of sexually transmitted infections. 
One respondent described the feelings of the time as, ‘You get it 
today; tomorrow, you go for treatment’ (Kirby, 2008: 7). In fact, 
becoming infected was even incorporated into the culture as a symbol 
of pride: according to one interviewee of that era, ‘A man who never 
suffered from syphilis or gonorrhoea was never a man’ (Kirby, 2008: 
7). Former World Health Organization (WHO) Director General 
Hiroshi Nakajima warned, shortly after ART was confirmed to be an 
effective treatment against AIDS, that ‘new therapies must not lead 
policy makers to abandon their commitment to essential long-term 
activities such as preventions programs’ (Kirby, 2008: 118). The same 
fear of risk compensation that was first voiced in relation to condoms 
was being raised again, now in relation to treatment. As one European 
official alleged, ‘in the gay community, prevention just went out the 
window as soon as the drugs came in: now you could have sex without 
condoms again’ (Kirby, 2008: 119).
The role of behavioural disinhibition that might result from the 
rollout of ART in sub-Saharan Africa was assessed in models by Gray 
and colleagues (2003). They found that a 100 per cent increase in 
the number of sexual partners for those on highly active antiretroviral 
therapy (HAART) would significantly attenuate the reduction of 
incidence, as would even a 50 per cent increase in the number of sexual 
partners (Figure 9.12). Moreover, an increase in the number of sexual 
partners by 25 per cent among those receiving a vaccine with 50 per 
cent preventative efficacy would actually lead to a rise in HIV incidence 
(see Figure 9.13).
Fears of increasingly risky behaviour after ART initiation were 
grounded in studies that documented a significant increase in the number 
of unsafe sexual episodes among men who had sex with men (MSM) in 
San Francisco in the late 1990s (Katz et al., 2002). In that study, the 
proportion of those who reported unprotected anal intercourse and mul-
tiple sexual partners increased from 24 per cent in 1994 to 45 per cent in 
1999. Furthermore, a study by Stolte and colleagues (2004) found that 
gay, HIV-infected men who perceived less of a threat from HIV/AIDS 
were more likely to engage in unprotected anal intercourse. Additionally, 
studies showing the efficacy of behavioural interventions in the MSM 
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population further supported behaviour change as a sustainable and 
preferable choice to ART overdependence (Herbst et al., 2005).
In response, a number of studies investigated whether this 
phenomenon of risk compensation had occurred with regards to the 
Ugandan epidemic. In a paper by Crepaz et al. (2004) published in 



























9.12 HIV incidence, treatment, and behavioural disinhibition (source: Adapted 





























9.13 HIV incidence, treatment, and disinhibition with a preventative vaccine 
of 50% efficacy (source: Adapted from Gray et al. (2003))
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HAART were explored with regard to the prevalence of unprotected 
sex, as well as beliefs about viral loads and unprotected sex. 
While HAART reduces the chance of HIV transmission by means of 
lowering viral loads, it does not eliminate this chance – yet the study 
found that the likelihood of unprotected sexual behaviour was 
significantly higher in people who believed that HAART reduced 
HIV transmission, as well as in people who were less concerned about 
engaging in unsafe sex given the availability of HAART, partially 
countering the beneficial effect of lower viral loads (Crepaz et al., 2004).
Nonetheless, studies have also shown that HAART provision 
has reduced risky behaviour, when coupled with counselling and 
behavioural interventions. In rural Uganda, Bunnell and colleagues 
(2006) found that, after six months of ART, risky sexual behaviour 
among 926 HIV infected individuals was reduced by 70 per cent. ‘Risky 
sexual behaviour’ was defined as inconsistent or no condom use with 
partners of HIV-negative or unknown serostatus during the course of 
the previous three months. The conclusions of this study pointed to 
the efficacy of ART when coupled with behavioural interventions and 
counselling. More specifically, the behavioural interventions that all 
participants received included group education on ART, family VCT, 
and (perhaps most importantly) personal sexual behaviour plans in 
which participants assessed their current risk situation and how they 
might cope with increased sexual desires. Risk reduction options 
were listed as ‘abstinence, condom use, reduced frequency of sex, 
and alternative forms of sexual expression’. Interestingly, 85 per cent 
of risky sexual behaviour occurred within married and cohabitating 
couples, among whom negotiation of condom use is notoriously 
difficult. Furthermore, both men and women experienced substantial 
increases in sexual desire and in opportunities to meet new partners 
after ART initiation, reinforcing the notion of risk inhibition.
In another study, this time in the context of an urban HIV/AIDS care 
centre in Kampala, receipt of ART was not found to be associated with 
a significantly higher likelihood of being sexually active (Bateganya et 
al., 2005). Both groups had 35 per cent of participants reporting one or 
more casual sexual partners in addition to a main partner – but this also 
points to the fact that ART counselling did not lead to a reduction in 
casual sexual partners. Like Bunnell and colleagues (2006), however, 
recipients of ART did report more consistent condom use than ART-
naive participants.
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A more recent study by Pearson and colleagues (2010) in 
Mozambique did not find results as promising as those of Bunnell and 
colleagues (2006). After twelve months of ART, there was found to 
be an increase in the proportion of participants having sex, the total 
number of partners, and the number of partners with HIV-negative 
or unknown serostatus. Like the other two studies, there was found to 
be an increase in consistent condom use, as compared to the baseline 
– but other findings were far more disconcerting, such as the fact that 
96 per cent of concurrent relationships reported at twelve months were 
newly formed. Also, almost half of those reporting concurrent sexual 
partnerships also reported unprotected sex with their HIV-negative or 
unknown-serostatus partners. Both men and women believed that social 
and cultural factors encouraged men to have multiple sexual partners, 
and that non-disclosure of serostatus was correlated with concurrent 
relationships, as well as unprotected sex. The notable difference 
between the studies conducted by Pearson and colleagues (2010) 
and Bunnell and colleagues (2006) was the significant counselling 
that the latter provided to patients along with ART provision. Most 
importantly, the personal sexual behaviour plans seemed to demand 
personal responsibility and ownership of sexual actions independent of 
the benefits of antiretrovirals.
In support of this observation, a large observational cohort study 
carried out between 2003 and 2010 in South Africa found that while 
HAART did reduce sexual activity such as unprotected sex and 
concurrent sexual partners, the participants were enrolled in primary 
care programmes ‘in which they received ongoing counselling and 
prevention messages’ (Venkatesh et al., 2010). Thus a crucial role of 
HAART in sexual behaviour improvement is that it brings patients 
into contact with counselling and prevention; when it is not adequately 
coupled with behavioural counselling, such as in the Mozambique 
study (Pearson et al., 2010), HAART seems to have negative effects 
on sexual behaviour.
Antiretrovirals and voluntary counselling/testing: Addressing the 
uninfected and unknown In sub-Saharan Africa, according to ten 
national population-based surveys in 2010, less than 40 per cent of 
those living with HIV know their serostatus (WHO, 2010). A large 
scale-up of routine HIV VCT is occurring, but the effect of this on 
sexual behaviour is unclear. In a study by Kiene and colleagues (2010), 
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‘risky sex’ was classified as sex with a serodiscordant partner. The 
authors hypothesized that once an individual knows that he or she is 
positive, the infected person will avoid HIV-negative partners to reduce 
the risk of transmission (Kiene et al., 2010). Results after three months 
of finding out their serostatus showed that participants who found out 
they were HIV positive were no more likely to start using condoms 
during every sex act with a serodiscordant couple than were those who 
were HIV negative. Among those who were HIV negative and married, 
or in cohabitating relationships, there was not a significantly higher 
rate of partners being tested than there was among single participants. 
Also, there was a low rate of behavioural change among married and 
cohabitating partners, especially with regard to concurrent, non-marital 
partnerships. The percentage of concurrent, non-marital partnerships 
(between 14 per cent and 19 per cent) did not decrease following HIV 
testing. As was made famous by Epstein (2007), long-term concurrent 
relationships are the most troubling aspect of the African HIV pandemic 
and thus data showing that knowledge of serostatus does not result in 
behavioural change in this population is especially concerning.
These findings point to the deeper issues of a culture of concurrency 
that is ingrained in African communities. Kiene and colleagues (2010: 
124) concluded that, ‘[d]espite evidence of some behaviour change, the 
magnitude of reduction in risk of HIV transmission in this sample was 
modest’ and that the total number of risky sex acts across all participants 
only decreased by 4 per cent, which was a ‘non-significant decrease’. 
The authors also promoted the notion of ‘tailored risk-reduction 
counselling’: a similar programme to that successfully implemented by 
Bunnell and colleagues (2006). Kiene and colleagues (2010) highlight 
the idea that even knowledge of serostatus is insufficient to stimulate 
behavioural change at the level that is required to curtail the pandemic 
– and this leads to a number of questions, one being the impact of 
myths (‘ART cures HIV’; ‘ART will always be available for free’) on 
individuals who do not know their serostatus and on individuals once 
they find out their serostatus.
Unintentionally, the widening of ART availability has resulted 
in a neglect of prevention among the much larger, uninfected 
population (Okware et al., 2005). While risk compensation has been 
suggested as a factor among those using condoms and those provided 
with ART, attention should be turned to those yet to utilize these 
resources. Based on hearsay and face-to-face communication, it 
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seems that there may be a growing cohort of people affected by the 
security of knowing that drugs have helped others. Those that are still 
HIV negative and thus do not come in contact with the counselling 
that is provided when one is enrolled on ART are most likely to be 
misinformed about the extent to which antiretrovirals can save their 
lives, or about the difficulty of adhering to physically demanding drug 
regimens. As already noted, testing and the provision of ART has 
been proving inadequate in driving changed sexual behaviour absent 
the education and interventions that force participants to realize risk 
and to take personal responsibility. Such educational and behavioural 
interventions must therefore be scaled up to include those who 
are not currently being treated with ART, those whose serostatus 
is unknown, and those who are HIV negative. Many studies have 
indicated people’s aversion to testing, based on factors including 
stigma and fear; unfortunately, this means that they are also avoiding 
the counselling that accompanies testing. It is imperative that people 
receive counselling that will dispel myths such as those regarding 
ART’s curative ability (Hirsch, 2007), and it is this pre-emptive 
measure that will be absolutely crucial in preparing for the even 
greater drug shortages than are now being experienced.
Antiretroviral myths and misconceptions: Fuelling dangerous 
dependency While sexual behaviour studies and knowledge, attitude, 
and practice (KAP) studies focusing on people who are HIV negative 
or who have unknown serostatus are limited, it is likely that high-
risk sexual behaviour has increased in these populations as a result 
of misconceptions regarding HIV and its treatment (Okware et al., 
2005).
A study by Nyanzi-Wakholi and colleagues (2009) examined the role 
of HIV testing, counselling and treatment among people both with and 
without HIV infection. The study revealed the presence of significant 
myths about ART, as well as some recognition of the problems relating 
to adherence to the regimen. Some believed that, after sufficient ART, 
they would become HIV negative; the actual difficulties of being on 
ART were also voiced, however, with participants feeling overwhelmed 
at the need to swallow a pill for a lifetime.
Fears that the wider availability of ART may erode the previous 
achievements of behavioural interventions in Uganda were captured 
in a study by Atuyambe and colleagues (2008). The authors utilized 
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focus group discussions, with purposeful sampling, to create twenty 
groups comprising individuals who had relevant knowledge of 
reproductive health and HIV/AIDS issues, youths who were familiar 
with attitudes in the adolescent and young adult communities, and 
members of influential positions in local policy, such as officials in 
the Kampala city council. Among the participants, there was a strong 
belief that increased access to ART would result in a greater spread 
of HIV because of a rise in unsafe sexual behaviour. According to one 
local council official:
When people see that [antiretrovirals] are now available, which 
makes the HIV dormant for some time, they know they can 
now engage in sex knowing that at the end of the day, before 
they die, a cure will be available. It looks as if it has now made 
people more promiscuous. Before, people knew that there was 
no alternative but death. But now, we see risky sexual activities 
begin to increase.
Opinions from a focus group of males in school, aged 15–18, included 
the following:
I want to supplement what he has said, the drug [antiretrovirals] 
has increased the AIDS transmission rate because in the past 
people could protect themselves using condoms but now they no 
longer protect themselves since the drug is available.
Others reported that knowing that there were drugs available is what 
kept them from abstaining from sex:
HIV transmission will continue to increase as long as drugs are 
available. Even though it was me, I can’t abstain because I know 
there are drugs (laugh) but if there were no drugs, I would have 
abstained from sex.
Some male participants also presented the idea that the cheaper the 
drugs, the more women it would allow them to be with concurrently. 
Moreover, there was a concern for the development of a false con-
fidence in the efficacy of ART to completely prevent infection, as 
demonstrated in the following:
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Automatically people’s sexual behaviour has changed and people 
now go for unprotected sex because they know that there are 
[antiretrovirals] that can be used to weaken HIV/AIDS. Some 
people have hope now that there is medicine to use and keep them 
living hence having unprotected sexual intercourse.
Another finding of these focus groups was that HIV/AIDS was no longer 
perceived to be a large threat – namely, because of the availability of 
drugs that allowed people to live longer and appear healthier on the 
outside. Participants explained that:
People no longer fear AIDS because there are drugs that fight 
against HIV/AIDS ... people no longer see it as a big threat 
because at first it was seen as a terrible disease. It could cut 
people’s nails, remove people’s hair, but now with use of ARVs, it 
is difficult to see such signs.
Moreover, the groups elaborated on misconceptions about ART that 
were of major concern, especially among people who were unaware of 
their status and thus had never been counselled. One male participant 
voiced the belief that ‘even if [a person] is infected, he/she can swallow 
[antiretrovirals] and live for a long time’. Others claimed that many 
people think that ART ‘can cure the disease so they are no longer 
afraid’.
Ultimately, the fears and concerns expressed by the participants 
point towards a need for counselling and education among not only 
those who are HIV positive and on HAART, but those whose status 
is unknown and those who are HIV negative. The misconceptions 
listed, such as ART being a cure, are most likely ‘confirmed’ by 
its success among HIV-positive people, who are living longer and 
remaining healthier because of the treatment. Similar misconceptions 
about the impacts of ART were noted in South Africa, where a cross-
sectional study of 105 HIV clinic patients found that almost 50 per 
cent believed that ART could cure HIV and 36 per cent believed that 
ART would not cause side effects (Nachega et al., 2005). Additionally, 
programmes that include tailored counselling and testing are likely not 
only to change sexual behaviours, but also studies have shown that 
they significantly reduce HIV myths and false beliefs (Kalichman and 
Simbayi, 2003).
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Ultimately, these misconceptions are extremely counterproductive 
and dangerous; it is therefore essential that they be addressed through 
behavioural and educational campaigns, especially delivered by those 
actually living with HIV/AIDS.
Ideologies revisited: Danger, dependency, and the current situation The 
dangers created by overdependence and faith in the curative effects of 
ART are obvious – and similar to those surrounding the use of condoms 
earlier in the epidemic. When patients believe that the intervention 
– be it condoms or ART – is effective enough to allow them to engage 
in higher levels of risky sexual activity, the benefit of the intervention is 
diminished. Furthermore, this creates a troubling culture of dependency 
in which the provision of the resource is necessary to maintain the 
status quo – and when the resource becomes unavailable, the results 
are disastrous. This was seen to some extent in the aftermath of the 
Engabu condom shortage in 2004 and it is on the verge with regards to 
HAART availability at time of writing in 2015.
In August 2010, Dr Eric Goosby reversed the funding caps that 
prevented new patients from being accepted off waitlists, serving as a 
temporary solution for those in need of drugs (Health E-News, 2010). 
Supported by PEPFAR, he also allowed for a temporary infusion of 
additional antiretrovirals to address the widespread, extreme shortages 
(PlusNews, 2010). Nonetheless, the level of funding provided by 
PEPFAR has relatively flatlined, increasing just $2 million in 2008–09 
as compared to almost $50 million in 2007–08 (PEPFAR, 2010b). 
In a statement on its website in early 2010, PEPFAR indicated that it 
would be taking a new focus on ‘personalized risk’ and placing more 
emphasis on prevention, as opposed to treatment (PEPFAR, 2010b). 
As the donor stance changes – as the United States shifts its goals from 
HIV/AIDS to maternal and child health – the resulting impact on 
recipient countries such as Uganda has been, and will continue to be, 
fatal (PEPFAR, 2010b).
Concerns from the outset of the ART scale-up had to do with 
its sustainability. As cautioned by a European Commission official 
in an interview in 2003: ‘People will say “this is costing too much, 
we already have X,000 people on treatment, the economy cannot 
support this anymore” ’ (quoted in Kinsman, 2010: 122). The 
official continued to predict the dialogue: ‘ “Sorry, we can’t treat you, 
somebody has to die before you can get treated.” ’ In an insightful 
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prediction, the official urged: ‘Don’t put people on treatment today 
that you can’t afford to have on treatment in 20 years’ time.’ This 
is the very same dialogue that was heard in Uganda during personal 
interviews with heads of NGOs and government officials in July 
2010: with treatment no longer available, a culture that had become 
dependent on donated drugs suddenly found itself suffocated and 
people were unsure what to do.
As noted already, the US government’s approach now, under 
PEPFAR, is to focus on prevention rather than treatment. Arguments 
for prevention have long been voiced, with studies showing that 
prevention may be up to twenty-eight times more cost-effective in 
the long run than HAART (Marseille et al., 2002). Unfortunately, 
however, these arguments do not solve the dilemma with which 
Uganda is faced: only 37 per cent of those needing HAART in sub-
Saharan Africa were receiving it by the end of 2009 (WHO, 2010). 
Coverage in Uganda was close to these levels, using various CD4+ 
count scenarios (see Figure 9.14). Moreover, prevention will not 
protect those who are already infected: the nearly 4 million people 
in sub-Saharan Africa who are currently on HAART, nearly 220,000 































9.14 Ugandan ART coverage using various criteria (source: Adapted from 
NACP (2010))
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of their lives, or until a cure is found (NACP, 2010; WHO, 2010). 
Ultimately, then, treatment must be maintained, but prevention is 
the only sustainable solution for controlling the pandemic, given the 
reality of AIDS funding.
While funding is currently being maintained at stable levels, the HIV 
epidemic in Uganda may be worsening. Recent reports from studies 
conducted in small antenatal clinic sites are suggesting that prevalence 
and incidence are again on the rise (see Figure 9.15) (Shafer et al., 
2008). Shafer and colleagues (2008) noted an increase in the proportion 
of participants reporting one or more casual partners between 1997 
and 2004, and there was a significant drop in condom use among those 
aged 20–24 (from 74.1 per cent in 1997 to 50.7 per cent in 2005). 
One possibility for these observations, say Shafer and colleagues 
(2008: 1648), is that ‘in the perception of the population, HIV has 
become ... a normal part of life’. Additionally, according the UNAIDS 
2010 Global Report, Uganda’s 2009 incidence was estimated at 0.74: 
a slight increase from the 2001 statistic of 0.71 (UNAIDS, 2010). 
These results are a cause for concern, and indicate that population-
wide changes in behaviour and an increase in risk inhibition must be 

























































9.15 HIV prevalence as observed in rural villages in southwest Uganda (source: 
Adapted from Shafer et al. (2008))
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successes of Museveni’s government and Ugandan civil society in the 
late 1980s and early 1990s must be replicated in the years to come.
Addressing culture: Why prevention makes sense While it may be 
convenient to call for a shift in sexual culture, prevention requires an 
extremely difficult and massive upheaval of social structures. However, 
successful treatment is limited by the same cultural factors and cannot 
succeed until these are fixed at their foundations – foundations that 
lie at the heart of prevention. The push for a reinstatement of national 
behavioural movements is supported by the inefficacy of ART and HIV 
testing based on complex social factors that impede the progress of a 
treatment-dependent culture. Issues of gender and sexual inequality 
impact testing, as well as initiation and adherence to ART.
For instance, reluctance to finding out one’s serostatus has much to 
do with an individual’s other life goals, such as marriage and fertility, 
which may be impeded should he or she be identified as HIV positive. 
A notion that is often undervalued in health care is that although 
biological health is important, for the patient it does not always take 
full priority over all other areas of life (Hirsch, 2007). For those who do 
test positive or who have partners who do so, the desire to form a family 
may still override a concern for transmission of the disease. As Hirsch 
(2007) elucidates: ‘Many HIV-negative women in serodiscordant 
couples feel compelled to risk the physical death of AIDS rather than 
the social death of childlessness.’ Moreover, the nature of sexual health 
is inherently gendered, which impacts on the level of access that men 
and women share disproportionately. For example, it may be taboo 
for a woman even to be tested for HIV, because the community 
may take this to mean that she is overly promiscuous. A study by 
Turan and colleagues (2011) found that pregnant women in Kenya 
were afraid of being tested, for they anticipated that it would break 
up their relationship or cause them to lose friends. Furthermore, the 
way in which individuals actually use medicines is impacted upon by 
the communities in which they live and often by the local methods 
of healing. The use of ART, with its specific regimens and fairly 
detrimental side effects, may be counter-intuitive in light of cultural 
norms of healing (Peltzer et al., 2008).
Another important point relates to antiretrovirals causing 
disinhibition. Hirsch (2007) highlights that the problem is often far 
more deeply rooted than something as simple as disinhibition. She 
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notes that, for many, having sex is far less a personal choice than it 
is often deemed to be. The societal factors that often push people on 
ART to have sex, including inequality and poverty, are exacerbated 
by the fact that antiretrovirals make people seem healthy and thus 
sexually safe again. Furthermore, when speaking of men who return to 
the sexual network once ART has improved their physical health, it is 
imperative to remember that they are also returning to a social network 
that is demanded of men in Ugandan society.
Ultimately, although treatment is seemingly utopian, it must deal 
with the same complex nets of anthropology that hinder effective 
prevention. The national behavioural change movements that are 
needed are those that will emulate the past by reducing stigma, 
incorporating local culture, and simultaneously reworking the way in 
which people behave on a regular basis. In effect, these movements will 
open avenues for both prevention and treatment.
Sexual network: A cradle for the epidemic The sexual network is one 
of the most important factors in terms of the spread of HIV in sub-
Saharan Africa. This aspect of transmission is deeply ingrained in the 
culture and impacts on behaviour, while at the same time asserting 
the success of tangible interventions such as condoms and ART as 
reinforcement. The sexual network is mainly perpetuated by men 
who have concurrent partnerships. Traditionally, women in Uganda 
were expected to remain monogamous, while for men having multiple 
sexual partners was a sign of status and wealth (Kirby, 2008: 6). 
According to a survey in 1988, up to 80 per cent of rural women 
reported their husbands having multiple sexual partners (Kirby, 2008: 
5). Furthermore, studies have indicated that the single most important 
behavioural characteristic associated with incident HIV infection was 
the number of times that a person had sex with people whom they 
suspected or knew were having sex with others – that is, what is termed 
‘concurrency’ (Guwatudde et al., 2009).
More difficult to confront because of even deeper cultural inherencies 
are the traditions in particular rural areas that lead to concurrency. 
These include: adolescent males who are circumcised ‘cleansing’ 
themselves by having sex; polygamy among Muslim Ugandans; father-
in-laws having first sexual rights to a new bride; and wife-sharing, which 
was supposed to show respect and hospitality to brothers or guests in 
the home (Kirby, 2008: 6).
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Furthermore, in interviews with boda-boda men, the most ‘common 
adult sexual partner’ in Uganda (a boda-boda being basically a cheap 
taxi in the form of a motorcycle), several aspects of concurrency 
were elucidated (Nyanzi et al., 2005). For instance, sexual activity, 
and specifically promiscuity, was noted as a sign of manhood, which 
was measured by the number of sexual partners, while polygamy was 
reported as being institutionalized within the Buganda and Islamic 
cultures. Surprisingly, there were even myths that abstinence causes 
severe disease.
Even more disheartening was the notion of fatalism that pervaded the 
dialogue: many said that it was inevitable that they would catch HIV, if 
not through sex, then through another avenue, such as transfusions or 
hospital injections. One man was quoted as saying, ‘everybody knows 
that all boda-boda men are infected with the virus’ (Nyanzi et al., 2005: 
117). This fatalism reinforces the sexual network by giving people no 
incentive to leave it.
The sexual networks will not succumb to symptomatic interventions 
such as drugs and condoms. They cost nothing, unlike drugs, which 
cost billions of dollars, and will outlive all Western donor efforts that 
do not include support for behavioural change. Unfortunately, these 
networks are reinforced by condoms and drugs: without them, AIDS 
would ravage the networks, killing those most involved. Simply put, 
the more sexual partnerships in which an individual is engaged, the 
higher the chance that he or she has of being infected and, ultimately, 
the higher the chance him or her dying. Those who choose to remain 
outside these networks would survive. It is an ethical imperative not to 
let this be the mechanism that curbs HIV in Africa. With the current 
funding situation as dire as it is, drugs are unlikely to sustain the lives 
of infected people in the sexual networks for much longer. If drugs 
become unavailable and people fail to realize that HIV can no longer 
be maintained as a chronic condition, the result will be several million 
deaths – unless behavioural and educational movements are established 
immediately.
Moving forward: The future of HIV/AIDS in Uganda
Looking ahead: What Uganda needs It will be critical to approach 
the epidemic efficiently and effectively. Identifying sociodemographic 
factors could be beneficial in efficiently predicting risky sexual behaviour 
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and targeting interventions accordingly. In South Africa, HIV-infected 
individuals who were urban, young, married (or cohabitating) people 
without casual sexual partners, and with higher education and income 
levels, were more likely to use condoms consistently (Lurie et al., 2008). 
Predictors of sexual partners for men included being from urban areas, 
having higher education and income levels, and having CD4 counts 
higher than 200 cells/mm3. Furthermore, studies have shown that the 
presence of alcohol resulted in significantly higher instances of unsafe 
sex, that women were more likely than men to report unsafe sex at 
last sexual encounter (most likely because of the gender inequity that 
prevents the negotiation of condom use), and that disclosure of serostatus 
is associated with lower rates of unsafe sex (Lurie et al., 2008).
Furthermore, effective movements will need to capitalize on catchy 
slogans and pop culture. Artists such as Phil Lutaya, who tried to 
reduce the stigma around AIDS in the late 1980s, are being followed 
by young Ugandans such as Barbara Kemigisa. Kemigisa is an activist 
and artist living with HIV in Kampala who has recorded several songs 
about hope, confidence, and surviving the epidemic (Voice of America, 
2012). Current successful campaigns to reinstate behavioural change 
include the ‘OneLove’ campaign by the Uganda Health Marketing 
Group, which uses the slogan ‘Get off the sexual network’. The 
group has made clear the notion of a large sexual network in which all 
Ugandans are linked by the fact that they have multiple partners, and 
their partners have multiple partners, who have multiple partners, and 
so on. This approach drives people to withdraw from a constrictive 
and harmful network of which they may not have realized they were 
a part. The notion of this sexual network has also been taken up 
by Robert Thornton in his ‘One, One, One’ campaign. Thornton’s 
approach encourages people to stick to one partner at a time, to wait 
one month before starting sex with a new partner (because people 
are most infectious during their first month of HIV infection), and 
to choose sexual partners from one geographic area. As proposed by 
Epstein (2007), sexual networks in Africa are particularly well suited 
to sustaining the spread of HIV because of the long-term, concurrent 
nature of many partnerships. Thus these campaigns are addressing the 
epidemic at its heart.
Glancing behind: Learning from past weaknesses Uganda’s early suc-
cesses included a multisectoral approach that involved organizations 
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and citizens at the national, district, and community levels. The Uganda 
AIDS Commission (UAC) was supposed to be the body overseeing 
the several ministries and organizations involved. However, from the 
start, a number of reports on inefficiencies within the Commission 
were filed, indicating wastage of large amounts of money as well as 
poor coordination of policy (Kirby, 2008). Thus it is important to be 
cautious of overcentralized, overly bureaucratic systems; work on the 
ground should instead be directed by those on the ground themselves 
and within the target communities.
The Masaka intervention trial (MIT), a large five-year study 
attempting to isolate a behavioural intervention programme, can 
provide valuable insight: contrary to expectations, it did not reduce 
incidence (Quigley et al., 2004). The trial was one of Uganda’s most 
promising interventions, based on an information, education, and 
communication model that aimed to raise awareness of HIV and to 
promote safer sexual behaviour and practices through a community-
based approach. Information was disseminated in an engaging manner 
through village drama and video shows, as well as group meetings and 
one-on-one discussions with community educators.
Quigley and colleagues (2004: 2056) note that ‘suboptimal 
implementation of the intervention ... insufficient coverage ... or the 
intervention being inappropriate for the setting’ could have been reasons 
for its failure. Furthermore, it may be that the intervention effected 
behaviour change and reduced incidence in a small number of individuals, 
meaning that large-scale changes on the community level would have 
been imperceptible. Kinsman (2010: 168) elaborates that there was 
extremely limited awareness of the study among relevant district officials. 
The results of the intervention did show a lower incidence in women who 
attended at least one intervention event, as compared to those who had 
not attended any, but there was no behavioural mechanism for the effect 
(Quigley et al., 2004). The lessons from the study included the need to 
identify subgroups not reached by behavioural interventions, the need 
to correct for reporting bias that occurs with sexual behaviour data by 
utilizing biological markers such as seroconversion, and the realization 
that randomized controlled trials may be insufficient to explain the 
mechanisms that dictate why behavioural interventions do or do not 
succeed (Quigley et al., 2004).
Challenges to the actual implementation of behavioural change 
were also noted by a regional project in Uganda, Kenya, Tanzania, and 
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Ethiopia, undertaken by the African Medical Research Foundation, 
which worked with young people (Amuyunzu-Nyamongo et al., 1999). 
In this study, the situations that were found to lead to sexual intercourse 
were often informal and not readily conducive to use of a condom, or 
were too sudden to address by saying ‘no’. Furthermore, many adults 
were wary of allowing children to be given sexual information, even 
though the average age of first sexual intercourse is 12–14 – and even 
younger in slums and poorer areas. As mentioned earlier, condom use 
and even condom promotion are impeded by large challenges, not least 
opposition among religious groups and a general cultural conservatism 
in the public arena regarding sex. Furthermore, some participants were 
noted as expressing the belief that ‘everybody will die anyway’ and such 
fatalism is difficult to expunge. Gender imbalances were pervasive too, 
with boys indicating that a girl who carried a condom would be seen 
as a prostitute or as having AIDS herself. Amuyunzu-Nyamongo and 
colleagues (1999) suggest that the debunking of rumours and myths 
surrounding such matters as condom use should be incorporated into 
marketing strategies; moreover, to address the sense of indestructibility 
found among these young people, having HIV-positive peers speak 
to them would be particularly meaningful. Working with religious 
organizations was also suggested as likely to be beneficial – but only 
those organizations that are progressive, and willing to acknowledge 
that abstinence and core behavioural changes are to be reached only 
via more piecemeal approaches first, including condom use.
Anecdotal evidence: Homegrown strategy
To determine the vision of Uganda’s future AIDS policy among the 
several entities involved, a number of interviews were conducted with 
members of leadings NGOs and care facilities, including TASO, the 
JCRC, the PEPFAR team at the US Embassy, and the AIDS Control 
Programme in the Ministry of Health.
Godfrey Musaaya, TASO regional manager in the northern Gulu 
district, indicated in a personal interview that there was at TASO a 
sense of frustration with the government’s neglect of health as one of 
Uganda’s priorities (interview with the author, July 2010). Currently, 
the government of Uganda does not meet the requirements under the 
2001 Abuja Declaration, which called for African countries to allocate 
at least 15 per cent of their budgets to the health sector (Uganda 
currently allocates 9 per cent), and it has declared that it does not have 
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enough money to meet this promise (Womakuyu, 2010). The failure 
to meet this goal, along with instances of corruption with regards to 
aid money, has heavily contributed to Ugandan aid being cut (Nyanzi, 
2011).
In another personal interview, Dr Elizabeth Namagale, head of 
ART Rollout at the Ministry of Health’s AIDS Control Programme, 
suggested that the Ugandan health sector is unlikely to be able to 
supplement the lost PEPFAR funding and lamented that Ugandans 
had developed a mentality that ‘drugs should be free’, which will 
certainly prove disastrous given the funding dilemma (interview with 
the author, July 2010). As of February 2012, Uganda had also suffered 
severe funding cuts from the Global Fund, receiving the least among 
the East African countries: only $300 million compared to $1.2 billion 
in Ethiopia and $1 billion in Tanzania (The Monitor, 2012).
According to a personal interview with a TASO medical coordinator 
in Mulago Hospital, Kampala, smaller clinics in the area had been 
sending their waiting-list patients to TASO because of the drug 
supply shortage (interview with the author, July 2010). She explained 
the need to use fear to promote prevention: staff are now saying to 
family members of patients, ‘If you get the disease, you will die.’ The 
coordinator described it as ‘reverting back to mechanisms when drugs 
actually weren’t available’, and also added that success in treatment 
and behavioural change is ‘largely based on perceptions’. This method 
of fear arousal is parallel to the movements in the 1990s identified by 
Halperin (2006).
In another personal interview, Nicholas Mugumya, the deputy 
director of TASO, said that he felt that while the Ministry of Health 
could allocate more money to HIV, it was impossible to expect the 
Ministry to sustain the health sector of the country (interview with the 
author, July 2010). Mugumya also commented that most people were 
unaware that slots for ART were quickly diminishing – a fact that, if 
known, would surely facilitate changes in sexual behaviour.
Deputy PEPFAR Coordinator of Uganda Reuben Haylett 
recognized Uganda as having several internationally recognized figures 
and a very strong civil society, as compared to a weaker base of human 
rights activists and a government that was weakening under the weight 
of corruption and scandals (interview with the author, July 2010). 
He further commented that small, unpublished surveys showed that 
while knowledge of HIV-related material is relatively good, risk-taking 
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behaviours have become significantly worse as access to testing and 
ART has increased. On both a societal and individual level, then, the 
scenario today is the exact opposite of that in the late 1980s.
Final thoughts: Case for a socio-behavioural movement
With all of this in mind, what is Uganda’s path forward in battling 
the HIV epidemic? While it may be infeasible for Uganda to assume 
the costs of programmes such as PEPFAR and the Global Fund, it may 
not need to do so completely. Because donor funding is approaching 
flatlined levels, incidence must be brought down quickly, because 
maintenance of a non-zero incidence would require a growth in the 
amount of funding received. Assuming that funding levels are steady 
over the next few years, Uganda must take the following steps.
First, a move towards meeting requirements under the Abuja 
Declaration is critical. As of 2014, Uganda is allocating only 8 per cent 
of its national budget to the healthcare sector (State House of Uganda, 
2014) – an amount that has been in steady decline since 2010 (with 
around 9 per cent allocated at that time) and is far from the 15 per cent 
proposed at the Abuja Declaration. Uganda therefore needs to allocate 
a greater proportion of its national budget to health.
In practice, this means funding both treatment and prevention. 
However, more specifically, this means a replication of the societal 
change that took place in the late 1980s and throughout the early 1990s. 
This change is to be fuelled by a mobilization of the masses, including 
teachers in schools, religious leaders in churches and mosques, figures 
in the film and music industries, children and youths, traditional 
healers and village heads, local and national politicians, people living 
with HIV, and (first and foremost) President Museveni and the 
government who first spearheaded this effort twenty years earlier. 
Mr James Kigozi, spokesperson for the Uganda AIDS Commission, 
commented that donor largesse has made Uganda complacent and 
that HIV is no longer receiving the government attention that it did in 
the past because of the ‘tremendous donor support’ (Rukmundo and 
Lirri, 2010). The reality of the donor situation must therefore be made 
publicly known, and it must be reinforced that while treatment will 
continue for those infected, funding cannot accommodate the growing 
number of HIV-positive persons that it has over the past few years. 
Moreover, the culture of dependency on free drugs and the expectation 
that free drugs will always stock the local clinics must be replaced with 
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the harsh reality of personal responsibility for their own sexual actions 
among those who are HIV negative or who have unknown serostatus.
Additionally, as emerged from the personal interviews with TASO 
managers and directors, it is clear that the government must abandon 
its traditions of excessive bureaucracy, instead providing oversight 
and decentralization in its efforts for both treatment and prevention. 
Following the success of TASO, the Ministry of Health must find ways 
in which to engage and work with civil society adopting a bottom-up 
approach. Empowering local organizations and local leaders is the key 
to social mobilization and culture-shifting. Many successful activities 
have been coordinated by NGOs located within the communities and 
these should be capitalized upon, just as they were in the 1990s.
The corruption and lack of transparency within the government 
must also be addressed. Scandals such as that relating to the Global 
Fund in 2005 must be avoided, for they exploit the dire political strife 
that has made donor aid difficult to secure and, more importantly, 
they dishearten the public and challenge the legitimacy of leaders 
(Washington Times, 2006). For those who are HIV-positive, the 
continuation of HAART should be coupled with public demonstrations 
and education about what a life with HIV actually entails for others. 
People living with HIV/AIDS are bound to be the most influential in 
any behavioural movement: they will be the most credible in dispelling 
myths about HIV and ART, and will be able to expose the realities of 
how difficult adhering to drug regimens is, how physically and mentally 
taxing antiretrovirals are on the body, and how personal sexual choice 
is one’s only means of overcoming the epidemic.
This raises the more complex notion of addressing the culture that 
bars the prevention of HIV from being as simple a matter as exercising 
personal sexual choice – that is, the inequality, poverty, and issues of 
gender and discrimination that make sex far more than a straightforward 
physical act. It is absolutely crucial to begin by incorporating messages 
within cultural frameworks. The sexual networks must be counteracted 
through culturally tuned educational movements such as the Uganda 
Health Marketing Group’s ‘OneLove’ and Robert Thornton’s ‘One, 
One, One’. For example, the OneLove campaign used billboards that 
portrayed a child asking his mother and father to please get off the sexual 
network and enjoy a happy life. Smart, culturally sensitive messages 
such as these are bound to succeed. Moreover, by working with 
leaders within communities – such as heads of villages and traditional 
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medicinal healers – the cultures of structural violence may be mitigated 
and eventually eliminated. Target groups that have an influence on 
public life, such as boda-boda men, should also be identified and micro-
mobilized as starting points.
Ultimately, fear arousal may be the catalyst that any successful 
behavioural change movement will need, and this may be promoted 
both formally and informally. As was the case in TASO Mulago, family 
members and HIV-negative people may have to be warned that if they 
contract HIV, they are likely to die. Educational demonstrations should 
be provided free to the public, with graphic images or documentation 
of the ill effects of HIV on the body, to recreate a level of concern 
regarding HIV that, it is claimed, has been lost (Nyanzi-Wakholi et al., 
2009). Of course, this must be balanced against an attitude of fatalism 
that itself allows individuals to abdicate personal responsibility, 
meaning that a careful mediation of messages must be established. It 
will also be important to explain the fact that treatment is available for 
those who find out their serostatus (at time of writing, at least), so as 
to increase testing willingness among those with unknown serostatus 
– for prevention is useless without the promise of treatment for those 
who are already infected.
The replication of Uganda’s past successes may be hindered by the 
unstable donor politics that have already engendered a level of distrust 
among the populace. As mentioned in interviews conducted by Cohen 
and Tate (2005), the condom recall in 2004 led to confusion about 
whether condoms worked at all and reinvigorated myths that condoms 
were actually a cause of HIV or conspiracy theories of an ulterior motive 
among the US donors. Another sudden shift – from treatment to 
abstinence – will perhaps cause a similar reaction: people may question 
whether ART was effective at all. If not carefully framed, this may be 
counterproductive and future antiretroviral regimens may not be taken 
seriously by misinformed masses. Public transparency of the Ugandan 
government’s underfunding of the health sector must be made clear and 
the shifting HIV strategy must be linked to the economic downturn, not 
to a message that behavioural change is necessarily better than ART. 
The reality is that both are needed: they are complementary to one 
another, as evidenced in the successful sexual behaviour monitoring 
programmes linked with treatment in clinics, and they are likely, in 
combination, to be a solution to the spread of HIV in sub-Saharan 
Africa (Bunnell et al., 2006). Unfortunately, however, when ART is 
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withdrawn, a behavioural change movement will become that much 
more critical.
Lastly, the government must avoid creating and propelling stigma 
around people living with HIV/AIDS. The HIV Prevention and 
Control Act, passed by the Ugandan Parliament in 2014, serves to 
criminalize those who intentionally transmit HIV/AIDS, and mandates 
testing for pregnant women and their partners (Human Rights Watch, 
2014). While this law is meant to curtail the spread of illness, it does 
so in a way that fails to promote partnership between the government 
and the public, and which may actually serve to scare people further 
away from testing. Laws should instead be sensitive to the reality that 
HIV continues to be stigmatized in the African – and, in fact, the global 
– context.
Uganda’s future success in changing culture and behaviour is not a 
pipe dream. The country that once served as a beacon of hope in the 
fight against AIDS may yet do so again in the face of the tragedy that 
is both donor politics and the global economic crisis. This unfortunate 
combination of politics and economics is quickly becoming the largest 
challenge to the fight against HIV/AIDS, and is a direct call for a united 
and mobilized African continent in the coming years. Hopefully, in 
a not-too-distant future, Dr Goosby will be acclaiming the ‘Kampala 
situation’ as an example that the epidemic can be curtailed by people’s 




Wambua, L., Babishangire, B., 
Nyagero, J., Yitbarek, N., Matasha, 
M., and Omurwa, T. (1999) ‘Barriers 
to behaviour change as a response 
to STD including HIV/AIDS: The East 
African experience’ [online]. Available 
at http://htc.anu.edu.au/pdfs/
resistances_ch1.pdf
Asiimwe, D., Kibombo, R., and 
Neema, S. (2003) ‘Focus group 
discussion on social cultural 
factors impacting on HIV/AIDS 






Atuyambe, L., Neema, S., Otolok-Tanga, 
E., Wamuyu-Maina, G., Kasasa, S., 
and Wabwire-Mangen, F. (2008) 
‘The effects of enhanced access to 
antiretroviral therapy: A qualitative 
study of community perceptions in 
Kampala city, Uganda’, African Health 
Sciences, 8(1): 13–19.
Bateganya, M., Colfax, G., Leigh, A. S., 
Kityo, C., Mugyenyi, P., Serwadda, 
D., Mayanja, H., and Bangsberg, D. 
(2005) ‘Antiretroviral therapy and 
sexual behavior: A comparative study 
244 | n ine
between antiretroviral-naive and 
-experienced patients at an urban 
HIV/AIDS care and research center in 
Kampala, Uganda’, AIDS Patient Care 
and STDs, 19(11): 760–8.
Bunnell, R., Ekwaru, J. P., Solberg, P., 
Wamai, N., Bikaako-Kajura, W., Were, 
W., Coutinho, A., Liechty, C., Madraa, 
E., Rutherford, G., and Mermin, J. 
(2006) ‘Changes in sexual behavior 
and risk of HIV transmission after 
antiretroviral therapy and prevention 
interventions in rural Uganda’, AIDS, 
20(1): 85–92.
Cohen, J., and Tate, T. (2005) ‘The less 
they know the better: Abstinence-
only HIV/AIDS programs in Uganda’, 
Human Rights Watch, 17(4): 1–79.
Cohen, S. (2004) ‘Beyond slogans: 
Lessons from Uganda’s experience 
with ABC and HIV/AIDS’, 
Reproductive Health Matters, 12(23): 
132–5.
Crepaz, N., Hart, T. A., and Marks, G. 
(2004) ‘Highly active antiretroviral 
therapy and sexual risk behavior: A 
meta-analytic review’, Journal of the 
American Medical Association, 292(2): 
224–36.
Epstein, H. (2007) The Invisible Cure: 
Africa, the West, and the Fight Against 
AIDS, New York: Farrar, Straus & 
Giroux.
Geng, E. H., Mwebesa, B. B., Kabakyenga, 
J., Muyindike, W., Emenyonu, N. I., 
Musinguzi, N., Mugyenyi, P., Martin, 
J. N., and Bangsberg, D. R. (2010) 
‘Diminishing availability of publicly 
funded slots for antiretroviral 
initiation among HIV-infected ART-
eligible patients in Uganda’, PLoS 
ONE, 5(11): e14098.
Gray, R., Xianbin, L., Wawer, M. J., Gange, 
S. J., Serwadda, D., Sewankambo, N. 
K., Moore, R., Wabwire-Mangen, F., 
Lutalo, T., and Quinn, T. C. (2003) 
‘Stochastic simulation of the impact 
of antiretroviral therapy and HIV 
vaccines on HIV transmission, Rakai, 
Uganda’, AIDS, 17(13): 1941–51.
Green, E. C. (2009) ‘The Pope may be 
right’, 29 March, The Washington 




Green, E. C., Halperin, D. T., Nantulya, V., 
and Hogle, J. A. (2006) ‘Uganda’s HIV 
prevention success: The role of sexual 
behavior change and the national 
response’, AIDS and Behavior, 10(4): 
335–46.
Guwatudde, D., Wabwire-Mangen, F., 
Eller, L. A., Eller, M., McCutchan, 
F., Kibuuka, H., Millard, M., 
Sewankambo, N., Serwadda, D., 
Michael, N., and Robb, M. (2009) 
‘Relatively low HIV infection rates in 
rural Uganda, but with high potential 
for a rise: A cohort study in Kayunga 
District, Uganda’, PLoS ONE, 4(1): 
e4145.
Halperin, D. T. (2006) ‘The controversy 
over fear arousal in AIDS prevention 
and lessons from Uganda’, Journal of 
Health Communication, 11(3): 266–7.
Health E-News (2010) ‘Uganda: PEPFAR 
makes U-turn’, allAfrica.com, 4 
August [online]. Available at http://
allafrica.com/stories/201008040406.
html
Herbst, J. H., Sherba, R. T., Crepaz, N., 
DeLuca, J. B., Zohrabyan, L., Stall, R. 
D., and Lyles, C. M. (2005) ‘A meta-
analytic review of HIV behavioral 
interventions for reducing sexual risk 
behavior of men who have sex with 
men’, Journal of Acquired Immune 
Deficiency Syndromes, 39: 228–41.
Hirsch, J. S. (2007) ‘Gender, sexuality, 
and antiretroviral therapy: Using 
social science to enhance outcomes 
and inform secondary prevention 
strategies’, AIDS, 21(5): S21–9.
Human Rights Watch (2014) ‘Uganda: 
Deeply flawed HIV Bill approved’, 14 
karan | 245




Joint United Nations Programme on HIV/
AIDS (UNAIDS) (2010) Report on the 
Global AIDS Epidemic 2010 [online]. 
Available at http://www.unaids.org/
globalreport/Global_report.htm
Joint United Nations Programme on 
HIV/AIDS (UNAIDS)/World Health 
Organization (WHO) Working Group 
(2008) Epidemiological Fact Sheet 
on HIV and AIDS, Uganda [online]. 
Available at http://www.who.int/hiv/
pub/epidemiology/pubfacts/en/
Kaleeba, N., Namulondo, J., Kalinki, D., 
and Williams, G. (2000) Open Secret: 
People Facing up to HIV and AIDS in 
Uganda, London: ActionAid.
Kalichman, S. C., and Simbayi, L. C. (2003) 
‘HIV testing attitudes, AIDS stigma, 
and voluntary HIV counseling and 
testing in a black township in Cape 
Town, South Africa’, Sex Transm 
Infect, 79: 442–7.
Katz, M. H., Schwarcz, S. K., Kellogg, T. A., 
Klausner, J. D., Dilley, J. W., Gibson, S., 
and McFarland, W. (2002) ‘Impact of 
highly active antiretroviral treatment 
on HIV seroincidence among 
men who have sex with men: San 
Francisco’, American Journal of Public 
Health, 92: 388–94.
Kiene, S., Bateganya, M., Wanyenze, R., 
Lule, H., Nantaba, H., and Stein, M. 
D. (2010) ‘Outcomes of provider-
initiated routine HIV testing and 
counseling during outpatient care 
at a rural Ugandan hospital: Risky 
sexual behavior, partner HIV testing, 
disclosure, and HIV care seeking’, 
AIDS Patient Care and STDs, 24(2): 
117–26.
Kinsman, J. (2010) AIDS Policy in Uganda: 
Evidence, Ideology, and the Making of 
an African Success Story, New York: 
Palgrave Macmillan.
Kirby, D. (2008) Success in Uganda: 
A History of Uganda’s Successful 
Campaign to Decrease HIV Prevalence 




Lurie, M., Pronyk, P., de Moor, E., 
Heyer, A., de Bruyn, G., Struthers, 
H., McIntyre, J., Gray, G., Marinda, 
E., Klipstein-Grobusch, K., and 
Martinson, N. (2008) ‘Sexual behavior 
and reproductive health among HIV-
infected patients in urban and rural 
South Africa’, Journal of Acquired 
Immune Deficiency Syndromes, 47: 
484–93.
Marseille, E., Hofmann, P. H., and Kahn, 
J. G. (2002) ‘HIV prevention before 
HAART in sub-Saharan Africa’, The 
Lancet, 359: 1851–6.
Masaba, J. (2012) ‘Uganda’s HIV infection 
rate rises to 6.7%’, 18 March, New 




Mbulaiteye, S. M., Mahe, C., Whitworth, 
J. A. G., Ruberantwari, A., Nakiyingi, 
J. S., Ojwiya, A., and Kamali, A. (2002) 
‘Declining HIV-1 incidence and 
associated prevalence over 10 years 
in a rural population in south-west 
Uganda: A cohort study’, The Lancet, 
360: 41–4.
McNeil, Jr, D. G. (2010) ‘At front 
lines, AIDS war is falling apart’, 




Médecins sans Frontières (MSF) (2011) 
Reversing HIV/AIDS? How Advances 
Are Being Held back by Funding 




246 | n ine
Monitor, The (2012) ‘East Africa: 
Global Fund cuts AIDS cash’, 
allAfrica.com, 12 February [online]. 
Available at http://allafrica.com/
stories/201202130161.html
Nachega, J., Lehman, D. A., Hlatshwayo, 
D., Mothopeng, R., Chaisson, R. E., 
and Karstaedt, A. S. (2005) ‘HIV/
AIDS and antiretroviral treatment 
knowledge, attitudes, beliefs, and 
practices in HIV-infected adults 
in Soweto, South Africa’, Journal 
of Acquired Immune Deficiency 
Syndromes, 38: 196–201.
National AIDS Control Programme 
(NACP) (2010) Status of Antiretroviral 
Therapy in Uganda: Quarterly Report 
for January–March 2010, Kampala: 
Ministry of Health.
Nyanzi, P. (2011) ‘Aid to Uganda hits $1.8 
trillion in 2010’, Daily Monitor, 18 




Nyanzi, S., Nyanzi, B., and Kalina, B. 
(2005) ‘Contemporary myths, 
sexuality misconceptions, 
information sources, and risk 
perceptions of boda-boda men in 
southwest Uganda’, Sex Roles, 52(2): 
111–19.
Nyanzi-Wakholi, B., Lara, A. M., Watera, 
C., Munderi, P., Gilks, C., and 
Grosskurth, H. (2009) ‘The role 
of HIV testing, counselling, and 
treatment in coping with HIV/AIDS in 
Uganda: A qualitative analysis’, AIDS 
Care, 21(7): 903–8.
Okware, S., Opio, A., Musinguzi, J., and 
Waibale, P. (2001) ‘Fighting HIV/
AIDS: Is success possible?’, Bulletin 
of the World Health Organization, 79: 
1113–20.
Okware, S., Kinsman, J., Onyango, S., 
Opio, A., and Kaggwa, P. (2005) 
‘Revisiting the ABC strategy: HIV 
prevention in Uganda in the era of 
antiretroviral therapy’, Postgraduate 
Medical Journal, 81: 625–8.
Pearson, C. R., Cassels, S., Kurth, A. E., 
Montoya, P., Micek, M. A., and Gloyd, 
S. S. (2010) ‘Change in sexual activity 
12 months after ART initiation among 
HIV-positive Mozambicans’, AIDS and 
Behavior, 15(4): 778–7.
Peltzer, K., Preez, N. F., Ramlagan, S., 
and Fomundam, H. (2008) ‘Use of 
traditional, complementary and 
alternative medicine for HIV patients 
in KwaZulu-Natal, South Africa’, BMC 
Public Health, 8(1): 255.
PlusNews (2010) ‘Uganda: Optimism 
as PEPFAR increases funding’, 7 
September [online]. Available at 
http://www.highbeam.com/doc/1G1-
236510042.html
Quigley, M. A., Kamali, A., Kinsman, J., 
Kamulegeya, I., Nakiyingi-Miiro, J., 
Kiwuwa, S., Kengeya-Kayondo, J., 
Carpenter, L. M., and Whitworth, 
J. (2004) ‘The impact of attending 
a behavioral intervention on HIV 
incidence in Masaka, Uganda’, AIDS, 
18: 2055–63.
Rukmundo, E., and Lirri, E. (2010) 
‘Cash taps go dry as AIDS cases 
increase’, 1 December, Daily Monitor 




Saxinger, W., Levine, P., Dean, A., de The, 
G., Lange-Wantzin, G., Moghissi, J., 
Laurent, F., Hoh, M., Sarngadharan, 
M., and Gallo, R. (1985) ‘Evidence 
for exposure to HTLV-III in Uganda 
before 1973’, Science, 227(4690): 
1036–8.
Serwadda, D., Mugerwa, N., Sewankambo, 
N., Lwegaba, A., Carswell, J., Kirya, G., 
Bayley, A., Downing, R., Tedder, R., 
and Clayden, S. (1985) ‘Slim disease: 
A new disease in Uganda and its 
association with HTLV-II infection’, 
The Lancet, 326(8460): 849–52.
karan | 247
Shafer, L. A., Biraro, S., Nakiyingi-Miiro, 
J., Kamali, A., Ssematimba, D., Ouma, 
J., Ojwiya, A., Hughes, P., Van der 
Paal, L., Whitworth, J., Opio, A., 
and Grosskurth, H. (2008) ‘HIV 
prevalence and incidence are no 
longer falling in southwest Uganda: 
Evidence from a rural population 
cohort 1989–2005’, AIDS, 22: 1641–9.
Slutkin, G., Okware, S., Naamara, W., 
Sutherland, D., Flanagan, D., Carael, 
M., Blas, E., Delay, P., and Tarantola, 
D. (2006) ‘How Uganda reversed its 
HIV epidemic’, AIDS and Behavior, 10: 
351–61.
State House of Uganda (2014) Budget 






Stockman, F. (2010) ‘US Seeks to rein in 
AIDS program’, 11 April, The Boston 





Stolte, E. G., Dukers, N., Gesku, R. B., 
Coutinho, R. A., and de Wit, J. (2004) 
‘Homosexual men change to risky 
sex when perceiving less threat of 
HIV/AIDS since availability of highly 
active antiretroviral therapy: A 
longitudinal study’, AIDS, 18: 303–9.
Stoneburner, R. L., and Low-Beer, D. 
(2004) ‘Population-level HIV declines 
and behavioral risk avoidance in 
Uganda’, Science, 304: 714–18.
Straight Talk Foundation (2010) ‘About 
us’ [online]. Available at http://
straighttalkfoundation.org
Turan, J. M., Bukusi, E. A., Onono, M., 
Holzemer, W. L., Miller, S., and 
Cohen, C. R. (2011) ‘HIV/AIDS stigma 
and refusal of HIV testing among 
pregnant women in rural Kenya: 
Results from the MAMAS study’, 
AIDS and Behavior, 15(6): 1111–20.
United Nations General Assembly 
Special Session (UNGASS) (2010) 
Country Progress Report: Uganda 




USAID (2002) What Happened in 
Uganda? Declining HIV Prevalence, 
Behavior Change, and the National 
Response [online]. Available at 
http://www.unicef.org/lifeskills/files/
WhatHappenedInUganda.pdf
USAID (2008) Case Study: Helping Each 
Other Act Responsibly Together 
(HEART) – Campaign in Zambia 




US Center for Disease Control and 
Prevention (US CDC) (2009) Memo to 
Ugandan ART Implementing Partners, 
October, Atlanta, GA: US CDC.
US President’s Emergency Plan for 
AIDS Relief (PEPFAR) (2010a) 
The United States Government 
Global Health Initiative: Strategy 
Document [online]. Available at 
http://www.pepfar.gov/documents/
organization/136504.pdf
US President’s Emergency Plan for AIDS 
Relief (PEPFAR) (2010b) Partnership 
to Fight HIV/AIDS in Uganda [online]. 
Available at http://www.pepfar.gov/
countries/uganda/index.htm
US President’s Emergency Plan for 
AIDS Relief (PEPFAR) (2010c) 
‘Uganda’ [online]. Available at 
http://www.pepfar.gov/about/2010/
africa/150628.htm
Venkatesh, K. K., de Bruyn, G., Lurie, M. 
N., Mohapi, L., Pronyk, P., Moshabela, 
M., Marinda, E., Gray, G. E., Triche, 
E. W., and Martinson, N. A. (2010) 
‘Decreased sexual risk behavior in the 
248 | n ine
era of HAART among HIV-infected 
urban and rural South Africans 
attending primary care clinics’, AIDS, 
24(17): 2687–96.
Voice of America (2012) ‘Uganda woman 
works to end HIV stigma’, 10 July 




Washington Times, The (2006) ‘Uganda 
shaken by fund scandal’, 15 June 




Womakuyu, F. (2010) ‘Uganda cannot 
allocate 15% of budget to health’, 
19 July, New Vision [online]. 
Available at http://www.newvision.
co.ug/D/8/13/726334
World Health Organization (WHO) 
(2010) Towards Universal 
Access: Scaling up Priority 
HIV/AIDS Interventions in 
the Health Sector [online]. 
Available at http://www.who.
int/hiv/pub/2010progressreport/en
1 0  |  H E A L T H  I M P A C T  F U N D :  A L I G N I N G 
I N C E N T I V E S
Thomas Pogge1
The pharmaceutical industry has a poor reputation around the world. 
This is surprising because its products have a much more positive impact 
than those of other widely disliked industries, such as arms, coal, and 
tobacco. Much public opinion about the pharmaceutical industry makes 
it sound as though its leaders are especially immoral in comparison to 
other captains of industry. This chapter is based on a different hypoth-
esis: the pharmaceutical industry is widely regarded as especially immoral 
because it is placed under rules that create exceptionally sharp tensions 
between the objectives of acting morally and making money. These ten-
sions often lead pharmaceutical firms to act in ways that are morally 
regrettable and, as understood by the public, these tensions also sustain 
the perception that these firms must be having a poor moral record, espe-
cially when they are thriving economically. Both problems can be much 
diminished by reducing the tension. This requires a reform of the way in 
which pharmaceutical companies are rewarded for their innovative work. 
We should institute an incentive and reward system that is better aligned 
with the key moral purpose of the pharmaceutical industry: to promote 
progress in human health. We should place pharmaceutical firms under 
rules that are so designed that these firms will do well by doing good.
To explore what such rules might look like, we can begin with 
three obvious desiderata that would make a system for the provision of 
medicines highly effective in improving human health. In light of these 
facts, a reasonable system for the provision of medicines under modern 
conditions ought to display the following three features.
1 Access Given that medicines, once they are known, can be mass 
produced at a marginal cost that is very small relative to the human 
and economic harms that they forestall, any important existing 
medicine should be accessible to all patients who need it, regardless 
of their income and nationality.
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2 Tracking Investments in research and development (R&D) should 
always be concentrated on those innovation efforts from which the 
most cost-effective health gains can be expected.
3 Efficiency The entire system should be made cost-effective by 
avoiding deadweight losses and by ensuring that the money spent 
on paying for medicines is used to sustain the R&D, as well as the 
manufacture and distribution, of medicines.
Currently, most basic pharmaceutical research is done with public 
funds at universities and governmental institutions. The later stages 
of development and testing are typically funded by pharmaceutical 
companies. When such firms begin work on a promising compound, 
they patent it around the world, thereby securing a temporary 
monopoly on its manufacture and sale once it is allowed on the market. 
During this period of market exclusivity, companies can drastically 
mark up the price of their medicine, selling it at many times the 
average manufacturing and distribution cost. At the end of the period, 
competing generic producers usually make the medicine available at 
much lower prices.
This system for encouraging and rewarding pharmaceutical innovators 
has been extended worldwide and made uniform under the 1994 
Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS),2 which the United States, with other affluent countries, imposed 
as a condition for membership in the World Trade Organization (WTO). 
The Agreement entitles an innovator firm to protect new medicines with 
twenty-year product patents, which allow it to veto the manufacture and 
sale of patented medicines, and then to sell them at prices far above 
the average manufacturing and distribution cost. Product patents can 
be contrasted with process patents, which allow the patent holder to veto 
only a specific way of making the medicine. To be TRIPS-compliant, 
countries had to phase out process patents in favour of twenty-year 
product patents (WHO, 2011). A key example of this transition is 
India, the leading supplier of medicines in the less-developed countries 
(LDCs). Under TRIPS, India was required to replace its process patents 
with twenty-year product patents by 1 January 2005; India complied by 
passing appropriate national legislation in December 2004.
The next three sections demonstrate that the TRIPS regime does 
poorly in regard to the three features that a system for the provision of 
medicines ought to possess under modern conditions.
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Access
Progress has two essential components: innovation (creation, 
invention, discovery) and diffusion (dissemination, uptake). A key 
problem with the present system is that it rewards innovation with 
very large mark-ups that greatly impede diffusion. As a result of high 
failure rates and the high costs of clinical trials, developing a new safe 
and effective medicine is very expensive. Under the TRIPS regime, the 
only way in which pharmaceutical innovators can recover such large 
R&D expenses and make a profit is through mark-ups during their 
period of market exclusivity.
A firm will try to price its product so as to maximize its profit, which 
is the mark-up multiplied by the sales volume. The profit-maximizing 
price level depends on the demand curve, which plots the sales volume 
as a (typically decreasing) function of the sales price. Important 
medicines inspire a strong willingness to pay a high price, but ability 
to pay is, of course, very unequally distributed among households and 
national health systems. Table 10.1 shows the 2008 distribution of 
global household income.3
Table 10.1 shows at a glance that making patented medicines 
affordable to the world’s poor would require massive price reductions 
that could not be fully compensated through larger sales volumes. In 
fact, a firm choosing a single price for the global market would rarely find 
it profitable to make an important medicine affordable even to the third 
decile of humanity. Certainly, firms have some limited opportunities to 
increase their profits by charging differential prices across countries.4 
But even intra-national inequalities are nowadays so large that, in many 
TABLE 10.1 Distribution of global household income, 2008
Segment of world 
population
Share of 2008 global 
household income
Average monthly per capita 
income (US$)
Richest decile 66.546% $2,522.98
Second decile 18.342% $695.41
Third decile 6.340% $240.37
Fourth decile 3.442% $130.50
Fifth decile 1.993% $75.56
Third quarter 2.403% $36.44
Poorest quarter 0.934% $14.16
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LDCs, an important medicine’s domestically profit-maximizing sales 
price will place it out of reach of the majority of the country’s population 
(Flynn et al., 2009). In so far as existing institutional arrangements 
are unjust on account of the excessive economic inequalities that they 
engender, the poor suffer a double penalty, because the impact of their 
excessively low incomes is compounded by higher prices for vitally 
important medicines. Given high income inequality, the TRIPS regime 
foreseeably guides pharmaceutical innovators to mark up the price of 
their patented products to twenty, fifty, or even 100 times the marginal 
cost of production.
It is not hard to understand why the wealthier countries have been 
pressing – and continue to press – the LDCs to extend market exclusivity 
and to strengthen enforcement efforts.5 Thanks to their large capital 
advantage, firms in the wealthier countries are leading innovators and 
eager to profit from their innovations through sales to affluent people 
in the developing world. But the moral downside of these efforts is 
evident as well: under the TRIPS regime, poor people are excluded 
from many advanced medicines that, without TRIPS, would have 
been available to them as cheap generics. As a side effect of ensuring 
that well-off people in the developing world, as well as populations of 
the affluent countries, pay for pharmaceutical innovation in the form 
of hefty mark-ups, the TRIPS regime causes grave harms and deaths 
among poor people in the developing world who cannot afford these 
high prices now charged for patented medicines.
Proponents of broad and vigorously enforced intellectual property 
rights often defend them in strong moral language, levelling accusations 
of theft, counterfeiting, and piracy against generic firms, and also against 
those countries that they view as insufficiently protective of intellectual 
property. This strong language conveys the idea that the unlicensed 
copying of an innovation is a moral crime that any decent legal system 
must criminalize and suppress. But, thus far, no sound defence of this 
loud claim has been provided. The crucial move is evidently to liken 
intellectual property to physical property: just as an owner of physical 
property must be free to do with it as he or she pleases, so an owner of 
intellectual property ought to be free to dispose of it as he or she sees fit. 
But this appealing analogy is difficult to support. The difficulty lies in 
explaining how one owner, by configuring his or her physical property 
in a certain way, can unilaterally make it wrong for another owner to 
do likewise. Suppose that I have made some new medically effective 
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molecules from chemicals that I justly own: why should this act morally 
entitle me – unilaterally (that is, without any voluntary undertaking on 
your part) – to divest you of your right to convert chemicals that you 
justly own into molecules of the same kind? On reflection, the invocation 
of physical property rights not merely fails to support, but actually 
undermines, the moral case for intellectual property rights.6
Certainly, there is the pragmatic argument that broad and vigorously 
enforced patents do more good than harm in the long run by stimulating 
innovations that will eventually also benefit the poor. This argument 
may well show that the current TRIPS regime is morally preferable to 
a system under which pharmaceutical innovation is not rewarded at all. 
But to use this argument in defence of the TRIPS regime is to appeal 
to a false dichotomy. As we will see, pharmaceutical innovation can be 
incentivized through rewards other than patent-protected mark-ups in 
ways that do not exclude poor patients.
Tracking
Existing massive income inequalities also lead pharmaceutical 
innovators to prioritize even minor ailments of the affluent over 
diseases concentrated among the poor. Innovators can make large 
profits from a new remedy against hair loss, erectile dysfunction, or 
minor skin ailments. But it is difficult or impossible to profit from a 
new remedy against Dengue, pneumonia, or tuberculosis, because the 
innovator is forced to choose between accepting either a tiny mark-
up or a tiny sales volume. This distortion of research incentives leads 
to the so-called 10–90 gap: only 10 per cent of pharmaceutical R&D 
expenditure worldwide is focused on diseases that account for 90 per 
cent of the global burden of disease, and vice versa – that is, 90 per cent 
of pharmaceutical R&D expenditure worldwide is focused on diseases 
that account for only 10 per cent of the global burden of disease. The 
accuracy of these figures is contested and difficult to assess in the absence 
of reliable data about the actual R&D spending of pharmaceutical 
companies. But it is indisputable that the composition of the disease 
burden differs substantially across global income groups and that many 
serious diseases that do great damage to poor populations are very rare 
in the richest quarter of humanity, which drives the pharmaceutical 
innovation efforts. The current TRIPS regime leads profit-oriented 
innovators to neglect such diseases even when additional research on 
them would deliver disproportionately cost-effective health gains.
254 | ten
Efficiency
Primarily affecting poor and marginalized people, the access and 
tracking problems are unlikely, by themselves, to motivate successful 
reform efforts. It is therefore important to add that the TRIPS regime 
is not doing well in terms of serving the interests of affluent populations 
either.
Humanity spends close to US$1 trillion on medicines each year: 
about 1.2 per cent of world income. Is this money well spent? Data 
for answering this question are sparse. While new medicines must pass 
through elaborate clinical trials before they are allowed on the market, 
there is little systematic study of their subsequent use and impact. We do 
not know to what extent medicine dispensed (a) is actually used, (b) while 
it still has its potency, (c) in accordance with the correct instructions, 
(d) by patients for whom it is indicated, and (e) whose condition and 
circumstances allow them to benefit from it. Given the magnitude of the 
expenditure, we ought to learn more. But we know enough to conclude 
that there are huge inefficiencies in the current system.
The current TRIPS regime predictably creates much unneeded 
innovation. When one company pioneers a genuinely new type of 
medicine, other firms scramble to introduce similar drugs. The 
availability of more than one medicine in a therapeutic class can be 
beneficial because physiological variations among patients affect how 
well they respond to specific treatments. But this benefit rapidly declines 
as additional ‘me too’ drugs are introduced: the ninth cholesterol-
lowering product, for example, adds little value for patients. It can, 
however, add much value to the bottom line of the company introducing 
it, especially because competition among patented medicines rarely 
results in meaningful price reductions.
This leads to four important inefficiencies.
1 The incentives for copycat innovations are too strong: too much 
is spent on developing and introducing me-too drugs that barely 
improve our pharmaceutical arsenal.
2 The incentives for genuine breakthrough innovations are too weak: 
the profits of the first-in-class innovator are predictably decimated 
as me-too competitors gain market share at its expense.7
3 Marketing battles among therapeutically similar high-margin drugs 
are extremely costly and represent a major component of total 
industry expenditures.
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4 Such marketing often has adverse effects, inappropriately influencing 
doctors and patients to prefer a suboptimal product, or one that 
does not benefit the patient at all.
The TRIPS regime also sustains three important biases that cause 
additional inefficiencies. One bias is against medicines likely to come into 
wide use only after their patent has expired. To prevent the build-up of 
drug resistance, medical practitioners use certain advanced treatments 
only on patients who do not respond to the usual ‘first-line’ regimens. It is 
extremely important to have such last-resort treatments available (for drug-
resistant tuberculosis, for instance, which is infectious and unresponsive 
to any of the standard treatments). But the resulting anaemic outlook for 
profits – dependent as they are on sales volume prior to patent expiration 
– provides only weak incentives for developing such drugs.
The second bias favours maintenance drugs and disfavours vaccines. 
The former are to be taken continuously in order to relieve patients’ 
symptoms and perhaps to prolong their lives. They tend to earn much 
more for their patentees than do cures of similar therapeutic benefit. 
Preventative medicines (such as vaccines) tend to earn even less, 
because they are typically bought by large purchasers (such as states, 
international agencies, or non-governmental organizations – that is, 
NGOs) who can press for substantial reductions in the mark-up. This 
bias not only influences the approach that pharmaceutical companies 
prefer to take against some given disease, but also affects even more 
profoundly their research priorities: in favour of diseases for which 
research is likely to yield a maintenance drug and against diseases for 
which a vaccine or cure is the likely outcome.
Already discussed in relation to ‘Tracking’, the third bias disfavours 
research on diseases concentrated among the poor.
Poor people are also the main victims of two further inefficiencies 
engendered by monopolies. Owing to the large gap between price and 
marginal manufacturing cost, a patentee loses many profitable sales to 
patients who are willing and able to pay more than the marginal cost of 
manufacture and distribution, but not the much higher monopoly price. 
The patent-holding firm may wish to sell to the poor at lower prices, but 
if it were to serve the poor more cheaply, then many of the more affluent 
would also find ways in which to buy at lower prices. Thus the poor are 
excluded and humanity loses mutually beneficial sales. The monetary 
value of this loss can be estimated. Suppose a patent holder is selling 
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a medicine at the profit-maximizing price r, while its marginal cost of 
production is m. And consider a potential buyer who is willing and able 
to pay up to p for the product (with m < p < r). Here, buyer and seller 
would find it mutually beneficial to transact at any price n between m and 
p. Because this transaction does not come about, the frustrated buyer 
incurs a loss of p – n and the frustrated seller incurs a loss of n – m. These 
two losses total p – m. Adding up all forgone mutually beneficial sales 
of all patented medicines, these so-called deadweight losses are likely 
to be in the hundreds of billions annually. And, of course, the problem 
is not only dead money, but also dead people: millions of poor patients 
avoidably die or suffer because generic manufacturers are no longer able 
to serve and save them under the tight patent rules that affluent states 
have entrenched as a condition of WTO membership.
When life-saving medicines are known to be available at huge mark-
ups, the desperation of poorer patients creates illegal supply. Some such 
illegal products are bioequivalent to the genuine article, but most are 
not. Common in LDCs are counterfeit products that contain a much-
diluted dose of the genuine medicine. The product makes patients feel 
a little better (so they buy more) – but it may have the pernicious effect 
of allowing the disease to survive and to adapt to the medicine. Diluted 
counterfeits accelerate the development of drug-resistant strains of the 
target disease, which, in the case of communicable diseases, endanger 
us all.
Patent litigation constitutes a tenth major inefficiency. Innovators 
patent their discoveries in many countries, monitor all of these 
jurisdictions for possible infringements, and then fight protracted legal 
battles with other innovators and especially with generic suppliers. This 
activity has very little social value. But it sharply reduces the profits 
of pharmaceutical companies – as does the extensive lobbying that 
these firms undertake toward defending and expanding their patenting 
and other privileges. Countless billions are wasted annually on these 
rent-seeking activities, which are funded out of medicine sales, but 
contribute nothing to human health.
A way forward
The great inefficiencies of the TRIPS regime are well known, as are 
the burdens that it places on the poor – but what choice do we have? 
If high mark-ups protected by patents were to be discontinued, most 
commercial pharmaceutical R&D would cease – and, in any case, there 
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is no chance in the WTO for the unanimous decisions that any revision 
of TRIPS would presuppose.
Yet we do have a choice – and it’s a good one: we can create the 
Health Impact Fund as a complement to the TRIPS regime. The HIF 
would be a pay-for-performance mechanism that would offer innovators 
the option – but no obligation – to register any new medicine or, under 
certain conditions, also a traditional medicine or a new use of an 
existing medicine. By registering a product, the innovator would agree 
to make it available, during its first decade on the market, wherever 
it is needed at no more than the lowest feasible cost of manufacture 
and distribution (at which we will look shortly). The innovator would 
further commit to allowing, at no charge, generic manufacture and 
distribution afterwards.
In exchange, the registrant would receive, during those ten years, 
annual reward payments based on its product’s health impact.8 Each 
reward payment would be part of a large annual payout – initially, 
some $6 billion, perhaps – with every registered product receiving 
a share equal to its share of the assessed health impact of all HIF-
registered products in the relevant year.9 The amount of $6 billion is 
only 0.6 per cent of current annual global spending on medicines, but 
its health impact per dollar would be vastly larger. Funded at this level, 
the HIF would be expected to support between twenty and thirty new 
medicines at any given time, with two or three entering and two or three 
expiring each year.10 If all countries were to participate, a contribution 
of 0.007 per cent of gross national income would suffice to reach the 
initial $6 billion per annum. Realistically, however, a higher rate would 
be necessary. At a contribution rate of 0.03 per cent of gross national 
income, the HIF would need only the support of China plus the United 
States, or of Brazil plus the European Union, to commence operations. 
Once the HIF were working smoothly, its annual reward pools could 
be scaled up to attract an increasing share of new medicines.
The HIF would greatly mitigate the greatest injustice of the current 
system by limiting the price of any registered medicine to the lowest 
feasible cost of manufacture and distribution. This price ceiling would 
enable humanity’s poor majority to gain immediate access to the fruits of 
pharmaceutical innovation – either through their own funds or through 
national health systems, NGOs, international agencies, or insurance 
programmes (all of which would be able to serve more patients more 
cheaply thanks to much lower medicine prices). In addition, the HIF 
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would foster the development of new high-impact medicines against 
the formerly neglected diseases of the poor. As a further bonus, the 
HIF would also motivate registrants to ensure that their products are 
widely available, perhaps even below the price ceiling, and that they 
are competently prescribed and optimally used. Registrants would be 
rewarded not for merely selling their innovative products, but also for 
making them effective toward better health around the world.
If some pharmaceutical R&D were financed through HIF rewards, 
most of the cost (allocated among countries in proportion to their gross 
national income) would be borne by affluent populations and people – as 
it is today. But by funding innovation through health impact incentives 
rather than through patent-protected mark-ups, affluent populations 
would avoid the need to exclude the poor. Including the poor in this way 
costs the affluent nothing, because the cost of manufacturing additional 
doses is covered by the sales price. The expansion of production may 
even benefit the affluent through lower unit costs and generally better 
global health.
The HIF would also benefit the affluent by changing profoundly 
the marketing and promotion of new medicines. The HIF would 
pay nothing for the creation or promotion of a ‘me-too’ product that 
merely takes market share from a competitor’s earlier no-less-effective 
medicine. And even with a highly superior product, a HIF registrant 
would make no profit from the sale of its medicine as such, but would 
profit only in so far as this medicine were actually made effective toward 
improving human health. Thanks to this new incentive, all patients 
would be more likely to receive medicines that would actually improve 
their condition.
Secure funding
Before registering a new medicine with the HIF, a pharmaceutical 
innovator will wonder whether the promised rewards can really be 
counted upon. Absent convincing assurance, the HIF will elicit few 
or no product registrations – or so one might worry (Buchanan et al., 
2011).
There is an obvious partial solution to this problem: the contracts 
offered by the HIF should entitle the innovator to withdraw the 
registration of its product as soon as the HIF fails to meet its obligations, 
for example because it lacks the funding necessary to underwrite 
reward pools of the advertised minimum size. With this escape option, 
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registrants have little to lose if the advertised reward pools do not 
materialize – and much to gain, because the more reluctant other 
innovators are to register products with the HIF, the more profitable 
registration will be. The HIF, after all, promises to distribute pools of 
$6 billion each year and to include each registered product in ten such 
distributions. Therefore, by being the sole registrant or one of a few, 
an innovator can earn very substantial amounts (up to $60 billion on 
a single product),11 while also enjoying the assurance that, should the 
flow of HIF money ever run dry, it can easily switch its product back 
to the mark-up track. Given these conditions, the HIF would certainly 
attract product registrations.
This conclusion is further supported by the existence of innovators 
– notably so-called public–private partnerships (PPPs) or product 
development partnerships (PDPs) – with standing commitments 
against charging high prices. An organization such as the Drugs for 
Neglected Diseases Initiative (DNDi), for example, would have little 
reason not to register any of its innovations: it has no interest in 
marking up its product in any case. And it would have strong reasons 
in favour of registration, because any reward payments that it received 
from the HIF would facilitate work to which it is deeply committed: 
the development of additional new medicines for neglected diseases.
Certainly, the escape option described is only a partial solution 
to the assurance problem, applicable to medicines that commercial 
innovators develop regardless of the HIF’s existence. Estimating 
that one of its products can earn more on the HIF track than on the 
conventional mark-up track, an innovator could register this product 
with the HIF confident that if the HIF were not to pay up for any reason, 
the product could be switched over to the mark-up track. This is only a 
partial solution, because the HIF is meant to encourage innovators not 
only to forgo mark-ups on some of the more important new medicines 
that they are developing anyway, but also to conceive and develop new 
medicines that they would not have found it profitable to pursue for 
the sake of patent-protected mark-ups. In particular, the HIF is meant 
to encourage neglected-disease research that, absent the HIF, would 
not be undertaken at all. To stimulate such research, the HIF must 
inspire long-term confidence because pharmaceutical innovation takes 
time: candidate medicines must go through years of testing before they 
are allowed on the market, and then another ten years will go by until 
an R&D effort will have been fully rewarded. Given these substantial 
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lags, the HIF will encourage additional innovation only if its annual 
reward pools are judged secure far into the future. This is problematic 
because it is not easy to make credible financial promises that extend 
twenty years into the future – even for governments, which are typically 
not authorized to commit their successor’s tax revenues in legally 
binding ways. Is there nonetheless a sufficiently credible agreement 
that governments might be willing and able to execute?
To meet this challenge, agreement to fund the HIF should take 
the form of an international treaty that clearly specifies, inter alia, 
each country’s obligations, sanctions for non-compliance, and 
procedures for exit (Hollis and Pogge, 2008: ch. 5). This agreement 
should allocate burdens in such a way that all countries can expect, 
over time, to be net beneficiaries, or at least not to be significant net 
losers. When these two conditions are met, international agreements 
work quite well, as is shown by examples such as the UN Convention 
on Contracts for the International Sale of Goods (CISG),12 WTO 
Agreement on Technical Barriers to Trade (TBT),13 International 
Telecommunications Convention,14 Convention on International Civil 
Aviation,15 International Air Services Transit Agreement,16 International 
Convention for the Safety of Life at Sea (SOLAS),17 International 
Convention for the Prevention of Pollution from Ships (MARPOL),18 
Montreal Protocol on Substances That Deplete the Ozone Layer,19 
Antarctic Treaty System,20 and World Health Organization (WHO) 
Framework Convention on Tobacco Control.21
Mindful of such successful examples, let us explore whether the 
proposed HIF can be shaped to meet these two conditions. Suppose 
a national government, G, considers three possible outcomes: (a) the 
HIF is created, backed by a fully credible treaty to which G is a party; 
(b) the HIF is created with some start-up funds and pledges by G 
and other governments; or (c) the HIF does not come into existence 
at all (the status quo). It is fairly clear that G will find option (b) 
inferior to option (c). Relying on pledges only, the agreement might 
unravel and the start-up expenses would then be lost. Even if the 
agreement based on pledges were to last, it would be disadvantageous 
for governments, making them overpay for innovation. They would 
be overpaying because pharmaceutical innovators, when considering 
a research project that would not be profitable on the mark-up track, 
would naturally discount monies allocated to future HIF pools by the 
probability that these monies would not actually be forthcoming. This 
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would substantially reduce the number of such projects that innovators 
would pursue and thereby increase the HIF reward rate. The greater 
doubt lies in whether governments will actually stick to their pledges 
the more money that they end up paying per unit of health impact. 
This is analogous to what goes on in credit markets: the more doubt 
there is about whether some would-be borrower will repay, the higher 
the rate of interest that this borrower will have to pay to find a willing 
lender. It is thus collectively advantageous for the funding partners 
underwriting the HIF, much as it is advantageous for borrowers in the 
credit markets, to make its promised future payouts as ironclad as they 
can be. The more credible the governments’ commitments are, the less 
they will end up paying, through the HIF, per unit of health impact.
Can a government make ironclad commitments if it chooses? 
Simply put: yes. A government can issue and then gift to the HIF 
long-maturity or perpetual bonds22 backed by its full faith and credit, 
for example, or it can make an interest-free loan to enable the HIF to 
buy such bonds. Interest on these bonds could be inflation-adjusted or 
pegged to the country’s gross national income to ensure that the value of 
the annual reward pools does not decline over time. If these bonds were 
freely tradable, the HIF might sell some of them to create a diversified 
endowment, managed to maintain its real value over time and to generate 
a stable income stream that would cover at least a substantial portion of 
the annual reward pools. The HIF endowment could accept contributions 
also from international and NGOs, foundations, corporations, individuals, 
and estates. It would follow the example of private US universities, which 
have enjoyed excellent credit ratings despite many adversities and have 
grown their endowments while funding up to about a third of their 
operating budgets from endowment income.
Another solution is a dedicated international tax on financial 
transactions, for instance, or on pollution. Such taxes would be 
beneficial on the revenue side by moderating speculative excesses in 
financial markets or by slowing greenhouse gas emissions. And they 
could be useful on the expenditure side as well – by funding the HIF, 
for example. A similar proposal is that of an alternative minimum tax for 
multinational corporations, which often manage to pay few or no taxes 
on their worldwide profit. Various proposed international taxes would 
each raise in the tens of billions of dollars annually. Commencing with 
an annual budget of $6 billion, the HIF would consume only a fraction 
of such a revenue stream.23
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Health Impact Fund in relation to other global health initiatives
The initiative for, and design of, the HIF owe much to other global 
health initiatives, such as the Global Fund, the patent pool initiated 
by UNITAID, and advance market commitments. The HIF would 
nonetheless play a unique role that cannot be filled as well by these 
other mechanisms.
The initiatives mentioned all fit the label ‘development aid’: 
predominantly funded by the affluent, they are designed to benefit 
poor populations. By contrast, the HIF would be jointly funded by rich 
and poor countries, with each funding partner contributing according 
to its gross national income. The HIF would also benefit rich and poor 
populations alike through lower drug prices, and by stimulating much 
greater efforts toward ensuring that medicines are directed to the right 
patients and used to optimal effect.
While the Global Fund supports large purchases of medicines, 
it does not aim to incentivize innovation. One might say that its 
purchases do have an incentive effect: innovators can now expect 
that if they develop a high-impact medicine for AIDS, tuberculosis, 
or malaria, they will earn money from mark-ups on sales supported 
by the Global Fund in behalf of poor patients. This is true, but the 
HIF would provide more suitable incentives because its funding 
would be locked in for a longer time period and also because it would 
offer rewards based not on how much a new product can achieve, 
but on how much more it does achieve than the current standard 
of care enjoyed by the various patient groups. The present system 
provides large rewards for a new medicine that is only slightly better 
than the treatment that patients would otherwise have had: as buyers 
(including the Global Fund) switch over to the better medicine, 
this medicine now appropriates all, or nearly all, the profits of its 
predecessor. The HIF would reward a new medicine only for the 
improvement that it brings relative to the treatment that patients 
would otherwise have had. In this way, the HIF would incentivize 
innovators to concentrate their efforts on those areas in which they 
can realize the largest incremental health benefits. This is not a 
criticism of the Global Fund, which was not designed to stimulate 
innovation – but it shows how the HIF would usefully complement 
the Global Fund by rewarding more accurately the innovation 
component of new drugs. The Global Fund could then purchase 
these new drugs without mark-up. The HIF has been designed in 
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collaboration with the Global Fund, which may end up hosting the 
HIF in Geneva much as it is now hosting the Affordable Medicines 
Facility – malaria (AMFm).
UNITAID has created a patent pool intended to facilitate licensing 
by pharmaceutical innovators to generic firms, initially limited to 
HIV/AIDS medicines in specified developing countries and improving 
access to existing or slightly modified HIV/AIDS treatments. So far, 
this improvement has typically been tightly limited, excluding the 
populations of many low- and middle-income countries. The benefits 
of this pool are likely, over time, to be extended to more countries 
and more therapies. But the patent pool does not (and is not meant 
to) stimulate pharmaceutical R&D and therefore does not obviate 
the need for the HIF. Conversely, the HIF does not obviate the need 
for the patent pool: even with the HIF in operation, UNITAID’s 
patent pool would continue to be useful for facilitating access by poor 
people to products unregistered with the HIF, including combination 
therapies.
Similar points apply to compulsory licensing, as provided for 
in TRIPS Article 31 and clarified in the 2001 Doha Declaration. 
Under TRIPS, governments may compel a patentee to license a 
domestic company to manufacture and sell its medicine, in exchange 
for a (typically small) licensing fee, the rate of which is set by the 
government and which the generic manufacturer pays to the patentee. 
The point of compulsory licences is to enable governments to make 
important new medicines accessible to their populations. Although 
compulsory licences are perfectly legal, they have been issued only 
rarely – mainly because pharmaceutical companies lobby strongly 
against them, often by calling upon the support of agencies of their 
own government (such as the Office of the US Trade Representative, 
which can inflict serious penalties upon countries deemed to be 
hostile to US economic interests presented as free trade principles). 
Compulsory licences have given poor patients access to urgently 
needed medicines – and they might come to do so on a grander scale 
if LDCs were to combine more effectively against political pressures 
from the leading pharmaceutical innovator states. But compulsory 
licences do have a dampening effect on innovation by creating 
uncertainty about the extent to which successful innovators will be 
allowed to profit from their innovations. Unlike the HIF, compulsory 
licences cannot stimulate innovation (especially against the diseases 
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of the poor), nor can they provide incentives to market and promote 
medicines for optimal health impact. Even if compulsory licences 
were deployed in the best possible way, they would not undermine 
the need for the HIF.
Advance market commitments (AMCs), a leading species of 
innovation prize, assure profitable sales to developers of a predefined 
vaccine or other medicine. An AMC may legally guarantee, for example, 
that the first 200 million doses of a new kind of vaccine – if they meet 
certain specific requirements and are sold into LDCs at $3 a dose – are 
rewarded with an additional subsidy of $15 per dose. The described 
AMC would incentivize an innovator firm to work hard to collect as 
much of the $3 billion prize as possible: by developing a qualifying 
vaccine more quickly than its competitors, and by selling doses of it 
sooner and faster into the developing world.
Although AMCs are more similar to the HIF than the other three 
mechanisms, they are inferior in five significant ways.
1 Each innovation prize targets a specific disease, which is chosen 
by politicians, bureaucrats, or experts – presumably with an eye to 
selecting that disease against which the most cost-effective health 
gains can be achieved. The HIF, by contrast, would let each 
innovator firm decide which disease(s) to target. The latter design 
is superior because insiders have proprietary information that gives 
them a much better understanding of how they can reduce the global 
burden of disease most cost-effectively. Insiders also have powerful 
incentives to get it right: if they do well in setting research priorities, 
they will end up with products that will bring large health gains and 
hence large health impact rewards. Innovation prize designers lack 
such incentives: they lose nothing by selecting an inferior research 
target, and lobbying by companies and patient groups may then 
easily lead them to do just that.
2 Funding of innovation prizes depends on donor willingness, which 
can easily dry up because the subsequent prizes will be for different 
diseases. Guaranteeing annual reward pools far into the future, the 
HIF would be a permanent source of pharmaceutical innovation, 
supporting some twenty or thirty products at any given time. 
Undoubtedly, this advantage comes at a cost: establishing the HIF 
in the first place will be much harder than getting funding for an 
innovation prize.
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3 Innovation prizes must specify rather precisely what is to count as 
a qualifying innovation; yet such a precise ‘finish line’ is difficult 
to specify optimally in advance of the research that the prize is yet 
to encourage. Suboptimal specification may lead to no qualifying 
innovation (with much wasted effort) or to qualifying products 
that, with a little extra effort, could have been substantially better. 
The HIF needs no advance specifications; it simply rewards each 
registered medicine according to its measured health impact.
4 An innovation prize must fix the size of the reward – in the case of an 
AMC, the subsidy per dose and the number of doses to be subsidized. 
Since innovators have every reason to conceal and exaggerate the true 
cost of their R&D, it is likely that an innovation prize, if it motivates 
successful innovation efforts at all, will pay more than would have 
been necessary, thereby producing a windfall profit for innovators. 
Rewards under the HIF would, by contrast, be paid at a self-adjusting 
(dollars per QALY) rate that reflects the innovators’ own and accurate 
assessment of their R&D costs.24 A reward rate perceived as rich 
would soon decline as it encouraged additional HIF registrations; a 
reward rate perceived as puny would soon increase by discouraging 
some new HIF registrations. Such self-adjustment assures taxpayers 
that their funds are spent efficiently, while also assuring firms that 
they will earn a decent return on their HIF-registered products.
5 An AMC gives any successful innovator strong incentives to sell 
doses eligible for the subsidy quickly, but no reason to care about 
what happens to these doses beyond the point of sale. The innovator’s 
earnings are unaffected if some of the sold medicine is never used, 
loses its efficacy, is taken by patients who do not benefit from (or 
are even harmed by) it, or is consumed without adherence to the 
proper protocol. The HIF, by contrast, would pay according to the 
product’s actual health impact, thereby incentivizing the innovator 
to take all cost-effective measures toward increasing this impact: to 
safeguard freshness, to ensure supply to patients who benefit the 
most, to lower the price below the ceiling in order to reach additional 
patients, and to instruct medical personnel and patients in how the 
product is to be taken for optimal effect.
While AMCs can work better than simpler innovation prizes, espe-
cially in stimulating the development of new vaccines, the HIF would be 
much more cost-effective in terms of its impact on global health.
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Lowest feasible price
The HIF would contractually constrain registrants to ensure 
that their medicine is supplied wherever it is needed at the lowest 
feasible cost of manufacture and distribution. In exploring the diverse 
ways of specifying and implementing this requirement, the guiding 
consideration should be to maximize the health impact of the HIF 
itself. We should want the HIF to be constructed so that its operation 
contributes as much as possible to human health.25
One way in which to promote access to HIF-registered products is 
to require the registrant to offer zero-cost licences immediately upon 
registration, so that competing generic suppliers can compete down 
the price.26 But such open licensing is not always the best method for 
achieving low prices, for example in small markets with inadequate 
competition. Another problem is that generic firms compete not 
merely over ultimate purchasers (such as patients, NGOs, national 
health systems, or international agencies), but also over intermediaries 
(such as wholesalers and pharmacies). Such intermediaries care less 
about the price at which they buy than about the mark-up that they are 
allowed to charge. They may therefore prefer to move or stock a more 
expensive generic version of a medicine than a less expensive one if the 
former offers them a higher profit margin.
Competition among generic suppliers can be organized in a different 
way that will typically work better in terms of access and efficiency. 
With this method, a HIF registrant would be permitted to retain 
exclusive marketing rights, but required to put the manufacture of the 
product out for tender, with two-thirds of manufacturing going to the 
lowest bidder, perhaps, and a third to the second-lowest. The registrant 
would then buy the medicine at these lowest bid prices and sell it on 
without any mark-up. The tender process should be repeated every 
few years to capture any new price advantages afforded by improved 
manufacturing technologies.
This tender method would typically be a more effective way of 
organizing competition among generic manufacturers.27 This is so in 
part because of improved economies of scale: instead of many firms 
gearing up to produce the product in many countries, only two (the 
winners of the tender) do so and then produce much larger quantities. 
Moreover, generic firms will be more willing to compete, and to cut 
their price to the bone, when they can hope to win a large share of the 
entire global market rather than only a slightly increased share of some 
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national market. Furthermore, intermediaries face only a single source 
of supply – the innovator/registrant of the medicine – and thus have 
no opportunity to play off competing suppliers against one another 
in pursuit of a higher profit margin. With the tender method, the 
bargaining power of such intermediaries derives exclusively from the 
threat not to move or stock the medicine at all – and this threat has 
limited effect because, by fulfilling it, an intermediary would erase its 
own profit. To find wholesalers and pharmacists willing to move and 
stock its product, a registrant must allow these intermediaries mark-ups 
that make their collaboration profitable for them. The registrant need 
not allow larger mark-ups to win the collaboration of intermediaries in 
the face of competing suppliers of the same medicine (because, under 
the tender method, such competing suppliers do not exist).
It is worth mentioning, as an ancillary point, that the tender method 
is especially favourable to smaller manufacturing firms, because, by 
winning the tender to produce one or two HIF-registered medicines, 
they could take advantage of the same substantial economies of scale 
that larger firms exploit for several dozen products. With open licensing, 
by contrast, small suppliers labour under a handicap, because they 
must compete with larger firms that manufacture the same products in 
much larger quantities for a global market.
There are three further reasons for favouring the tender method 
over open licensing. First, assessing the impact of the introduction of 
a new product is much easier and cheaper if sales all pass through the 
registrant; such assessment is much more difficult and expensive when 
there are many other authorized sellers who may not want to provide 
accurate sales data to the HIF.
Second, the registrant will find it profitable voluntarily to sell 
its product below cost in very poor areas whenever it gains more 
from the extra rewards for additional health impact than it loses on the 
sale price; competing generic firms, by contrast, will sell above their 
cost.
Third, with only one authorized seller, the timing of HIF rewards 
can be adjusted for the special case of medicines the long-term utility 
of which is endangered by the development of resistance. For example, 
the important goal that new anti-infectives should be used sparingly, 
only in cases in which the older products fail, is best promoted when 
distribution is controlled by a single agent incentivized to maintain the 
medicine’s efficacy for as long as possible (Outterson et al., 2011).
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Weighty as they are, these reasons do not show that the tender 
method is best in all cases. When there is doubt about which of the 
two methods would produce the best outcomes, a subtle compromise 
method is possible: let the registrant choose between the two methods. 
Since the registrant earns money only through health impact rewards, 
it will try to choose the method under which health impact is larger 
(Hollis, 2009). With HIF registrations of an unpatented medicine 
(Syed, 2009) or of a new use of an off-patent medicine (Hollis and 
Pogge, 2008: 16, 86), the tender method is not an option, because 
open licensing is already a reality. Finally, in cases in which competition 
among manufacturers is expected to be anaemic – perhaps because the 
worldwide market is small and/or because the manufacturing capacity 
is unusually expensive to acquire – neither method may be satisfactory. 
In such cases, the HIF might negotiate with the registrant a price ceiling 
based on independent estimates of the lowest achievable average cost 
of production. This ceiling could be periodically adjusted to reflect 
new experience and cost changes.
The choice among these four methods depends on the technological 
characteristics of production in a specific market; there is no reason to 
suppose that a single mechanism will fit every circumstance.
Tightening Health Impact Fund registration conditions
Those who favour open licensing often also believe that the HIF 
should require registrants to relinquish their right to control follow-on 
innovations.28 As the critics contend, this requirement would helpfully 
remove an impediment to collaborative research. But it would also be 
costly in terms of innovation: the more registrants are required to give 
up as a condition for participating in the HIF reward pools, the more 
reluctant they will be to register and the higher the reward rate will 
therefore tend to be. This means that the proposed requirement would 
come at the expense of achieving health impact. We believe that this 
requirement would be costly in terms of raising the reward rate and 
that, even without it, the HIF would give a substantial boost to open 
science.29
Similar remarks apply to the suggestion that the HIF should favour 
manufacturers or innovators from the Global South. Automatic 
disqualification of Northern manufacturers (from tenders and contracts 
based on independent estimates) would probably make little difference, 
because Southern manufacturers, especially in India, are already far 
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more cost-effective than manufacturers in affluent countries. But it 
would still seriously disturb the presentation of the HIF as a global 
public good, the costs and benefits of which are equitably shared by all 
of humankind. The same can be said about automatic disqualification 
of Northern innovators, which would also lose some very cost-effective 
product registrations and thereby reduce the overall cost-effectiveness 
of the HIF. Even without a special handicap, the HIF would shift 
the balance in favour of Southern innovators who find it difficult 
and expensive to compete in the development of drugs against global 
diseases, on which ‘big pharma’ has already spent untold billions. The 
HIF would, first and foremost, encourage new research on the more 
neglected Southern diseases, and here Southern innovators are much 
more competitive because they have easy access to patients and because 
better resourced Northern firms have not yet invested much effort.
These considerations notwithstanding, we do not believe that 
the HIF should impose no constraints at all. One constraint that 
seems compelling is the requirement that all HIF-rewarded products 
must be manufactured under decent labour conditions, even when 
medicines manufactured under sweatshop conditions would lead to 
lower prices.
Piloting the Health Impact Fund
Governments will muster the political will to create the HIF only if 
they are convinced that it would work. In this regard, a main concern 
is the measurement of health impact: is it really possible, at reasonable 
cost, to assess credibly the therapeutic benefits of a new medicine in 
poor and rich countries around the world? The best way to reassure 
governments and innovators on this point is to conduct a ‘pilot’ of the 
HIF concept. Such a pilot would consist of a contractual arrangement 
in which a firm or other organization is rewarded on the basis of 
the health impact it achieves with one product in one jurisdiction. 
Depending on the size of the jurisdiction and the volume of drug sales, 
a pilot could be run at relatively low cost.
A pilot would demonstrate the feasibility of reliable health impact 
assessment and show the effect on behaviour of rewarding an 
organization according to health impact, rather than through mark-
ups. A pilot would also provide practical evidence on the best methods 
for assessing health impact and opportunities to learn how to write 
contracts governing rewards based on health impact.
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In a suitable pilot, a firm would agree to reduce the price of a 
newly launched (or existing) product in one jurisdiction, which could 
be a city, province, country, or region. In exchange, it would receive 
rewards based on its product’s measured health impact. The incentives 
should be designed so that if the firm appropriately responds to them 
(enhancing the health impact of its product by safeguarding freshness, 
focusing on patients who benefit the most, and promoting proper 
adherence to a treatment protocol), its profits would be no less than 
what they would be without the pilot. For example, in the case of an 
antiretroviral, a firm would receive no reward for patients switched 
from an equally effective antiretroviral, small rewards for patients 
switched from a less effective antiretroviral with greater toxicity and 
therefore typically lower compliance, and large rewards for patients 
who had previously had no treatment at all. The scheme of rewards 
would be agreed with the firm in advance.
We have made preparations for pilots in two major meetings. 
In April 2010, we made substantial progress on the measurement 
of health impact at a collaborative workshop with various health 
economists and epidemiologists at the National Institute for Health 
and Clinical Excellence (NICE) in London. Concrete pilot possibilities 
were then discussed at a three-day workshop held in May 2011 at the 
Rockefeller Foundation’s conference centre in Bellagio, with experts 
in epidemiology, health economics, health outcomes, and trial design 
from Canada, China, Colombia, India, Mexico, South Africa, the 
United Kingdom, the United States, and Vietnam. The latter workshop 
settled on the following five desiderata.
1 A pilot must involve a change in practice – ideally, the introduction 
of a new drug or a reduction in price – that has a measurable impact 
on health. To be measurable, the impact must be substantial and 
capable of being documented with suitable evidence. If the pilot 
involves a reduction in the price of an existing drug, the health 
impact may arise from improved take-up of the drug owing to 
increased volume or a shift in take-up towards patients who benefit 
more.
2 A pilot should be cost-effective from a health or humanitarian 
perspective – that is, it should lead to measurable health improvements 
at reasonable cost. Here, it is helpful that, because the rewards paid to 
the firm are based on assessed health benefits, their cost-effectiveness 
pogge | 271
is known in advance. If the firm’s efforts to enhance the health impact 
of its product bear little fruit, the cost of the pilot is correspondingly 
reduced.
3 A pilot must be feasible in a defined area so that its cost can be 
controlled by limiting the territory in which data on health outcomes 
and drug usage must be obtained.
4 A pilot should not undermine market competition. When a firm is 
rewarded for selling at a low price, it may be able to undercut other 
firms in the market. This unfairness should be avoided by ensuring 
that if a product is already available generically, all firms selling this 
product are offered the same rewards. Even if the product is not yet 
generically available, the rewards should be designed so that they do 
not inhibit generic entry in the future.
5 To demonstrate the feasibility of the HIF, several pilots should be 
run. There is great international diversity in conditions relevant to 
health impact assessment, including diversity in the availability, 
reliability and cost of data, in the prevalence of insurance coverage, 
in the extent to which medicines are supplied through the private 
sector, and in the extent to which prescriptions are required. 
Moreover, medicines themselves differ in various important ways, 
such as mode of action, time lag, risk of product deterioration, and 
importance of compliance. A variety of pilots, involving different 
medicines and diverse locations, would provide much better 
preparation for the creation of the HIF than any single pilot could.
Various promising pilot projects have emerged, and we are now 
involved in specifying each pilot plan so that it is acceptable to the 
company whose product is to be marketed in the new way, to the 
funder(s) of the health impact assessments and reward payments, and 
to the relevant political authorities in the pilot jurisdiction.
Joining forces for justice in global health
The current international system for encouraging pharmaceutical 
innovation is highly inefficient because the rewards it offers are only 
very tenuously related to health outcomes. This system is unsustainable 
because even the wealthiest countries cannot afford skyrocketing 
healthcare costs forever. The HIF is a concrete proposal for tying cost 
to therapeutic benefits in the important domain of pharmaceutical 
innovations. The HIF is not cheap, and its creation therefore involves 
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financial and political risks. These risks can be greatly reduced through 
appropriate pilots. The paramount task now is to gather financial and 
political support for a suitable set of pilots, each of which requires a willing 
firm, a cooperative jurisdiction, funding for the reward payments, and 
funding for the health impact assessment. Fortunately, these pilots have 
their own intrinsic value in the form of delivering health improvements 
at reasonable cost. But their potentially much greater value consists in 
preparing the way for the HIF itself, which could be an amazing revolution 
in global health and a concrete model of a just global institution.
Should the HIF work as expected, the medicines that it supports 
would bring enormous health gains, especially in the world’s poorer 
areas, even while its net costs would be negligible or (more likely) 
negative. While funding the HIF, taxpayers would save through 
reduced expenses on public health facilities, foreign aid, insurance 
premiums, and private drug purchases. They would save expenses for 
costly hospitalizations averted by additional, earlier, or more effective 
pharmacological interventions. And they would benefit from the 
diffuse economic effects of a massive reduction in the global burden of 
disease. Last and foremost, humanity would have taken an important 
step toward global justice by reducing the artificial exclusion of poor 
people from the fruits of pharmaceutical R&D. Let us at least explore 
this great opportunity through a set of suitable pilots.
Notes
1 An earlier version of this paper 
was presented in September 2011 as the 
Mahbub ul Haq Memorial Lecture at the 
meeting of the Human Development and 
Capability Association in The Hague, then 
published as Pogge (2012). I am grateful 
to the editors of the Journal of Human 
Development and Capabilities for their kind 
permission to reprint it here. Many persons 
have been contributing to the work on 
the Health Impact Fund (HIF) proposal. 
This ongoing collaboration is documented 
online at http://www.healthimpactfund.
org, which also offers free downloads of 
the first full statement of the HIF proposal 
(Hollis and Pogge, 2008).
2 Annex 1C of the Marrakesh 
Agreement Establishing the World Trade 
Organization, signed on 15 April 1994 and 
entered into force 1 January 1995.
3 The figures show that average 
income in the top decile (tenth) of 
humanity is nearly seven times the 
global average, while average income in 
the bottom quarter is ¹/₂₇ of the global 
average. One person in the top 10 per 
cent has as much income, on average, 
as 178 people in the bottom quarter. 
The income data used here were kindly 
supplied by Branko Milanovic, lead 
economist in the World Bank’s Research 
Department, in a personal email 
communication dated 7 December 2012, 
on file with the author. Milanovic is the 
leading authority on the measurement 
of economic inequality and his published 
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work contains similar, albeit somewhat 
less frequently updated, information (see 
Milanovic, 2005, 2009, 2011). Wealth is 
even more unequally distributed than 
income: the poorest 69 per cent of 
humankind has only about 3 per cent of 
global private wealth versus 8 per cent of 
global household income (Crédit Suisse 
Research Institute, 2013: 93).
4 These opportunities are limited by 
parallel import problems, which involve 
the illicit importation of medicines from 
countries in which they are cheaper 
to countries in which they are more 
expensive. They are also limited by 
practices of reference pricing, whereby a 
national health system agrees to fund or 
reimburse only medicines the domestic 
price of which is in line with their price in 
other countries.
5 Recent examples of such 
pressure include concerted efforts to 
wrest data exclusivity provisions from 
poor countries. Such legal provisions 
discourage market entry by generic firms 
even after patent expiration by assigning 
the patentee exclusive rights to the 
clinical data that it initially submitted to 
obtain marketing approval. As a result, 
a generic firm cannot win marketing 
approval simply by showing that it has a 
bioequivalent product; instead, it must 
bear the substantial – and socially wholly 
wasteful – expense of producing its own 
clinical data to show that the medicine is 
safe and effective.
6 A further problem with the analogy 
is that it fails to provide any rationale 
for limiting the duration of intellectual 
property to twenty years (or any other 
specific period). Libertarian and other 
defences of the status quo are much more 
extensively discussed in Hollis and Pogge 
(2008: ch. 6).
7 These two points are more fully 
discussed in Hollis (2004).
8 Health impact can be measured 
in quality-adjusted life years (QALYs) 
saved. The QALY metric has been 
refined over the last twenty years and 
is already extensively used in many 
contexts, including by public and private 
insurers for deciding which new drugs 
to cover (Phillips, 2009). Its basic idea 
is straightforward: giving a patient an 
additional year of life in good health is 
worth one QALY. Appropriate fractions 
of QALYs are awarded for additional 
years in less than good health and also for 
life years in which patients are in better 
health than would otherwise have been 
the case. QALY awards for periods longer 
or shorter than a year are proportionately 
adjusted. A new medicine’s impact is to 
be assessed relative to the standard of 
care that patients would have received 
in its absence or before its introduction. 
For many poor patients, this would be 
no effective care at all. Assessments 
of health impact would draw on data 
gathered from clinical trials, pragmatic or 
practical trials, sampling of product use in 
different environments and demographic 
groups, audited sales data, and correlation 
with global burden of disease data.
9 The costs of the HIF’s own operation 
– which are mostly costs of health impact 
assessment – should be covered from 
registration fees rather than from the 
annual HIF budget. Overall, this comes 
out in the wash: if registrants cover these 
costs, then there is more money in the 
annual pools to be distributed to them. But 
at the level of individual registrants, there 
is an important difference. If operational 
costs are paid out of the annual pools, 
then the most successful medicines will 
contribute the most and medicines with 
little health impact will contribute little. 
Yet it is evidently undesirable to pay part 
of the cost of assessing weak and poorly 
promoted products out of the reward 
shares of innovators with really strong and 
well-promoted products. It makes more 
sense to avoid such cross-subsidization 
by making each innovator pay its own 
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way: by making each innovator pay a fee 
that roughly covers the cost to the HIF of 
assessing its registered product(s). This 
cost allocation discourages innovators 
from registering products in which they 
have little confidence; it also encourages 
any innovator to promote its registered 
products so as to enhance their health 
impact (because none of the extra reward 
resulting from better product promotion 
is lost to an increased contribution to 
operational expenses).
10 Lower funding levels would lose 
economies of scale in health impact 
assessment and would also lead to an 
excessively volatile reward rate (dollars 
per QALY), which would discourage 
registrations.
11 To ensure that the HIF is cost-
effective relative to other public health 
expenditures, there should be a ceiling 
specified on the reward rate, a maximum 
dollar amount per QALY. With this ceiling 
in place, only a genuine miracle drug 
could by itself collect the full $60 billion. 
Still, if the reward rate ceiling is set at a 
generous level, then, given the escape 
options, registrations are bound to occur.
12 Creating a uniform regime for the 
international sale of goods, improving 
certainty and reducing transaction costs 
in transnational transactions – one of the 
most universally adopted international 
agreements.
13 Increasing international uniformity 
in technical regulations and product 
standards, and working with developing 
countries to allow them to participate in 
standards-setting.
14 Establishing the International 
Telecommunications Union for the 
purposes of unifying and coordinating 
international telecommunications 
standards.
15 Establishing a specialized UN 
agency to coordinate international 
aviation rules and establishing early rules 
for international air travel.
16 Facilitating international air travel 
by allowing, inter alia, aircraft access to 
foreign airspace.
17 International maritime safety 
treaty considered essential for 
guaranteeing the safety of merchant ships 
in international and foreign waters.
18 Creating rules for dealing with 
spills of oil and other hazardous materials 
carried in bulk.
19 One of the most widely adopted 
and implemented international 
environmental treaties, with high rates 
of compliance, expected to produce real 
reversals in ozone damage.
20 Promoting peaceful scientific 
cooperation and exchange on the 
Antarctic territories.
21 Causing some 120 states parties, 
after ratification, to adopt or strengthen 
their tobacco control legislation. Very 
substantial help from Megan Corrarino 
in the composition of this paragraph is 
gratefully acknowledged. For further 
discussion, see Chayes and Handler 
Chayes (1998), Goldsmith and Posner 
(2005), Haffeld, Siem, and Røttingen 
(2010: esp. 616), Hathaway (2002: esp. 
1942–1962), Koh (1997), and Vagts (2001: 
esp. 313 and 331).
22 Perpetual bonds are bonds without 
a maturity date. The borrower need never 
repay the principal, but must pay interest 
forever. The British government issued 
such bonds (‘consolidated annuities’, or 
‘consols’) in the 1750s and is still paying 
the interest on them. Various banks have 
issued US dollar-denominated perpetual 
bonds in recent years, including Credit 
Suisse Group AG, BNP Paribas SA, and 
HSBC Holdings plc.
23 For the various proposals of 
an international financial transaction 
tax, see the Wikipedia entry online at 
http://en.wikipedia.org/wiki/Financial_
transaction_tax. For a proposed scheme 
that would raise money in combination 
with slowing environmental degradation 
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and natural resource depletion, see Pogge 
(2008: ch. 8).
24 This model was first proposed and 
explored in Abramovicz (2003).
25 Strictly, the objective is to 
maximize the health impact of the HIF 
per dollar of net cost. Here, net cost 
is the funding absorbed by the HIF 
less the savings realized by buyers of 
medicines that they would otherwise have 
purchased with a high mark-up.
26 I initially favoured this option 
across the board (Pogge, 2005, 2008: ch. 
9), but extensive discussions with Aidan 
Hollis and others (in December 2007) 
have convinced me that other options are 
superior in many cases. See Hollis (2009) 
for an excellent treatment that informs 
and complements the present section.
27 The following thoughts were in part 
developed in response to Sakiko Fukuda-
Parr, who was the official respondent to 
my Mahbub ul Haq Memorial Lecture. She 
argued that allowing HIF registrants to 
retain exclusive marketing rights would, 
relative to open licensing, lead to higher 
prices and heavy concentration in the 
pharmaceutical industry. Her critical 
comments, composed with Proochista 
Ariana, are available, along with our 
replies, on the website of Intellectual 
Property Watch, online at http://www.
ip-watch.org
28 This point is made, for instance, in 
the critique by Fukuda-Parr and Ariana, 
cited in the preceding endnote.
29 This issue is further discussed 
in HIF (2010), the September 2010 
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